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LUNG CANCER — A MAN-MADE DISEASE.
A HISTORICAL REVIEW
H. Hansen The Finsen Center, Copenhagen/DENMARK
The history of lung cancer is closely related to the tobacco plant, which is
native only to the Americas. Estimate for its first dates of cultivation in the
Peruvian/Equadorian Andes ranges from 5000 to 3000 BC, from where its
use spread northwards on the American continent and later to Europe. The
link between tobacco smoke and lung cancer was shown in 1930 by Roffo
and the preponderance of smokers among lung cancer patients was demon-
strated in epidemiologic studies in subsequent years. In the early 16th
century, the disease entity was first described in the miners of Schneeberg as
Morbus metallicorum imprimis pulmonum. In the early 20th century, phy-
sicians recognised lung cancer as an uncommon and untreatable disease – a
picture that has since changed dramatically. Presently, approximately 11
million new cases of cancers are diagnosed each year, of which one in eight
is lung cancer. Over one million people die from lung cancer each year. With
respect to treatment, the first successful lobectomy was performed in 1908
and pneumonectomy in 1933. Radiotherapy was introduced in the 1940s and
antineoplastic chemotherapy in the 1960s, with increasing use of all three
modalities since then. Lately, personilized treatment based on the newest
information on the molecular biology of lung cancer has emerged as a
treatment option. Antismoking program remains, however, the best option
for decreasing the epidemics of lung cancer deaths.
2IN
THORACIC NEOPLASMS AND BIOMARKERS IN BODY
FLUIDS: WHERE ARE WE?
H.I. Pass Cardiothoracic Surgery, NYU School of Medicine, New York/
UNITED STATES OF AMERICA
Progress in the determination of early detection, classification, prognostica-
tion, and response to therapy markers for thoracic malignancies parallels the
explosion of novel technologies in genomics and proteomics. The inability,
specifically in lung cancer, to be able to obtain tissue easily leads investi-
gators to explore the use of serum, plasma, pleural effusion, sputum, and
occasionally urine for biomarker discovery. Crucial to any discussion of
biomarker discovery is the methods by which the specimens were obtained,
processed, and archived, as well as the ability to obtain cohorts through
which these biomarkers can be validated. The Early Detection Research
Network of the National Cancer Institute has sponsored Biomarker Discov-
ery and Validation Laboratories in the United States for both mesothelioma
and lung cancer, and some of the markers which have been investigated
through epigenetic screening, proteomic platforms including autoantibody
arrays, MALDI and SELDI platforms, and genomic microarray profiles are
in the process of validation using reference sets. For mesothelioma these
markers include soluble mesothelin related protein and osteopontin, both of
which have been shown to have potential to distinguish asbestos exposed
individuals from those with the disease. Novel lung cancer markers include
methylation profiles in the serum and the sputum and the annexins. Innovative
platforms which are now beginning to extend to fluids includes the profiling of
glycosylated moieties, circulating RNA expression profiles, and microRNA
profiles. Some of the novel markers including osteopontin may have both early
detection and prognostication potential. This discussion will give an overview of
these studies that are ongoing through the EDRN as well as to touch on other
fluid based biomarker profiles being investigated outside of the US.
3IN
TOBACCO POLICY
D.W. Bettcher Tobacco Free Initiative, World Health Organisation, Geneva/
SWITZERLAND
Tobacco Policy. The WHO-Framework Convention on Tobacco Control
(WHO FCTC) as a cancer prevention tool Tobacco is the largest preventable
cause of death in the world, killing more than five million people annually.
Half the people that smoke, about 650 million people, will eventually be
killed by tobacco. Tobacco remains available as a consumer product because
of its addictive properties and as a result of global market strategy that
aggressively targets low- and middle-income countries. The association
between tobacco smoking and cancer was demonstrated by Sir Richard Doll
in 1950. After a half of a century the Report of the Surgeon General stated
that cancer “was among the first diseases causally linked to smoking”. Lung
cancer is the leading cause of cancer death. 87% of lung cancer deaths can
be attributed to tobacco use. Besides lung cancer, tobacco use causes
increased risk for cancer of the mouth, nasal cavities, larynx, pharynx,
oesophagus, stomach, liver, pancreas, kidney, bladder, uterine cervix, and
myeloid leukaemia. Responding successfully to the public health challenges
posed by tobacco requires a mutually reinforcing combination of population-
based policies and interventions that focus on individuals. WHO, in collab-
oration with global partners, is working with countries on the implementation
of a package of six cost-effective policies that builds on the demand
reduction measures of the WHO FCTC and is part of the WHO Strategies
related to Cancer Prevention and Control: raising tobacco taxes and prices;
enforcing bans on tobacco advertising, promotion and sponsorship; warning
people about the dangers of tobacco; protecting people from tobacco smoke
in public places and workplaces; offering help to people who want to stop
using tobacco; monitoring successes and challenges. There are no borders
between advocating for cancer prevention and tobacco control. Health
professionals can add value to the WHO “saving lives” global effort by
bringing prevention and treatment perspectives together more effectively,
promoting tobacco cessation in the practice, and helping spearhead estab-
lishment of smoke-free environments in health-care settings. These can be
done through raising awareness among politicians, health professionals and
society, eventually implementing the WHO FCTC at large.
MEET THE EXPERT
4IN
EXTENSIVE SCLC
N. Thatcher Medical Oncology, Christie and Wythenshawe Hospitals,
Manchester/UNITED KINGDOM
Despite a general view, survival with cisplatin etoposide (PE) regimens
either alone or alternating with cyclophosphamide, doxorubicin, vincristine
(CAV), was not significantly better in randomised clinical trials (RCTs) than
CAV alone for ES patients. A Norwegian trial of ES patients found no
survival or quality of life difference between PE and an anthracycline
regimen [Sundstrom et al 2002]. A similar result was obtained comparing
CDE with carboplatin etoposide, CbE [de Jong et al 2007] However a small
but statistically significant survival advantage with less hospitalisation was
found for paclitaxel carboplatin versus CAV [Baka et al 2006]
Single agent oral etoposide had an inferior survival and was associated with
more toxicity than combination CT [Thatcher et al; Souhami et al., 1997].
Single agent carboplatin gave similar survival with less hospitalisation
compared with CAV in a poor prognosis patient group [White et al 2001].
Survival benefit for irinotecan cisplatin over PE in Japanese patients was not
confirmed in a western population [Noda et al 2002; Hanna et al 2006].
However a relatively small trial revealed a superior survival for irinotecan
carboplatin over carboplatin etoposide [Hermes et al 2007].
Paclitaxel combinations have also been compared in poorer prognostic
groups e.g. ES, as triplets, paclitaxel etoposide cisplatin (PET)  GCSF
versus PE with no survival benefit [Mavroudis et al 2003; Niell et al 2005].
However an update of a German trial in LS and ES patients of CbE
paclitaxel was superior to CbE vincristine, [Reck et al 2006.] RCTs of
gemcitabine carboplatin, oral topotecan cisplatin have not improved survival
compared with PE. [James et al 2002; Eckardt et al 2006].
Journal of Thoracic Oncology • Vol. 3, No. 4, Supplement 1, 2008 S9
A Phase II trial compared pemetrexed with either cisplatin or carboplatin and
has lead to a global trial in ES of pemetrexed carboplatin vs. carboplatin
etoposide [Socinski et al 2006]. In the largest phase III trial no survival
difference was found when thalidomide was added to CbE [Lee et al 2007].
The most important result recently was the demonstration that PCI in ES
patients who had a response to CT reduced the risk of symptomatic brain
metastases but actually increased survival [Slotman et al 2007].
Future
The incorporation of radiotherapy and novel drugs [Board et al 2006] make
the future of SCLC exciting.
5IN
HISTOLOGICAL CLASSIFICATION OF LUNG TUMORS
F. Thivolet-Bejui Centre De Pathologie Est, Hôpital L Pradel Hospices
Civils de Lyon, Bron Cedex/FRANCE
According to the most recent WHO classification 2004, histological classi-
fication of lung tumors is simple based on light microscopic criteria. The aim
of this classification is to provide practical guidelines for tumor diagnosis in
order to evaluate patient prognosis and therapy. Almost all lung tumours are
carcinomas (99%). Squamous carcinoma (25%–44%) and adenocarcinoma
(28%–42%) are the commonest types of lung carcinomas, in variable
proportion related to the sex and the smoking habit. Small cell carcinomas
comprise about 20% of cases. Adenocarcinomas are subclassified in five
sub-types and the definition of bronchioloalveolar carcinomas is strictly
restricted to mucinous and non-mucinous in situ tumours. Neuroendocrine
tumours ranged from well differentiated to poorly differentiated lesions are
separated in four categories of different prognosis: small cell carcinoma
(SCLC), carcinoid tumours - typical (TC) and atypical carcinoid (AC), and
large cell neuroendocrine carcinoma (LCNEC) considered as a variant of
large cell carcinomas. Large cell carcinomas (9% of all lung cancers) is a
diagnosis of exclusion of squamous cell carcinoma, adenocarcinoma ans
small cell carcinoma and include several variants. The sarcomatoid carcino-
mas group includes pleomorphic, spindle cell and giant cells variants and
tumours with an continuum of epithelial and mesenchymal differentiation.
Three pre-invasive lesions are identified as precursors of invasive lung carci-
noma: squamous dysplasia/carcinoma in situ, atypical adenomatous hyperplasia
and idiopathic pulmonary neuro-endocrine cell hyperplasia. The various others
histological types comprise under 1% of lung tumours.
6IN
INTERVENTIONAL ENDOSCOPY
M. Noppen University Hospital Uz Brussel, Interventional Endoscopy Clinic
and CEO, Brussels/BELGIUM
Endoscopic procedures play an increasingly important role in the diagnosis,
staging and management of lung cancer. Development of new (eg, electro-
magnetic navigation) and optimalization of existant techniques (e.g., rapid
on-site evaluation) increase the yield of diagnostic bronchoscopy ; real-time
endobronchial and esophageal ultrasound will change the staging algorithms
and –quality significantly, which hopefully will lead to a better patient
selection and outcome. Nevertheless, at the time of diagnosis, only about 20
tot 25 % of patients with lung cancer are candidates for curative treatment,
mainly offered by surgery. Thus, for the large majority of patients, treatment
remains palliative, and consists of chemotherapy, external beam irradiation,
or a combination of both. About one-third of lung cancer patients will present
symptoms of neoplastic obstruction of the central airways, often resulting in
severe morbidity and ultimately in death. Various interventional broncho-
scopic techniques are now available which have shown their utility in
controlling local tumor progression. The modern approach to inoperable lung
cancer should therefore always include an endoscopic assessment of the
central airways, and multimodality treatment should – when indicated -
include endoscopic modalities. An overview of the various endoscopic
treatments is provided, as well as an algorithm for the management of locally
advanced lung cancer.
7IN
LIMITED SURGERY (LESS THAN LOBOCTOMY)
B. Passlick Department of Thoracic Surgery, University Medical Center
Freiburg, Freiburg/GERMANY
Segmentectomy for the treatment of lung cancer was first described by Jensik
et al. in 1973. Nevertheless, lobectomy combined with systematic lymph
node dissection has been accepted as the standard treatment for lung cancer
even for small primary tumours for a long time. The only randomised trial
worldwide, investigating the question whether limited resection is compara-
ble to standard lobectomy has been published in 1995 by the Lung Cancer
Study Group (LCSG) demonstrating frequent local recurrences and a ten-
dency towards poorer survival in patients with limited resections. However,
in this trial, wedge resections and segmentectomies were grouped together as
limited resections and survival data could not be analysed separately. This
was considered a major limitation of the LCSG trial because wedge resec-
tions were associated with an increased risk of locoregional recurrence
compared to segmentectomies. Recently, it has been reported that segmen-
tectomy for small-sized stage IA lung cancers can yield outcomes equivalent
to lobectomy. The studies by Okada et al. and Koike et al. showed that
survival and local recurrence rate were not compromised following segmen-
tectomy with intraoperative lymph node assessment when the indication was
limited to stage IA tumours up to 2 cm. The most convincing advantage of
segmentectomy is that it spares pulmonary function compared to lobectomy
without compromising survival or local recurrence in stage IA NSCLC.
Thus, patients undergoing segmentectomy have a better ability to withstand
further pulmonary resection in the future if a second primary lung cancer
should develop. Furthermore, preserving pulmonary function will likely
reduce perioperative mortality and morbidity. However, it is repeatedly
reported that patient selection for segmentectomy in stage IA NSCLC needs
to be performed carefully. The most common parameter for patients selection
is a tumour size of  2 cm or even  1 cm. However, tumour localisation,
width of resection margins, tumour histology, tumour differentiation, and age
might theoretically also impact the further clinical course, and thus be
important in patient selection.
8IN
MOLECULAR BIOLOGY
M. Sanchez-Ce´spedes Molecular Pathology Program, Centro Nacional de
Investigaciones Oncol, Madrid/SPAIN
Current efforts are focusing towards the development of drugs that specifi-
cally target abnormal regulatory pathways of cancer cells. Therefore, it is
becoming increasingly important in order to identify the set of genes altered
in cancer and to discriminate tumors by their genetic background. Lung
tumors carry alterations at known genes, some of them highly specific to
their histology. Wide screening for chromosomal deletions allowed us to
unveil that LKB1 located at chromosome 19p13.3 was somatically mutated
in one third of lung tumors. Through the impair of the AMPK/mTOR
pathway, LKB1 inactivation abrogates the cell energetic checkpoint control,
an obligatory step for cancer development. In addition to LKB1, we recently
observed that chromosome 19p13 targets the tumor suppressor BRG1, which
encodes the ATPase of the SWI/SNF chromatin-remodelling complex.
BRG1 inactivating mutations were identified in 40% of the cancer cells
tested, mainly NSCLC, and did not coexist with MYC amplification. Our
data strongly supports that BRG1 is a bona fide tumor suppressor and a major
factor in lung tumorigenesis. We searched for alterations at other genes that
signal through mTOR such as PIK3CA. Activating PIK3CA mutations were
low in frequency but amplification was frequent in squamous cell carcinomas
and correlated with increased gene expression. This constitutes a potential
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key mechanism for PIK3CA oncogenic activation and, possibly, a determi-
nant of sensitivity to therapies with PI3K inhibitors. To identify novel
oncogenes, we performed combined Comparative Genome Hybridization
microarrays and cDNA microarrays. Following this approach we identified
several amplicons with increase in gene expression. We mapped the bound-
aries and measured gene expression levels within an amplicon at chromo-
some 6p. The SOX4 gene, encoding a transcription factor involved in cell
differentiation, was over-expressed relative to normal cells. SOX4 levels
were also high in a fraction of primary tumors and associated with increased
in gene copy number, supporting that SOX4 is a candidate oncogene in lung
cancer. In conclusion, we provide novel genes altered in lung tumors and
amplified regions that may contain oncogenes relevant for lung carcinogen-
esis.
9IN
PROTON THERAPY FOR NON-SMALL CELL LUNG CANCER
J. Cox1, S. Sejpal2, J.Y. Chang2, M.K. Bucci2, M.F. McAleer2, Z. Liao2,
D. Karp3, K. Pisters3, R. Komaki1 1Radiation Oncology, M.D. Anderson
Cancer Center, Houston/UNITED STATES OF AMERICA, 2Department of
Radiation Oncology, UT M. D. Anderson Cancer Center, Houston/UNITED
STATES OF AMERICA, 3Department of Thoracic/head and Neck Medical
Oncology, UT M. D. Anderson Cancer Center, Houston/UNITED STATES
OF AMERICA
Proton Therapy for Non-small Cell Lung Cancer The most effective treat-
ment of locally advanced, unresectable non-small lung cancer (NSCLC) is
radiation therapy with concurrent chemotherapy. With favorable perfor-
mance status and little weight loss, median survival rates average 20 months
and 5-year survival rates are about 20%. Toxicity rates of concurrent
chemotherapy and radiation therapy are high. More than 90% of patients
have uncomfortable esophageal reactions during treatment and nearly one-
third of patients develop treatment related pneumonia (TRP) after completing
treatment: some patients die from this complication.
Protons distribute energy differently than x-rays (photons). Instead of having
the maximum dose near the skin surface and penetrating completely through
the body, protons deliver the maximum dose at the depth of the tumor and
then stop, delivering no dose beyond the tumor. These features permit higher
doses to be delivered to tumors while avoiding normal structures.
In May, 2006, the Proton Therapy Center opened at the M. D. Anderson
Cancer Center. Concurrent chemotherapy and proton beam therapy (PBT)
for NSCLC was a priority from the beginning. Thirty patients have com-
pleted treatment with PBT and chemotherapy with sufficient follow up to
evaluate toxicity. These patients received a median total dose to the tumor of
74 cobalt-Gray equivalent (CGE). Comparisons were made with 222 patients
treated with 3-dimensional conformal radiation therapy (3D CRT) and 68
patients treated with intensity modulated radiation therapy (IMRT) with
concurrent chemotherapy (median tumor dose 63 Gy). Symptomatic esoph-
ageal reactions were observed in 93% of patients treated with 3D CRT and
IMRT compared with 60% with PBT. Severe esophageal reactions were
reported in 18% with 3D CRT, 37% with IMRT and 16% with PBT. TRP of
all degrees of severity was seen in 62% and 67% with 3D CRT and IMRT
respectively, compared with 32% for PBT. Grade 3 TRP was seen in 32%
of patients with 3D CRT, 9% with IMRT and no patient with PBT. The data
support the hypothesis that PBT can permit dose escalation to the tumor
while sparing critical normal structures. More patients treated with PBT and
longer follow up will provide a clearer picture of the potential for PBT and
chemotherapy for NSCLC.
10IN
SPECTRUM OF NEUROENDOCRINE TUMORS
W. Travis Department of Pathology, Memorial Sloan Kettering Cancer
Center, New York/UNITED STATES OF AMERICA
The diagnostic criteria for neuroendocrine lung tumors are summarized in the
2004 WHO Pathology and Genetics: Tumors of the Lung, Pleura, Thymus
and Heart. This is very similar to the previous 1999 WHO/IASLC classifi-
cation. This classification includes the preinvasive lesion diffuse idiopathic
pulmonary NE cell hyperplasia (DIPNECH) that appears to be a potential
precursor for carcinoid tumors of the lung. DIPNECH with obstructive
airways disease was reported by Aguayo in 1992 in 6 patients with obstruc-
tive airways disease who had unexplained diffuse pulmonary NE cell
hyperplasia and airway fibrosis in their lung biopsies. The occurrence of
carcinoid tumors in this setting suggests that DIPNECH may be a preneo-
plastic lesion. Since the vast majority of NE cell hyperplasias appear occur
as reactive lesions only the very rare cases of DIPNECH should be regarded
as preneoplastic. Neuroendocrine tumors of the lung are a distinct subset of
tumors, which share certain morphologic, ultrastructural, immunohistochem-
ical and molecular characteristics. The major categories of morphologically
identifiable neuroendocrine tumours are the high grade small cell carcinoma
(SCLC) and large cell neuroendocrine carcinoma (LCNEC) as well as the
low grade typical carcinoid (TC) and intermediate grade atypical carcinoid
(AC). AC is separated from TC by the presence of necrosis or an increased
mitotic count of 2 to 10 mitoses per 2 mm2. AC is separated from LCNEC
and SCLC primarily because the latter have a mitotic count of 11 or more
mitoses per 2 mm2. However, LCNEC and SCLC usually have very high
mitotic rates, with an average of 70–80 per 2 mm2. SCLC is kept separate
from LCNEC for several reasons. SCLC is relatively common, accounting
for 15–25 percent of all lung malignancies, while typical and atypical
carcinoids, and LCNEC, collectively make up only 2–3 percent. SCLC is
also the most clinically distinctive of the major types of lung cancer. Its
biologic characteristics and responsiveness to chemotherapy sharply distin-
guish it from most non-small cell carcinomas. In surgical series, five year
survival for TC is 90–95%, for AC is 50–70%, for LCNEC is 10–30% and
for SCLC is 10–30%. Therapy for AC and LCNEC is not known, while
surgery and chemotherapy are primarily recommended for TC and SCLC
respectively.
11IN
SURGERY FOR OLIGOMETASTATIC DISEASE
P. Van Schil Dept. of Thoracic and Vascular Surgery, University Hospital of
Antwerp, Edegem/BELGIUM
Patients with metastatic disease (stage IIIB or IV) of a non-small cell lung
cancer (NSCLC) have a very poor prognosis and surgery is rarely indicated.
No controlled randomised trials are available. Different subgroups of patients
with metastatic NSCLC exist. Intrapulmonary metastases In preparation of
the new TNM classification, the IASLC created a large database collecting
data of lung cancer patients from all over the world. Pathologic T4 disease
by ipsilateral pulmonary nodules in the same lobe had a similar survival to
T3 patients, and pathologic M1 by ipsilateral pulmonary nodules in a
different lobe showed a similar survival to a comparator T4 group. So, the
Staging Committee proposes to reclassify T4 tumours by additional nodules
in the primary lobe as T3 disease, and to reclassify M1 by ipsilateral nodules
in a different lobe as T4 disease. Contralateral nodules are considered to be
M1a disease. Malignant pleural effusion Although isolated reports of pleu-
rectomy or even pleuropneumonectomy have been described in patients with
malignant pleural effusion and pleural nodules, so-called “wet T4 disease”,
prognosis is generally very poor. The IASLC Staging Committee recom-
mends to reclassify malignant pleural effusion from T4 to the new M1a
category. Extrathoracic single or multiple metastases M1 - extrathoracic
metastases In the IASLC database report patients with distant metastases also
had a poor prognosis. From the available data it was not possible to perform
a thorough analysis of single versus multiple sites in any extrathoracic organ.
So, they are all considered to be M1b disease. M1 – brain Aggressive
treatment of brain metastases in selected cases includes surgical resection or
stereotactic radiosurgical techniques. Most reported series of resected brain
metastases are retrospective. Overall survival ranges from 8 to 21%. In
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patients with resected brain metastases adjuvant chemotherapy may be
considered. The role of whole brain radiotherapy remains controversial as
conflicting data have been reported. M1 – adrenal In highly selected patients
resection of an isolated adrenal metastasis from a primary NSCLC may be
considered. At the present time adrenalectomy can be performed by laparo-
scopic techniques. Overall 5-year survival rate ranges from 10 to 23%.
12IN
THE FUTURE OF IMAGING
Cristina Game´z Institut de Diagnostic per la imatge, L’Hospitalet de
llobregat/SPAIN
No abstract received at time of going to print
13IN
ASSOCIATION OF VEGF, AND MMP-9 EXPRESSION IN
THE PRIMARY NON-SMALL CELL LUNG CANCER
LESION WITH BRAIN METASTATIC LESION
R. Komaki1, I. Milas2, J.Y. Ro2, L.A. Langford2, R. Sawaya3, P.K. Allen4,
J.D. Cox4, M. O’Reilly4, R.S. Herbst5, W.K. Hong6 1Radiation Oncology,
M.D. Anderson Cancer Center, Houston/UNITED STATES OF AMERICA,
2Pathology, M. D. Anderson Cancer Center, Houston/UNITED STATES OF
AMERICA, 3Neurosurgery, M. D. Anderson Cancer Center, Houston/
UNITED STATES OF AMERICA, 4Radiation Oncology, M. D. Anderson
Cancer Center, Houston/UNITED STATES OF AMERICA, 5Thoracic/h & N
Medical Oncology, M. D. Anderson Cancer Center, Houston/UNITED
STATES OF AMERICA, 6Thoracic/h & N Medical Onocology, M. D.
Anderson Cancer Center, Houston/UNITED STATES OF AMERICA
Purpose: This study was conducted to determine whether the biomakers
VEGF, and MMP-9 of primary non-small cell lung cancer (NSCLC) will
predict the incidence of brain metastasis and whether the intrapatient expres-
sion of these biomarkers (in the primary tumors versus metastatic brain
lesions) is correlated. Experimental Design: Tumors from 29 patients with
primary lung and brain metastasic tumors and 29 control patients without
brain metastasis who had their primary lung tumors were examined for
immunohistochemical expression. VEGF, and MMP-9 were analyzed in
resected primary lung, lymph node, and metastatic brain tumors. Results:
There was no significant difference in the expression of the biomarkers in
primary lung tumors between patients with and without brain metastasis.
When the groups were considered together, we found in lung primary tumors
that expression of the four biomarkers was higher in adenocarcinoma (AC)
versus squamous cell carcinoma (SCC) histology. When we compared mean
expression of biomarker in lung primary tumors with mean expression in the
corresponding brain metastasis, MMP-9 was expressed much higher in brain
metastases (86%) than in lung primary tumors (29%)(P0.001). There was
a positive correlation between VEGF and MMP-9 in brain metastases
(P0.001, r20.663). Conclusions: Our study showed a higher biomarker
expression in AC histology for all biomarkers. Brain metastases had a higher
expression level of MMP-9 than did the primary lung tumor. Using new
therapies such as metalloproteinase and angiogenesis inhibitors may reduce
brain metastasis, although this possibility needs to be investigated.
14IN
THYMOMAS
R.O. Mirimanoff Radiation Oncology, Centre Hospitalier Univ Vaudois,
Lausanne/SWITZERLAND
Thymomas : Consensus or Controversies ? Rene´-Olivier Mirimanoff M.D.
Department of Radiation Oncology, University of Lausanne Hospital,
CHUV, CH-1011 Lausanne, Switzerland. Purpose: Given the paucity of
EBM on the management of thymomas, to review the most relevant aspects
of the available literature concerning these tumours. Classification: The most
widely accepted histopathological classification is that of Muller-Hermelink
with the cortical, mixed and medullary type, while the Masaoka is the most
used staging system and is divided into four stages related to the degree of
invasion (I to III) and the presence of pleural, pericardial (IVa) or distant
(IVb) metastases. Data suggest a correlation between the Muller-Hermelink
and the Masaoka staging system. Treatments: Surgical resection is the
mainstay of treatment, its extent being correlated to local control (LC),
disease-free (DFS) and overall survival (OS). LC, DFS and OS are also
linked to stage. In unresectable cases, debulking is controversial. Adjuvant
radiotherapy (RT) is not indicated in stage I. In R0, stage II or III, the role
of RT is uncertain,while in R1 or R2, RT improves LC or even OS.
Preoperative RT in invasive tumours may increase resectability and OS, RT
doses are 50 Gy for micro- and 60 Gy for macroscopic residues. Current
trend is towards a limited volume with 3D conformal or IMRT. Thymomas
are sensitive to chemotherapy (CXT), with response rates of up to 90% in
neoadjuvant series (up to 20 pCR). CXT is used in advanced diseases and
more and more frequently in the neoadjuvant setting. Many protocols use
cisplatin-based CXT, with doxorubicin, cyclophosphamide, and vincristine
or etoposide. Yet in stage III and IV, there is no consensus on the best
treatment combination or sequence of surgery, RT and CXT. Prognosis: On
multivariate analyses, consistent prognostic factors are stage and complete-
ness of surgery. Histology, tumour size, age, MG or other auto-immune
disorders give controversial results. Conclusions: Thymomas offer a wide
spectrum of patterns, behaviours and managements. Reliable studies and
classification systems help in the management of these tumours. Surgery is
the mainstay, RT and CXT have an increasing adjuvant or neoadjuvant role,
but because of numerous controversies, further investigation is greatly
needed.
CONTROVERSY: STAGE III NSCLC
15IN
SURGERY STILL HAS A ROLE TO PLAY IN STAGE III
NSCLC
K.S. Albain Cardinal Bernardin Cancer Center, Loyola University Chicago
Stritch School of Medicine, Maywood/UNITED STATES OF AMERICA
This presentation considers whether surgery has a role to play in the
treatment of patients with stage III NSCLC for whom the standard treatment
recommendation is chemoradiotherapy. It will not consider those with
“minimal” N2 disease or earlier stage tumors for whom upfront surgical
resection is an acceptable approach. Patients with low volume or microscopic
mediastinal nodal involvement have a 5-year survival of 25–40% when
treated with surgical resection alone (improved further by adjuvant chemo-
therapy), whereas the same treatment in patients with macroscopic N2
metastases results in less than 10% 5-year survival. Similarly, survival within
the stage IIIB category (T4 and/or N3) is heterogenous, dependent upon the
sub-stage and tumor volume. For all these scenarios with high tumor and/or
mediastinal or supraclavicular disease volume, initial surgical resection even
if technically feasible initially would not offer a survival advantage. How-
ever, it is possible that surgical resection might improve on the potential for
longer survival and cure when it is employed following chemotherapy or
chemoradiotherapy.
Nevertheless, after 2 decades of clinical research, the role for surgery within
combined modality treatment for stage III non-small cell lung cancer
(NSCLC) when there is significant volume of N2 or N3 disease remains
controversial. Despite a multitude of phase II studies and the more recent
mature survival reports of 2 large phase III trials internationally (North
American Intergroup 0139 and EORTC 8941), studies that took many years
to accrue, this issue most likely will continue to be debated indefinitely.
Based on results from these trials, can a surgical resection be recommended
for any patient with stage III disease (apart from the special group with
T4N0/1 or Pancoast presentations)?
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The EORTC trial showed equivalence of surgery versus radiotherapy fol-
lowing a response to induction chemotherapy. In fact, both arms of the study
yielded disappointing results in a group of patients with advanced local
disease. Thus, concurrent chemoradiotherapy without surgery would seem to
be the standard choice for this group. The Intergroup trial also showed
equivalent survival overall for concurrent chemoRT vs chemoRT followed
by surgery. However, based on exploratory modelling of matched cohorts
from this trial, there is a strong suggestion that if a lobectomy can be
performed, concurrent chemoradiotherapy followed by surgical resection
using the regimen tested in this study is also a valid and possibly preferable
option. This is with the caveat that the patient must meet the strict selection
criteria of the trial and is treated by a multidisciplinary team experienced in
this approach. The patients had excellent performance status, lacked major
co-morbidities and had good pulmonary function. Surgical resection after
chemoradiation if a pneumonectomy is needed is a questionable approach
given high postoperative mortality. If considered, it should be done only with
great caution and informed consent and only in a very fit patient by a very
experienced surgeon.
The two trials used very different criteria for entry and resection apart from
the similar inclusion of documented N2 disease. The EORTC surgeons
referred patients with “irresectable” (unresectable) disease, whereas the
Intergroup surgeons enrolled “potentially resectable” tumors; and in both of
these trials, the control arm was either concurrent or sequential chemoradio-
therapy alone. However, the EORTC trial tested the role for surgery only in
patients who achieved a radiographic response to chemotherapy, and thus
excluded a large number of registered patients from the randomization;
whereas, the Intergroup trial randomized patients upfront and mandated
resection of radiographically stable disease (many of whom had significant
pathologic downstaging). Therefore, the achievement of a clinical response
should not be used as sole criteria for selecting patients for surgery. Another
interpretation of the results of both trials is that downstaging to N0 yielded
the best long-term survival, and only those patients should be selected to
undergo surgical resection. Since the survival in the Intergroup trial was also
quite good in those with residual nodal disease, a benefit to the surgical
resection in this group cannot be ruled out. Results in the surgical arm of the
EORTC trial are confounded by the use of PORT, which in previous reports
may adversely impact survival.
These two large phase III trials provide some direction to the practicing
clinician who is regularly faced with treatment decisions for the patient with
advanced, high volume stage IIIA(N2) NSCLC. Concurrent chemoradiother-
apy should be considered standard in this subset, with one exception: if a
lobectomy can be performed, this appears to be a viable alternative following
concurrent chemoradiotherapy. Extrapolation of this recommendation to
chemoradiotherapy regimens not tested in these trials should not be done,
since many of these regimens do not employ full dose chemotherapy with
RT, or only prescribe two cycles of chemotherapy. The role for surgery in
stage IIIB awaits the completion of a prospective phase III trial ongoing in
Germany and collaborating centers.
16IN
SURGERY HAS NO ROLE TO PLAY IN STAGE III NSCLC
J. van Meerbeeck Thoracic Oncology, University Hospital Ghent, Ghent/
BELGIUM
Stage III NSCLC groups a heterogeneous pool of patients with either
minimal parietal pleural invasion and hilar node metastasis (N1), or medi-
astinal lymph node invasion (N2/3) or with malignant pleural effusion (T4)
[1]. These different categories have been lumped in 1997 because of their
similar survival rates, and share a high propensity to recur with distant
metastases after a radical locoregional treatment, making the latter look
futile. Adequate staging, including FDG-PET-scan and (minimally) invasive
mediastinal staging are hence prerequisites for a good patient selection and
the source for the observed differences in outcome between expert center
series and large community-based randomised trials. The need for a systemic
therapy, preceding or following the locoregional treatment is not anymore
debated. What remains is the choice of the optimal locoregional treatment:
surgery or not. Several series have shown that in appropiately selected
patients, surgery is feasible and can result in impressive rates of complete
resection and of survival [2–6]. The authors of these series are to be
commended for their laudable audacity in shifting the borders of surgery.
With 2 randomized trials showing no significant improved survival with
adjuvant surgery as compared to chemoradiotherapy, the debate seems
however closed but for the believers in surgery [7, 8]. The relative merits and
achievements of both modalities will be discussed elsewhere in this journal.
This presentation will review a number of traps for the unwary in surgical
series in clinical stage III NSCLC. Patients with T3N1 and malignant pleural
effusion are excluded, as their treatment approach is similar to stages II and
IV, respectively.
17IN
SURGERY STILL HAS A ROLE TO PLAY IN STAGE III
NSCLC
D. Waller General Thoracic Surgery, Glenfield Hospital, Leicester/UNITED
KINGDOM
Two recent randomized clinical trials have suggested that the routine addi-
tion of surgery to induction chemoradiotherapy is of no survival benefit.
These findings have been interpreted to imply that evaluating the role of
surgery in stage IIIA NSCLC is no longer a clinical priority. This presenta-
tion will systematically analyze the following points in the pathway where
surgical intervention may benefit the patient with stage IIIA or IIIB disease.
Mediastinoscopy remains the gold standard for confirming pathological N2
disease and remains the most accurate method of restaging after induction
therapy. Surgery has a higher sensitivity and specificity than any non-
invasive imaging (CT-PET) or biospy technique (EBUS/EUS). The subset of
patients in whom induction therapy has caused “mediastinal downstaging”
may behave like stage I or II and therefore benefit from surgical resection if
pneumonectomy can be avoided. Even in the subset of patients in whom
restaging demonstrates persistent pathological N2 disease may receive better
local control from surgery if complete resection can be achieved without
pneumonectomy. In some clinical scenarios i.e, with a large peripheral
tumour and central lymph node involvement or in patients with borderline
performance status chemoradiotherapy may not be feasible or tolerated. Even
with extensive preoperative staging using CT-PET and mediastinoscopy with
intraoperative systematic nodal dissection N2 disease may be detected in
over 5% of cases. Survival in this subgroup of III disease may be comparable
with stage IIB. Although this scenario should be unlikely with modern
staging methods even if intraoperative pathological analysis confirms N2
then resection should be performed if clear margins can be achieved.
Adjuvant mediastinal radiotherapy should then be considered. There are les
controversial areas where surgery for stage III NSCLC may be applied
including : Stage T3 (chest wall) N1; Stage IIIB (T4 satellite nodules) and
some Stage IIIB (T4 N0 locally invasive) tumours. Conclusion The lung
cancer community may have been too easily persuaded by two potentially
flawed trials that surgery has no therapeutic role in stage III NSCLC.
18IN
SURGERY HAS NO ROLE TO PLAY IN STAGE III NSCLC
A. Turrisi Radiation Oncology, Wayne State University, Detroit/UNITED
STATES OF AMERICA
The provocative title was assigned. My thesis is that surgery alone is
inadequate for stage IIIa/b NSCLC, and that its role speculative and unsup-
ported by clinical trials isolating its use. The standard treatment for IIIa/b
NSCLC is chemo-radiotherapy. Underpowered prospective trials have hinted
at a role for chemotherapy followed by surgery with surgery alone as control.
Since CALGB 8433, C - RT, and reports from RTOG 9410 and Japan
Journal of Thoracic Oncology • Vol. 3, No. 4, Supplement 1, 2008 Abstracts
Copyright © 2008 by the International Association for the Study of Lung Cancer S13
indicate that concurrent C/RT are the benchmark. The hypothesis that C/RT
cause the nodal downstaging and survival in SWOG 8805 that spurred
Intergroup 0139/RTOG 9309. This trial randomized patients to C/RT 61Gy
or C/RT 45Gy followed by resection. The results have not yet been pub-
lished; a manuscript is in preparation. There is no difference in survival.
There is DFS difference, as well as subset analyses done to explore benefits
in subsets not planned prior to study. To date, no large randomized prospec-
tive trial has established a survival benefit for surgery when compared to
chemoradiotherapy without surgery.
Throughout the world, we seek optimal methods to treat patients with locally
advanced NSCLC. Five year survival for IIIa/b ranges between 25–35% 5
year depending on patient selection, more than specifics of chemotherapy
agents, dose and volume of radiotherapy, or use of surgery. There may be
subsets that benefit from either using or not using surgery, but the criteria are
not clearly defined at this time. A proportion of patients are now locally and
systemically controlled and failing with isolated brain metastases. While
there cannot be improved long term survival without local control, improve-
ments in local control with surgery will not result in overall survival benefits
unless systemic and regional control is achieved. The use of surgery in this
population is anecdotal, and not appropriate without down-staged N-2 nodes
or requiring a right pneumonectomy. Application in pN0 nodes with residual
lobar disease removable by lobectomy may prove to be the best setting to
establish its use.
IASLC STAGING REPORT
19IN
T STAGE
R. Rami-Porta1, D. Ball2, J. Crowley3, D.J. Giroux3, J. Jett4, W.D. Travis5,
M. Tsuboi6, E. Vallières7, P. Goldstraw8 1Thoracic Surgery Service, Hospi-
tal Mutua de Terrassa, Terrassa/SPAIN, 2Radiation Oncology, Peter Mac-
Callum Cancer Centre, East Melbourne/AUSTRALIA, 3Statistics, Cancer
Research and Biostatistics, Seattle/UNITED STATES OF AMERICA, 4Inter-
nal Medicine and Respiratory Diseases, Mayo Clinic, Rochester/UNITED
STATES OF AMERICA, 5Pathology, memorial Sloan-Kettering Cancer Cen-
ter, New York/UNITED STATES OF AMERICA, 6Thoracic Surgery, Tokyo
Medical University, Tokyo/JAPAN, 7Thoracic Surgery, Swedish Cancer
Institute, Seattle/UNITED STATES OF AMERICA, 8Thoracic Surgery, Royal
Brompton Hospital, Imperial College, London/UNITED KINGDOM
Objective: To propose changes in the seventh edition of the TNM classifi-
cation for lung cancer to be published in 2009. Methods: Data on 100,869
patients with lung cancer, diagnosed between 1990 and 2000, were submitted
to the international database of the IASLC from 20 countries and 45
databases of different nature (registries, clinical trials, series, consortia). Data
were collected at and analysed by Cancer Research and Biostatistics
(CRAB), Seattle, WA, USA. Data for 18,198 of these patients fulfilled the
inclusion criteria for the T component analysis. Survival was calculated for
clinical and pathologic T1, T2, T3, T4N0M0 completely resected (R0), and
for each T descriptor. A running log-rank test was used to assess cutpoints by
tumour size. Results were internally validated (by geographic region and
type of database) and externally validated by the Surveillance, Epidemiology
and End Results (SEER) registry. Results: On the basis of the optimal
cutpoints, pT1N0R0 was divided into pT1a / 2 cm (n  1816) and pT1b
 2 to 3 cm (n  1653) with 5-year survival rates of 77 and 71% (p 
0.0001). The pT2N0R0 cutpoints resulted in pT2a  3 to 5 cm (n  2822),
pT2b  5 to 7 cm (n  825), and pT2c  7 cm (n  364). Their 5-year
survival rates were 58, 49, and 35% (p  0.0001). For clinically staged N0,
5-year survival was 53% for cT1a, 47% for cT1b, 43% for cT2a, 36% for
cT2b, and 26% for cT2c. pT3N0 (n  711) and pT4 (any N) (n  340) had
5-year survival rates of 38 and 22%. pT4 (additional nodules) in the same
lobe (n  363) had a 5-year survival rate of 28%, similar to pT3 (p  0.28)
and better than other pT4 (p  0.0029). For pM1 (ipsilateral pulmonary
nodules) (n  180), 5-year survival was 22%, similar to pT4. For cT4-
malignant pleural effusion/nodules, 5-year survival was 2%. Other T2, T3
and T4 descriptors could not be evaluated because of the small number of
patients, inconsistent clinical and pathologic results, or lack of validation.
Conclusion: Recommended changes in the T classification are 1) to subclas-
sify T1 into T1a and T1b; 2) to subclassify T2 into T2a and T2b; 3) to
reclassify T2c as T3; 4) to reclassify additional nodule(s) in the same lobe as
T3; 5) to reclassify nodule(s) in the ipsilateral nonprimary lobe as T4; and 6)
to reclassify malignant pleural or pericardial effusion as M1.
20IN
M STAGE
P.E. Postmus1, E. Brambilla2, K. Chansky3, P. Goldstraw4, J. Crowley5, E.F.
patz6, H. Yokomise7 1Department of Pulmonary Diseases, VU University
Medical Centre, Amsterdam/NETHERLANDS, 2De´partement D’anatomie Et
Cytologie Pathologiques, University hospital Grenoble, Grenoble Cedex
09/FRANCE, 3Cancer Research And Biostatistics, Cancer Research And
Biostatistics, Seattle/UNITED STATES OF AMERICA, 4Thoracic Surgery,
Royal Brompton Hospital, Imperial College, London/UNITED KINGDOM,
5Statistics, Cancer Research and Biostatistics, Seattle/UNITED STATES OF
AMERICA, 6Radiology, Duke University Medical Centre, durham/UNITED
STATES OF AMERICA, 7Surgery, Kagawa University, kagawa/JAPAN
“The IASLC lung cancer staging project”: Proposals for revision of the M
descriptors in the forthcoming (7th) edition of the TNM classification of lung
cancer. Purpose: To analyse all non-lymphatic metastatic components (T4
and M1) of the current TNM system of lung cancer with the objective of
providing suggestions for the next edition of the TNM classification for lung
cancer. Material and Methods: Data on 100,809 patients were submitted to
the International Association for the Study of Lung Cancer International
Database. 5,592 selected T4M0 and M1 patients fulfilled the inclusion
criteria for the analysis. Specific categories of clinically staged T4 (lesions
not continuous with the primary tumor) and M1 cases were compared with
respect to overall survival using Kaplan-Meier survival estimates and com-
parisons via Cox regression analysis. Relevant findings were internally
validated by geographic area and type of database, and externally validated
by the North-American Surveillance, Epidemiology and End Results Regis-
tries. Results: Median survival for cT4M0 with malignant pleural effusion
was significantly worse than that of other cT4M0 patients (8 months vs. 13
months) and was more comparable to M1 cases with metastases to the lung
only (10 months). M1 cases with metastases outside the lung/pleura had a
significantly poorer prognosis than those with metastases confined to the
lung, with a median survival of 6 months. Conclusions: Revisions to the
TNM classification system for lung cancer should include grouping cases
with malignant pleural effusions and cases with nodules in the contralateral
lung in the M1a category, and cases with distant metastases should be
designated M1b. In addition, cases with nodule(s) in the ipsilateral lung
(non-primary lobe), currently staged M1, should be reclassified as T4M0, in
accordance with the recommendations of T descriptor sub-committee of the
IASLC International Staging committee.
21IN
GROUPING
P. Goldstraw Department of Thoracic Surgery, Royal Brompton Hospital,
London/UNITED KINGDOM
The origins and evolution of the IASLC Lung Cancer Staging Project has
been covered in an article published in the Journal of Thoracic Oncology.
The recommendations of the T, N and M descriptors sub-committees, the
validation process and the recommendation for the TNM subsets and stage
groupings have now been submitted to the 2 non-governmental organisations
that regulate the TNM staging system; the American Joint Committee on
Cancer (AJCC) and the International Union Against Cancer (UICC)), and
have been published in detail in the Journal of Thoracic Oncology. It is
anticipated that following consultation these proposals will be incorporated
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into the 7th edition of the TNM Classification of Malignant Tumours due to
be published early in 29. Where analysis of the T, N or M descriptors
identified that a descriptor had a prognosis that differed from the other
descriptors in that T or M category, two alternative strategies were consid-
ered. i) Retain that descriptor in the existing category, identified by alpha-
betical subscripts. For example, additional pulmonary nodules in the lobe of
the primary, considered to be T4 in the 6th edition, would become T4a,
whilst additional pulmonary nodules in other ipsilateral lobes, designated as
M in the 6th edition, would become Ma. ii) Allow descriptors to move
between categories, to a category containing other descriptors with a similar
prognosis, e.g. additional pulmonary nodules in the lobe of the primary
would move from T4 to T3, and additional pulmonary nodules in other
ipsilateral lobes would move from M to T4. The first strategy had the
advantage of allowing, to a large extent, retrograde compatibility with
existing databases. Unfortunately this generated a large number of descrip-
tors (approximately 2) and an impractically large number of TNM subsets
(over 8). For this reason backwards compatibility was compromised and
strategy ii) was preferred for its clinical utility. The resultant TNM subsets
were entered into a recursive partitioning and amalgamation (RPA) algo-
rithm. This analysis was performed on a randomly selected training set
comprising 2/3 of the available data, reserving the other /3 for later valida-
tion. The random selection process was stratified by type of database
submission and time period of case entry (99–995 vs 995–2). Bootstrap
re-sampling was used to correct for the adaptive nature of the splitting
algorithm. With the resultant terminal nodes as a guide, several proposed
stage groupings were created by combining adjacent groups. Selection of a
final stage grouping proposal from among the candidate schemes was based
upon its statistical properties in the training set and its relevance to clinical
practice, and was arrived at by consensus. The proposed changes to the stage
groupings are as follows:
● Incorporate proposed changes to T and M (affects T2,T3,T4 and M1
categories).
● Reclassify T2aN1 tumours (5 cm) as stage IIA (from IIB).
● Reclassify T2bN0 tumours (5–7 cm) as stage IIA (from IB).
● Reclassify T4N0 and T4N1 tumours as stage IIIA (from IIIB).
The resultant TNM stage groupings are summarised as:
Occult
Carcinoma TX N0 M0
Stage 0 Tis N0 M0
Stage IA T1a N0 M0
T1b N0 M0
Stage IB T2a N0 M0
Stage IIA T1a N1 M0
T1b N1 M0
T2a N1 M0
T2b N0 M0
Stage IIB T2b N1 M0
T3 N0 M0
Stage IIIA T1a N2 M0
T1b N2 M0
T2a N2 M0
T2b N2 M0
T3 N1 M0
T3 N2 M0
T4 N0 M0
T4 N1 N0
Stage IIIB T4 N2 M0
Any T N3 M0
Stage IV Any T Any N M1a
Any T Any N M1b
The table below summarises the descriptors, proposed T and M categories,
and proposed stage groupings. Shaded cells indicate a proposed change from
the 6th Edition of the TNM Classification for lung cancer for a particular
TNM category.
UICC6 T/M and
Descriptor
Proposed
T/M N0 N1 N2 N3
T1 (2cm) T1a IA IIA IIIA IIIB
T1 (23 cm) T1b IA IIA IIIA IIIB
T2 (5cm) T2a IB IIA IIIA IIIB
T2 (5–7cm) T2b IIA IIB IIIA IIIB
T2 (7cm) T3 IIB IIIA IIIA IIIB
T3 invasion IIB IIIA IIIA IIIB
T4 (same lobe nodules) IIB IIIA IIIA IIIB
T4 (extension) T4 IIIA IIIA IIIB IIIB
M1 (ipsilateral lung) IIIA IIIA IIIB IIIB
T4 (pleural effusion) M1a IV IV IV IV
M1 (contralateral lung) IV IV IV IV
M1 (distant) M1b IV IV IV IV
In addition the IASLC Lung Cancer Staging Project has produced proposals
for the validity of TNM in the clinical staging of small-cell lung cancer and
is finalising supplementary proposals concerning the role of TNM in carci-
noid tumours of the lung. We have agreed a harmonised international nodal
chart to reconcile the Japanese and Mountain/Dressler Nodal Charts, devel-
oped a precise and usable definition of “visceral pleural invasion” and
conducted a thorough review of the role of those additional prognostic
factors available in the database. We have undertaken a meta-analysis of the
prognostic value of biological markers in lung cancer. All of these aspects of
the project will, subject to editorial review, be published in the JTO over the
next 6 months.
EARLY NSCLC STATE-OF-THE-ART
22IN
ENDOSCOPIC MANAGEMENT OF CARCINOMA IN SITU
R.M. Huber Div. Respiratory Medicine, University of Munich, Munich/
GERMANY
Prognosis of even early stages of lung cancer is poor. Therefore detection
and treatment of preinvasive or microinvasive lesions seems to be desirable.
Unfortunately the natural history of these lesions is not well known and
definite diagnosis of carcinoma in situ (CIS) requires a surgical specimen.
Standard approach also for these lesions is surgery. Disease-free survival
after surgical resection of lung CIS has been reported as over 90%. In
resected specimens overall prevalence of a pre-invasive lesion is 6 -7%,
synchronous early lung cancers occur in about 9 %. In small series with
photodynamic diagnosis and surveillance progression from CIS to invasive
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cancer occurred between 17 % and 87.5 %. As these lesions are usually
centrally located, surgery is a major procedure for these pts. and may be
disproportionally invasive and costly. Minute early stage lesions within
bronchoscopic visibility never had nodal disease. Therefore bronchoscopic
treatment (BT) was attempted - primarily in medically inoperable patients.
As the diagnosis of CIS is difficult under these circumstances, usually the
term radiographically occult lung cancer (ROLC) is used. There are data with
photodynamic therapy (PDT), Nd-YAG laser therapy, electrocautery, kryo-
therapy and argon plasma coagulation. Case series with up to 100 pts. have
been reported. For PDT there are reviews with up to 523 pts. and a systematic
review. BT has a curative potential for these patients with intraluminal
microinvasive ROLC. Success rates with BT have been in the 90–100%
range, translating itself to local cure due to the reported follow-up time of 
5 yrs. The best evidence exists for PDT with about 70 % primary CR in
larger series and in experienced centres 90% cancer-specific survival. Con-
clusion: The best evidence regarding efficacy exists for surgery. As BT of
ROLC seems to provide similar disease-free survival with less perioperative
mortality, morbidity, and cost, this may be an alternative, at least for
medically unfit patients. Although all bronchoscopic procedures seem to be
effective the greatest published experience is with photodynamic therapy.
Overall more (controlled) data and at least registers for these lesions and their
treatment are necessary.
23IN
INDIVIDUAL PATIENT DATA (IPD) META-ANALYSES IN
RESECTABLE NON-SMALL CELL LUNG CANCER
(NSCLC)
J.P. Pignon1, S. Burdett2, A. Auperin3, J. Tierney2 1Biostatistics and Epide-
miology, Institut Gustave-Roussy, Villejuif/FRANCE, 2Meta-analysis Group,
MRC Clinical Trials Unit, London/UNITED KINGDOM, 3Service De Bio-
statistiques, Institut Gustave-Roussy, Villejuif/FRANCE
Background Previous IPD meta-analyses of chemotherapy (CT) (BMJ 1995;
311:899) and post-operative radiotherapy (PORT) (Lancet 1998;352:257) in
NSCLC have been updated and the results on overall survival (OS) are
summarized here. Methods Systematic searches for randomized clinical trials
(RCTs) were carried out, updated IPD were centrally collected, checked and
re-analysed. RCTs were combined using the stratified (by trial) log rank test
to calculate individual and pooled hazard ratios (HRs). Results Surgery 
CT versus surgery alone IPD were obtained from 30 RCTs (8,147 patients).
15 RCTs used a cisplatin combination without Tegafur/TegafurUracil
(TTU), 8 RCTs used TTU without cisplatin and 7 RCTs used both TTU and
cisplatin. The results show a significant benefit of CT on OS (HR0.86, 95%
CI 0.81–0.93, p0.0001), with an absolute benefit of 4% (from 60% to 64%)
at 5 years. Surgery  RT  CT versus surgery  RT IPD were obtained
from 11 RCTs (2,626 patients). 10 RCTs used sequential radio-chemother-
apy. 8 RCTs used cisplatin  vinca alkaloid/etoposide, 1 RCTs cisplatin 
Tegafur and 2 other cisplatin regimens. There is a significant benefit of CT
on OS (HR0.88, 0.80–0.96, p0.0062), with an absolute benefit of 5%
(from 29% to 34%) at 5 years. In both comparisons the results of older and
more recent RCTs were comparable. There was no clear evidence of a
difference in effect by type of CT, nor was there clear evidence that any
patient subgroup defined by age, sex, stage or histology benefited more or
less from CT. Surgery  RT versus surgery alone 2,232 patients from 10
RCTs were included. The results showed a significant adverse effect of
PORT on OS, HR1.18 (1.07–1.31, p0.002), equivalent to an absolute
detriment of 6% (from 58% to 52%) at 2 years. Subgroup analyses suggested
that this detrimental effect was most pronounced for patients with stage I/II,
whereas for stage III, N2 patients there was no clear evidence of an adverse
effect. Conclusions The meta-analyses of CT demonstrate the benefit of
adjuvant CT in NSCLC for a large range of patients. All three meta-analyses
provide reliable estimates on which to base future policies and research.
Supported by MRC and LNCC
24IN
THE POTENTIAL ROLE OF MOLECULAR BIOLOGY IN
THE MANAGEMENT OF EARLY NON-SMALL CELL
LUNG CANCER
D.H. Johnson Vanderbilt-Ingram Cancer Center, Nashville, TN/UNITED
STATES OF AMERICA
As modern techniques have facilitated the identification of specific genetic
factors that may play a role in disease progression and patient response to
therapy, customized or personalized treatment plans for individual patients soon
may be feasible. For example, the nuclear excision repair (NER) pathway is
highly specialized process for the repair of damage caused by polycyclic
aromatic hydrocarbons, ultraviolet light or exogenous chemicals that induce
bulky DNA adducts. Alkylating agents such as platinum components interfere
with DNA-replication by inducing DNA adducts that lead to cell death. The
excision repair cross-complementation group 1 (ERCC1) enzyme plays a rate-
limiting role in the NER pathway that can recognize and remove cisplatin-
induced DNA adducts. As a consequence of their increased capacity of DNA
repair some cancer cells are resistant to the effects of chemotherapy. Indeed, in
vitro studies have linked platinum resistance to the expression of ERCC1 mRNA
in various cell lines. These data suggest knowledge of ERCC1 status may permit
greater precision in selecting a chemotherapy regimen for NSCLC patients. In
fact, in resected early stage NSCLC, patients with tumors overexpressing
ERCC1 protein do not appear to benefit from platinum-based adjuvant chemo-
therapy whereas patients with ERCC1 negative tumors do. In more advanced
disease, Spanish investigators performed a trial in which ERCC1 mRNA
expression was determined by quantitative real-time reverse transcriptase PCR
using RNA isolated from pretreatment biopsies. Patients were randomized to
either a control or genotypic arm (1:2 ratio) before ERCC1 assessment. Patients
with low ERCC1 levels in the genotypic arm received docetaxel plus cisplatin
and those with high levels received a non-platinum regimen (docetaxel plus
gemcitabine). Patients in the control arm received standard docetaxel plus
cisplatin. The primary end point was the objective response rate. The response
rate in the control arm was 39% and 51% in the genotypic arm (P  0.02).
Overall survival was not significantly different; nonetheless, these data strongly
suggest that ERCC1 mRNA levels may be of value in predicting response to
platinum-based therapy.
Ribonucleotide reductase M1 (RRM1) encodes the regulatory subunit of ribo-
nucleotide reductase, the rate limiting enzyme in DNA synthesis. Ribonucleotide
reductase converts ribonucleotide 5-diphosphate to deoxyribonucleotide 5-
diphosphate. Of note, gemcitabine competes with ribonucleotide 5-diphosphate
for incorporation into DNA. Consequently, the overexpression of ribonucleotide
reductase would be expected to interfere with the efficacy of gemcitabine.
Preclinical studies and two recently completed clinical studies support the
potential predictive value of RRM1. For example, Bepler and colleagues re-
ported that the levels of RRM1 expression was significantly (P  0.002) and
inversely correlated (r  -0.498) with disease response after two cycles of
gemcitabine and carboplatin in patients with locally advanced NSCLC. Among
a group of NSCLC patients treated with cisplatin plus gemcitabine, Spanish
investigators found low RRM1 mRNA expression levels were associated
with a significantly longer median survival than those with high levels
(13.7 vs. 3.6 mo; 95% CI, 9.6 –17.8 mo; P0.009). RRM1 and ERCC1
mRNA was assessed in paraffin-embedded samples by real-time quanti-
tative reverse transcription-PCR.
Beta-tubulin is a major components of microtubules. Taxanes bind to
beta-tubulin and produce growth arrest at the G2-M phase of the cell cycle.
High levels of beta-tubulin, which exists as multiple isotypes, are associated
with resistance to taxanes. More specifically, high levels of class III beta-
tubulin are associated with taxane resistance in lung cancer cell lines. The
clinical relevance of this observation has been highlighted by Seve and
colleagues who assessed the prognostic and predictive value of class III
beta-tubulin in tumors taken from patients with locally advanced or meta-
static NSCLC treated with paclitaxel-based or other non-tubulin-binding
agents. Tumor samples were obtained before treatment with a paclitaxel-
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based regimen or a non-tubulin-binding agent. Treatment response, progres-
sion-free survival, and overall survival were then correlated with the expres-
sion of class III beta-tubulin protein. The response rate was 37.5% among
patients receiving paclitaxel. Patients whose tumors expressed low levels of
class III beta-tubulin isotype had a better response rate (P0.001), longer
progression-free survival (P0.004), and overall survival (P0.002),
whereas this variable was not found to be predictive in patients receiving
regimens without tubulin-binding agents. Taking into account sex, age,
histology, stage, and class III beta-tubulin, a multivariate analysis confirmed
that low-level class III beta-tubulin expression was independently correlated
with progression-free survival (P0.003) and overall survival (P 0.003).
These findings suggest that the expression levels of class III beta-tubulin in
tumor cells may predict response to therapy and survival outcome in patients
with NSCLC receiving paclitaxel-based chemotherapy; however, expression
level is not a general prognostic factor.
Thymidylate synthase (TS) catalyzes the methylation of dUMP to dTMP and is
the rate limiting irreversible step in de novo DNA synthesis. As the sole source
of de novo thymidylate in the cell it is an important target for chemotherapy
drugs such as 5-fluorouracil (5-FU), methotrexate, capecitabine and other novel
folate-based drugs such as pemetrexed. TS expression has been shown to be an
independent prognostic and predictive factor in several cancers, including lung
cancers, and over-expression of TS has been linked to resistance to these drugs.
TS mRNA levels (P0.0001) and protein levels (P0.027) have been shown to
be significantly higher in squamous cell carcinomas of the lung as compared
with adenocarcinomas. Keeping in mind that pemetrexed targets TS, the poten-
tial significance of this finding is highlighted by the results of a large phase III
trial in which cisplatin plus pemetrexed was found to be more effective than
cisplatin plus gemcitabine in adenocarcinomas and large cell carcinomas
whereas cisplatin plus gemcitabine was noted to yield a better survival in
squamous carcinomas compared to the pemetrexed regimen. The observed
survival difference may have been related to differences in intratumoral TS
expression although no definitive data pertaining to intratumoral TS expression
have yet been presented.
In summary, the available evidence clearly indicates that the identification and
possible exploitation of genetic markers, predictive of response to specific
cytotoxic drugs, is an achievable goal. Moreover, these early results indicate that
the application of pharmacogenomics has the potential to profoundly influence
outcomes and improve overall survival in early lung cancers.
25IN
EARLYNSCLCSTATEOFTHEART–SURGICALAPPROACH
W. Weder Thoracic Surgery, University Hospital Zurich, Zurich/
SWITZERLAND
Early stage non small cell lung cancer (NSCLC) includes patients with stage I
(T1-T2 N0 M0) or stage II (T1–2 N1 M0 or T3 N0 M0). Approximately 30%
of all patients present with stage I or stage II disease at diagnosis. Clinical
experience based on large retrospective data indicates that the best chance of
cure for patients with stage I and stage II lung cancer is surgical resection. The
5 year survival rates are 60 – 80% for stage I and 40 – 50% for stage II. A
lobectomy should be performed preferentially by a sub-lobar resection in all
patients who tolerate this procedure. Local recurrence rate is decreased three fold
and long term survival is improved. However, patients with peripheral lesions
less than 2 cm in size with absence of lymph node metastasis have an equally
good long term survival with sub lobar resection only compared to lobectomy.
Additionally, patients who do not tolerate larger resection due to poor lung
function may be treated by a segmentectomy. Surgery is best performed by
thoracic surgeons with prominent focus on lung cancer treatment since periop-
erative mortality and long term survival are better compared to general surgeons
who do the operation occasionally. The use of minimal invasive procedure by
VATS is an acceptable alternative to procedures done by open thoracotomy for
surgeons experienced in these techniques. Intraoperative systematic mediastinal
lymph node dissection is an integral part of the procedure and allows accurate
pathological staging. Platinum based adjuvant chemo therapy should be offered
to patients completely resected with stage II lung cancer and a good performance
status. Adjuvant chemotherapy can be applied earlier and is better tolerated in
patients who underwent VATS lobectomy. Non surgical treatment approaches in
stage I or II disease should be done only in controlled comparative studies.
Reference: Treatment of Non-small Cell Lung Cancer Stage I and Stage II
ACCP Evidence-Based Clinical Practice Guidelines (Chest. 2007; 132:234S-242)
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PROGNOSTIC AND PREDECTIVE FACTORS IN EARLY
NON-SMALL CELL LUNG CANCER
F.A. Shepherd Medical Oncology, Princess Margaret Hospital, Toronto/
CANADA
Clinical and pathologic markers of prognosis in patients with non-small cell
lung cancer (NSCLC) have been recognized for some time. More recently,
molecular markers of prognosis have been identified, and some are also
predictive of differential benefit from adjuvant treatment. Distinguishing
prognostic from predictive makers is crucial, and this can only be accom-
plished when an untreated control arm is present. In the adjuvant setting,
several markers have now been studied extensively. Patients with an elevated
DNA repair capacity, evidenced by increased tumor expression of ERCC1,
may not benefit from cisplatin-based adjuvant chemotherapy. Furthermore,
ERCC1 is both a prognostic and a predictive marker. When mutations of
KRAS are present, it does not appear that patients benefit from adjuvant
chemotherapy. P53 protein expression is associated with poor prognosis,
while conversely it predicts for greater survival benefit from adjuvant
chemotherapy. The presence of p53 mutations is also associated with poor
prognosis, but an interaction with adjuvant chemotherapy has not been
demonstrated to date. In one study of adjuvant chemotherapy, greater benefit
from adjuvant chemotherapy was seen in patients with high beta tubulin III
expression, while high expression was associated with poorer survival in the
untreated control group. In advanced NSCLC epidermal growth factor receptor
(EGFR) markers have been shown to be both prognostic and predictive of
response to EGFR inhibitors. Adjuvant trials of EGFR inhibitor therapy are
ongoing presently, and studies of EGFR markers including protein expression,
gene mutation status and copy number are planned for these trials. Microarray
profiling can identify gene signatures that are prognostic of outcome, even within
early T and N stage groupings. It has been postulated that patients with Stage I
NSCLC and a poor prognostic signature might benefit from adjuvant chemo-
therapy, and conversely, that patients with Stage II or III tumors with a
favourable prognostic signature may not need adjuvant chemotherapy. These
hypotheses have yet to be validated. Likely in the the future, clinicians will
evaluate a panel of biologic markers in order to customize therapy for patients
with early and advanced stage NSCLC.
EARLY NSCLC INVITED PAPERS
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PHASE III STUDY COMPARING PREOPERATIVE (PRE)
AND PERIOPERATIVE (PERI) CHEMOTHERAPY (CT)
WITH TWO DIFFERENT CT REGIMENS IN RESECTABLE
STAGE I-II NON-SMALL CELL LUNG CANCER (NSCLC):
THE IFCT 0002 PROTOCOL
V. Westeel1, B. Milleron2, E. Quoix3, M. Puyraveau4, D. Braun5, J. Breton6,
L. Bigay-Game7, J. Pujol8, F. Morin9, A. Depierre10 1Chest Disease Depart-
ment, Uniersity Hospital, Besançon/FRANCE, 2Chest Disease Department,
Tenon University Hospital, Paris/FRANCE, 3Department of Respiratory
Diseases, Hôpitaux Universitaires de Strasbourg, Strasbourg/FRANCE,
4Biostatistics Department, Universite´ de Franche-Comte´, Besançon/
FRANCE, 5Chest Disease Department, General Hospital, Briey/FRANCE,
6Chest Disease Department, General Hospital, Belfort/FRANCE, 7Chest
Disease Department, University Hospital, Toulouse/FRANCE, 8Hopital Arnaud
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De Villeneuve, Montpellier Academic Hospital, Montpellier/FRANCE, 9Direc-
tion, Intergroupe Francophone de Cance´rologie Thoracique, Paris/FRANCE,
10Chest Disease Department, University Hospital, Besanc¸on/FRANCE
Background: The association of surgery and chemotherapy (CT) is a standard
in resectable non-small cell lung cancer (NSCLC). The primary objective
was to define the best timing of CT: all before surgery (PRE) versus
perioperative (PERI). Another objective was to compare two regimens,
gemcitabine-cisplatin (GP) and paclitaxel-carboplatin (TC) (GP: Gemcitab-
ine 1250 mg/m2/d1, 8 and cisplatin 75 mg/m2/d1 q3 wk; TC: Paclitaxel 200
mg/m2/d1 and carboplatin AUC 6, q3 wk). Methods: 528 stage I-II resectable
NSCLC were randomized to 4 arms: A: 2 GP  in responders, 2 GP, then
surgery, B: 2 GP surgery in responders, 2 GP, C: 2 TC in responders,
2 TC then surgery, D: 2 TC  surgery  in responders, 2 TC. Quality of life
was evaluated with the EORTC QLQ C30 – LC13 questionnaire at days 1,
42 and 147. Results: The addition of 2 preoperative CT cycles in responders
did not influence tumor volume, intratumoral necrosis, pleural, venous or
intrapulmonary lymphatic invasions. Pathological complete response rates
were not statistically different (PRE: 6.3%, PERI: 7.6%, GP: 8.2%, TC:
5.6%). Objective responses were comparable (PRE: 50.6%, PERI: 50.9%,
GP: 52.2%, TC: 49.2%). 30-day postoperative mortality and the number of
toxic deaths at 6 mo did not differ with the number of preoperative CT cycles
(PRE:3%, PERI:3.21%). Only grade 2 neuropathy at 6 mo (GP: 6.5%, TC:
24.4%, p 10–3) and G 2 nausea (GP: 22.17%, TC: 4.22%, p 10–3)
differed betweeen GP and TC. Proportions of pts receiving cycles 3 and 4
were higher when they were given before surgery (PRE: 90.4%, PERI:
75.2%, p.0011). Percentages of non operated pts were identical in both
groups (PRE: 4.5%, PERI: 4.3%). Quality of life decreased in the same
proportion in each group within the 6 months after randomization.
Conclusions: 1- GP and TC were both effective and safe, although with
different toxicity profiles. 2- Results of pathological response suggested that
2 preoperative cycles might be as effective as 4. 3- Dose intensity was higher
when all chemotherapy was given before surgery compared to both before
and after surgery. 4- There was no difference in Quality of Life.
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S9900 TRIAL OF SURGERY VS NEOADJUVANT
CHEMOTHERAPY
E. Vallieres Surgical Director Lung Cancer Program, Swedish Cancer
Institute, Seattle/UNITED STATES OF AMERICA
S9900: Phase III trial of surgery alone vs. surgery plus preoperative (ind)
paclitaxel/carboplatin (PC) chemotherapy clinical T2N0, T1–2N1 and
T3N0–1 (NSCLC): A Follow-up. E. Vallières, K. Pisters, P. Bunn, K.
Chansky, J. Crowley, R. Ginsberg, B. Meyers, D. Gandara, Southwest
Oncology Group Background: The primary objective of this study was to
determine if induction PC (PCS) could improve survival over surgery (S)
alone in treating early stage NSCLC. Preliminary results of this trial were
reported at ASCO and IASLC 2005 (J Clin Oncol, ASCO Proc 23(16S)
2005:7012) and updated at ASCO 2007 (J Clin Oncol ASCO Proc 25 (18S)
2007:7520). Median follow up for patients alive at last contact is now 55
months for the PCS group, 59 months for the S group. Methods: Pts with
clinical stage T2N0, T1–2N1, and T3N0–1 NSCLC (excluding Pancoast
tumors) were randomized to preop PC (P:225 mg/m2 over 3 hours,
C:AUC6) on day 1, every 3 weeks x 3 or surgery alone(S). Eligible pts had
performance status 0–1, age  18 years (yrs), predicted post-resection FEV1
 1.0L. Surgery was at least a lobectomy and mediastinal nodal sampling.
The primary endpoint was a 33% increase in overall survival over expected
2.7 yrs median (med) for surgery. Planned sample size was 600 pts, 81%
power, 1-sided test, 0.025 significance. Results: S9900 closed 07/04 when
adjuvant chemotherapy became standard. 354 pts had accrued; 174-surgery
alone, 180-preop PC; 19 were ineligible. Median age 65 yrs, 66% male, 70%
IB/IIA, 30% IIB/IIIA. Major radiographic response to PC was 41%. Three
treatment-related deaths occurred during induction PC, seven deaths occurred
within 30 days of surgery in the preop PC arm, 4 in the surgery alone arm.
Progression-free (PFS), overall (OS) survival rates and hazard ratios are shown.
Exploratory analysis found no significant interaction between arm and stage.
Conclusions: PFS and OS continue to trend in favor of induction PC with hazard
ratios (HR) similar to those observed in adjuvant trials, supporting the role of
chemotherapy in operable NSCLC. Randomized trials comparing induction to
adjuvant chemotherapy are warranted. Supported by SWOG CA30102.
PFS, HR0.77
(.59–1.02), p0.07
OS, HR.083
(.61–1.12), p0.21
Med 1 yr 3 yr
5
yr Med 1 yr 3 yr 5 yr
PC 33
mos
68% 48% 42% 55
mo
82% 60% 50%
Surgery 21
mos
68% 38% 32% 46
mo
79% 57% 43%
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NEOADJUVANT VS ADJUVANT VS SURGERY ALONE
E. Felip Medical Oncology Department, Vall d’Hebron Hospitals, Barce-
lona/SPAIN
Although radical surgery is the primary treatment for early NSCLC, the
long-term survival of patients who undergo surgery alone is disappointing.
Between 2003 and 2005, three positive randomized controlled trials (IALT,
BR.10, ANITA) validated the role of adjuvant cisplatin-based chemotherapy
for completely resected stage II-III NSCLC patients. The role of adjuvant
chemotherapy for stage IB disease remains controversial. Completion of
planned adjuvant therapy has been consistently problematic in the postop-
erative setting, with most trials delivering only 60% of planned chemother-
apy treatment. The Bimodality Lung Oncology Team conducted a phase II
trial to explore neoadjuvant chemotherapy in early-stage NSCLC. In this
study, 94 patients received 2 cycles of neoadjuvant chemotherapy with
paclitaxel/carboplatin. Response rate was 53% and 5-year survival rate 45%.
The SWOG Group designed a phase III trial in which stage IB-II-T3N1
NSCLC patients were randomized to surgery alone or neoadjuvant chemo-
therapy with carboplatin/paclitaxel. A total of 354 patients were accrued.
This trial was closed earlier than planned. Response rate was 40%. The
results, although not statistically significant, seemed to favour the neoadju-
vant arm since median survival was 47 months for patients receiving
neoadjuvant chemotherapy and 40 months for those in the surgery-alone arm
(HR0.84; p0.32). From the current data, more than 90% of patients
receiving neoadjuvant chemotherapy undergo the planned surgical resection.
The superiority of neoadjuvant or adjuvant chemotherapy in early-stage
NSCLC remains an open question. The NATCH trial was designed in order
to address whether neoadjuvant or adjuvant paclitaxel/carboplatin improves
disease-free survival compared to surgery alone in early-stage NSCLC.
Clinical stage I ( 2 cm), II, T3N1 NSCLC consenting patients were
randomized to surgery alone or 3 cycles of neoadjuvant paclitaxel/carbopla-
tin or surgery followed by 3 cycles of adjuvant paclitaxel/carboplatin.
Between April 2000 and March 2007, 623 patients have been accrued.
Mature survival results of the NATCH trial are expected in 2009. Further-
more, subanalyses of several genetic abnormalities in paraffin-embedded
tumor samples are being carried out.
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RISK-ADAPTED 4D STEREOTACTIC RADIOTHERAPY
FOR STAGE I NSCLC: EARLY EXPERIENCE WITH THE
FIRST 300 PTS TREATED AT THE VU UNIVERSITY
MEDICAL CENTER
F.J. Lagerwaard1, C.J.A. Haasbeek2, E.F. Smit3, B.J. Slotman2, S. Senan4
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1Radiation Oncology, VU University Medical Center, Amsterdam/NETHER-
LANDS, 2Radiation Oncology, VU University Medical Center, Amsterdam/
NETHERLANDS, 3Pulmonary Diseases, VU University Medical Center,
Amsterdam/NETHERLANDS, 4Department of Radiation Oncology, VU Uni-
versity Medical Centre, Amsterdam/NETHERLANDS
Background Stereotactic radiotherapy (SRT) using 4-dimensional (4D) target
definition for Stage I NSCLC is performed at our center since April 2003. Pts
are followed-up using a standard schedule of up to 4 CT scans in the two
years following SRT. Outcomes in the first 304 pts with 322 primary lung
tumors are reported. Methods 83% of pts were medically inoperable and 17%
had refused surgery. 201 T1 tumors (79%) and 121 T2 tumors (21%) were
treated. Pre-SRT confirmation of malignancy was obtained in 38% of pts. All
other pts had new and/or growing 18FDG-PET-positive lesions (a prior
randomised Dutch study had shown a 5% incidence of benign lesions in
such a situation). Individualized target volumes were generated using 4DCT
scans. SRT was delivered with 8–12 non-coplanar beams and risk-adapted
SRT schemes: 3x20 Gy (n126) for T1 tumors, 5x12 Gy (n155) for T1
tumors adjacent to the thoracic wall/mediastinum or T2 tumors, and 8x7.5
Gy (n41) for lesions adjacent to the pericardium or hilus. Results Actuarial
overall survival at 1 and 2 years was 83% and 65%. Follow-up imaging showed
local failures in 11 pts, resulting in a local failure-free survival rate of 92% at 2
years. Regional failure-free survival at 1 and 2 years was 94% and 84%; distant
failure free survival rates at 1 and 2 years were 88% and 74%, respectively.
Overall and disease-free survival were not significantly different in pts with or
without histological confirmation of malignancy (p0.56 and p0.49, respec-
tively). Outcomes in stage IB disease were worse than in stage IA for both
overall (p0.02) and disease-free survival (p0.003). Early toxicity was mild,
with fatigue (30%), nausea (7%), and chest pain (7%) being the most frequently
reported. Late toxicity consisted of grade 3 radiation pneumonitis in 9 pts
(3%), and rib fractures, chronic chest wall pain, and pleural effusion in 3 pts
each. Conclusions Local control rates of90% are achieved using SRT, making
it an effective alternative to surgery in pts who are marginally fit for operation
or refusing surgery. Regional and/or distant failure is the most common pattern
of relapse in stage I NSCLC despite pre-SRT PET scans. The incidence of severe
early or late toxicity is low.
EARLY NSCLC CONTROVERSIAL ISSUES
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STEREOTACTIC BODY RADIATION THERAPY FOR NON
SMALL-CELL LUNG CANCER PATIENTS
J. Belderbos Radiotherapy, The Netherlands Cancer Institute, Amsterdam/
NETHERLANDS
SBRT has been used to treat primary NSCLC and solitary lung metastases
with high local tumor control rates. SBRT is characterized by one or a few
fractions (fx) with a high dose per fraction and a high geometrical accuracy.
There is however a concern for increased long-term toxicity of healthy
tissues. Factors influencing treatment outcome after SBRT are tumor volume
(T1 vs T2), the dose prescribed and tumor location. In an analysis of 245
NSCLC patients (pts), stage I, treated with SBRT [1] the 3 year overall
survival for pts refusing surgery was 80%, and for medical inoperable pts
50%. The results of SBRT were better if a biological effective dose of 100
Gy was given. In a phase II study high rate of local tumor control was
achieved (95% at 2 years) in 70 pts with inoperable stage I NSCLC irradiated
with SBRT to 60–66 Gy in 3 fx. [2]. However both local recurrence and
toxicity occurred late. In 14 out of the 70 pts grade 3 to five toxicities
occurred. The median time to observe toxicity was 10.5 mo (median FU-time
17.5 mo). If the lung tumor was located peripheral the toxicity was signifi-
cantly lower compared to centrally located tumors. It was concluded that
60–66 Gy in 3 fx should not be used for pts with tumors near the central
airways. Lagerwaard et al [3] reported on “risk-adapted” fractionation
schemes and concluded that SBRT in 27 (out of 206) pts with centrally
located tumors irradiated with 8 fx of 7.5 Gy was safe (median FU-time 12
mo). SBRT trials In the Scandinavian group a multi-center phase II trial
comparing SBRT and conventional RT in medical inoperable stage I NSCLC
pts is ongoing. Within the RTOG a phase II trial for central located tumors
is scheduled, as well as the addition of systemic therapy. A Dutch random-
ized phase III trial comparing surgery and SBRT for operable stage I NSCLC
pts will open in the near future. Conclusion SBRT is an effective treatment
with high local tumor control rates  90% in pts with inoperable stage I
NSCLC. Initial studies report a low incidence of severe early and late
toxicity. The result of phase II trials rivals the best surgical control rates for
operable pts. 1) Onishi H, et al. Cancer. 2004;101(7): 1623–1631 2) Tim-
merman R, et al. J Clin Oncol. 2006;24(30):4833–9 3) Lagerwaard F, et al.
Int J Radiat Oncol Biol Phys. 2007 Dec 28
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THE ROLE OF CHEMOTHERAPY IN STAGE I
G. Scagliotti Department of Clinical and Biological Sciences, University of
Torino, Orbassano (Torino)/ITALY
The 1995 meta-analysis generated enthusiasm to prompt the planning of
several prospective randomised phase III studies, all platinum-based (/-
thoracic radiotherapy), evaluating the role of modern platinum-based regi-
mens in all resectable stages of NSCLC. All these studies included patients
with stage I (A and B) disease. Globally, five cisplatin-based adjuvant studies
(ALPI, IALT,BLT, BR10 and ANITA) included 347 patients with stage IA
(185 in the chemotherapy group and 162 in the control group) and 1371
patients with stage IB (671 patients in the chemotherapy group and 700 in the
control group). These 5 studies were recently included in a pooled analysis.
After exclusion of the small numbers of stage IA patients, there was no
significant variation of chemotherapy effect according to stage. However, in
stage IB even if the benefit pointed in the direction of adjuvant chemotherapy
it was not statistically significant. The results of this pooled analysis are fully
consistent with 2 adjuvant studies which focused on very early stages. In the
BR10 study the subset analysis by stage showed a greater benefit at 5 years for
stage II (20%) than for stage I (7% not statistically significant). Cancer and
Leukemia Group B study tested the role of adjuvant chemotherapy only in
patients with resected stage Ib disease. At the time of closure to accrual 344
patients had been entered and randomly assigned to receive carboplatin AUC 6
and paclitaxel 200 mg/m2 every 3 weeks for a total of 4 cycles: an early report
detected a 12% absolute improvement in overall survival at 4 years (71% versus
59%; HR 0.62; p0.028). Unfortunately a recently updated analysis could not
confirm such favourable outcome (HR 0.80; p0.10). In a meta-analysis
comparing the outcome of 2,003 Japanese patients treated with adjuvant oral
UFT as a single agent or in combination with other cytotoxic agents, UFT
significantly improved overall survival (HR0.74, 4.6% benefit at 5 years
(p0.001) and 7% at 7 years (p0.001) and this therapeutic effect has been
mainly observed in adenocarcinoma in stage I. Currently the use of adjuvant
chemotherapy in stage I should be restricted to clinical trials which evaluate the
potential for refining and individualizing the treatment of early stage and improv-
ing the efficacy of cytotoxic chemotherapy.
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RADIO FREQUENCY
A. Gangi Pavillon Clovis Vincent, H, Strasbourg cedex/FRANCE
Radiofrequency (RF) ablation has proved its efficacy in the treatment of
unresectable primary and metastatic liver cancer. Study results have demon-
strated that RF can be used to fully ablate other tumor location like kidney,
bone and lung. Recent reports on RF ablation in the lung presented promising
short-term and mid-term results. Inclusion criteria were as follows: unilateral
or bilateral unresectable primary (non small cell carcinoma) or metastatic
lung tumors measuring up to a maximum diameter of 40 mm and five or
fewer tumor deposits in the lung. Tumors had to be located more than 1 cm
from the hilum, with no invasion of the soft tissues or mediastinum.
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Malignancy had to be histologically proved for targeted pulmonary nodules
in patients with no history of cancer outside the lung. Targeted lung tumors
in patients with a known distant history of cancer had to either be histolog-
ically proved or demonstrate a change in size of at least 25% in their largest
diameter at CT at some time during the previous year of follow-up imaging.
Palliative RF ablation was performed in patients with painful chest wall
lesion and in these cases; the size could exceed 4 centimeters. Exclusion
criterion was uncorrectable coagulopathy. The procedures are performed
under CT scan guidance. The patient is positioned in supine or prone position
depending on the location of the tumor. The procedure is performed under
conscious sedation or general anesthesia. Complete ablation is achieved in
80% of cases with tumor less then 4 cm. The best results are obtained with
tumor less then 3 cm diameter. The main adverse event is a pneumothorax,
which occurred in 50% of procedures, but a chest tube is required in only 5%
of the procedures. RF ablation has a high local efficacy and is well tolerated.
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SURGERY
B. Passlick Department of Thoracic Surgery, University Medical Center
Freiburg, Freiburg/GERMANY
Surgery is the essential prerequisite for cure of non-small cell lung cancer.
Large studies have demonstrated that in patients with small primary tumors
and without nodal involvement a long-term survival can be achieved without
additional treatment. The surgical approach for small primary tumors is
discussed controversially. Wedge or atypical resections are associated with a
higher risk of locoregional recurrences and should therefore be strictly
avoided. In contrast, segmentectomies can be performed with equal results as
compared to lobectomy in lesions 1 cm. Only in the upper parts of the lung
(S 1 - 3) segmentectomies should not be performed due to a higher local
recurrence. In patients with early central lung tumors bronchoplastic procedures
such as sleeve segmentectomies can be performed in order to preserve as much
lung tissue as possible. Due to an improved pre- and postoperative management
even patients with a severely compromised lung function can undergo a surgical
procedure. Therefore, surgical resection is the gold standard for the treatment of
early central and peripheral non-small cell lung cancer.
STAGE III NSCLC STATE-OF-THE-ART
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INDIVIDUAL PATIENT DATA (IPD) META-ANALYSES (MA)
OF CHEMOTHERAPY (CT) IN LOCALLY ADVANCED NON-
SMALL CELL LUNG CANCER (NSCLC)
C. Le Pechoux1, S. Burdett2, A. Auperin3 1Dept. of Radiotherapy, Institute
Gustave Roussy, Villejuif/FRANCE, 2Meta-analysis Group, MRC Clinical
Trials Unit, London/UNITED KINGDOM, 3Biostatistics Department, Institut
Gustave Roussy, Villejuif/FRANCE
Background Previous IPD MA of CT (BMJ 1995;311:899, Ann Oncol
2006;17:473) in locally advanced NSCLC treated by radiotherapy (RT) have
been updated. Methods Systematic searches for randomized clinical trials
(RCTs) were carried out, updated IPD were centrally collected. RCTs were
combined using the stratified (by trial) log rank test to calculate pooled
hazard ratio (HR). Results RT  sequential CT versus RT The overall
survival (OS) analysis included 22 RCTs and 3839 patients (78% of all
patients). Sixteen RCTs used induction CT/-alternated or consolidation
CT, 7 used consolidation/-concomitant CT or alternated CT. There was a
benefit of CT on OS (HR0.88, 95% CI[0.82–0.94], p0.0001), with an
absolute benefit of 2.7% (from 9.7% to 12.4%) at 3 years. RT concomitant
CT versus RT The OS analysis included on 16 RCTs and 2910 patients (87%
of all patients) and the progression free survival (PFS) analysis on 13 RCTs
and 2246 patients. There was a benefit of CT on OS (HR0.88, [0.81–0.95],
p0.001), with an absolute benefit of 3.2% (from 13.4% to 16.6%) at 3
years. For PFS, the HR was 0.84 ([0.77–0.91], p0.001). Concomitant
RT-CT versus sequential RT-CT The OS and PFS analyses included 6 RCTs
and 1205 patients (92% of all patients). For sequential CT, all RCTs used at
least cisplatin, induction CT in 5 RCTs and consolidation CT in 1. For
concomitant CT, cisplatin was used in 5 RCTs, carboplatin in 1. Concomitant
RT-CT increased acute oesophageal toxicity. There was a benefit of con-
comitant CT as compared to sequential on OS (HR0.84, [0.74–0.95],
p0.004), with an absolute benefit of 5.7% at 3 yearrs (from 18.1% to
23.8%). For PFS, the HR was 0.90 ([0.79–1.01], p0.07). Concomitant CT
decreased loco-regional progression (HR0.77, [0.62–0.95], p0.01) but
there was no difference between the two treatments on distant progression
(HR1.04, [0.86–1.25], p0.69). Conclusion: These results demonstrate a
benefit on OS of sequential and concomitant CT in locally advanced NSCLC
treated by RT. Concomitant RT-CT, as compared to sequential RT-CT,
improved survival, mainly due to the decrease of loco-regional progression,
at the cost of increased acute oesophageal toxicity. Supported by PHRC,
LNCC, Sanofi-Aventis
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OPTIMIZED RADIATION THERAPY
H. Choy Radiation Oncology, Southwestern, Dallas/UNITED STATES OF
AMERICA
Radiation therapy is the primary locoregional modality for locally advanced
NSCLC. The relationship between increasing radiation dose with resultant
improvements in local control has been well defined. However, the ability to
escalate the dose is limited by the tolerance of adjacent normal structures
including the surrounding normal lung parenchyma, spinal cord, heart, and
esophagus. Advancements in the precision of tumor volume definition (e.g. by
using PET-CT), better understanding of the patterns of failure (e.g. elimination
of elective nodal irradiation), assessment of tumor motion (e.g. gating, diaphrag-
matic immobilization, etc.), and radiation dose distribution/delivery (e.g. 3D
conformal radiotherapy, intensity modulated radiotherapy, SBRT) should allow
us to optimize accurate radiation delivery to the tumor while minimizing the
dose to the surrounding normal critical structures. Incorporating these advance-
ments into a combined modality regimen should allow us to escalate dose safely,
thereby providing better local control, ultimately resulting in survival bene-
fits.10–12 One of the most important goal in locally advanced non small cell lung
cancer is to optimize radiation therapy to improve our lung cancer patient’s
overall outcome. In this meeting we will address: 1. Optimizing Radiation Dose
2. Optimizing Radiation Technique and Technology 3. Optimizing Radiation
Fractionation Schedule
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STAGING THE MEDIASTINUM
P. De Leyn Dept. of Thoracic Surgery, University Hospital Lauven, Leuven/
BELGIUM
Mediastinal lymph node (LN) involvement is present in 30 to 45% of newly
diagnosed lung cancers. Correct mediastinal staging guides the choice of
optimal treatment. Patients with positive mediastinal LN’s (Stage III) have a
poor prognosis when treated by single modality treatment. Stage III NSCLC
is a very heterogeneous group with different prognostic and therapeutic
subsets, depending especially on the N-factor. A subgroup of patients
benefits from surgical multimodality treatment. Therefore, mediastinal stag-
ing procedures are a guidance of the multidisciplinary to select patients for
resection, based on both baseline and post-induction assessment. Different
techniques of invasive mediastinal staging are available. They vary in
accuracy and procedure-related morbidity. For primary staging, mediastinos-
copy remains the gold standard for the superior mediastinal LNs. Ultrasound-
guided bronchoscopy with fine-needle aspiration (FNA) and endoscopic
esophageal ultrasound-guided FNA are techniques that also provide cyto-
histological diagnosis and are minimally invasive. These technique are
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complementary to mediastinoscopy. The sensitivity of endoscopic FNA is
quite high but the negative predictive value is low. If they yield negative
results, an invasive surgical technique is indicated. In patients with poten-
tially resectable N2 disease, mediastinoscopy has several advantages over
endoscopic FNA. By cervical mediastinoscopy a full mapping is performed
excluding N3 disease. Visual inspection distinguishes intra-from extranodal
LN disease. Multilevel or extranodal disease have a dismal prognosis when
treated with surgical multimodality treatment. For restaging in a surgical
multimodality regimen, invasive techniques providing cyto-histological in-
formation are advisable despite the encouraging results with the use of
re-PET/CT imaging. Both endoscopic techniques and surgical procedures are
available. The accuracy of remediastinoscopy is much lower than obtained
with baseline mediastinoscopy and this questions the timing of mediastinos-
copy (baseline or at restaging). We conclude that optimal staging is a truly
multidisciplinary process, with a variety of possible techniques, to be
performed by experienced hands.
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OPTIMIZED CHEMOTHERAPY WITH RADIATION FOR
LOCOREGIONALLY ADVANCED NSCLC
E.E. Vokes1, J.E. Ultmann2 1Medicine, University of Chicago, Chicago/
UNITED STATES OF AMERICA, 2Radiation and Cellular Oncology, Uni-
versity of Chicago, Chiacago/UNITED STATES OF AMERICA
Concomitant chemoradiotherapy is a firmly established treatment principle for
patients with locoregionally advanced NSCLC. The great majority of patients
develop disease recurrence either within the irradiated field or systemically.
Systemic failures reflect the initial presence of micrometastatic disease as well as
the inability of concurrent chemoradiotherapy to eradicate such disease. This
observation has led to efforts at further increasing systemic tumor control
through the addition of a sequential systemic treatment component either prior to
concurrent chemoradiotherapy as induction or following concurrent chemora-
diotherapy as consolidation chemotherapy. Randomized trials have tested both
approaches. Unfortunately, both induction and consolidation chemotherapy have
failed to effect increase survival rates in randomized clinical trials and can
therefore not be considered current standard therapy. Comparative analyses of
concurrent chemoradiotherapy regimens suggest that regimens using systemi-
cally doses concomitant chemoradiotherapy might be superior. In particular, the
combination of cisplatin and etoposide in both single arm and randomized trials
has been shown repeatedly to lead to encouraging survival rates. The combina-
tion of carboplatin and paclitaxel with concurrent radiation, while clearly active
and well-tolerated, has led to less encouraging survival data in some trials. While
other factors can possibly account for this divergence, published data are
compatible with a hypothesis that “systemically dosed” concurrent chemoradio-
therapy will lead to superior survival data compared with “sensitizing dosed”
chemoradiotherapy.
Current efforts at improving concurrent chemoradiotherapy are focused on
developing novel regimens using systemically dosed concomitant chemoradia-
tion. Other directions of interest include the addition of targeted agents. Finally,
radiation dose escalation to 74 Gy has been demonstrated to be feasible at the
cooperative group level and has led to encouraging survival data in several pilot
trials. Randomized testing of such a regimen has recently begun.
STAGE III NSCLC INVITED PAPERS
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IS THERE ROOM FOR SURGERY IN STAGE III B?
W.E.E. Eberhardt1, T.C. Gauler2, T. Krbek3, C. Po¨ttgen4, M. Stuschke5, G.
Stamatis6 1Department of Internal Medicine, West German Cancer Center,
Essen/GERMANY, 2Internal Medicine (Cancer Research), University Hos-
pital of Essen, Essen/GERMANY, 3Thoracic Endoscopy and Surgery, Ruhr-
landklinik, Essen/GERMANY, 4Dept. of Radiation Oncology, West German
Cancer Centre, Essen/GERMANY, 5Department of Radiotherapy, Medical
School, University Duisburg Essen, Essen/GERMANY, 6Dept. of Thoracic
Endoscopy and Surgery, Ruhrlandklinik, Essen/GERMANY
Rationale: Management of stage III non-small-cell lung cancer (NSCLC) is
still open for debate. While in IIIA a number of treatment (Tx) groups still
consider S to be included for some pts, stage IIIB is considered inoperable;
and treated with definitive chemoradiation (CTx/RTx). Material and Meth-
ods: We undertook a comprehensive literature search in PUBMED and
abstract books from major Conferences for trials in stage IIIB, with S
included into Tx. An emphasis was laid on modern CTx as systemic Tx
included and on reporting of long-term survival (SURV). Results: Stage IIIB
NSCLC according to the Mountain classification (CLASS) - as well as the
new CLASS published 2007 in JTO - spans from biologically different
diseases such as T4N0/1 tumors (TU) with small primaries (Prim) in
unfavourable locations with small/no lymph node (LN) metastases (N0/N1)
to T4N3 with very large Prim TU (T4) as well as extensive locoregional
LN-involvement (N3). Therefore, it seems inappropriate to handle IIIB as
one homogeneous pts group. Some trials have described combined modality
Txs including induction CTx and/or induction CTx/RTx followed by S in
these subsets. The majority chose T4N0/1 pts for this strategy. A few reports
have also looked at a subset with proven N3. In our own experience with a
complex induction CTx-CTx/RTx protocol, long-term SURV could be ob-
served within the T4N0/1 and the N3-subset. Other investigators could
identify T4N0/1 as a prognostically defined group showing favourable
long-term SURV following S. When S is performed, critical risk/benefit
evaluations have to be calculated as both complex S and S following
induction Tx has reported increased perioperative complications. Manage-
ment of these complications requires advanced experience with multidici-
plinary Tx. Conclusions: When modern CTx is included early into the Tx of
stage IIIB NSCLC, some pts may qualify for an aggressive multidisciplinary
approach including S. S in this setting has to be critically weighted against
concurrent CTx/RTx with curative intent. With brain metastases being the
important competing risk in these pts, future data on PCI in this setting are
of major importance to improve long-term SURV. Once this issue has been
settled, improving local control at the Prim (S or stereotactic/conformal RTx)
may become the predominant issue.
40IN
PCI
M. Stuschke Department of Radiotherapy, University Duisburg-Essen/
GERMANY
The risk of brain metastases as first site of relapse is 15–50% at 4 years, in
patients with Stage-III-NSCLC, depending on the histopathologic subgroup
(squamous cell carcinomas vs. others), extent of mediastinal spread and response
to induction chemo- and radiochemotherapy. Prophylactic cranial irradiation is
effective treatment modality that can reduce the hazard of brain metastases by
50%. This is a similar effect of PCI in NSCLC than in SCLC. In addition, some
prospective studies did not reveal major toxicities in long term survivors after
PCI, however, the number of patient studied is small and retrospective studies
did show such a risk. To become a standard option, a large randomized study
showing a survival benefit of PCI is needed. One such critical test was the RTOG
0214 trial that, however, was prematurely closed due to slow accrual. One way
to improve the therapeutic ratio of PCI and is to selectively spare parts of the
limbic system from full dose, where metastases seldom occur. At present, PCI in
Stage-III NSCLC should be given within clinical trials.
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HOW TO MINIMIZE THE TOXICITY
S. Senan Department of Radiation Oncology, VU University Medical Centre,
Amsterdam/NETHERLANDS
Current treatment guidelines recommend platinum-based combination
chemo-radiotherapy (CT-RT) as the primary treatment in patients with stage
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IIIA NSCLC and ipsilateral mediastinal disease [Robinson 2007]. The same
strategy is also recommended for patients with stage IIIB NSCLC and a good
performance score with minimal weight loss [Jett 2007]. However, an
increase in toxicity is seen with concurrent CT-RT, and a meta-analysis
reported an increase in grade 3 or greater esophagitis from 4% to 18% for
concurrent CT-RT, as opposed to sequential CT-RT [Rolland 2007]. Al-
though this meta-analysis revealed no significant differences in acute pul-
monary toxicity between the two approaches, data from many recent trials
clearly show an increase in pneumonitis. One example is the as yet unpub-
lished INT0139 study, where patients randomized to full-dose only concur-
rent CT-RT developed Grade 3–4 esophagitis in 44% of cases and radiation
pneumonitis in 24% [Albain 2005]. Definitions of G3–4 toxicity (CTC AE
3.0) are as follows: G3 esophagitis: symptomatic and severely altered
eating/swallowing; IV fluids, tube feedings, or TPN indicated24 hrs, G4
esophagitis: Life-threatening consequences (e.g. obstruction, perforation) G3
radiation pneumonitis: symptomatic and interfering with ADL; oxygen
indicated, G4 radiation pneumonitis: Life-threatening; ventilatory support
needed. Two approaches that can decrease toxicity are (i) the use of
involved-field radiotherapy as standard, and (ii) routine use of individualized
radiotherapy planning using 4-Dimensional CT scans Involved-field radio-
therapy (IFRT) Traditional radiotherapy fields have encompassed the radio-
logically normal mediastinum, and occasionally the ipsilateral supraclavic-
ular region, in order to treat potential sub-clinical disease. The large elective
mediastinal fields increase the volumes of irradiated lung and esophagus, and
thereby increase the risk of toxicity as was observed in the abovementioned
INT 0139 study [Albain 2005]. The presumed benefits of so-called prophy-
lactic, or elective, nodal irradiation has never been demonstrated. The
European Organization for Research and Treatment of Cancer recommended
use of IFRT as the standard approach for stage III NSCLC [Senan 2004].
Recent data from a randomized phase III clinical trial [Yuan 2007] and a
single institution analysis of nearly 500 patients [Rosenzweig 2007], con-
firmed that IFRT led to isolated recurrences in lymph node regions not
included in the tumor volume, in less than 8% of patient. Early studies have
defined IFRT fields by including nodes with a short-axis diameter of 1cm.
Although FDG-PET scans have been shown to be superior to CT scans alone
for staging the mediastinum [Gould 2003], a meta-analysis found that
FDG-PET negative nodes measuring 16 mm had a post-test probability of
containing metastatic disease of 21% [de Langen 2006]. The last finding
suggests that pathological confirmation of nodal status is justified before
excluding enlarged, PET-negative nodes from the treatment field. Radiation
pneumonitis with IFRT The risk of radiation pneumonitis can be estimated
using the V20, i.e. the percentage volume of normal lung minus the planning
target volume which receives doses of 20 Gy or more. Patients with a V20
of 35% have not only an increased risk of high-grade radiation pneumo-
nitis, but also a significantly poorer survival [Kelly 2007]. V20 is a treatment
planning parameter that cannot be reliably estimated from diagnostic CT
scans. However, patients with multiple level N2 disease, bilateral hilar
metastases and a peripheral lower lobe tumor with contralateral upper
mediastinal nodes, often have high V20 values despite optimal radiotherapy
planning. In recent randomized studies where IFRT was used with concur-
rent CT-RT, the reported incidence of G3 radiation pneumonitis was 10%
or less [Fournel 2006; Kelly 2007; van Meerbeeck 2007; Pilar Garido 2007].
Esophagitis with IFRT The Incidence of radiation esophagitis is related to the
volume of organ irradiated as well as the total dose. In 3 recent randomised
phase II European studies where IFRT was specified, the reported incidence
of G3 esophagitis was between 17–24% [Fournel 2006; van Meerbeeck
2007; Pilar Garido 2007]. Acute esophagitis is an important cause of
morbidity and can potentially lead to treatment interruptions. Measures to
minimize the deleterious impact of high-grade esophagitis include referral to
a dietician prior to commencing treatment, careful monitoring of body
weight twice-weekly, aggressive symptomatic treatment with analgesics,
proton pump inhibitors, and early placement of feeding tubes in high-risk
patients. Individualized radiotherapy planning using 4-Dimensional CT
scans In radiotherapy planning, margins are added to the visible tumor (or
‘gross tumor volume’) in order to account for microscopic tumor extension,
motion induced by respiration or cardiac action, and variations in daily
patient set-up at the treatment unit. A number of studies in the last decade
have clearly shown that smaller, individualized planning target volume are
possible using 4-dimensional CT scans. Several strategies for mobility
management during radiotherapy of lung tumors are available in clinical
practice, including full incorporation of target motion, freezing target mo-
tion, intercepting target motion, or tracking the tumor [Lagerwaard 2007]. It
is essential that a department first consider the accuracy, workload, patient
tolerance, imaging dose and resources required for the chosen approach. A
promising approach is respiration-gated radiotherapy, which permits a re-
duction in field sizes as irradiation can be limited to phases in which the
mobile target volume is in a predetermined position [Underberg 2005].
42IN
SELECTION OF PATIENTS FOR RADICAL
CHEMORADIATION (RCR) OF NON-SMALL CELL
LUNG CANCER (NSCLC)
D. Ball Radiation Oncology, Peter MacCallum Cancer Centre, East Mel-
bourne/AUSTRALIA
Five year survival following RCR for stage III NSCLC is approximately
20%. This outcome is dependent not only on treatment, but also on careful
patient selection. The following factors need to be taken into account when
judging a patient’s suitability for RCR. PATIENT RELATED PROGNOS-
TIC FACTORS (PF). 1. Performance status (PS). Five year survival is
unusual if ECOG PS 1. 2. Weight loss. 3. Comorbidity. Closely related to
PS, however may provide independent prognostic information. Scoring
systems such as the simplified comorbidity score (Colinet et al. Br J Cancer
2005; 93: 1098) require further evaluation. 4. Age. Not by itself a contrain-
dication to RCR. May influence choice of chemotherapy agents. 5. Pre-
treatment pulmonary function. Related to PS and comorbidity, but not a risk
factor for radiation pneumonitis. DISEASE RELATED PF. 1. Staging.
Requires CT/PET scanning. EUS shows promise for accurately mapping
extent of mediastinal node involvement. 2. T stage. Little data on upper limit
of primary tumor size; in a prospective study of 292 patients with inoperable
NSCLC treated with either RCR or radiation alone, we observed long term
survivors even in patients with tumour diameter 9 cm (Ball et al. Lung
Cancer 2005; 49 suppl 2; abstr P351). 3. N stage. Further studies are needed
to define the prognostic importance of involvement of the various lymph
node stations, especially N3. Long term survival is possible in spite of
supraclavicular node involvement (Machtay et al. IJROBP 1999; 44: 847). 4.
M stage. Solitary brain metastasis treated definitively should not be a
contraindication to RCR (Flannery et al IJROBP 2006: 66 suppl 3: abstr
152). TREATMENT RELATED PF. 1. Toxicity. 3D volumetric tools should
be used to estimate of risk of pneumonitis and determine ‘safe’ treatment
volumes. FUTURE DIRECTIONS. The following warrant further study as
potential prognostic or predictive factors in the application of RCR. 1.
Genetic determinants of radiosensitivity to allow individualisation of dose. 2.
Tumour hypoxia as measured by functional imaging techniques (e.g. F18
miso). 3. EGFR expression as a predictor for accelerated repopulation.
43IN
INDUCTION OF CONSOLIDATION
P. Garrido Lopez Hospital Ramon y Cajal, Madrid/SPAIN
More than a third of non small cell lung cancer (NSCLC) patients have stage
III at the moment of diagnosis. In unresectable patients with good perfor-
mance status and minimal weight loss, the concurrent approach has resulted
in a statistically significant improvement in overall survival rates compared
with sequential approach in randomized clinical trials. However, several
important questions remain controversial and unanswered. One of the most
important is whether survival could be improve by administered full dose of
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chemotherapy during radiation treatment as opposed to the commonly used low
dose of CT. Other outstanding question is the role of induction or consolidation
CT in addition to concurrent chemoradiotherapy, particularly after the negative
results of recent phase III trials. The 39801 CALGB phase III trial was designed
to test the value of induction CT administered in the context of standard
concomitant chemoradiotherapy. At a median follow-up time of 38 months,
treatment differences in survival were not statistically significant (p0.3).
Furthermore, their data demonstrated that the addition of induction CT increased
neutropenia and overall maximal toxicity, although severe RT related toxicities
were not affected. Consolidation chemotherapy has been tested in the Hoosier
Oncology Group (HOG LUN 01–24/USO 02–033) phase III trial. In this study,
the addition of docetaxel did not improve progression-free survival or overall
survival. Consolidation CT resulted in increased rates of infection, pneumonitis
and treatment–related death. Three European randomized phase II studies
compared induction versus consolidation CT using different regimens. No
differences in survival were found in any of them but these trials were not
designed to address the best sequence of CT in addition to chemoradiotherapy.
In summary, several large randomized prospective studies have now demon-
strated that concurrent chemoradiation therapy yields better results in terms of
response rate, time to progression and survival in fit, unresectable stage III
NSCLC patients in spite of their high toxicity rate. However, this treatment is
still very much restricted by its narrow therapeutic index and a significant
research effort is still necessary in order to define the best sequence of use and
the best chemotherapy agents for combination.
IMAGING STATE-OF-THE-ART
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IMAGING FOR SCREENING
R.J. van Klaveren Pulmonology, Erasmus MC, Rotterdam/NETHERLANDS
The high frequency of non-calcified pulmonary nodules (NCN) 10 mm
incidentally detected on a multi-detector CT (MDCT) of the chest raises the
question of how clinicians and radiologists should deal with these nodules.
Management algorithms for solitary pulmonary nodules 10 mm do not carry
across to sub-centimeter lesions. Based on advances in knowledge derived from
lung cancer screening trials recommendations for the management of NCN 10
mm have been made, but it is an evolving field and adjustments of these
recommendations can be expected in the future. The purpose of this presentation
is to provide a 10-step approach for routinely detected NCN on a MDCT in
healthy persons in order to be able to make an optimal discrimination between
benign and malignant NCN-s. Recommendations are primarily based on indi-
vidual cancer risk, the presence or absence of calcifications and nodule size. For
nodules 4–5 mm additional nodule characteristics should be taken into
account. For nodules 4 mm, a follow-up CT at 12 months is recommended in
high risk persons, whilst for low-risk persons no follow-up is needed. If no
growth is observed at 12 months, no further follow-up is required. For solid,
smooth or attached indeterminate NCN between 5–10 mm we recommend an
annual repeat scan, whilst for purely intra-parenchymal nodules a 3-month repeat
scan should be made to assess growth. Growing lesions with a volume doubling
time 400 days require further work-up and diagnosis, otherwise an annual
repeat scan to assess growth is recommended.
45IN
ROLE OF PET IN STAGING AND RESTAGING
J. Vansteenkiste Respiratory Oncology Unit, University Hospital Gasthuis-
berg, Leuven/BELGIUM
FDG-PET has become an important staging modality in lung cancer patients.
Several studies and meta-analyses have convincingly demonstrated that
locoregional lymph node staging by FDG-PET (in correlation with CT
images) is significantly superior to CT, with a negative predictive value equal
or even superior to mediastinoscopy. FDG-PET also improves extrathoracic
staging, due to detection of lesions missed at conventional imaging, or due
to characterisation of lesions that remain equivocal on conventional imaging.
Randomised studies have shown a reduction of invasive procedures and of
futile surgery. In most of the recent studies, PET-CT is used. Before the
advent of truly integrated PET-CT machines, software fusion – where images
from a patient lying in the same position during consecutive PET and CT
acquisition in different scanners – were fused by a computer algorithm. This
fusion was far from perfect, as patient position and respiratory status were
difficult to control. In truly integrated PET-CT, a combined scanner creates
both datasets, that are subsequently merged to a single image. The most
significant improvement by integrated PET-CT relates to the accuracy of T
staging, rather than N-staging. For the T-factor, more precise evaluation of
chest wall and mediastinal infiltration or correct differentiation between
tumor and peritumoral inflammation or atelectasis have been described. For
the N-factor, the extra effect of integrated scanning is more limited, except
in one report. In the latter study, the accuracy of PET alone was only 49%,
far below what has been consistently reported in the literature. Finally for
M-staging, only a few results are known. In a large retrospective survey on
patients with different tumours, there was significant advantage of integrated
PET-CT versus PET or CT alone, but not versus side-to-side correlated
images. As a whole, it seems that visual side-by-side comparison of images
is a reasonable approach at present, even if technological evolution will lead
to integrated scanning as the standard approach in the near future.
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THE ROLE OF EBUS IN STAGING AND RESTAGING
M. Krasnik Thoragic Surgery, Gentofte Hospital, /DENMARK
Up to 10% of operations for non-small-cell lung cancer (NSCLC) result in
explorative thoracotomies without tumour resection, and an additional 25–
35% of the operations are unsuccessful because of postoperative recurrent
disease (1–2). Therefore, surgery may be regarded as futile or unnecessary in
up to 45% of patients operated, apparently because the stage of the disease
is more advanced than expected preoperatively. This combined with the
introduction of stage-dependent multi-modality treatment of NSCLC under-
lines the importance of exact staging of the disease. Staging of lung cancer
determines the proper treatment modality for these patients. The accurate
mediastinal staging until recently depended on invasive surgical interven-
tions, such as mediastinoscopy, a procedure which still is the standard for
mediastinal staging in most centers With the EBUS TBNA it is possible to
target lesion in the mediastinum anterior and the hillar regions not reachable
with EUS FNA so theoretically the whole mediastinum can be examined
with the combination of EBUS TBNA and EUS FNA. Soon after the
introduction of the EBUS TBNA scope publications showed the benefits of
EBUS TBNA. It was safe, easy, non invasive and highly acceptable.
Sensitivity, specificity, and accuracy of EBUS-TBNA in distinguishing
benign from malignant lymph nodes were 95.7%, 100%, and 97.1%, respec-
tively. And results were published that the combination of EUS FNA and
EBUS TBNA in reality covered the whole mediastinum resulting in better
results than either EUS FNA or EBUS TBNA alone could produce. In the
same period studies with neoadjuvant and adjuvant therapy in lung cancer
were introduced. This aspect raised increased demand of the accuracy of
staging and restaging. . The current restaging modalities either have a low
diagnostic accuracy (computed tomography) or can be technically difficult
(Re-mediastinoscopy). Endobronchial ultrasound guided TBNA shows a
sensitivity, specificity and diagnostic accuracy of EBUS-TBNA per patient
in restaging mediastinal LN were 70, 100 and 75%, respectively.
GENE SIGNATURES IN STAGE I NSCLC
47IN
GENOMIC STRATEGIES FOR PERSONALIZED CANCER
THERAPY
J.R. Nevins Duke University Medical Center, Duke Institute for Genome
Sciences and Policy, Durham/UNITED STATES OF AMERICA
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The ability to tailor cancer therapy to characteristics of the individual patient
is key in achieving a successful outcome. We have made use of genomic data
to develop predictors that assess risk and sensitivity to potential therapeutic
options. The current standard of care for Stage 1A patients is surgery and
observation. Nevertheless, 25% of Stage IA patients will have a disease
recurrence suggesting the need to identify individuals in this subgroup for
more effective therapy. We developed gene expression profiles that could
predict risk of recurrence, performing significantly better than previously
described clinical prognostic factors. Importantly, we show that this provides
an opportunity to re-classify Stage IA patients to identify a subset of higher
risk patients that might be appropriate for adjuvant chemotherapy. We have
also developed a series of gene expression signatures that have the capacity
to predict sensitivity to cytotoxic chemotherapeutics, including those used in
the treatment of lung cancer. Many of these predictors have been validated
with chemotherapeutic response data from patient samples, including a
prospective breast neoadjuvant study, demonstrating a capacity to identify
those patients most likely to respond to a given drug. Importantly, these
predictions also accurately identify those patients likely to be resistant to
current standard of care regimens emphasizing the importance of developing
strategies for effective therapy of these individuals. One approach has made
use of predictions of pathway deregulation in cancer cell lines that are shown
to coincide with sensitivity to therapeutic agents that target components of
the pathway, underscoring the potential for such pathway prediction to guide
the use of targeted therapeutics. Finally, we have combined the chemother-
apy predictive signatures with the signatures of oncogenic pathway deregu-
lation to identify therapeutic strategies that make use of all available drugs,
matched to the characteristics of the individual patient. We suggest that this
approach provides a strategy towards the development of personalized
treatment options for the individual patient.
48IN
VALIDATION OF PREDICTION MODEL
D.G. Beer Section of Thoracic Surgery, University of Michigan, Ann Arbor/
UNITED STATES OF AMERICA
Gene expression profiling has helped to improve our understanding of the
histological heterogeneity of non-small cell lung cancer and has identified
gene signatures for classifying patients with significantly different survival
outcomes. These classifiers could potentially identify early stage lung cancer
patients who may benefit from additional adjuvant therapy. The performance
and general applicability of most published classifiers however are difficult
to compare due to small tumor sample sizes, multiple tumor types, non-
uniform criteria for sample inclusion, annotation, sample processing, and
data analyses. To address these issues and to generate a large gene expression
database of lung adenocarcinomas, the specific type of lung cancer that is
increasing in incidence, a large retrospective, multi-site, blinded study was
conducted. The study included a blinded validation step to characterize the
performance of several prognostic models using a total of 442 lung adeno-
carcinomas. Several steps were taken to ensure scientific validity of the
results. Patient samples along with all relevant clinical, pathological and
outcome data were collected by investigators at four institutions using data
from six lung cancer treatment sites with a priori defined inclusion criteria.
Gene expression data on subsets of lung adenocarcinomas were generated by
each of four different laboratories using a common platform and following a
protocol previously demonstrated to be robust and reproducible. The four
pre-specified hypotheses of the study were to develop and validate prognostic
models that use either gene expression data alone, or use a combination of gene
expression and clinical data, to predict patient outcome for either all stages of
lung cancer or for stage I patients. Data generated at two sites was used as a
training set and the results were validated using the independent datasets from
the other two participating sites. Several of the classifiers were found to
demonstrate adequate performance on both independent test sets whereas others
performed well on only one. In all instances the addition of clinical data
improved performance. This study provides not only a valid assessment of
outcome prediction in the multi-institutional setting but also a rich dataset for
future analysis and provide an example of how large datasets can be generated
and tested by cooperation and pooling of resources among many investigators.
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QUANTITATIVE (Q) RT-PCR 3-GENE EXPRESSION
SIGNATURE PREDICTS SURVIVAL IN EARLY-STAGE
NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
(PTS)
M. Skrzypski1, E. Jassem,1 S. Benlloch2, D. Jablons3, W. Rzyman4, G.
Gulida5, J.J. Sanchez6, M. Taron,7 J. Jassem8, R. Rosell7 1Allergology,
Medical University of Gdansk, Gdansk/POLAND, 2Laboratory, Hospital
General Universitario de Alicante, Alicante/SPAIN, 3Thoracic Surgery,
UCSF Helen Diller Family, San Francisco/UNITED STATES OF AMERICA,
4Toracic Surgery, Medical University of Gdansk, Gdansk/POLAND, 5Pa-
thology, Medical University of Gdansk, Gdansk/POLAND, 6Statistics, Au-
tonomous University of Madrid, Madrid/SPAIN, 7Hospital Germans Trias I
Pujol Badalona, Catalan Institute of Oncology, Barcelona/SPAIN, 8Aka-
demii Medycznej W Gdansku, Klinika Onkologii Radiotherapii, Gdansk/
POLAND
Background: Around 50% of early stage NSCLC pts will have disease
recurrence after surgery, with distant metastasis being the main cause of
treatment failure. Adjuvant chemotherapy improves survival, but the abso-
lute gain is modest and largely limited to stage II-IIIA. High-risk pts may be
selected by gene expression profiles and considered for adjuvant chemother-
apy. We earlier developed a 3-gene expression prognostic gene model in
squamous cell lung cancer SCC) (J Clin Oncol 2007; 25 [supl]: 412s). In the
present study this model was validated in a large group of NSCLC pts
including both SCC and adenocarcinoma (AC) types. Methods: Snap frozen
primary tumor specimens were obtained at the time of surgery from142
NSCLC pts who underwent complete surgery between 2000 and 2005.
Eighty percent of pts were stage I and II; 66% and 33% had SCC and AC
types, respectively. Expression of CSF1, EGFR and CA IX (constituting a
3-gene prognostic signature) was analyzed by qRT-PCR using low density
arrays, with TBP as the endogenous control. Risk scores were used to
classify pts into high- or low-risk groups according to the expression of the
3 genes. Results: The high prognostic value of the risk score based on the
expression of CSF1, EGFR and CA IX was re-confirmed. Median survival
(MS) in low-risk pts with SCC was not reached, whereas it was 34 months
(m) for high-risk SCC pts (P0.05). The 3-gene expression signature had
prognostic value also in AC pts. MS was not reached for low-risk pts,
whereas it was 61.2 m for high-risk pts (P0.04). The risk score also
predicted MS in the entire group of NSCLC pts (MS for high- and low-risk
risk pts 41.0 and 62.4 m, respectively; P0.009). Conclusions: The 3-gene
signature is prognostic for NSCLC pts irrespective of histology. The signa-
ture may allow selecting high-risk pts for adjuvant chemotherapy.
UNCOMMON TUMORS STATE-OF-THE-ART
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SUPPORTIVE AND PALLIATIVE CARE FORMALIGNANT
MESOTHELIOMA
M. Muers Respiratory Medicine, St. James University Hospital, Leeds/
UNITED KINGDOM
100% of patients with mesothelioma need supportive care, and very nearly
all need symptom palliation. Both should be considered before diagnosis.
Early symptom relief, (eg, by treating effusions and pain) clarifying uncer-
tainties about diagnosis, causation and prognosis are essential. Active symp-
tom control should proceed in parallel with any active cancer treatment such
as palliative chemotherapy. Most mesothelioma pain has a neuropathic
component and there should be early use too, of co-analgesics, eg, steroids,
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tricyclic anti depressants, Gabapentin). Breathlessness in the absence of a
treatable effusion, is due usually to lung compression and is difficult to treat.
However, co-morbidity as a cause of sudden breathlessness must not be over-
looked, eg, pulmonary embolism, COPD, CCF, and these are increasingly
common in this elderly population. Later symptoms are dominated by the
anorexia, malaise and weight loss complex, and anxiety may need separate
treatment with Benzodiazepines or similar. Local extension of disease may need
specific treatment, for example SVCO (stent), pericardial effusion, contralateral
pleural effusion, or ascites (tap), oesophageal compression (stent). Metastatic
disease rarely causes symptoms in life although scans and post mortem studies
show that these are common.
References: Ahmedzai SH, Muers MF, Supportive care in respiratory dis-
ease, Oxford OUP 2005 BTS statement on malignant mesothelioma in the
UK 2007. Thorax 2007 62 supp.II pp 1–19.
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IMPROVING OUTCOME IN MALIGNANT PLEURAL
MESOTHELIOMA: DEVELOPMENTS INMULTIMODALITY
THERAPY AND TARGETED THERAPY
R.A. Stahel Clinic and Policlinic of Oncology, University Hospital, Zu¨rich/
SWITZERLAND
Multimodality therapy of MPM including extrapleural pneumonectomy
(EPP) has increasingly gained acceptance in dedicated centers and many
phase II studies using variations of such an approach are being conducted.
The use of adjuvant chemotherapy following EPP has been pioneered by the
Brigham Group. However, based on current knowledge chemotherapy reg-
imens used in this approach have been suboptimal and only a proportion of
patients were able to tolerate chemotherapy as planed. The later observation
and our experience with neoadjuvant chemotherapy in lung cancer prompted
us to explore a neoadjuvant approach in MPM. Our pilot study and subse-
quent experience in a multicenter study using cisplatin and gemcitabine
demonstrated the feasibility of such an approach with no apparent increase in
surgical morbidity and a median time of survival of 23 months for operated
patients. These results were subsequently confirmed in a Swiss multicenter
trial including 61 patients. The results of this trial will be presented in detail
and available results of multimodality trials of other groups will be reviewed.
Major clinical questions regarding the multimodality of MPM include the
role of the individual modalities on the ultimate outcome, since EPP and
postoperative radiotherapy add considerable to the burden of treatment in this
usually fatal disease. The MARS trial will ultimately look at the role of EPP.
We are currently examining the role of high dose postoperative radiotherapy
after neoadjuvant chemotherapy and EPP in randomized phase II study.
While chemotherapy has undoubtedly a beneficial role, major open questions
include a role of maintenance treatment after surgery and the identification of
predictive tumor characteristics. Several lines of targeted approaches of
MPM are under preclinical and clinical investigations. These include sur-
vivin antisense, antibodies inducing the death receptor pathway and clinical
studies with mesothelin antibodies. A first study on bevacizumab with or
without chemotherapy has been negative, while phase II studies II studies
with tyrosine kinase inhibitors targeting VEGFR2 have reported objective
responses and further trials are ongoing.
52IN
HOW TO INTEGRATE RADIATION IN THE
THERAPEUTIC MANAGEMENT OF SCLC
P. Van Houtte1, M. Roelandts2 1D, Institut Jules Bordet, Brussels/BEL-
GIUM, 2Radiation Oncology, Institut Jules Bordet, Brussels/BELGIUM
The introduction of chemotherapy in the management of small cell lung
cancer was the first great step to a clear benefit in survival. The recognition
of the benefit due to chest irradiation and prophylactic cranial irradiation
(PCI) was another very important step. This was demonstrated by metaanaly-
sis based on individual patient data included in randomised trials testing the
role of): both yield a similar results, a 5.4% survival benefit at 3 years but
they did not allow to define the optimal schedule. There are several ques-
tions: the total dose, the fractionation, the volume to be treated, the timing,
the sequence and the type of chemotherapy. SCCLC is very radiosensitive
with a fast response leading to a wrong assessment: moderate radiation doses
may be high enough to control it. This was wrong; local failure is very
common: after doses of 45 Gy, failure rates of 50 % are reported. There is
several ways to improve the local control: increasing the total physical dose
or the biological dose using a hyperfractionated and accelerated schedule,
combining radiation with concurrent chemotherapy. In a concurrent ap-
proach using cisplatine-etoposide, it is possible with 1.8 Gy daily fractions to
reach 60 Gy or more but the maximum tolerated dose with 2 daily fractions
seems to be around 45 Gy due to grade 3 esophagitis. Increasing the dose or
adding additional drugs imply to move from the old concept of large volume
to limit the radiation field to reduce the toxicity. Trials conducted in the past
were using old radiation technique and not the current 3D conformal
radiotherapy or IMRT which may limit esophageal toxicity. Adding a third
drug to cisplatine and etoposide did not improve the results but increased the
toxicity. Another interesting observation is the wide variation in long term
survival rates from one trial to another suggesting different selection criteria,
different staging procedures or different definitions for limited disease. The
current approach is to prefer a concurrent to a sequential schedule with the
chest irradiation be delivered during the first cycles of chemotherapy but this
is still controversial due to conflicting data while PCI is delivered to patients
in complete remission.
53IN
SURGERY FOR SCLC
G. Stamatis Thoracic Surgery and Endoscopy, Ruhrlandklinik, Essen/GER-
MANY
Surgery for SCLC Georgios Stamatis, Ruhrlandklinik Essen, Germany Ab-
stract: SCLC represents a distinct pathological and clinical entity, accounting
for about 15–20% of all lung cancer cases. Due to its tendency to disseminate
early, systemic combination chemotherapy has been the standard treatment.
Retrospective analysis and non randomised trials suggest that the addition of
surgical resection allows longer disease-free survival and higher rates of
long-term survival than chemoradiation alone. Finally in 5–10% of the
patients mixed histology with non-small cell components was described in
surgical specimens. Between 1978 and 2007 five different treatment strate-
gies including surgery have been used in patients with SCLC. In the eighties
surgery alone has been reported in patients with stage I-IIIA SCLC. Al-
though there was conserned only retrospective reviews with small number of
patients, long term survival between 12 and 57% in stage I, 13 and 25% in
stage II and 14% in stage IIIA could be achieved. Between 1978 and 2001
a noumerous of authors published their experience with surgery followed by
chemotherapy. Survival rates were 26–76% for stage I, 14–50% for stage II
and 0–24 for stage III and if N1 or N2 disease was found at surgery
postoperative radiotherapy was recommended. Other investigators reported
about induction chemotherapy followed by surgery in patients with limited
SCLC. The overall 5-yrs survival was 29 to 36% the median survival
between 18.5 and 62 months. Adjuvant surgery showed improvement of local
control and long term survival. The only substantive report of neoadjuvant
chemoradiotherapy followed by surgery is published by Eberhardt 1999. Median
survival and five-year survival rate in all patients were 36 mo and 46%. In this
monoinstitutional study with well selected patients high rates of curative resec-
tions (72%) and pathological complete response (34%) was observed. Scheperd
1991, published the only compete report about the role for salvage operations in
28 patients with limited SCLC. Median survival and the 5-years survival were
24.5 months and 23%. In conclusion, for T1 lessions without sign of nodal
involvement but diagnosed as SCLC on needle aspiration or on frozen section,
surgical resection is effective. Postoperative chemotherapy is recommended. In
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stages IB and IIA surgery can be considered following chemotherapy. For
selected patients with stage IIB and IIIA disease and good response to chemo-
therapy or chemoradiotherapy surgery can contribute to better local control and
survival. In potentially resectable patients with drug resistance, mixed cell type,
neuroendocrine tumor or tumor recurrence at primary site, salvage surgery may
be considered.
METASTATIC NSCLC STATE-OF-THE-ART
54IN
WHAT IS THE STANDARD CHEMOTHERAPY?
J. Sculier Intensive Care and Thoracic Oncology, Institut Jules Bordet,
Brussels/BELGIUM
Randomised trials and meta-analyses have shown benefits for cisplatin-based
chemotherapy in comparison to supportive care alone in terms of palliation,
improvement of survival, symptom control, quality of life and cost. Chemo-
therapy is thus recommended in patients with good PS. Regimens regimens
should include cisplatin with at least one other active drug. Old active
(second-generation) drugs are ifosfamide, mitomycin C, vindesine and vin-
blastine. New active (third-generation) drugs are gemcitabine, paclitaxel,
docetaxel and vinorelbine. If the other drug is a new one, there is no evidence
for the addition of a third agent outside the context of a clinical trial. There
is also no evidence that combinations with new drugs are superior to those
with old drugs in terms of survival. Cost of the treatment including support-
ive care and complications management has to be taken into consideration in
the choice of the regimen. Single agent chemotherapy with a drug shown to
be effective compared with supportive care, may be considered in patients
with poor PS, and the choice among the active ones depends on the medical
condition of the patient. Cisplatin-based chemotherapy with one of the
regimens shown to be effective should be preferred. There is no demonstra-
tion that high dosages of cisplatin (100–120 mg/m2) provide better results
than standard lower dosages (50–60 mg/m2) in terms of survival. Standard
dosages are associated with reduced toxicity and are thus recommended.
Cisplatin should be preferred to carboplatin because of a better effect on
survival. Carboplatin or a non-platinum based regimen may be prescribed if
the patient is unable or unwilling to take cisplatin. The optimal duration of
chemotherapy is poorly defined. A minimum of 4 to 6 cycles is proposed in
responding patients. Prolongation with single drug appears ineffective in
terms of survival. The attitude to continue treatment until best response
merits further assessment. Second-line chemotherapy should be offered to
patients with good performance status, failing platinum-based first-line
chemotherapy. Evidence is in favour of docetaxel, with pemetrexed. as
alternative. These recommandations are based on the guidelines of the
European Lung Cancer Working Party, accessible on the website www.elc-
wp.org.
55IN
CHEMOTHERAPY AND TARGETED THERAPY
R. Pirker Department of Oncology, Clinic for Internal Medicine I, Vienna/
AUSTRIA
Targeted therapies, either alone or in combination with chemotherapy, offer
new options for systemic therapy of lung cancer. Growth factors and their
receptors as well as angiogenesis have become clinically relevant targets.
Several EGFR-directed monoclonal antibodies or tyrosine kinase inhibitors
have been studied. Cetuximab in combination with palliative chemotherapy
has shown efficacy in several phase II trials and has been evaluated in 2
phase III trials in chemo-naïve patients with advanced NSCLC. In the FLEX
trial, cisplatin/vinorelbine plus cetuximab resulted in a significant prolonga-
tion of survival in comparison to chemotherapy alone in patients with
advanced EGFR-detectable NSCLC. Other EGFR-directed monoclonal an-
tibodies are in earlier stages of clinical development. EGFR-directed tyrosine
kinase inhibitors have shown efficacy as single agents in pre-treated patients
but failed to enhance the outcome when simultaneously added to first-line
chemotherapy in patients with advanced NSCLC. Inhibition of angiogenesis
can be achieved by blockade of the VEGF/VEGFR pathway and other strategies.
Bevacizumab, an anti-VEGF monoclonal antibody, increased the efficacy of
paclitaxel/carboplatin with regard to both survival, progression-free survival and
response rates in selected patients with advanced non-squamous NSCLC. In a
similar trial, bevacizumab improved progression-free survival when added to
cisplatin/gemcitabine. Dual kinase or multikinase inhibitors block two ore more
targets but their clinical efficacy has yet to be demonstrated in phase III trials.
Tumor vaccines are at various stages of clinical development but their benefit
has yet to be proven in phase III trials. Gene therapy requires the development
of vectors that can safely be administered systemically. Other targeted therapies
such as matrix metalloproteinase inhibitors, farnesyl transferase inhibitors, apri-
nocarsen and bexarotene did not improve the outcome in selected groups with
lung cancer. So far, EGFR-directed therapies and bevacizumab have entered
clinical practice in advanced NSCLC and are further evaluated in earlier disease
stages. Many other targeted therapies are in clinical development.
56IN
NEW AVENUES FOR SECOND-LINE TREATMENT
C. Gridelli Division of Medical Oncology, S.G. Moscati Hospital, Avellino/
ITALY
In recent years, the efficacy of several drugs in the second-line treatment of
advanced non-small-cell lung cancer (NSCLC) has been demonstrated.
Docetaxel was the first drug to be approved in this setting. Pemetrexed was
compared to docetaxel in a phase III trial and efficacy outcomes were similar
for pemetrexed and docetaxel, respectively. Recent data from a large ran-
domized phase III trial show that oral topotecan is not inferior to docetaxel
in terms of overall survival but patients receiving docetaxel had significant
advantages in quality of life. Vinflunine, a new vinca alkaloid, was compared
to docetaxel in a phase III trial in pre-treated NSCLC patients. All efficacy
endpoints were similar, but safety profile favoured docetaxel. Erlotinib and
gefitinib are two orally available reversible inhibitors of Epidermal Growth
Factor Receptor (EGFR) tyrosine kinase. Erlotinib, in a phase III randomized
placebo-controlled trial has been proven to prolong survival compared with
placebo in NSCLC patients after first or second line chemotherapy. Results
of a phase III randomized trial comparing gefitinib to docetaxel in patients
with advanced NSCLC pretreated with platinum-based chemotherapy have
been presented very recently. Median survival was 7.6 monthjs for gefitinib
and 8.0 months for docetaxel (HR1.020). These data conclude for non-
inferiority of gefitinib in the overall population. Safety data showed a better
safety profile for gefitinib. Bevacizumab, a humanized anti-Vascular Endo-
thelial Growth Factor (VEGF) monoclonal antibody, in a phase II random-
ised trial, has demonstrated a trend to a lower risk of disease progression
when combined with chemotherapy or with erlotinib versus chemotherapy
alone in the second-line treatment of advanced NSCLC. ZD6474 (Vandet-
anib) is an orally available multi-target tyrosine kinase inhibitor, inhibiting
the tyrosine kinase domain of the VEGF receptor-2 (VEGFR2) and also the
EGFR tyrosine kinase. Vandetanib has shown promising results in random-
ized phase II trials, both as a single agent and in combination with docetaxel
in this setting. These phase II trials are the basis of two relevant ongoing
phase III randomized trials. Sunitinib and sorafenib, two multi targeted
agents showed activity in pretreated patients and their further evaluation is
warranted.
57IN
CURRENT THERAPY OF STAGE IV NSCLC, MOVING
TOWARDS PERSONALIZED MEDICINE
D.R. Gandara Department of Internal Medicine Hematology/Oncology, Univ
of California Davis Cancer Ctr, Sacramento/UNITED STATES OF AMER-
ICA
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Current Therapy of Stage IV NSCLC: Moving Toward Personalized Medi-
cine David R. Gandara, MD UC Davis Cancer Center Sacramento, CA At
present, selection of chemotherapy regimens, or even so–called targeted
therapies, for individual patients with lung cancer remains largely an empiric
process. Nevertheless, developing pharmacogenomic (PG) approaches for
selection of chemotherapy, or targeted therapies, through predictive biomar-
kers now appears feasible due to improved understanding of underlying
molecular mechanisms. Although diverse terminology has been applied to
such PG approaches (individualizing, customizing, or personalizing therapy),
all rely on commonly shared principles for assessing tumor– or host–related
factors. Emerging data regarding PG approaches to treatment selection for
non-small cell lung cancer (NSCLC) are addressed, focusing primarily on
biomarkers relevant to two important chemotherapeutic drug classes: plati-
num compounds and anti–microtubule agents. The results of pilot studies and
the first randomized prospective trials testing this concept are described,
including limitations in the clinical setting of advanced stage disease.
Methodological and technical aspects of PG approaches are elucidated,
recommendations for clinical application are provided, and new directions in
this field are projected.
METASTATIC NSCLC, BIOLOGY FROM THE
BENCHMARK TO BEDSIDE
58IN
IS ADENOCARCINOMA OF THE LUNG ONE DISEASE?
T. Mitsudomi1, Y. Yatabe2 1Thoracic Surgery, Aichi Cancer Center Hospi-
tal, Nagoya/JAPAN, 2Pathology and Molecular Diagnositcs, Aichi Cancer
Center Hospital, Nagoya/JAPAN
Subsets of patients with non-small cell lung cancer (NSCLC) respond
remarkably well to small molecule tyrosine kinase inhibitors (TKI) specific
for epidermal growth factor receptor (EGFR) such as gefitinib or erlotinib.
Those patients are typically of East Asian ethnicity, female gender, no
history of smoking or those with adenocarcinoma. In 2004, it was found that
NSCLC occurring in patients with above-mentioned characteristics fre-
quently harbors activating mutations of the EGFR gene. We sequenced
EGFR, HER2, KRAS gene and transmembrare region of the MET gene in a
cohort of 213 Japanese lung adenocarcinomas. These mutations were found
in 49%, 2%, 14%, 3%, respectively. Of interst, These four mutations had a
strict mutual exclusionary relationship. However, mutations of the TP53
(40%), LKB1 (4%) or PIK3CA (3%) examined in smaller cohorts did not
have such relationship. G to T transversion of the TP53 gene, a hallmark of
tobacco-related carcinogenesis was almost absent in EGFR or HER2 tumors.
Never-smokers were frequent in patients with EGFR(68%) , HER2(67%) ,
PIK3CA (100%) tumors but rare in KRAS(25%) or LKB1(100%) tumours.
There appear to exist two classes of cancer genes in lung adenocarcinomas;
i.e., those associated with non-smoking-related carcinonogenesis, and those
associated with smoking-related one. Indeed, our case-control study indi-
cated that EGFR mutations occurred independent of smoking and apparent
inverse relationship with smoking was due to dilution by tumors without
EGFR mutations that increased with smoking history. We proposed a
terminal respiratory unit (TRU) type of adenocarcinoma characterized by
distinct cellular features (expression of thyroid transcription factor 1 (TTF-1)
and surfactant proteins, and lepidic growth in the periphery), which resemble
those of adenocarcinomas with non-mucinous bronchioloalveolar cell fea-
tures. In our series of 195 adenocarcinomas, 149 were of the TRU type and
46 were of other types. TRU-type adenocarcinoma is associated with a
significantly higher incidence of females, never-smokers, and EGFR muta-
tions, but fewer KRAS and TP53 mutations than other type of adenocarci-
noma. Of 97 adenocarcinomas harboring EGFR mutations, 91 were catego-
rized as TRU-type adenocarcinomas. It is of note that EGFR mutations can
also occur in poorly differentiated adenocarcinomas, as long as the tumor
belongs to the TRU cellular lineage. Adenocarcinoma of the lung is quite
heterogenous in terms of carcinogens invovled (tobacco-related or not),
usage of oncogenes of tyrosine kinase pathway and hence strategy of targeted
drugs and also in terms of pathologic features.
59IN
SHOULD WE ADAPT THERAPIES ACCORDING TO
HISTOLOGY, BIOLOGY. . .
J. Soria1, D. Planchard2 1Medical Dpt (7), Institut Gustave-Roussy, Ville-
juif/FRANCE, 2Departement of Medecine, Institut Gustave Roussy, Villejuif/
FRANCE
The majority of patients with a diagnosis of lung cancer have non-small cell
lung cancer (NSCLC). Adenocarcinoma (ADK) accounts for approximately
50% of all cases of NSCLC, and its incidence continues to increase. In daily
practice, chemotherapy is used in all histological subtypes. There is limited
evidence suggesting that a specific doublet (either platin-based or not) is of
higher value in a specific histological subtype. In contrast, molecular targeted
agents use in NSCLC is clearly influenced by histological subtype. Bevaci-
zumab approved use is restricted to non-squamous histologies not by lack of
activity but because of safety issues. Erlotinib (E) is approved in all NSCLC
subtypes in the 2nd and 3rd line setting, and the BR21 trial demonstrates
efficacy in all histological subtypes. Nevertheless a substantial proportion of
clinicians tend to favour the use of E in patients with ADK or ADK with
BAC features. This is related to the fact that such histological subtypes are
associated with a higher rate of objective responses to E, notably because
such tumors frequently harbour EGFR mutations or amplifications. Thus,
while histology may help predict efficacy or toxicity, it is probably the
specific biology of the tumor that should guide therapeutic choices. Recent
results of a randomized phase III study comparing pemetrexed and cisplatin
with gemcitabine and cisplatin (GV Scagliotti-WCLC) showed no significant
difference in median survival. However ADK and large cell carcinomas were
shown to have improved survival on cisplatin plus pemetrexed. This differ-
ence may be due to the differential expression of TS in different histotypes.
The application of pharmacogenomics to cytotoxic chemotherapy could lead
to the development of “individualized” drugs for patients with cancer.
Numerous studies have reported the role of ERCC1 expression in the repair
mechanism of cisplatin-induced DNA adducts in cancer. These studies
suggest that ERCC1 is a potentially useful marker to predict resistance to
cisplatin, carboplatin and oxaliplatin. RRM1 as well as BRCA1 may also be
potential indicators that may help select those patients with the highest
probability of response to cisplatin and/or gemcitabine. Angiogenic-depen-
dent biomakers remain to date quite elusive.
60IN
IS THERE A RATIONAL DEVELOPMENT OF TARGETED
TREATMENT?
G. Giaccone Chief Medical Oncology Branch, CCR, National Cancer Insti-
tute, NIH, Bethesda/UNITED STATES OF AMERICA
Despite strong preclinical rationale, most targeted agents that have been
developed for lung cancer have not selected any patient subgroup. This has
been the case for EGFR tyrosine kinase inhibitors and many others. For
monoclonal antibodies, however, there have been some restriction to patient
accrual, e.g. EGFR by immunohistochemistry for cetuximab development
and Her2 for Her2 development. Bevacizumab has been restricted to
non-squamous histologies and no brain metastases and no major bronchial
bleeding, mainly out of safety concerns.
Although it is felt that lack of patient selection has been responsible for
several negative results, by the time that large clinical studies were launched,
no strong biological markers were available to support a different develop-
ment. A well known example is that of EGFR TKIs in the treatment of
advanced non-small cell lung cancer. Still now, with the knowledge that
EGFR mutations and high copy number may select a better patient popula-
tion that will benefit from the treatment, no firm markers (clinical or
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biological) has been approved for treatment with these agents. However,
important randomized studies that compare EGFR TKIs to chemotherapy is
several settings, will eventually shad some light on this important issue.
Given the heterogeneity of lung cancer and the difficulty in finding a
predictive marker that can be adequately assessed in the clinical setting, it
may be difficult to have a rationale development of targeted agents for a
while.
61IN
ANGIOGENESIS PROGNOSTIC AND THERAPEUTICAL
APPLICATIONS
G. Zalcman F, Centre hospitalier Universitaire, Caen/FRANCE
Inhibition of angiogenesis, the differentiation of new vessels from the
pre-existing normal vasculature, was proposed as a therapeutic strategy
against malignancies by Folkman in early seventies. 30 years after, a better
knowledge of angiogenesis signaling pathways and stroma/cancer cells
cross-talks, led to the first clinical studies with anti-angiogenic targeted
therapy, showing a survival benefit in patients with cancer. Vascular endo-
thelial growth factor (VEGF) is the major target of these trials, since it was
shown to be essential for endothelial cell (EC) homeostasis and pathological
malignant angiogenesis. In patients with advanced non-squamous lung can-
cer, the combination of bevacizumab, a humanized monoclonal antibody
against VEGF, plus chemotherapy led for the fist time in a large randomized
phase III trial, to a median survival exceeding 1 year. However, the impact
in lung cancer has been limited by hemorrhagic and thrombotic adverse
events in proximal bronchial and/or squamous cancers, in patients with brain
metastasis, or with cardiovascular chronic diseases. These results remain to
be confirmed in the second phase III trial associating bevacizumab with
another CT doublet. VEGFR Tyrosine Kinase Inhibitors (TKIs) are still in
early development in lung cancer, and seem to exhibit different predominant
toxicity profile. Future clinical trials will have to show whether VEGFR
TKIs used with CT, or after first-line cisplatin-based CT, could add efficacy
or lower toxicity compared with the proposed standard association of CT
plus bevacizumab in first line setting. Other clinical developments will
include the combination of bevacizumab with targeted therapies directed
toward other receptors (epidermal growth factor receptor). Results of clinical
trials are awaited with newer generation VEGFR TKIs, either with higher TK
inhibition efficacy (better IC-50), or with broader specificity, and the ability
to inhibit other angiogenic or mitosis pathways using other cell tyrosine
kinases. At last, some anti-angiogenic treatments are currently tested in early
NSCLC, either in adjuvant or in neoadjuvant settings to inhibit metastatic
process. An extensive review of available pre-clinical and clinical data in
lung cancer will be presented.
MOLECULAR BIOLOGY WORKSHOP
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RNA MACHINERY, SPLICING AND LUNG CANCER
L.M. Montuenga1, R. Pio2 1Oncology Division, CIMA, Center of Applied
Medical Research. University of Navarra, Pamplona/SPAIN, 2Oncology,
CIMA-University of Navarra, Pamplona/SPAIN
Pre-mRNA processing and mRNA selective degradation have recently
emerged as important mechanisms for globally modifying cellular protein
composition. Through alternative pre-mRNA splicing, several related pro-
teins with diverse and even antagonistic functions may be expressed from a
single gene. Alterations in the mRNA processing machinery and aberrant
mRNA splicing have been associated to various diseases, including cancer.
The analysis of cancer-specific alternative splicing and its biological conse-
quences is a promising field in Molecular Oncology. We will summarize the
current knowledge about alterations of the mRNA processing machinery and
of alternative splicing in lung cancer. In particular, we will discuss recent
data on the relevance of hnRNP A1, ASF/SF2, CP4 and other RNA-binding
proteins in the biology of lung cancer. hnRNP A1 and SF2/ASF are two key
alternative splicing regulators with opposite splice site selection effects that
have an altered expression in lung tumors. We have studied the role of these
factors in the control of proliferation and apoptosis in lung cancer. We have
demonstrated that siRNAs targeting SF2/ASF mRNA significantly inhibit
cell growth in a concentration dependent manner, whereas siRNAs targeting
hnRNP A1 have an opposite effect. We have proposed that CP-4 may
function as a lung tumor suppressor. CP-4 is a RNA binding protein coded
by a gene at 3p21, one of the most common altered regions in lung cancer.
Lack of CP-4 expression is frequent in highly proliferative lung tumors and
correlates with CP-4 allele losses. We have evaluated in vitro and in vivo
that the expression of CP-4 can inhibit proliferation and tumorigenesis of
lung cancer cells by inducing cell cycle arrest. In our presentation we will
also mention the biological significance of alternative splicing of several
relevant lung cancer-associated genes like VEGF or the ADAMs. Finally, we
will describe a new tool for the high-throughput analysis of alternative
splicing. We have designed and developed a whole-genome splicing-specific
microarray to search for differentially expressed splicing isoforms in lung
cancer. The use of alternative splicing as a potential source for new
diagnostic, prognostic, predictive and therapeutic tools will be also dis-
cussed.
63IN
KRAS REGULATORY ELEMENTS AND EXON 4A
DETERMINE MUTATION SPECIFICITY IN LUNG
CANCER
M.D. To1, C.E. Wong1, A.N. Karnezis1 R. Del Rosario2, R. Di Lauro3, A.
Balmain1 1Cancer Research Institute, UCSF Helen Diller Family Compre-
hensive Cancer Center, San Francisco/UNITED STATES OF AMERICA,
2Cancer Research Institute, UCSF Helen Diller Comprehensive Cancer
Center, San Francisco/UNITED STATES OF AMERICA, 3Research, Statzi-
one Zoologica Anton Dohrn, Naples/ITALY
Kras is the most frequently mutated ras family member in lung carcinomas
while Hras mutations are common in tumors from stratified epithelia, such as
bladder or skin. The mechanism of specificity involving ras gene mutations
among different tumor types is not known, and could involve differences in
regulation or protein functions. Using a mouse model (HrasKI) in which the
Hras coding sequence was inserted into the Kras locus, we demonstrated that
specificity for Kras mutations in lung tumors and Hras mutations in skin
tumors is determined by local regulatory elements in the target ras genes. We
further showed that, while Kras-4B is essential for mouse development, the
alternative Kras-4A splice isoform is essential both for efficient transforma-
tion of lung cells and for the inhibitory effect of wild-type Kras on the
transforming properties of the mutant Kras protein. Kras-4A expression is
detected in a sub-population of Clara cells lining the tracheal tree, extending
into the bronchio-alveolar junctions, locations of the putative bronchio-
alveolar stem cells. The levels of Kras-4A in lung tumors are very low,
suggesting that Kras-4A is essential for tumor initiation, but may not be
necessary for the maintenance of tumor growth and progression. Since
Kras-4A and Kras-4B proteins undergo different post-translational modifi-
cations, these findings can have important implications for the design of
therapeutic strategies for inhibiting oncogenic Kras activity in the prevention
and treatment of lung cancer.
64IN
HEDGEHOG/WNT INTERPLAY IN NSCLC
D. Jablons Thoracic Surgery, UCSF Helen Diller Family, San Francisco/
UNITED STATES OF AMERICA
Stem cells are rare within any given cell population, However, several factors
make them a likely culprit in the development of cancers. First is their
capacity for self-renewal and replication. Second is their long-lived potential
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as undifferentiated cells, creating a larger window of opportunity for molec-
ular alterations accumulate over time. Thus, it is not surprising that the
Hedgehog and Wnt pathways, regulatory mechanisms for stem cell renewal,
tissue repair and tissue regeneration, are implicated in the development of
cancers when aberrantly activated. The concept of cancer stem cells origi-
nated from findings in the haematopoietic system and acute myelogenous
leukaemia. Cancer stem cells and normal stem cells share numerous prop-
erties, including the expression of common cell-surface markers, capacity to
self-renew, and unlimited replication potential and the quality of being
long-lived, allowing the accrual of multiple mutations over time to increase
the rate of cell proliferation and produce cancer. Therefore, identifying and
characterizing cancer stem cells should accelerate the development of ther-
apeutic drugs that target them. Our lab was among the first to discover the
fundamental role that Hedgehog (Hh) and Wnt signaling pathways play in
the development of lung cancer which likely develops from stem cell
population. These pathways are critical determinants of cell survival and
programmed cell death in developing organisms, but are normally dormant
after embryologic development. Re-awakening of Hh/Wnt signaling path-
ways was recently found to be a critical element in lung cancer cell survival,
making them ideal targets for highly potent and safe molecular cancer
therapies. Although there are no specific in vivo trials with treatments
targeting cancer stem cells, one could postulate that blocking components of
the Hh/Wnt pathways could be an important way to inhibit the signalling
required for cancer stem cells. In addition, it may be possible to manipulate
other signaling pathways to inhibit Hh/Wnt signaling. It may also be possible
to discriminate between levels of risk of tumor development and to develop
predictive screening strategies. This concept represents a paradigm shift in
cancer pathogenesis and may translate into effective novel cancer treatments.
65IN
NOVEL COMPONENTS OF LUNG CANCER
DEVELOPMENT AND PROGRESSION
M. Sanchez-C´espedes Molecular Pathology, Spanish National Cancer
Centre, Madrid/SPAIN
Current efforts are focusing towards the development of drugs that specifi-
cally target abnormal regulatory pathways of cancer cells. Therefore, it is
becoming increasingly important in order to identify the set of genes altered
in cancer and to discriminate tumors by their genetic background. Lung
tumors carry alterations at known genes, some of them highly specific to
their histology. Wide screening for chromosomal deletions allowed us to
unveil that LKB1 located at chromosome 19p13.3 was somatically mutated
in one third of lung tumors. Through the impair of the AMPK/mTOR
pathway, LKB1 inactivation abrogates the cell energetic checkpoint control,
an obligatory step for cancer development. In addition to LKB1, we recently
observed that chromosome 19p13 targets the tumor suppressor BRG1, which
encodes the ATPase of the SWI/SNF chromatin-remodelling complex.
BRG1 inactivating mutations were identified in 40% of the cancer cells
tested, mainly NSCLC, and did not coexist with MYC amplification. Our
data strongly supports that BRG1 is a bona fide tumor suppressor and a major
factor in lung tumorigenesis. We searched for alterations at other genes that
signal through mTOR such as PIK3CA. Activating PIK3CA mutations were
low in frequency but amplification was frequent in squamous cell carcinomas
and correlated with increased gene expression. This constitutes a potential
key mechanism for PIK3CA oncogenic activation and, possibly, a determi-
nant of sensitivity to therapies with PI3K inhibitors. To identify novel
oncogenes, we performed combined Comparative Genome Hybridization
microarrays and cDNA microarrays. Following this approach we identified
several amplicons with increase in gene expression. We mapped the bound-
aries and measured gene expression levels within an amplicon at chromo-
some 6p. The SOX4 gene, encoding a transcription factor involved in cell
differentiation, was over-expressed relative to normal cells. SOX4 levels
were also high in a fraction of primary tumors and associated with increased
in gene copy number, supporting that SOX4 is a candidate oncogene in lung
cancer. In conclusion, we provide novel genes altered in lung tumors and
amplified regions that may contain oncogenes relevant for lung carcinogen-
esis.
PATHOLOGY WORKSHOP
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14–3-3ZETA IN LUNG CANCER
H. Fu Emory University School of Medicine, Department of Pharmacology
and Winship Cancer Institute, Atlanta/UNITED STATES OF AMERICA
The family of mammalian 14–3-3 proteins has seven defined isoforms: b, e,
g, h, s, t, and z. They have emerged as critical regulators of diverse cellular
responses under both physiological and pathological conditions. Through
regulated interactions with key client proteins, 14–3-3 controls vital cellular
processes ranging from cell proliferation and differentiation, to cell cycle
checkpoint control, and programmed cell death. Recent studies have revealed
a critical role of 14–3-3 isoforms in tumorigenesis. The z isoform has been
shown to be upregualted in lung cancer cells and patient tissue samples. Data
will be presented that support a role of 14–3-3z in lung cancer development
through a mechanism that involves anoikis resistance. Through an RNAi
approach using human lung adenocarcinoma-derived A549 cells as a model
system, we have found that knockdown of  isoform alone is sufficient to
restore the sensitivity of cancer cells to anoikis and to impair their anchorage-
independent growth. Mechanistically, 14–3-3z seems to be required by lung
cancer cells to maintain balanced Mcl-1/Bim ratio for survival during matrix
detachment. Knockdown of z enhances anoikis in part by up-regulated Bad
and Bim, coupled with decreased Mcl-1, resulting in the subsequent activa-
tion of Bax. This study not only reveals a critical role of 14–3-3z in anoikis
suppression in lung cancer cells, but also identifies and validates 14–3-3z as
a potential molecular target for anticancer therapeutic development. In order
to discover small molecule 14–3-3 inhibitors, we have carried out high
throughput screening campaigns. An update will be presented.
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ADENOCARCINOMA SUBCLASSIFICATION
W. Travis Department of Pathology, Memorial Sloan Kettering Cancer
Center, New York/UNITED STATES OF AMERICA
Despite the remarkable advances in the molecular biology of lung adeno-
carcinoma, surprisingly few studies are supported by carefully detailed
pathologic data. Lung adenocarcinoma histologic subtyping continues to
evolve following the 2004 WHO classification. The search for a clinically
and biologically meaningful way to further characterize the mixed subtype
adenocarcinomas needs to be based on careful attention to the histologic
criteria being applied so the data can be compared to other studies. There are
widely varying published results regarding the correlation of histologic
subtypes with different molecular features including EGFR, k-RAS and gene
expression profiling. The methods of some of these papers indicate varied
pathologic definitions, suggesting that some of these differences may be
attributed to interpretation of the histologic subtyping. Most articles also
focus on a single subtype of lung adenocarcinoma, mostly bronchioloalveo-
lar carcinoma (BAC), comparing this with all other adenocarcinomas. Cor-
relations between histology and molecular findings also vary depending
whether the study involves non-small cell carcinoma or purely adenocarci-
noma. For example associations between EGFR mutations and non-smokers,
female gender, Asian descent, and adenocarcinoma, particularly with BAC,
are generally much stronger if all non-small cell carcinomas are studied.
These correlations are often lost in studies of pure adenocarcinoma. While
there is much emphasis in the literature about BAC and EGFR mutations,
several investigators showed a lack of association of EGFR mutation with
BAC subtype suggesting an association with invasive adenocarcinoma rather
than BAC. One study found a dominant papillary subtype is a significant
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predictor of response to gefitinib. K-ras mutations are associated with
mucinous BAC. Gene profiling studies using cDNA arrays have consistently
identified 3–4 clusters among of lung adenocarcinomas, but we are still
awaiting studies that make correlations with detailed adenocarcinoma histo-
logic subtyping and where other tumors such as large cell neuroendocrine
carcinomas are reliably excluded. Future molecular studies of lung adeno-
carcinoma should be accompanied by careful histologic subtyping of the
tumors.
68IN
IMPROVED INTEGRATIVE “OMICS” VIEW AND AN
UNRESOLVED QUESTION IN LUNG CANCER
PATHOGENESIS
T. Takahashi Division of Molecular Carcinogenesis, Center of Neurological
Diseases and Cancer, Nagoya University Graduate School of Medicine,
Nagoya/JAPAN
The long-term survival rate for lung cancer patients remains unsatisfactory
and no more than 50% of those who successfully undergo a potentially
curative resection survive for more than 5 years after the operation. More
detailed, accurate, and objective methods for classification of non-small cell
lung cancer (NSCLC), especially adenocarcinomas, are therefore greatly
anticipated, not only for a better understanding of the pathogenesis, but also
for improving the currently inadequate diagnostic capabilities to develop
more effective treatment strategies. Presently, there is no accurate means for
predicting individual patient prognosis, though it is indispensable to maxi-
mize the effects of therapy without over-treating those without residual
disease. The expression profile in a given tumor can be regarded as the
outcome of complex influences resulting from accumulated genetic and
epigenetic changes important for pathogenesis, as well as from the differen-
tiation-commitment status of the progenitor cells. Our recent comprehensive
study of lung cancer transcriptome signatures allowed us to establish an
expression profile-defined, highly robust classification of adenocarcinomas,
divided into terminal respiratory unit (TRU) and non-TRU types, which also
made it possible to reconcile the results of previous expression profiling
studies. In addition, evidence for the existence of an expression profile-
defined group of patients with very poor prognosis based on both transcrip-
tome and proteome signatures will be reported from our findings. Detailed
expression profiling analyses of transcriptomes and proteomes thus appear to
have potential to provide increased understanding of the molecular biology
of NSCLC, and their clinical applications in the very near future are
anticipated. I will also briefly speak about molecular investigations, which
represent another area of research into the genomic instability issue of lung
cancer. The underlying mechanisms of genomic instability in lung cancer
remain surprisingly elusive, even though it is considered to be important for
a better understanding of the molecular pathogenesis as well as for devel-
oping novel therapeutics.
TARGETED THERAPIES WORKSHOP
69IN
EGFR MUTATIONS
J. Engelman Massachusetts General Hospital Cancer Center, Massachu-
setts/UNITED STATES OF AMERICA
The last five years have witnessed an explosion of knowledge about the
biology of NSCLC. We have identified patients who are uniquely sensitive
to EGFR inhibitors including patients with mutations in the EGFR gene and
those with extra copies of the gene as detected by FISH. We have learned
about important DNA repair enzymes that predict response to platinum based
agents in the adjuvant setting. In 2006, we learned of at least two gene
expression profiles that are able to predict for outcome in lung cancer
patients. More recently, a new oncogenic translocation involving the ALK
gene has been identified in a subset of lung cancer patients.
As we move forward over the next ten years, it has become clear that there
is a major emphasis on developing “targeted therapies” that disrupt specific
cell growth and survival signals. We have learned that lung cancers are a
heterogeneous group of malignancies characterized by a wide range of
different genetic mutations. Each subset possesses a distinct cellular signal-
ing network that underscores its differential sensitivity to specific targeted
therapies. Laboratory studies have provided insight into why certain targeted
therapies are effective in only molecularly defined subsets of lung cancer.
Additionally, we are learning why most cancers may not be successfully
treated with single-agent targeted therapies. These insights should expedite
the development of effective therapeutic strategies for patients with lung
cancer.
Studies on EGFR inhibitors have provided great biological insight into the
basic issues surrounding cancer sensitivity and resistance. Although most
EGFR mutant lung cancers are initially sensitive to these drugs, they
invariably become resistant to them. Both laboratory and clinical studies
have identified two bona fide resistance mechanisms, a secondary mutation
in EGFR, T790M, and amplification of the MET oncogene. Besides the
immediate clinical implications of these findings, these studies have yielded
insight into the fundamental concept of cancer sensitivity or resistance to a
targeted therapy. Additionally, these studies point to a future when we treat
specific cancers with a combination of targeted therapies that combat the
emergence of resistance, as we do for HIV and tuberculosis.
In summary, the future of lung cancer treatment rests with studies that are
based on appropriately selected patient populations. By understanding mech-
anisms of sensitivity and resistance, we may develop novel, more effective
first line treatments using combinations of targeted therapies.
70IN
ANTIANGIOGENIC DRUGS IN NON-SMALL-CELL LUNG
CANCER
F. Ciardiello1, F. Morgillo2 1Dipartimento Medico-chirurgico Di Internistica
Clinica E Sperimentale \\\\, Seconda Universita´ degli studi di Napoli,
Naples/ITALY, 2Dipartimento Medico-chirurgico Di Internistica Clinica E
Sperimentale “F. Magrassi E A. Lanzara”, Seconda Universita´ degli studi di
Napoli, Naples/ITALY
Despite the improvement in cancer treatment, survival of non small cell lung
cancer (NSCLC) patients is still disappointing, being lung cancer the leading
cause of cancer-related mortality in both men and women. Consequently,
there has been great interest in the development of novel agents for the
treatment of this disease. One of the targeted approaches most widely studied
in the treatment of NSCLC is the inhibition of angiogenesis. In NSCLC
vascular endothelial growth factor (VEGF) plays an important role in
angiogenesis, growth of the primary tumor, and development of metastases.
Our understanding of the VEGF pathway is increasing, as are the number of
available targeted agents. Among angiogenesis inhibitors, the anti–vascular
endothelial growth factor monoclonal antibody (mAb) bevacizumab (Avastin
; Genentech Inc., South San Francisco, CA) represents the most successful
targeted therapy. In fact, in chemotherapy-naive advanced NSCLC patients
with nonsquamous histology, the combination of bevacizumab with chemo-
therapy has demonstrated, in two large phase III randomized trials, better
efficacy outcomes than with chemotherapy alone. In addition to the mono-
clonal antibody, bevacizumab, VEGF receptor tyrosine kinase inhibitors
(RTKIs), and several multitargeted RTKIs are in advanced clinical evalua-
tion in NSCLC, including vandetanib, AZD2171, sorafenib, axitinib, and
sunitinib. Among these agents, vandetanib (ZD6474), an inhibitor of the
VEGF receptor (VEGFR)-2 and epidermal growth factor receptor tyrosine
kinase, has been the most extensively studied. In a randomized phase II
study, it demonstrated a prolongation of progression-free survival compared
with gefitinib in patients with platinum-refractory NSCLC, including squa-
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mous histology. Moreover, in another phase II trial, an improvement in
progression-free survival was observed for vandetanib in combination with
docetaxel compared with docetaxel alone. AZD2171, an inhibitor of
VEGFR-1, VEGFR-2, and VEGFR-3 and other tyrosine kinases, has shown
clinical activity in NSCLC in combination with carboplatin and paclitaxel.
Several phase III trials are under way testing these agents either as mono-
therapy or in combination with chemotherapy in patients with lung cancer.
71IN
PROTEOMIC-RELATED STUDIES
D.G. Beer Section of Thoracic Surgery, University of Michigan, Ann Arbor/
UNITED STATES OF AMERICA
Lung cancers show increased expression of proteins that can either directly
or indirectly influence disease development and progression. Prior work by
our laboratory has utilized two-dimensional protein separations and identi-
fication by mass spectroscopy to help identify proteins over-expressed in
lung adenocarcinomas as well as those associated with a poor clinical
outcome. Some of these protein alterations result from changes in copy
number variation or regulatory mechanisms affecting gene expression in
these cancers such as DNA methylation and chromatin modification. Anal-
yses at both the genomic and protein level of several candidates significantly
associated with poor clinical outcome revealed a role in promoting tumor cell
survival via NFkB signaling. We have also explored the potential that
proteins elaborated from lung cancer elicit a humoral response and may be
useful for early lung cancer detection. A T7-phage microarray approach to
express a cDNA library constructed from a pool of lung adenocarcinoma and
squamous cell carcinomas was used to selectively identify fusion proteins
that are recognized by lung cancer patient serum. Affinity selection and
biopanning were performed using serum samples from lung cancer patients
and control sera. In order to maintain diversity of the clones and optimize the
enrichment of the phage library, we carried out 5 cycles of biopanning with
biological amplification of the phage after each cycle. A high-density phage
epitope microarray was constructed by printing 2300 single individual clones
(2.3K) randomly selected after 5 biopanning cycles of the lung cancer cDNA
library. Most autoantibodies are found in small subsets of patients however
several are present in a large percentage of lung cancer patients and we
demonstrate that specific autoantibodies may have utility when used in a
panel for lung cancer detection.
72IN
MOUSE MODELING DATA FOR LUNG CANCER RISK
M.D. To1, J. Perez-Losada1, J. Mao1, J. Hsu1, T. Jacks2, A. Balmain1
1Cancer Research Institute, UCSF Helen Diller Family Comprehensive
Cancer Center, San Francisco/UNITED STATES OF AMERICA, 2Center
For Cancer Research, Massachusetts Institute of Technology, Cambridge/
UNITED STATES OF AMERICA
There is growing evidence for a genetic component to human lung cancer
risk, but the identification of susceptibility genes is a daunting task due to
confounding environmental factors. Susceptibility to lung cancer devel-
opment varies among different strains of inbred mice, and interspecific
crosses between susceptible and resistant strains of mice are useful for the
mapping and identification of susceptibility genes. Using this approach
we and others have identify a number of regions in the mouse genome
that are involved in the control of lung cancer risk, but in most cases the
relevant gene(s) remain to be identified. Pulmonary adenoma suscepti-
bility 1 (Pas1) is the major mouse lung cancer susceptibility locus on
chromosome 6. The minimal Pas1 region contains 6 genes, including
Kras, which is mutated in 30% of human adenocarcinoma and in the
majority of carcinogen induced mouse lung tumors. Using a combination
of chemical carcinogenesis and KrasLA2 lung cancer model, we demon-
strated that Kras is the elusive Pas1 gene. There is no coding sequence
polymorphism in Kras among the different strains of mice, but the level
of Kras expression tightly correlates with susceptibility/resistance. We
propose that a sensitive balance between expression levels of wild-type
and mutant alleles of Kras determines lung tumor susceptibility. This
reflects the ability of wild-type Kras to efficiently suppress the oncogenic
activity of mutant Kras. These data demonstrate that cancer predisposi-
tion should also be considered in the context of somatic events and could
major implications for the design of human association studies in order to
identify cancer susceptibility genes.
CASE REPORTS
73IN
CASE REPORT: HOW TO OPTIMIZE RADIATION FOR
STAGE III
A. Turrisi Radiation Oncology, Wayne State University, Detroit/UNITED
STATES OF AMERICA
Radiotherapy to the chest has made steady progress over the last 15 years.
Issues of Dose; Target; Volume of Irradiation; Safe Volume of Normal Lung
(v20); combination with a variety of chemotherapeutics for concurrent or
sequential treatment, or blends of both have been established. A number of
benchmarks are established. A dose of 74 Gy can readily be achieved without
undo toxicity, but we are not sure about the use of that dose with concurrent
therapy, where 66–70Gy remains common practice. The target seems to be
the tumor and nodes that we can see with imaging without prophylactic or
‘elective’ nodal irradiation, and the level of evidence for this statement is
increasing. It appears that keeping V-20 under 35% of normal bilateral lung
is established practice. While there is no clear universal standard, the uses of
full doses of cisplatin and etoposide with full dose radiotherapy can be
achieved. Exploring higher doses with concurrent therapy remains a subject
of clinical investigation. Taxanes require weekly administration with con-
current therapy and the results in larger trials are disappointingly lackluster.
Upfront cycles of chemotherapy before concurrent chemotherapy have been
tried in large phase II studies, but do not appear to offer substantial gains
over concurrent therapy. Preliminary results seem favorable for the use of
full dose cisplatin and pemetrexed. Concurrent therapy seems prudent in
medically fit patients with good performance status, and sequential therapy
seems more prudent in the aged or those with co-morbidities. Adjuvant or
consolidative chemotherapy gained short-lived popularity in the US, but
randomized data have not supported the uses of supplementary docetaxel. A
prospective trial using prophylactic cranial irradiation accrued 300 patients
in the USA, but was closed prematurely due to slow accrual. As many as
20–30% of patients may suffer isolated CNS relapse. We need results form
the closed study to point the way, even if the results are under-powered.
Integration of anti-VEGF, EGFR antibodies and small molecules remain in
investigation, and not ready for incorporation to standard therapy. Full dose
chemo-radiotherapy provides the best prospects for long term survival for
locally advanced Stage IIIa/b NSCLC.
74IN
CASE REPORT: CHEMOTHERAPY IN STAGE IV
D.R. Gandara Department of Internal Medicine Hematology/oncology, Univ
of California Davis Cancer Ctr, Sacramento/UNITED STATES OF AMER-
ICA
Case: Advanced Stage NSCLC A 55 year female never-smoker has a 4 
3.5cm (T2) left upper lobe mass on CT scan. There are multiple bilateral
pulmonary & bone metastases (M1). At bronchoscopy there is a RUL
endobronchial lesion, positive for TTF-1 positive adenocarcinoma.
PS1
Wants aggressive treatment
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What is your choice for initial treatment 55 y/o never smoker female
patient?
1. Platinum-based Doublet
2. Bevacizumab  Platinum Doublet
3. Erlotinib-Single Agent
4. Erlotinib  Platinum Doublet
5. Cetuximab  Platinum doublet
What dose of Bevacizumab do you use with chemotherapy in NSCLC?
1. 15 mg/kg q 3 weeks
2. 7.5 mg/kg q 3 weeks
3. Another dose schedule
BIOLOGY
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EGFR SOMATIC MUTATION DATABASE:
WWW.EGFR-MUTATIONS.ORG
S. Murray1, H. Linardou2, I.J. Dahabreh3, P. Kosmidis4 1Molecular Biology
and Genetics, Metropolitan Hospital, N. Faliro/GREECE, 2Medical Oncol-
ogy, Metropolitan Hospital, N. Faliro/GREECE, 3Medicine, Medical School,
National University of Athens, Athens/GREECE, 4Department of Medical
Oncology, Hygeia Hospital, Athens/GREECE
Background: In 2004 somatic mutations in the tyrosine kinase domain (exons
18–24) of the epidermal growth factor receptor (EGFR) were correlated with
dramatic responses of non-small cell lung cancer (NSCLC) to tyrosine kinase
inhibitors (TKIs). A comprehensive catalogue of the somatic mutational
spectrum of EGFR in NSCLC together with response correlates and inci-
dence according to clinico-pathological factors will aid in the development of
personalized treatment strategies in this disease.
Methods: A computerized search of the PubMed database (01/01/04–30/06/
07) was performed in order to identify peer reviewed published articles
dealing with the identification of somatic mutations in EGFR pertaining to
NSCLC. Mutational spectrum, frequency, demographic, clinico-pathological
and treatment related efficacy data were extracted. Author confirmation is
ongoing, and encouraged for this free access q6m updated resource.
Results: A total of 122,44 screened NSCLC patients have identified 3381
with somatic mutations in EGFR. These have been extracted from 202
eligible articles. The mutational spectrum is extensive, 254 different muta-
tions were identified affecting109 of 186 amino acids constituting exons
18–21. A total of 158 different mutations have been reported on only one
occasion, and only 9 occur at a frequency of  1% (L858, T790M, G719,
L861, delE746-A750, delE746-S752insV, delL747-A750insP, delL747-
T751, delL747-P753insS). L858R and delE746-A750 account for 32.84%
and 24.28% of all mutations respectively; deletions’ and ‘deletional-inser-
tions’ (exon 19) account for 47.35%. A meta-analysis of pooled data for each
of the three clinico-pathological factors (gender, histology and smoking
history) will be presented indicating the usefulness of this database in patient
selection for the presence of somatic mutations in EGFR.
Conclusions: We have generated a free-access online analytical database of
somatic EGFR mutations in NSCLC. Cumulative information will be made
available through routine updates of the dataset, its associated tables and
graphical representations. Updates and direct submissions to the online site
(www.egfr-mutations.org) are encouraged, as are comments and suggestions.
An update will be presented.
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COEXPRESSION OF BOTH INSULIN-LIKE GROWTH
FACTOR RECEPTOR 1 (IGFR-1) AND EPIDERMAL
GROWTH FACTOR RECEPTOR (EGFR) IS ASSOCIATED
WITH SHORTER DISEASE-FREE SURVIVAL IN
RESECTED NON-SMALL-CELL LUNG CANCER PATIENTS
L. Crino´1, V. Ludovini,1 G. Bellezza2, L. Pistola3, F. Bianconi4, L. Di Carlo5,
A. Sidoni2, A. Semeraro5, F.R. Tofanetti,1 M. Tonato6 1Medical Oncology,
Azienda Ospedaliera Perugia, Perugia/ITALY, 2Institute of Pathology, Uni-
versity of Perugia, Perugia/ITALY, 3Medical Oncology, Azienda Osped-
aliera, Perugia, Perugia/ITALY, 4Department of Electronic and Information
Engineering, University of Perugia, Perugia/ITALY, 5Department of Tho-
racic Surgery, University of Perugia, Perugia/ITALY, 6Perugia Regional
Cancer Center, Perugia/ITALY
Purpose: Insulin-like growth factor receptor 1 (IGFR-1) represents a novel
molecular target in NSCLC. IGFR-1 and EGFR activation are essential to
mediate tumor cell survival, proliferation and invasion. The prognostic
significance of IGFR-1 and EGFR in early NSCLC patients (pts) remains to
be defined. We conducted a retrospective analysis on a series of surgical
NSCLC pts to evaluate the relationship between IGFR and EGFR and their
impact on outcome. Experimental Design: Tumors from 130 surgical
NSCLC pts were evaluated for IGFR-1 and EGFR expression by immuno-
histochemistry (IHC). Kaplan-Meier estimates of survival and time to recur-
rence were calculated for clinical variables and biologic markers using the
Cox model for multivariate analysis. Results: Median age was 66 years
(range 40–84), M/F 111/19, PS 0/1 128/2, stage I/II/III 81/21/28, squamous/
adeno/bronchiolalveolar/large-cell/mixed 64/40/7/13/6. IGFR-1 protein
overexpression was observed in 36% of NSCLC pts and was associated with
larger tumor size (p0.04) but not with other clinical or biological charac-
teristics. EGFR protein overexpression was observed in 55.2% of NSCLC,
more frequently in squamous cell carcinoma SCC than non-SCC (63.7% vs
36.3%, X29.8, p0.001). IGFR-1 protein expression was associated with
EGFR protein expression (p0.03). At median follow-up time of 21 months,
46 pts have died, 84 are still alive. At the multivariate analysis, the
coexpression of both IGFR-1 and EGFR emerged as an independent factor
for shorter disease free survival (DFS) (p0.01). Conclusion: In patients
with radically resected stage I–III NSCLC, the coexpression of IGFR-1 and
EGFR predicts shorter DFS. According to these data, the overexpression of
IGFR-1 and EGFR could define a subset of patients with early NSCLC at
higher risk for relapse after radical resection.
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ABRAXAS AND RAP80 EXPRESSION IN THE SPANISH
LUNG ADENOCARCINOMA TRIAL (SLAT) OF
CUSTOMIZED TREATMENT BASED ON EGFR
MUTATIONS (MUT) AND BRCA1 MRNA EXPRESSION
R. Rosell1, R. de las Pen˜as2, J.A. Macias-Cerrolaza3, R. Ibeas4, E. Polo5, P.
Martínez del Prado6, J. Castro7, T. Mora´n8, M. Domenech9, J. Terrasa10
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1Medical Oncology Service, Catalan Institute of Oncology, Badalona, Bar-
celona/SPAIN, 2Oncology Service, Hospital Provincial de Castello´n, Cas-
tello´n/SPAIN, 3Oncology Service, Hospital Gral Univ.. J.M. Morales Me-
seguer, Murcia/SPAIN, 4Oncology Service, Hospital Municipal de Badalona,
Badalona, Barcelona/SPAIN, 5Oncology Service, Hospital Ernest Lluch,
Calatayud, Zaragoza/SPAIN, 6Oncology Service, Hospital de Basurto, Bil-
bao/SPAIN, 7Oncology Service, Hospital La Paz, Madrid/SPAIN, 8Oncology
Service, Institut Català d’Oncologia, Hospital Germans Trias i Pujol,
Badalona, Barcelona/SPAIN, 9Oncology Service, Hospital Althaia, Man-
resa, Barcelona/SPAIN, 10Oncology Service, Hospital Universitario Son
Dureta, Mallorca/SPAIN
Background: We carried out a study in metastatic NSCLC where treatment was
customized according to EGFR mut status and BRCA1 mRNA levels. Loss of
BRCA1 function increases sensitivity to cisplatin and resistance to antimicrotu-
bule drugs (Quinn et al. Cancer Res 2003). The Abraxas-RAP80 complex can
modulate BRCA1 function (Wang et al. Science 2007). A gene signature
including BRCA1 predicts poor survival (Deeb et al. Cancer Res 2007).
Methods: 93 patients (p) with lung adenocarcinoma or large-cell carcinoma were
screened for EGFR D746–750 deletion and L858R mut and BRCA1 mRNA
expression. 15 p with EGFR mut received erlotinib; 78 p without mut received
chemotherapy according to BRCA1 levels (low: gemcitabine/cisplatin; interme-
diate: docetaxel/cisplatin; high: docetaxel alone). In addition, Abraxas and
RAP80 mRNA expression were examined in 60/78 p without mut.
Results: With a median follow-up of 10 months (m) for all 92 p, median
survival (MS) has not been reached in 15 p with EGFR mut. MS has not been
reached in 32 p with low BRCA1 levels; MS is 9 m in 34 p with intermediate
BRCA1 levels and 11 m in 12 p with high BRCA1 levels (P0.03). For the
60 p in whom Abraxas and RAP80 were analyzed, MS has not been reached
in p with intermediate levels of all 3 genes; MS is 6 m in p with low or high
levels of all 3 genes and 11 m in other p. In the multivariate analysis of
survival (table), BRCA1 expression emerged as a significant prognostic
marker (hazard ratio [HR] for p with intermediate levels, 4.8 [P0.02]; HR
for p with high levels, 13.4 [P0.004]).
Conclusions: Low levels of BRCA1 indicate a favourable outcome to
chemotherapy, and BRCA1 may be both a prognostic and predictive biomar-
ker. The Spanish Lung Cancer Group has initiated the BRCA1 Expression
Customization (BREC), a phase III randomised trial, to further elucidate the
role of BRCA1.
Hazard Ratio 95% CI P
RAP80 mRNA levels
0.71 1 (ref.)
0.71–1.36 0.08 0.01–0.48 0.005
1.36 0.20 0.04–0.88 0.03
BRCA1 mRNA levels (terciles)
4.44 1 (ref.)
4.44–10.9 4.8 1.29–17.84 0.02
10.9 13.4 2.34–77.46 0.004
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GENE EXPRESSION PROFILES IN WOMAN WITH LUNG
ADENOCARCINOMA (AC) ACCORDING TO CIGARETTE
SMOKING HISTORY
E. Jassem1, A. Szymanowska2, M. Skrzypski1, T. Muley3, H. Dienemann3,
W. Rzyman4, M. Jarzab5, M. Taron6, R. Rosell6, J. Jassem7 1Allergology,
Medical University of Gdansk, Gdansk/POLAND, 2Dept. of Allergology,
Medical University, Gdansk/POLAND, 3Thoraxclinic, University of Heidel-
berg, Heidelberg/GERMANY, 4Toracic Surgery, Medical University of
Gdansk, Gdansk/POLAND, 5Oncology, Institute of Oncology, Gliwice/PO-
LAND, 6Hospital Germans Trias I Pujol Badalona, Catalan Institute of
Oncology, Barcelona/SPAIN, 7Oncology and Radiotherapy, Medical Uni-
versity, Gdansk/POLAND
Background: Approximately 2–5% of all lung cancer patients (pts) have
never smoked. The majority of non-smoking lung cancer pts are women with
AC. A knowledge on molecular features of lung cancers not related to
smoking might lead to better understanding of their carcinogenesis and allow
development of new therapeutic targets. In this study we compared gene
expression profiles in female pts with lung AC in relation to smoking history.
Methods: Study group included 30 women with lung AC (mean age: 61,
range: 37–78 years), 15 of whom were never-smokers (WHO criteria) and
15 - current or past smokers (mean 47.9 pack-years, range 6–112). All pts
underwent curative pulmonary resection. qRT-PCR analysis was performed
on mRNA derived from snap frozen tumor specimens. Expression of 27
genes: potentially related to smoking, kinase receptors, hormone receptors,
growth factor receptors, transcription factors and factors involved in HPV
infection pathways was investigated. 18S rRNA subunit, POLR2A, ESD and
YAP1 were used as normalization genes. Gene expressions in both study
groups were compared by double-sided U-Mann-Whitney test.
Results: In univariate analysis 3 genes were particularly overexpressed in
tumors of nonsmokers: RRAD (p0.03), TGF-beta receptor-2 (TGFBR2;
p0.02) and progesterone receptor (PgR; p0.02). Also genes related to
TGF-beta receptor-3 (TGFBR3; p0.02), SOX9 (p0.02) and androgen
receptor (AR; p0.03) were significantly overexpressed in these tumors,
whereas c-MET was overexpressed in tumors of smokers (p0.05). After
correction for the impact of sex, histopathology, stage of disease, and
multiple comparisons, RRAD and TGFBR2 were independently correlated
with smoking history.
Conclusions: Non-smoking women with lung AC are characterized by a
specific gene expression signature. Overexpression of TGFBR2 provides the
basis for developing new targeted therapies.
79O
GENOMIC PROFILING OF ADENOCARCINOMA OF
LUNG IN HONG KONG CHINESE NEVER-SMOKERS
WITH C-DNA MICROARRAY
J.S. Au1, A. Chow2, C. Lim2, L. Tzang3, M. Yang3, S.C.K. Law2 1Clinical
Oncology, Queen Elizabeth Hospital, Hong Kong/HONG KONG, 2Clinical
Oncology, Queen Elizabeth Hospital, Hong Kong/HONG KONG, 3Biology
and Chemistry, City University of Hong Kong, Kong/HONG KONG
Background: Smoking is still the major identifiable cause of lung cancer in
Hong Kong but the attributable risk of lung cancer to smoking is only 45.8%
and 6.2% in men and women respectively. Nearly all lung cancer occurring
in never-smokers is of histology of adenocarcinoma. Objective: To study the
transcript expression profiles of adenocarcinoma of lung in never-smokers.
Material and Methods: With informed consent, tissue samples from the
tumour and non-neoplastic lung of 40 never-smokers with adenocarcinoma
were collected. Total RNA was extracted for competitive hybridization on a
specially designed spotted c-DNA microarray consisted of 1385 genes.
These genes were a subset from the 10k human clone set of Incyte Genomics,
Inc. and were selected based on the findings of a previous study using pooled
patient samples. We identified up- and down-regulated genes common to
NSCLC according to the following criteria: a) genes for which we were able
to obtain expression data in greater than 65% of the examined cases; and b)
genes whose normalized expression ratio was either greater than 2.0-fold or
less than 0.5-fold in at least 50% of the informative cases. 16 genes were
selected for real-time RT-PCR to confirm the microarray results.
Results: Of genes with known functions, 10 genes (PSG1, STK38, AKR1C4,
ENO3, IGL, LOC91316, IGKV2–40, IGLC1, TUBGCP2, TACSTD1) were
up-regulated and 5 genes (ADH1B, LDB2, A2M, AHNAK, LYN) were down-
regulated. The genomic profiles were analysed using hierachical clustering
alongside with 34 cases of squamous cell carcinoma. We observed 9 genes
(SLC25A5, HIST1H1D, HIST1H2AM, HIST1H2BD, HIST1H2AE, KRT5,
KRT2A, KRT7, KRT15) were up-regulated in squamous-cell carcinoma, mostly
of the keratin family and histone but not in adenocarcinoma. The findings were
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confirmed by q-PCR. Conclusion: The transcript expression profiles of non-
smoking-related adenocarcinoma of lung are distinct and further characterization
of such genes will throw light on the pathogenesis of this particular disease
entity.
80O
TARGETING PRO-APOPTOTIC BAK OVERCOMES
RESISTANCE TO PHARMACOLOGIC INHIBITION OF
PROTEIN KINASE C IN NON-SMALL CELL LUNG
CANCER
J.A. Meiler1, M. Guyot2, S. Hoffarth3, E. Wesarg3, Y. Höhn3, M. Schuler4
1Innere Klinik Und Poliklinik, Universita¨tsklinik Essen Essen, Essen/GER-
MANY, 2III. Medizinische Klinik, Universita¨tsklinik Mainz, Mainz/GERMANY,
3III. Medizinische Klinik, Uniklinik Mainz, Mainz/GERMANY, 4Innere Medizin
(tumorforschung), Universita¨tsklinikum Essen, Essen/GERMANY
Introduction: Cytotoxic treatments for patients with advanced Non-small cell
lung cancer (NSCLC) have only moderate clinical activity. Recently, inhib-
itors of epidermal growth factor receptor signalling showed efficacy in a
subgroup of NSCLC patients, and the modulation of additional signalling
pathways holds significant promise. To this end, we studied the induction of
apoptosis by the protein kinase C (PKC)-specific inhibitor PKC412 and
conventional cytotoxic drugs in NSCLC cells and the modulation of apopto-
sis by conditional expression of transgenic BAK.
Materials and Methods: NSCLC cell lines expressing transgenic BAK were
obtained using the BD RevTet-On vector system (BD Clontech). Replication
defective retroviral virions were produced by standard calcium phosphate
transfection in the FNX ampho packaging cell line. Apoptosis assays con-
sisted of quantitation of cells with fragmented DNA, activated caspases, lost
mitochondrial transmembrane potential, and measurement of cell cycle
distribution using flow cytometry (Coulter). For the mathematical analysis of
synergism and antagonism the isobologram method, as decribed by Beren-
baum (Berenbaum MC, 1989), was used.
Results: Interestingly, we found that cell lines resistant to cytotoxic antican-
cer drugs were also protected against PKC412. Combination therapy with
DNA damaging agents failed to sensitize NSCLC cells to PKC412. In fact,
variable outcomes including antagonistic effects were observed. In contrast,
targeting the mitochondrial pathway of apoptotic signal transduction by
conditionally expressed BAK reliably sensitized drug-resistant NSCLC to
PKC412-induced cell death.
In conclusion, NSCLC cells show similar patterns of apoptosis resistance to a
PKC inhibitor and cytotoxic anticancer drugs, which cannot be overcome by
combining such agents. Therapeutic targeting of the BCL-2 protein family is a
promising strategy to improve the efficacy of kinase inhibitors in NSCLC.
81O
MICRORNA’S IN LUNG CANCER
M. Gottfried1,2, D. Lebanony2 1Rosetta Genomics, Rehovot/ISRAEL and
North Brunswick/UNITED STATES OF AMERICA, 2Lung Cancer Unit, Meir
Medical Center, Kfar Saba/ISRAEL & Sackler Faculty of Medicine, Tel-Aviv
University, Tel Aviv/ISRAEL
Background: MicroRNAs are short non-coding RNAs that regulate differ-
entiation and development in various organisms, and have been shown to be
involved as regulators of many cancer-related processes. Therefore microRNAs
are potential biomarkers and novel drug targets for diagnostic and therapeutic
applications. Rosetta Genomics has developed an integrative platform for
profiling and characterizing all known, and several hundred novel human
microRNAs. We used this platform to study several indications in lung and
related cancers with emphasis on diagnosis and prognosis. Careful diagnosis
of lung cancer patients before treatment with angiogenesis inhibitor drugs is
critical due to life-threatening risk of pulmonary bleeding. Specifically,
squamous histology is an exclusion criterion due to increased risk of fatal
hemorrhage and other complications.
Methods: Protocols were established for the extraction of high-quality
microRNAs from formalin-fixed, paraffin-embedded archival tissues and
from fresh/frozen tissues. For accurate, high-throughput measurement of
microRNA expression levels, a microarray platform with probes for nearly
700 human microRNAs was developed. This microarray is reproducible with
sensitivity of 0.1 fmole, a linear dynamic range of about three orders of
magnitude and with a specificity of 10 fold for a single nucleotide mismatch.
In addition, a proprietary qRT-PCR platform was developed that has sensi-
tivity on the order of single molecules and allows the discrimination of
homologous microRNA family members differing by a single nucleotide.
Results: Microarray studies profiling more than 100 NSCLC samples, re-
vealed a single microRNA that is sufficient to discriminate squamous cell
carcinoma from other types of NSCLC. Based on these results, we developed
a qRT-PCR assay which quantitates the discriminator microRNA and two
other RNAs (one microRNA and one small RNA) used for normalization. A
near perfect separation between over 50 samples of lung squamous cell
carcinoma and samples of non-squamous origin was achieved by the assay.
Conclusions: We developed a highly accurate microRNA-based diagnostic
assay that identifies lung squamous cell carcinoma, an important exclusion
criterion in angiogenesis inhibitor treatments. These results emphasize the
major implications microRNAs hold for future clinical diagnostics and
possibly therapeutics in cancer.
82O
EVOLUTION OF MIRNAS EXPRESSION DURING LUNG
SQUAMOUS CARCINOGENESIS
C. Mascaux1, J.F. Laes2, G. Anthoine1, A. Haller3, F. Feoli3, V. Ninane4, A.
Burny5, J. Sculier6 1Intensive Care and Thoracic Oncology, Institut Jules
Bordet, Brussels/BELGIUM, 2Microarrays Unit, DNA Vision, Gosselies/
BELGIUM, 3Pathology, Institut Jules Bordet, Brussels/BELGIUM, 4Pneu-
mology, CHU Saint-Pierre, Brussels/BELGIUM, 5Laboratory of Molecular
and Cellular Biology, Faculte´ universitaire des Sciences Agronomiques de
Gembloux (FUSAGx), Gembloux/BELGIUM, 6Intensive Care and Thoracic
Oncology, Institut Jules Bordet, Brussels/BELGIUM
MiRNAs recently appeared as involved in carcinogenesis and as potential
therapeutic targets for cancer. To determine their potential role in the process
of lung squamous carcinogenesis we studied, by using Taqman LDA (Ap-
plied Biosystems). a series of 60 biopsies, obtainedby fluorescence bron-
choscopy, with 6 samples of each category : normal bronchial epithelium of
non smokers, normal normo- and hypofluorescent bronchial epithelium of
smokers, hyperplasia, metaplasia, mild, moderate and severe dysplasia, in
situ carcinoma (CIS) and invasive squamous cell carcinoma (SQCC). The
lesions were grouped according a classification established by a previous
genomic study performed on the same biopsies, the normal bronchial
epithelium of non smokers being a separate group (group 0). Normal norno-
and hyperfluorescent bronchial epithelium of mokers and hyperplasia belong
to group 1. Metaplasia, mild and moderate dysplasia on one side and and
severe dysplasia, CIS and SQCC on the other belong to group 2A and 2B
respectively. Some miRNAs show a linear evolution of their expression
level. Particularly, the expression of miR 34c and miR 642 progressively
decrease between the different stages and, for miR 34c, from between normal
bronchial tissues of non smokers and those of smokers. Other miRNAs
behave differently and their expression is only modified between two specific
stages. Between groups 1 and 2A, the expression of 14 miRNAs is reduced,
and with a very high statistical significance for miR 193a and miR 214. Only
two miRNAs have their expression increased between these two groups, miR
203 and miR 244. The expression of miR 244 also increases from group 2A
to group 2B. The expression rate of 13 miRNAs increases between groups
2A and 2B, the most significant of them being miR 196a, miR 9, miR 452
and miR 196b. However, the level of expression of 17 other miRNAs
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decreases at the same stage and particularly miR 375 and miR 135a. In
conclusion, this study, based on bronchial biopsies, is the first to assess
miRNAs expression during early steps of lung squamous carcinogenesis and
provide a global (linear) and specific (at each stage) view of the evolution of
their expression at the different steps of this pathogenic process.
83O
EVOLUTION OF GENOMIC PROFILE DURING LUNG
SQUAMOUS CARCINOGENESIS
C. Mascaux1, B. Hafbe-Kains2, G. Anthoine1, C. Desmet2, J.F. Laes3, A.
Haller4, F. Feoli4, V. Ninane5, A. Burny6, J. Sculier7 1Intensive Care and
Thoracic Oncology, Institut Jules Bordet, Brussels/BELGIUM, 2Microarrays
Unit, Institut Jules Bordet, Brussels/BELGIUM, 3Microarrays Unit, DNA
Vision, Gosselies/BELGIUM, 4Pathology, Institut Jules Bordet, Brussels/
BELGIUM, 5Pneumology, CHU Saint-Pierre, Brussels/BELGIUM, 6Labora-
tory of Molecular and Cellular Biology, Faculte´ universitaire des Sciences
Agronomiques de Gembloux (FUSAGx), Gembloux/BELGIUM, 7Intensive
Care and Thoracic Oncology, Institut Jules Bordet, Brussels/BELGIUM
Understanding the mechanisms involved in bronchial carcinogenesis could
provide markers for early detection of lung cancer, in order to improve the bad
prognosis of this cancer. We aimed to characterize the evolution of genomic
profile during successive steps of lung squamous cell carcinogenesis.
We hybridized (Agilent two colours Whole Human Genome 4x44k arrays),
against a common control (pool of normal bronchial biopsies from non-smok-
ers), at least 12 bronchial biopsies, obtained by fluorescence bronchoscopy, of
each histological category (normal bronchial epithelium of smokers, hyperplasia,
metaplasia, mild, moderate and severe dysplasia in situ carcinoma (CIS) and
invasive squamous cell carcinoma (SQCC), with a total of 122 biopsies.
We clearly identified 2 groups by clustering: 1) normal bronchial epithelium
of smokers and hyperplasia (group 1, phenotypically “normal” bronchial
epithelium) and 2) metaplasia, mild, moderate and severe dysplasia CIS and
SQCC (group 2, histologically (group 2, histologically modified bronchial
epithelium). This last group is subdivided in 2 subgroups: group 2A with
metaplasia, mild and moderate dysplasia (those lesions are often still revers-
ible) and group 2B containing severe dysplasia and CIS, (preneoplastic
lesions which are more likely to progress to invasive carcinoma) and SQCC.
On this basis, we obtained lists of genes with a statistically different
expression between the different groups and subgroups (corrected p value
0.05). Genes of which the protein product is known to be involved at early
steps of lung carcinogenesis (like COX-2, MDM2, Ki-67, cytokeratins, )
were also detected by using gene expression profiling. Moreover, we were
able to show that proteins described as active in invasive lung cancer but not
yet reported at pre-invasive stages (including the genes of the PTH-like,
TNF-, IGF- and Wnt-related proteins) are indeed involved at preneoplastic
stages. Finally this study allowed us in order to identify previously unknown
actors of lung carcinogenesis.
In conclusion, our study provides data on the evolution of the gene expres-
sion profile during lung squamous cell carcinogenesis and helps to under-
stand its mechanisms. This offers opportunity to discover potential markers
for early detection of lung cancer.
84O
MET INCREASED GENE COPY NUMBER AND PRIMARY
RESISTANCE TO GEFITINIB THERAPY IN NEVER
SMOKERS OR EGFR FISH POSITIVE NON-SMALL
CELL LUNG CANCER (NSCLC) PATIENTS
F. Cappuzzo1, M. Skokan2, S. Gajapathy2, E. Rossi3, P.A. Janne4, G.
Finocchiaro1, M. Roncalli5, A. Santoro1, L. Terracciano6, M. Varella-Garcia2
1
Oncology, Istituto Clinico Humanitas IRCCS, Rozzano/ITALY, 2Oncology,
University of Colorado Cancer Center, Aurora/UNITED STATES OF AMER-
ICA, 3Statistic, CINECA, Bologna/ITALY, 4Oncology, Dana Farber Cancer
Institute, Boston/UNITED STATES OF AMERICA, 5Pathology, Milan Univer-
sity, Milan/ITALY, 6Pathology, University Hospital, Basel/SWITZERLAND
Purpose: Gefitinib, an orally available Epidermal Growth Factor Receptor
Tyrosine Kinase Inhibitor (EGFR-TKI) demonstrated to induce dramatic and
durable response in certain patients with advanced non-small cell lung cancer
(NSCLC). MET, the gene codifying for the receptor for hepatocyte growth
factor, is amplified in approximately 20% of patients with EGFR mutations
progressing after an initial response to EGFR-TKI therapy. The incidence of
MET gene gain in NSCLC and its relevance for intrinsic resistance to
gefitinib therapy has not been previously investigated.
Methods: The study was conducted in two different cohorts of patients. A
cohort of 447 NSCLC that underwent radical resection for early stage disease
and a cohort of 42 never smoker or EGFR FISH positive patients previously
enrolled in a prospective phase II trial with gefitinib (ONCOBELL). MET
gene copy number was assessed by fluorescence in situ hybridization (FISH).
The analysis was conducted in tumor biopsies or surgical specimens obtained
at the time of primary diagnosis.
Results: Among the surgical specimens, high MET gene copy number (mean5
copies/cell) was observed in 43 cases, including 18 (4.3%) cases with gene
amplification and 25 (6.1%) with high polysomy. MET positive status was
significantly associated with advanced stage (p0.03), with no association with
any other clinical characteristic. Among the 42 NSCLC patients enrolled onto
the ONCOBELL trial, 24 had enough tumor tissue for MET FISH analysis.
Gene amplification was not found and high level of polysomy was observed in
only 2 cases (8.3%), both EGFR FISH positive and both sensitive to gefitinib
therapy. Conclusions: MET gene amplification is a rare event in NSCLC, not
occurring in individuals with clinical and biological features for EGFR-TKI
sensitivity. Further studies should investigate whether MET increased gene copy
number affect the outcome of patients treated with EGFR-TKIs.
85O
WILD TYPE OF EXONS 19 AND 21 AND POLYSOMY OF
CHROMOSOME 7 WERE DEFINED FOR EGFR GENE IN
SQUAMOUS CELL CARCINOMA OF THE LUNG
L.M. Carvalho Faculdade de Medicina da Universidade de Coimbra, Insti-
tuto de Anatomia Patolo´gica, Coimbra/PORTUGAL
Background: Tyrosine kinase inhibitors after first line chemotherapy are used
to complement conventional chemotherapy and several studies are required
to define molecular characteristics of non-small-cell lung cancer to predict
the response to those drugs. The present study intends to clarify the status of
EGFR gene by FISH, PCR and its immunohistochemical expression in
squamous cell carcinoma of the lung.
Method: Representative sections of squamous cell carcinoma were then
selected from 60 surgical specimens and submitted to tissue microarray
construction, determination of EGFR protein expression by immunohis-
tochesmistry (Zymed Laboratories), FISH (Fluorescence in situ Hibridiza-
tion) with LSI EGFR/CEP 7 (Vysis; Abbott Molecular, USA). Genomic
DNA was extracted from 40 cases and PCR amplified Exon 19 for delections
and Exon 21 for pontual mutations, by Capillary Electrophoresis and Re-
striction Fragment Length Polymorphism (RFLP), respectively.
Results: Immunohistochemical EGFR protein overexpression was identified in
35 cases, by the application of Hirsh’s scoring system of chromosome 7 in 32
cases. High polysomy EGFR copy numbers were seen in 32 cases by FISH,
scored according to Cappuzzo’s method. Throught Capillary Electrophoresis, the
delection in Exon 19 of EGFR was detected in 3 cases of 40 samples; the Exon
21 of EGFR was expressed in its wild type by RFLP in all cases.
Conclusions: Our study concerning only cases of squamous cell carcinoma of
the lung in surgical stages is the first to be done, to the best of our knowledge,
after reviewing the published medical literature. The cases of squamous
carcinoma referred in published studies of non-small-cell lung cancer, in
advanced stages, had higher expressions of the parameters included in the
present study. However the results obtained showed that squamous cell lung
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carcinoma in surgical stages, independently of the presence of lymph nodes
metastases, expresses EGFR protein and have high chromosome 7 polysomy
in 50% of the cases and the gene remains without molecular alterations.
These conclusions have to be correlated with follow-up of these patients to
define potential recurrence related with the results obtained.
86O
IMMUNE EVASION OF LUNG CANCER CELLS BY LOSS
OF EXPRESSION OF HLA CLASS I
K. Yasumoto1, T. Hanagiri2, M. Takenoyama3, T. Baba3 1School of Medi-
cine, 2nd Dept Surgery, University of Occupational and Environmental
Health, Kitakyushu/JAPAN, 2Surgery, University of Occupational and En-
vironmental Health, Kitakyushu/JAPAN, 3Surgery, University of Occupa-
tional and Environmental Health, Kitakyushu/JAPAN
Background: Cytotoxic T lumphocytes(CTL) attack cancer cells by means of
recognition of cancer specific Ags expressed on the HLA class I. However,
cancer cells sometimes genetically lose expression of HLA class I Ag and
escape from the attack by CTL.
[Methods] We established 21 permanent lung cancer cell lines from clinical
specimens. Among them, 3 cell lines lost HLA class I expression completely and
another 7 cell lines have haplotype loss of HLA class I. Genetic mechanisms to
induce such abnormal expressions of HLA class I were elucidated. Furthermore,
induction of CTL clones against HLA-restored lung cancer cells have been
applied and the Ags recognized by the CTL clones have been identified.
Results: The causes of complete loss of HLA expression were elucidated to
be due to genetic abnormalities of 2-microglobulin expression in 2 of the 3
cell lines. The cause of haplotype loss of HLA expression was ascribed to
loss of heterozygosity of the region mapping HLA in 6p. The HLA lost cell
line C831L was reconstituted HLA expression by transduction of wild type
2-microglobulin gene(2m-C831L) (Cancer Sci.2,007,98:1795–1802).
CTL could be induced from autologous regional lymph node lymphocytes by
in vitro stimulations with 2m-C831L. Finally, Ag recognized by the CTL
clone in the context of HLA-B7 was identified by the gene expression
cloning method as LRRC8A . In haplotypye-loss cell line A904L, the lost
HLA-B39 was transducted to A904L(B39-A904L), and CTL could be
induced from autologous regional lymph node lymphocytes by stimulation
with B39-A904L. The CTL clone established from the CTL recognized
SGT1 in the context of HLA-B39 (Cancer Res.2,005, 65:5945–5952).
Conclusion: Lung cancer cells can express specific Ag on HLA class I Ag at
the early phase of carcinogenesis without loss of HLA expression. However,
at the later phase such lung cancer cells frequently evade from cellular attack
by genetic loss of expression of HLA class I and developed to clinical cancer.
Genetic restoration of HLA class I Ag might be a possible treatment strategy
to improve outcome of prognosis of patients with lung cancer.
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HOXA9 GENE METHYLATION IN LUNG CANCER USING
PYROSEQUENCING ANALYSIS
M. Lee1, S.H. Hwang2, S.Y. Lee3, C.H. Lee4 1Internal Medicine, Pusan
National University Hospital, Busan/KOREA, 2Laboratory Medicine, Pusan
National University, Busan/KOREA, 3Biochemistry, Pusan National Univer-
sity, Busan/KOREA, 4Pathology, Pusan National University, Busan/KOREA
Background: DNA hypermethylation at promoter CpG islands shows great
promise as a cancer-specific marker that would complement visual lung
cancer screening tools such as spiral CT, improving early detection. We
investigated usefulness of DNA methylation of HOXA9 gene, a member of
the HOX gene family, which is known to play key roles during embryonic
development and in differentiation of adult cells as a marker for early
diagnosis of lung cancer.
Methods: We used pyrosequencing(Biotage, Inc., Charlottesville, VA, USA)
analysis to examine DNA methylation of HOXA9 quantitatively in forty
pairs of human lung cancer tissue and adjacent non-tumor lung tissue. We
also examined DNA methylation of HOXA9 in 25 induced sputum samples
including 18 lung cancer and 5 benign lung diseases.
Results: We analyzed pairs of normal lung tissue and lung cancer tissue
including 23 adenocarcinoma and 16 squamous cell carcinoma. We found
that HOXa9 were hypermethylated in lung cancer tissue compared to
adjacent non-tumor lung tissue (68.3  16.5 vs. 22.6  7.5%, P  0.001).
HOXA9 were hypermethylated in squamous cell carcinoma compared to
adenocarcinoma (76.7  12.6 vs. 63.0  16.9%, P0.005). HOXA9 was
also highly methylated in stage I lung cancer (65.9  16.1%). HOXA9
distinguished lung cancer from non-cancer lung with a sensitivity of 92.5%
and specificity of 100%. HOXA9 gene methylation in induced sputum
sample was 28.86.0% and 25.318.4% in benign lung disease and lung
cancer respectively (p0.446).
Conclusion: HOXA9 distinguished lung cancer from non-cancer lung with a
hingh sensitivity and specificity. HOXA9 gene is potentially useful as a DNA
methylation marker for early diagnosis of the lung cancer.
88PD
TISSUE MICROARRAY ANALYSIS OF EGFR COPY
NUMBER CHANGES IN NON-SMALL CELL LUNG
CANCER — CORRELETIONS WITH CLINICO-
PATHOLOGICAL PARAMETERS
R. Cherneva Internal Medicine, Medical Academy, Sofia/BULGARIA
Background: The epidermal growth factor receptor (EGFR) is an important
target for anticancer therapy. In non-small-cell lung cancer (NSCLC), mu-
tations in the tyrosine kinase domain of EGFR and EGFR gene copy number
have been demonstrated in order to identify patients most likely to benefit
from EGFR tyrosine kinase inhibitors-gefitinib, erlotinib, but there is not still
enough data on the influence of EGFR on tumor behaviour. To analyse this
we have investigated EGFR copy number changes by fluorescence in situ
hybridization on a set of 356 samples of non-small cell lung cancer arranged
on a tissue microarray. The aim of the study was to evaluate the relation
between the EGFR copy number imbalances and the clinico-pathological
factors. Methods: Tissue samples from 356 patients operated from non-small
cell lung cancer in the Department of Thoracic Surgery, Sofia were taken and
arranged in triples on two paraffin blocks. Samples were analyzed by dual
color FISH probe EGFR Spectrum orange/CEP17 Spectrum green. The
genetic abnormalities and pathological parameters were analyzed (T-factor,
N- factor, M- factor and histological grading.)
Results: EGFR genetic gain was detected in 0% of T1 (n0), 17.8% of T2
(n11), 20.9% of T3 (n14), 27.3% of T4 (n3). EGFR amplification was
found in 0% of T1 and T2 (n0), 3.0% of T3 (n2), 9.1% of T4 (n1).
There was a statistically significant association between the amplification of
EGFR and the progression of the T factor (p0.04). The frequency of normal
EGFR copy number progressively decreases from the low to the high
histological grade, reaching a statistical significance (p0.00001).The EGFR
genetic gain and amplification were also correlated to the high grade
(p0.00002 and p0.008, respectively). There was not a statistical signifi-
cance between EGFR copy number increases and the progression of the N or
M factor. Conclusion: EGFR amplification and genetic gain are factors for
increased local tumor proliferation and dedifferentiation.
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ERBB3 EXPRESSION CORRELATES WITH E-CADHERIN
IN PATIENTS WITH NSCLC AND IS INDUCED BY SNDX-
275 IN EGFR-TKI RESISTANT CELL LINES
S.E. Witta1, R. Dziadziuszko2, K. Yoshida1, F. Cappuzzo3, P.A. Bunn, Jr.4,
F.R. Hirsch4 1Medicine-oncology, University of Colorado Health Sciences
Center, Aurora/UNITED STATES OF AMERICA, 2Department of Oncology
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and Radiotherapy, Medical University of Gdansk, Gransk/POLAND, 3On-
cology, Instituto Clinico Humanitas IRCCS, Rozzano/ITALY, 4Medicine-
Oncology, University of Colorado Cancer Center, Aurora/UNITED STATES
OF AMERICA
Background: EGFR tyrosine kinase inhibitors are effective in a subset of
NSCLC tumors. We have previously showed that ErbB3 and E-cadherin
expression correlates with EGFR TKI activity in vitro. E-cadherin is regu-
lated by HDAC inhibitors and sensitizes cells to gefitinib. In this study we
correlated the expression of ErbB3 with E-cadherin and with EGFR in
NSCLC cell lines, in a cohort of patients with surgically resected stage I-III
NSCLC and another cohort with diagnostic stage IV NSCLC treated with
gefitinib. We have also evaluated the regulation of ErbB3 by the HDAC
inhibitor, SNDX-275 in NSCLC cell lines.
Methods: Gene expression analysis (E-cadherin, ErbB3 and EGFR) was
performed using real-time RT-PCR on RNA isolated from fresh frozen
resected tumors from a cohort of 59 patients, from paraffin embedded tissue
from a cohort of 66 patients with stage IV NSCLC, from 21 NSCLC cell
lines and from 5 gefitinib resistant cell lines treated with SNDX-275.
Results: In the first cohort, there was significant correlation between
expression of E-cadherin and ErbB3 (r0.42, P0.001) and between
E-cadherin and EGFR expression (r0.47, P0.001). Correlation of
ErbB3 and EGFR was not significant (r0.23, p0.078). Significant
correlation was detected between ErbB3 expression and E-cadherin
expression (r0.88, p0.001), and with response to gefitinib (r0.81,
p0.001) in cell lines. Furthermore, in all the 5 NSCLC cell lines
resistant to gefitinib, both ErbB3 and E-cadherin expression were induced
by SNDX-275. Expression analysis in the second cohort of patients
treated with gefitinib is ongoing.
Conclusion: Expression of ErbB3 and E-cadherin correlates with each other.
The hypothesis that both ErbB3 and E-cadherin associate to sensitivity is
currently studied in tumours from patients treated with EGFR-TKi. In
resistant cell lines expression of ErbB3 and E-cadherin is induced by
SNDX-275.
90PD
IS CIRCULATING DNA A PROGNOSTIC FACTOR FOR
SURVIVAL IN LUNG CANCER PATIENTS?
M.A. van der Drift1, C.H.W. Klaassen2, C.F.M. Prinsen2, B.E.A. Hol3, J. van
der Stappen2, P.N.R. Dekhuijzen4, F.B.J.M. Thunnissen2 1Department of
Pulmonology, Radboud University Nijmegen Medical Centre, Dekkerswald,
Groesbeek/NETHERLANDS, 2Pathology, Canisius-Wilhelmina Hospital, Ni-
jmegen/NETHERLANDS, 3Pulmonology, Canisius-Wilhelmina Hospital, Ni-
jmegen/NETHERLANDS, 4Pulmonology, Radboud University Nijmegen
Medical Centre, Nijmegen/NETHERLANDS
Aim of the study: The most important predictor for survival of lung cancer
patients is stage according to the TNM system. A possible new prognostic
tool might be circulating DNA in plasma, which is present in a considerably
higher concentration in lung cancer patients than in controls. The aim of this
study was to prospectively analyse the relationship of circulating plasma
DNA with overall survival (OS) and disease-free survival (DFS) of previ-
ously untreated lung cancer patients.
Patients and methods: Amplification of beta-globin was used as a marker of the
total amount of DNA present in plasma samples of 58 lung cancer patients (50
non-small cell lung cancer and 8 small cell lung cancer) and 21 controls. Based
on controls a DNA cut-off level of 48 ng/ml was increased plasma DNA.
Results: The results of this study show a significant correlation between
increased plasma DNA concentration and poor survival in lung cancer
patients. 11 cancer patients relapsed of cancer or developed metastases
(35.5%). No correlation between plasma DNA concentration and DFS was
found. The mean plasma DNA concentration of the cancer patients who died
was significantly increased compared to the cancer patients, who were alive
at the end of follow-up (498 ng/ml versus 54 ng/ml).
Conclusion: circulating plasma DNA is related for survival. In further
research it might be interesting to select patients with high plasma DNA
levels for adjuvant treatment and analyse prognosis.
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DNA-REPAIR GENE POLYMORPHISMS PREDICT
FAVORABLE CLINICAL OUTCOME IN ADVANCED
NSCLC
A. Voutsina1, A. Kalikaki1, M. Kanaki1, A. Xyrafas2, N. Androulakis2, N.
Vardakis2, S. Agelaki2, K. Kalbakis2, D. Mavroudis3, V. Georgoulias3
1Laboratory of Tumor Cell Biology, School of Medicine, University of Crete,
Heraklion/GREECE, 2Department of Medical Oncology, University General
Hospital of Heraklion, Heraklion/GREECE, 3Laboratory of Tumor Cell
Biology, School Of Medicine, University of Crete, Department of Medical
Oncology, University General Hospital of Heraklion, Heraklion/GREECE
Purpose: We retrospectively assessed whether single nucleotide polymor-
phisms (SNPs) in DNA-repair genes ERCC1, XPD, XRCC1, and metabo-
lizing genes glutathione S-transferase GSTP1, GSTT1 and GSTM1 predict
survival, response and toxicity in stage IV NSCLC patients receiving
platinum-based chemotherapy as first or second line treatment.
Methods: In 119 patients, polymerase chain reaction–restriction fragment
length polymorphism (RFLP) and sequencing approaches were used to
determine the frequency of the SNPs: ERCC1-C8092A, ERCC1-Asn118Asn
XRCC1-Arg399Gln XPD-Asp312Asn, XPD-Lys751Gln, GSTP1-Ile105Val
and GSTM1 and GSTT1 deletion polymorphisms in DNA from peripheral
lymphocytes.
Results: The frequencies of the distinct genotypes for the homozygous
common allele, heterozygous and homozygous polymorphic variants were:
72%, 39%, and 8% for ERCC1-C8092A; 16%, 67%, and 16% for ERCC1-
N118N; 30%, 56%, and 14% for XPD-K751Q; 34%, 43%, and 23% for
XPD-D312N; 28%, 64%, and 8% for XRCC1-R399Q; 64% (AA) and 36%
(AG) for GSTP1-I105V; 36.5% for the GSTM1-null genotype and 5% for
the GSTT1-null genotype, respectively. Overall median survival was 11.3
months. No significant difference was observed in overall survival (OS) of
patients who received platinum-based chemotherapy as 1st line (n69, 58%)
or second line (n50, 42%) treatment (breslow test p0.113). There was a
statistically significant association between the ERCC1-C8092A poly-
morphism and OS (log-rank test p0.009), with median survival times of
9.8 (C/C) and 14.3 (C/A or A/A) months, respectively. Additionally, there
was a statistically significant association between XRCC1-R399Q poly-
morphism and OS (log-rank test p0.001) with median survival times of
12.1 (G/G or G/A) and 7.1 (A/A) months, respectively. Patients with
either one or two C alleles (C/C or C/T) at ERCC1–118 were more likely
to respond to platinum-based chemotherapy compared to those without
the C allele (p0.012).
Conclusions: The ERCC1-C8092A and XRCC1-R399Q polymorphisms
may be useful prognostic indicators of OS in advanced NSCLC patients
treated with platinum-based chemotherapy.
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GENDER DIFFERENCES IN THE EXPRESSION OF
DOUBLE STRAND BREAKGENES IN EARLY NON-SMALL
CELL LUNG CANCER (NSCLC) PATIENTS
S. Novello1, S. Saviozzi2, P. Ceppi2, M. Longo1, E. Capelletto1, M. Giaj
Levra1, B. Crida1, M. Volante3, S.G. Rapetti1, M. Papotti3, G.V. Scagliotti1
1Thoracic Oncology Unit, University of Turin, Orbassano/ITALY, 2Clinical
and Biological Sciences, University of Turin, Orbassano/ITALY, 3Pathology
Unit San Luigi Hospital, University of Turin, Orbassano/ITALY
Background: Emerging data demonstrate gender-specific differences in
NSCLC susceptibility and several studies have determined that women have
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a better survival compared to men for each stage of disease. However, the
underlying biological reasons to explain this difference remains poorly
understood. Since genes involved in DNA repair are currently being exten-
sively investigated as prognostic markers in both treated and untreated
NSCLC, this work aimed at testing sex-related differences in the expression
of selected genes involved in DNA repair.
Methods: Total RNA was extracted from fresh snap-frozen tumors and
corresponding normal tissues from 50 consecutive early-stage chemo-naive
NSCLC patients (stage I/II/III 31/10/9; female/male13/37, median age
69 yrs). Transcript levels were quantified by Real-Time PCR (TaqMan), fold
changes were calculated with the 2-		Ct method. Statistical significance of
patient’s clinic-pathologic features to transcript expression levels was as-
sessed by the Mann-Whitney U test. POLR2A and 18SrRNA were used as
reference genes and normal specimens were the calibrator tissues. Differen-
tial mRNA levels of 22 DNA repair genes belonging to 5 different DNA
repair pathways were evaluated: direct, base excision, nucleotide excision,
double strand break (DSB) and post-replicative repair.
Results: Among all DNA repair pathways investigated, interestingly, genes
belonging to DSB were those with a significant sex-specific over-expression
rate (tumor vs normal ratio for each gene): significantly higher transcript
levels of 5 out of 7 (71%) DSB genes were found in male patients compared
to female (p0.03). In particular, BRCA1 (p0.01), BRCA2 (p0.005) and
XRCC3 (p0.004) were the DSB genes more strongly over-expressed in
male patients. All the other genes from other pathways were not significantly
correlated with gender.
Conclusion: The results of this study suggest that the worst prognosis and the
higher degree of chemotherapeutical resistance of male NSCLC patients,
compared to woman, could be related to the stronger up-regulation of some
DSB genes. This information, if confirmed in larger studies, could be useful
to understand the molecular basis of gender differences in terms of outcome
and could improve the therapeutical stratification in NSCLC.
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ROLE OF K-RAS MUTATIONS IN PATIENTS AFFECTED
WITH NSCLC AND TREATED WITH TYROSINE KINASE
INHIBITORS (TKIS): RESULTS OF A POOLED ANALYSIS
M.C. Garassino1, O. Martelli2, L. Rosso3, S. Veronese4, I. Floriani5, M.
Broggini6, L. Santambrogio3, M. Marabese6, G. Farina1, V. Torri5 1Oncol-
ogy, Ospedale Fatebenefratelli e Oftalmico, Milan/ITALY, 2Oncology, San
Giovanni e Addolorata, Rome/ITALY, 3Thoracic Surgery, Ospedale Mag-
giore, Milan/ITALY, 4Pathology, Ospedale Ca’granda Niguarda, Milan/
ITALY, 5Oncology, Istituto “Mario Negri”, Milan/ITALY, 6Oncology, Isti-
tuto “Mario Negri”, Milano/ITALY
A negative outcome of patients affected with non small cell lung cancer
(NSCLC) harbouring K-ras mutations and treated with TKIs is reported.
We performed a pooled analysis in order to assess the role of k-ras mutations
on the effect of TKIs in NSCLC patients.
An electronic search focused on all randomized trial assessing efficacy of
TKIs alone or associated with chemotherapy in NSCLC versus. A pooled
analysis was accomplished and Hazard Ratio (HR) with 95% confidence
interval was derived for each level of the factor.
Out of 17 retrieved papers only two were considered for analysis (TRIBUTE;
BR21).
Patients with K-ras mutations have and increased relative risk of death of
97% (HR 1.97 95%CI. 1.16–3.33 and interaction (p0.003)) and an in-
creased risk of progression of 90% (HR 1.90 95%CI. 1.05–3.44). Patients
without K ras mutations have a reduction risk of death of 31% (HR 0.79
95%CI. 0.59–1.05) and a risk of progression similar to placebo (HR 1.06
95%CI. 0.81–1.38).
Interaction suggests a detrimental effect of TKIs in pts with K-ras mutations
versus placebo; however, it is unclear whether this negative effect is related
only to the tratment with TKIs, in fact, the INTEREST trial failed in
demonstrating this effect in respect to chemotherapy.
Properly planned studies defining the exact role of this marker, in particular
in respect to chemotherapy are warranted in order to choose the most
appropriate therapy and to avoid any risks for these patients.
94PD
XPG MRNA LEVELS MODULATES PROGNOSIS IN
RESECTED NON-SMALL-CELL LUNG CANCER (NSCLC)
IN CONJUNCTION WITH BRCA1 EXPRESSION
J. Wei1, R. Bartolucci2, F. Puma3, S. Sabatini4, S. Catanzani4, M. Urbani4, P.
Saccenti4, P. Mendez1, M. Taro´n5, R. Rosell6 1Laboratory, Catalan Institute
of Oncology, Badalona, Barcelona/SPAIN, 2Oncology Service, Azienda Osped-
aliera, Terni/ITALY, 3Thoracic Surgery, Azienda Ospedaliera, Terni/ITALY,
4Oncology Service, Azienda Ospedaliera, Terni/ITALY, 5Laboratory, ICO Hos-
pital Germans Trias i Pujol, Badalona, Barcelona/SPAIN, 6Medical Oncology
Service, Catalan Institute of Oncology, Badalona, Barcelona/SPAIN
Background: DNA repair genes such as BRCA1 are induced by c-Myc
(Menssen and Hermeking, PNAS 2002), and high BRCA1 mRNA levels
have been related to poor survival in resected NSCLC (Rosell et al, PLoS
One 2007). ERCC1 and RRM1 have also been linked to prognosis. XPG
belongs to the flap endonuclease 1 (FEN1) family of nucleases. In the
absence of XPG cells without XPG expression survive better than wild-type
cells when exposed to a sequence-specific guanine N2 alkylator (Herrero et
al, Cancer Res 2006).
Methods: BRCA1, ERCC1, RRM1 and XPG transcripts were examined by
quantitative PCR in tumors of 54 resected NSCLC patients (p). Median age,
66 years; 51 male; 42 squamous cell carcinomas and 12 adenocarcinomas.
Median disease-free survival (DFS) was 40 months (m) for stage IA, not
reached for stage IB, and 25 m for stage II.
Results: DFS was not reached in p with low ERCC1 or RRM1 levels, while
p with high ERCC1 or RRM1 had a DFS of 26 m (Pns). DFS was not
reached in 18 p with low BRCA1 mRNA levels, while 37 p with high
BRCA1 mRNA levels had a DFS of 22.4 m (P0.02). In contrast, p with
high XPG had a 51-m DFS, while p with low XPG had a 26-m DFS. When
BRCA1 and XPG levels were considered jointly, DFS was not reached for p
with low levels of BRCA1 regardless of whether XPG was high (10 p) or low
(17 p). However, for p with high BRCA1 levels, DFS was shorter for 10 p
with low XPG (16.4 m) than for 17 p with high XPG (26 m) (Pns).
Conclusion: High BRCA1 mRNA expression conferS poor prognosis in
early NSCLC and the combination of high BRCA1 plus low XPG expression
still further increaseS the risk of shorter DFS. These findings could have
important implications for the optimal use of adjuvant chemotherapy.
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THE ROLE OF MONOTOTAL IN RELATION TO OTHER
CYTOKERATINS FOR PRIMARY DIAGNOSIS OF
PATIENTS WITH NON SMALL CELL LUNG
CANCER (NSCLC)
L. Holubec, O. Topolcan, J. Safrane, M. Prazakova, J. Vrzalova, M. Casova,
S. Svobodova, V. Treska, M. Pesek, J. Finek Faculty Hospital and Medical
School, Pilsen, Charles University, Prague/CZECH REPUBLIC
Aim of study: MonoTotal is a new cytokeratin tumor marker assay intended for
efficient management of patients with NSCLC. The aim of the study was to
evaluate the clinical importance of MonoTotal for primary diagnosis of NSCLC
in comparison to other conventionally used cytokeratin tumor markers.
Methodology: MonoTotal (IRMA, IDL, Sweden) was measured in serum of
69 patients with NSCLC stages Ia-IIIb (20 patients with adenocarcinoma and
49 patients with squamous cell carcinoma). As control group, we used sera
from 60 age-matched individuals without history or clinical symptoms of
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cancer disease or lung disease. The results were compared with other suluble
cytokeratin markers conventionally used in diagnosis and management of
NSCLC; TPA (IRMA, Dia Sorin, Italy), TPS (IRMA, IDL, Sweden) and
CYFRA 21.1 (TRACE method, Brahms, Germany).
Results: Statistically significant differences between control group and pa-
tients with NSCLC were found for all cytokeratins; TPA (p0.0001), TPS
(p0.0002), CYFRA 21.1 (p0.0001), and MonoTotal (p0.0001). Similar
significant differences were registered also per histological types (adenocar-
cinoma or squamous cell carcinoma). The preoperative sensitivity, at 95%
specificity, was for Monototal 71%, TPA 53%, CYFRA 21.1 51% and TPS
25%. Higher sensitivities were noticed in the subgroup of patients with
squamous cell carcinoma; Monototal 76%, TPA 63%, CYFRA 21.1 65% and
TPS 27%; compared to the subgroup of patients with adenocarcinoma, where
sensitivities were much lower.
Conclusions: MonoTotal is a more sensitive tumor marker for NSCLC than
cytokeratin markers currently used in routine clinical practice, especially in
patients with squamous cell carcinoma. This study was supported by the
grant IGA MZCR 9343–3 and VZ MSM 0021620819. Key words: Mono-
Total, soluble cytokeratins, tumor markers, early diagnosis.
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C-ERBB-2 EXPRESSION IN RELATION TO
GEMCITABINE-CISPLATIN CHEMOTHERAPY IN
PATIENTS WITH NON-SMALL CELL LUNG CANCER
Z. Calikusu1, Y. Yildirim2, O. Ozyilkan1, Z. Akcali1 1Medical Oncology,
Baskent University, Ankara/TURKEY, 2Medical Oncology, Sivas Numune
Hospital, Sivas/TURKEY
Objectives: The aim of the study was to investigate a relation between
c-erbB-2 expression in non-small cell lung cancer and the response of those
tumors to gemcitabine-cisplatin chemotherapy. Methods: The study included
55 consecutive patients with non-small cell lung cancer in stage IIIB or IV,
who were diagnosed at Baskent University Hospital, Adana, Turkey, be-
tween September 2000 and October 2005. All patients received gemcitabine
(1250 mg/m2 days 1 and 8) and cisplatin (75/m2 day 8) combination therapy
in every 21 days. The response of therapy was assessed as complete response
(CR), partial response (PR), stable disease (SD), and progressive disease
(PD) on the basis of computerized tomography scans. C-erbB-2 expression
was determined by immunohistochemically in paraffin-embedded specimens
of the tumors. Results: A response to therapy (CRPR) was observed 29
patients, while resistance (SDPD) to therapy was seen in 23 patients.
C-erbB-2 positivity (ranging from 1 to 3) was found 16% (9 patients) of
the patients. In patients with c-erbB-2 positive tumor, 6 of them were
resistant to therapy however 3 of them responded to the chemotherapy
(p0.47). One year survival rate of patients with c-erbB-2 positive and
c-erbB-2 negative tumors were 44% and %56 respectively, p0.71). Con-
clusion: C-erbB-2 positivity rate was low in patients with non-small cell lung
cancer. C-erbB-2 overexpression seems to be unrelated with survival rate or
cisplatin-gemcitabine chemotherapy response of the patients with lung cancer.
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MOLECULAR PROFILING IN RESPONDING AND LONG
SURVIVOR NSCLC PATIENTS TREATED WITH
SECOND-LINE PEMETREXED
A. Mancuso Petricca1, A. Leone2, S. Sacchetta3, L. Cerbone4, O. Martelli5,
O. Martelli6 1Medical Oncology, St. Camillo Hospital, Rome/ITALY, 2Anato-
mopathology Department, San Camillo/Forlanini Hospitals, Rome/ITALY,
3Medical Oncology Department, Moscati Hospital, Taranto/ITALY, 4Medi-
cal Oncology Depertment, San Camillo/Forlanini Hospitals, Rome/ITALY,
5Oncology, San Giovanni, Rome/ITALY, 6Oncology, San Giovanni e Addolo-
rata, Rome/ITALY
Background: Pemetrexed, a novel antifolate, shows to target at least three
different enzymes in the folate pathway [thymidylate synthase (TS), dihy-
drofolate reductase (DHFR) and glycinamide ribonucleotide formyl trans-
ferase (GARFT). Recently, two putative response pemetrexed-related genes,
Folylpolyglutamate synthetase (FPGS) and thymidine phosphorylase (TP)
have been correlated with its efficacy (Gurpide et al, 2005).
Methods: 9 cases of responding and long survivor patients with metastatic
NSCLC treated with second line Pemetrexed in 5 different medical oncology
departments in Italy between June 2005 and September 2007 were studied for
mRNA expression of ERCC-1, TS, DHFR, GARFT, FPGS and TP. Molecular
assays were conducted on pretreatment diagnostic tumor biopsies (formalin-
fixed, paraffin-embedded tumor tissue) using reverse transcriptase-PCR.
Results: The median age at presentation was 54 years (range 42–72),
Female/male: 2/7, median ECOG performance status (PS): 1, histologic type
was adenocarcinoma in (7/9) patients. First line regimen consisted of plati-
num-containing doublets administered to all patients with early progression.
Five patients exhibited a complete response (55%) while the rest showed
partial responses with a median progression free survival and median overall
survival respectively of 16 and 27 months. All patients were categorized as
“low” baseline TS expressors. DHFR and GARFT exhibited higher baseline
expression levels in complete responders compared to partial responders (5
and 3-fold higher than the positive control, Pemetrexed-sensitive non-small cell
lung cancer cell lines). FPGS showed high expression in all the patients while an
extreme variability was detected regarding TP expression. As expected ERCC1
mRNA gene expression did not correlate to response, with median expression
levels of 2.30 (platinum refractory disease). Conclusions: In our selected popu-
lation Alimta was able to induce long-lasting responses in a metastatic NSCLC
cohort characterized by low TS expression and high values of DHFR, GARFT
and FPGS. Prospective molecular profiling studies using selected panels of
predictive markers for drug response in NSCLC are warranted.
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PHENOTYPING OF ALPHA-1-ANTITRYPSIN IN
HOSPITALS OF THREE REGIONS OF AZERBAIJAN
A.B. Ismayilova Genetics, Baku State University, Baku/AZERBAIJAN
Alpha-1-antitripsin (1ÐÐ¢) is a low molecular protease inhibitor, synthe-
sized by liver cells and suppressing the activity of many serine proteoletic
enzymes: tripsin, chymotripsin, plasmin, thrombin, neutrophilic elastase,
tissue kallikrein, factor Ha, plasminogen, macrophages, microorganisms and
others. Now 90 mutant and normal alleles of 1ÐÐ¢ gene are known. In our
experiments for revealing subtypes of normal Pi alleles: M1, M2, M3 and
diagnosis of mutated alleles – PiZ, PiS we used analytical method of
isoelectrofocusing (IEF) in thin layer polyacrylamide ampholine gels
(PAAG), pH 4–6. We have done identification of 1ÐÐ¢ phenotypes in
quite healthy persons as well as in patients with COPD. Capillary blood (0,2
ml) with anticoagulation agent – heparin was collected in eppendorf tubes.
Altogether there were screened 919 persons’ blood samples. The results of
population investigations on revealing mutated variants of Pi alleles in
Siyazan, Khachmas and Khazakh regions are represented in table with their
phenotypic and genetic frequencies. Siyazan and Khachmas areas are located
110 km northward and Khazakh area 450 km west-northward from Baku
city. As it can bee seen from table the frequency of mutated gene PiZ and PiS
varied in the limits of 0.0046–0.0114 and 0.0037 and 0.0066 respectively.
The lowest frequencies PiZ of the gene were revealed at the rural population
of Khazakh region, PiS gene at the population of Siyazan region. In all the
three regions among the patients with COPD from centrals region hospitals
there were identified the homozygote state for PiZ mutations with phenotypic
frequency 0.83% (Khazakh region) up to 1.81% (Khachmas region) at the
average  1.16%. Only among the patients in Siyazan region there was
identified compound, i.e., double heterozygote state of PiZ and PiS genes.
The highest frequencies of PiZ and PiS genes were observed among the
relatives of probands at average 0.2670 and 0.0879 respectively. About the
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three regions there were revealed 32 mutations of of PiZ heterozygote,
homozygote  19 people, mutations of PiS heterozygote  22, homozygote
one and one compound with PiZ/PiS genotype. Thus using method of
analytical IEF there was conducted phenotyping of normal and mutated
alleles T in Siyazan, Khazakh and Khachmas regions of the Azerbaijan
Republic with calculation of their phenotypic and genetic frequencies. Table
Phenotypes and genes frequencies of PiZ and PiS alleles among the popu-
lations of Siyazan, Khazakh and Khachmas regions of Azerbaijan.
Population Quantity
Phenotypes Frequencies
Frequency
of GeneHomozygous Heterozygous Compounds
PiZ/PiZ PiS/PiS PiZÐœ PiSÐœ PiZ/PiS PiZ PiS
Siyazan Region
Patients of
hospital
145 1.38  1.38  0.69  0.0241 0.0034
Relatives of
patients
52 11.53   7.69 1.92  0.1250 0.0037
Population of
village
269   1.86 0.74  0.0093 0.0037
Khazakh Region
Patients of
hospital
120 0.83       
Relatives of
patients
45 0.67   4.44   0.6667 0.2222
Population of
village
328   0.91 0.91   0.0046 0.0046
Khachmas Region
Patients of
hospital
166 1.81  3.61 1.20   0.517 0.0086
Relatives of
patients
68 5.88  13.23 7.35   0.1250 0.0378
Population of
village
305   2.29 1.31   0.0114 0.0066
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FEASIBILITY OF LUNG CANCER SCREENING IN A
SOUTH FLORIDA COMMUNITY
R. Mudad1, M. Block2, P. Forsyth1, C. Frankel1, D. Annesty3, A. Hussein1
1Medical Oncology, Memorial Cancer Institute, Hollywood/UNITED
STATES OF AMERICA, 2Thoracic Oncology, Memorial Healthcare System,
Hollywood/UNITED STATES OF AMERICA, 3Radiology, Memorial Re-
gional Hospital, Hollywood/UNITED STATES OF AMERICA
Lung cancer is the leading cause of cancer-related deaths in the United
States. There are an estimated 90 million current and former smokers in the
United States, all of which are at high risk for the disease. The future of lung
cancer screening is dependent on the results of large randomized trials. We
set out to test the feasibility of- and public interest in a lung cancer screening
program in our community. Methods: During the months of November 2006
and November 2007, we offered free CT scans of the lungs for individuals
who are  50 yrs old, previous and current smokers of  20 pack-years,
without previous history of cancers. The response to this program was
overwhelming. Patients were interviewed over the telephone and if found
eligible, were scheduled for their scans.
Results: We have performed CT scans on 139 patients. Results were as follows:
Patient
number Percent
Lung cancer diagnosed 2 1.4%
Follow up needed now 1 0.7%
Follow up in 3 mo 7 5.0%
Follow up in 4 mo 0.72%
Follow up in 6 mo 35 25%
Follow up in 12 mo 12 8.6%
No abnormalities 81 58.2%
Conclusions: This limited pilot study demonstrates that smokers in the US
have increased awareness of their risk for lung cancer, and are very eager to
follow a screening program once and if this becomes standard of care.
Patients were also willing to pay an out-of-pocket fee to have this test
performed. We are continuing to analyze results from November 2007, an
update will be presented at the meeting.
100PD
PSYCHOLOGICAL COPING MECHANISMS AND
PREVALENCE OF GUILT IN LUNG CANCER PATIENTS.
FINDINGS FROM AN OBSERVATIONAL STUDY
S. Barni1, C. Moleri2, M. Cabiddu1, F. Petrelli1, M.L. Bonetti1 1Oncology,
Azienda Ospedaliera Treviglio, Treviglio/ITALY, 2Psychoncology, Azienda
Ospedaliera Treviglio, Treviglio/ITALY
Scientifica data confirms cigarette smoking well-estabilished role in the
development of lung cancer and adverse health consequences of continued
smoking for the diagnosed cancer patient. Few published studies describe the
emotional personal experiences of lung cancer patients (pts).
In our Department we compared the emotional experiences of smokers (S)
with non-smokers (NS) lung cancer pts. From November 2006 to January
2008, 60 pts in chemotherapy or in follow up were asked to undergo a
specific psychological interview divided into four areas: awareness of dis-
ease, life-style (personal and family), psychological coping mechanisms they
use to face up to their illness and possible feeling of guilt.
45 pts were in the S group: 43 males (95,56%) and 2 females (4,44%); mean
age 68,78 years old (range 65–69); 15 pts were in the NS group: 9 males
(60%) and 6 females (40%); mean age 71 years old (range 65–74). 75,56%
S and 73,33% NS were fully aware of having cancer. 51,11% S compared
with 73,33% NS had other serious health problems prior to the diagnosis of
cancer. There was a presence of familiarity for cancer in 18% NS against
70% S. 53,33% S were aware that smoking could cause lung cancer. Against
46,67% S believe that work, pollution and familiarity are possible causes of
their lung cancer but not smoking. There is a predominant fatalistic coping
style in the S group (42,22%), while the NS shows a prevalent reactive
approach (60%).
No feeling of guilt (80%) was noted in the S group regarding the cause of
their disease. Few lung cancer pts who smoked experience guilt and respon-
sibility for their disease. This could be due to their limited knowledge or
ability of reasoning as a result of their low level of education (64,44% S pts
had completed only primary school), due to a fatalistic coping style or due to
a defence mechanism which the pt creates so as not to feel responsible for his
disease and preserve a positive self image.
101PD
PROFILING SMOKING BEHAVIOUR IN PATIENTS
DIAGNOSED WITH CANCER
S. Mohan1, N. Selvarajah1, E. Smyth1, O.S. Breathnach2 1Dept. of Medical
Oncology, Beaumont Hospital Cancer Centre, Dublin/IRELAND, 2Medical
Oncology, Beaumont Hospital Cancer Centre, Dublin/IRELAND
Background: Cigarette smoking is the principal modifiable risk factor for
many diseases. Smoking cessation is a crucial factor in improving the health
status and overall survival of patients diagnosed with cancer. Ireland pio-
neered the highly successful smoking ban in workplaces in 2004. The
purpose of this study was to assess the profile of smoking behaviour in
patients diagnosed with cancer, focusing on the impact of a cancer diagnosis
on current smoking behaviour.
Methods: 320 patients (pts) attending the medical oncology services at
Beaumont Hospital Dublin over a 3 month period were assessed by confi-
dential direct interviews and questionnaire.
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Results: 314 of 320 pts (98.1%) agreed to participate. This consisted of
132 males and 182 females. 111 (35%) were non-smokers, 146 ex-
smokers and 57 current smokers. The median quantity of cigarettes
smoked was 20 and median duration was 32 yrs. 59.8% started smoking
due to peer pressure with a median onset age of 17yrs. The median age
of cessation was 48yrs and the majority quit due to health reasons. Of the
314 pts, 72.6% strongly agreed that smoking causes cancer. A total of 76
pts thought of quitting after the diagnosis and 21 of these quit specifically
due to their cancer diagnosis. Current smokers were much more moti-
vated to quit by fear of cancer than those who had quit previously
(p0.001). This latter group were motivated by health care concerns in
general (p0.001). Both groups were equally concerned about financial
costs of smoking. 64% of current smokers agreed that the cancer diag-
nosis might make them quit; however 25% of them were not planning to
quit within the next 6 months. Willpower was the principal method used
to quit (77%), and was the most successful approach (p0.001). Nico-
tine-replacement was less effective than those driven by will power alone.
None availed of the National Smokers’ Quitline.
Conclusions: The study highlights the complexity of smoking cessation in a
cohort of pts diagnosed with cancer. The reason why the majority of pts
relied on willpower and the lack of use of the National Smokers’ Quitline are
surprising and needs further consideration. Cohort-targeted smoking cessa-
tion programs for pts with cancer and their relatives should be a consider-
ation in hospital-based oncology services.
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RIBONUCLEOTIDE REDUCTASE (RR) SUBUNITS M1 AND
M2 MRNA EXPRESSION LEVELS ARE ASSOCIATED
WITH CLINICAL OUTCOMES OF PATIENTS WITH LUNG
ADENOCARCINOMAS TREATED WITH DOCETAXEL/
GEMCITABINE CHEMOTHERAPY
I. Boukovinas1, I. Souglakos2, M. Taron3, P. Mendez4, D. Mavroudis5, M.
Trypaki6, D. Hatzidaki7, A. Koutsopoulos8, R. Rosell3, V. Georgoulias5
1Second Department of Medical Oncology, Theagenion Cancer Hospital,
Thessaloniki/GREECE, 2Department of Medical Onoclogy, University Gen-
eral Hospital of Heraklion, Heraklion/GREECE, 3Hospital Germans Trias I
Pujol Badalona, Catalan Institute of Oncology, Barcelona/SPAIN, 4Hospital
Germans Trias I Pujol, Badalona, Catalan Institute of Oncology, Barcelona/
SPAIN, 5Laboratory of Tumor Cell Biology, School of Medicine, University
of Crete, Department of Medical Oncology, University General Hospital of
Heraklion, Heraklion/GREECE, 6Laboratory of Tumor Cell Biology, School
of Medicine, University of Crete, Heraklion/GREECE, 7Department of Med-
ical Oncology, University General Hospital of Heraklion, Heraklion/
GREECE, 8Department of Pathology, University General Hospital of Her-
aklion, Heraklion/GREECE
Background: Ribonucleotide reductase subunits M1 (RRM1) and M2
(RRM2) are involved in the metabolism of gemcitabine which is used for the
treatment of non-small cell lung cancer. The tumoral expression of RRM1
and RRM2 and correlation with clinical outcome of patients with lung
adenocarcinomas treated with docetaxel/gemcitabine (DG) was investigated.
Method: RMM1 and RMM2 mRNA levels were determined by a quantitative
Real-Time PCR from primary tumors of chemotherapy-naïve patients with
advanced lung adenocarcinomas treated with DG.
Results: Successful amplification could be obtained in 42 (79%) out of 53
enrolled patients. High levels of RRM2 mRNA were associated with re-
sponse to treatment (p 0.001). Patients tumoural mRNA expression of
RRM1 in the lower quartile had a significantly longer TTP (p 0.044) and
OS (p0.02) than patients with high (upper quartile) expression. Patients
with low tumoural RRM1/ low RRM2 mRNA expression had a significantly
higher response rates (60% vs 14.2%, p0.049), TTP (9.9 vs 2.3 months,
p0.003) and OS (15.4 vs 3.6, p0.031) than patients with high RRM1/
high RRM2 mRNA expression.
Conclusions: The tumoral expression of RRM1 and RRM2 in lung adeno-
carcinomas is associated with the clinical efficacy of DG combination and
prospective studies should evaluate their role for tailoring chemotherapy.
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PROGNOSTIC SIGNIFICANCE OF S100 PROTEINS
(S100A2, A4 AND A6) IN STAGE I NSCLC IN
CORRELATION WITH P53 EXPRESSION
L. De Petris1, L. Kanter2, F. Melotti3, L.M. Orre1, R. Lewensohn1, J.
Lehtiö”1 1Karolinska Biomics Center, Karolinska Institutet, Stockholm/
SWEDEN, 2Pathology and Cytology, Karolinska University Hospital Solna,
Stockholm/SWEDEN, 3Pathology, S.Andrea Hospital, University ‘La Sapi-
enza’, Rome/ITALY
Aim: To evaluate the prognostic implications of the expression of S100
proteins in stage I NSCLC, in correlation with clinico-pathological features.
Methods: 103 patients with radically resected stage I NSCLC were included
into study. Main patient and tumor characteristics were as follows: mean age
(range) 68 years (41–82), male/female 63/40, squamous/non-squamous 52/
51, well/moderate/low differentiation 22/39/42, T1/T2 40/63. Immunohisto-
chemical expression of S100-A2, -A4, -A6 and p53 was assessed on four 0.6
mm-core-replicates loaded on tissue microarray. The choice to evaluate the
expression of S100 proteins in correlation with p53 is based on our in vitro
study (Orre LM et al Mol Cell Proteomics 2007;6:2122–31) where we
showed up-regulation and changes in post-translational modifications pattern
of S100A6 and S100A4 in response to irradiation. This kinetic was depen-
dent upon functional p53. Moreover the transcription of S100A2 seems to be
dependent on the presence of wt TP53 (Tan M et al FEBS Letters1999;445:
265–8). Results: Positive expression of S100A2, S100A4, S100A6 and p53
was detected in 28%, 21%, 25% and 30% of tumors, respectively. S100A6
was significantly (p0.05) more expressed in non-squamous tumors and in
p53-negative cases. S100A6 significantly co-expressed with both S100A4
and S100A2, although a similar correlation was not found between S100A2
and S100A4. At univariate analysis, none of the analyzed biomarkers was of
prognostic importance. S100A6-positive cases showed a trend of longer
survival compared with S100A6-negative cases (p0.07). This difference
became significant when the analysis was restricted to p53-negative cases
(n72). In this subgroup of patients, whose tumors likely exhibit a functional
p53, S100A6 was an independent prognostic factor of improved survival at
multivariate analysis (HR 0.49, 95% CI 0.27–0.81, p 0.017).
Conclusions: The prognostic implications of S100A6 expression in correla-
tion with p53 support the proposed pro-apoptotic function of S100A6 and
suggest the hypothesis of a cross regulation between these two proteins. A
similar p53-dependent pattern of S100A4 and S100A2 expression could not
be confirmed in this patient cohort.
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MDM2 309T/G POLYMORPHISM AND THE RISK OF NON
SMALL CELL LUNG CANCER (NSCLC) DEVELOPMENT
A. Drozdowska1, A. Szymanowska2, E. Jassem3, M. Niedoszytko4, W.
Rzyman5, G. Gulida6, J. Limon7, J. Jassem8 1Dept. Pulmonology and Aller-
gology, Medical University of Gdansk, Gdansk/POLAND, 2Department of
Allergology, University of Gdan´sk, Gdansk/POLAND, 3Allergology, Medical
University of Gdansk, Gdansk/POLAND, 4Department of Allergology, Uni-
versity of Gdansk, Gdansk/POLAND, 5Thoracic Surgery, Medical University
of Gdansk, Gdansk/POLAND, 6Pathology, Medical University of Gdansk,
Gdansk/POLAND, 7Department of Biology and Genetics, Medical University
of Gdansk, Gdansk/POLAND, 8Akademii Medycznej W Gdansku, Klinika
Onkologii Radiotherapii, Gdansk/POLAND
Background: MDM2 is a key negative regulator of p53 activity and plays an
important role in regulating cell proliferation and apoptosis. Recently, a
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polymorphism located at position 309 in the first intron of the promoter
region of MDM2 gene has been described. T to G substitution is associated
with increased affinity of the transcriptional activator Sp1, resulting in higher
MDM2 mRNA and protein levels. The aim of this study was to assess the
association between MDM2 309T/G polymorphism and the risk of NSCLC
development. Materials and methods: Study group included 159 patients (35
females and 124 males), aged from 43 to 78 years (median 62) who
underwent complete pulmonary resection between 1996 and 2000. Tumor
types included 105 squamous cell carcinomas, 40 adenocarcinomas, 7 large
cell carcinomas and 7 mixed cell carcinomas. Pathological TNM tumor stage
distribution was as follows: IA (9 pts), IB (53 pts), IIA (1 pt), IIB (43 pts),
IIIA (39 pts), IIIB (12 pts) and IV (2 pts). The control group consisted of 419
healthy subjects with no evidence of lung cancer or other neoplasm. MDM2
309T/G polymorphism was evaluated by PCR-RFLP method in DNA iso-
lated from the lymphocytes. Samples were collected from patients prior to
surgery and stored at -80°C.
Results: The 309GG genotype was associated with a significantly increased
risk of NSCLC (OR1.39; 95%CI 1.01–1.9; p0.04) compared to the
309TT genotype. The strongest effect of the polymorphism was seen among
patients with adenocarcinoma (OR2.17; 95% CI 1.45–3.25; p0.0001) and
large cell carcinoma (OR2.2; 95% CI 1.01–4.78; p  0.04).
Conclusions: The 309GG genotype is associated with an increased risk of
NSCLC, particularly in regard to adenocarcinoma and large cell carcinoma.
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CELL CYCLE REGULATION AND PROLIFERATION,
APOPTOSIS AND ANGIOGENESIS IN NON-SMALL CELL
LUNG CANCER
J. Yoo1, S.Y. Park2, S.H. Kim3, D.G. Cho4, M.I. Ahn5, C.H. Kim6, K.D.
Cho4, H.K. Kim6 1Pathology, Catholic University St. Vincent’s Hospital,
Suwon/KOREA, 2Pathology, Catholic University, Suwon/KOREA, 3Radia-
tion Oncology, Catholic University St. Vincent’s Hospital, Suwon/KOREA,
4Thoracic Surgery, Catholic University St. Vincent’s Hospital, Suwon/KO-
REA, 5Diagnostic Radiology, Catholic University St. Vincent’s Hospital,
Suwon/KOREA, 6Internal Medicine, Catholic University St. Vincent’s Hos-
pital, Suwon/KOREA
Background: Recent molecular studies have provided increased understand-
ing of the biology of lung cancer and have identified multiple factors
responsible for the modulation of tumor growth and the prognosis. Never-
theless, the essential genetic features, along with factors for prognosis, have
yet to be fully understood. In the present study, altered expression of cell
cycle regulatory or proliferation-related, apoptotic, and angiogenic factors
was investigated and correlated with patient outcome to determine their
prognostic significance.
Design: Two hundred and nineteen specimens from the patients with previously
untreated NSCLC were were arrayed on a recipient paraffin block. Immunohis-
tochemical staining was performed using antibodies against p16, p21, p27,
cyclin E, cyclin B1, Ki-67, caspase-3, survivin, bcl-2, VEGF and endostatin.
Results: One hundred and sixty-eight patients (76.7%) were male and the
mean age was 65.8 years (SD 9.9; median 67; age range 19–89). Despite
previously described prognostic relevance of the 11 molecules investigated,
many were found not to be directly associated with recurrence or survival.
However, p16 and bcl-2 had an impact on 5-year survival. There was a trend
for p16 immunoreactivity to be related with a good prognosis (57% vs. 42%
in 5-year survival) (p0.071). Bcl-2 expression was strongly correlated with
a better outcome (65% vs. 45% in 5-year survival rate) (p0.029), and the
hazard ratio of death for bcl-2 positive patients was 0.42 times of that for
bcl-2 negative patients (p0.047). A multivariate analysis with Cox propor-
tional hazards model confirmed that the lymph node status (p0.043) and
stage (p0.003) were other independent prognostic factors.
Conclusions: The present study demonstrates that NSCLCs have heteroge-
neous expression of cell cycle regulatory proteins, apoptotic factors and
angiogenic factors. However, the expressions of p16 and bcl-2 are associated
with a trend toward a better survival in this selected group of patients. These
findings warrant additional molecular and clinicopathological studies of
those markers and their related pathways potentially relevant for outcome.
106PD
A RT-QPCR-BASED THREE-GENE PROGNOSTIC
CLASSIFIER FOR STAGE I NON-SMALL-CELL
LUNG CANCER
G. Natoli1, S. Scarpino2, A. Pasenen2, E. Duranti2, C. Pompili3, I. Paris4, E.
Rendina3, L. Ruco2, P. Marchetti4 1Oncology, University La Sapienza S.
Andrew Hospital, Rome/ITALY, 2Pathology, University La Sapienza, Rome/
ITALY, 3Surgery, University La Sapienza, Rome/ITALY, 4Oncology, Univer-
sity La Sapienza, Rome/ITALY
NSCLC are more frequently diagnosed at early stage, perhaps because of
sensitive imaging techniques, such as helical computerized tomography
scanning. Despite surgery, patients with pathologic stage I disease have
nearly 65% five-year survival after surgery alone and most patients relapse
at distant sites. However, the role of adjuvant therapy remains controversial.
Consequently, the recognition of indicators capable of identifying patients
with stage I NSCLC at higher risk for developing recurrent disease may help
clinicians to select adjuvant treatments. With this aim, we evaluated the
significance of three genes (excision repair cross-complementation group 1,
ERCC1; lymphocyte-specific protein tyrosin kinase, LCK; dual-specifity
phosphatase 6, DUSP6) in 26 stage I completely resected NSCLC patients
using reverse transcription (RT) quantitative polymerase chain reaction
(qPCR) from fresh-frozen specimens. Then, we evaluated the association
between the level of expression and relapse-free survival (RFS) and a risk
index was created; this index was defined as a linear combination of gene
expression value weighted by regression coefficients derived from previous
studies. Furthermore, we performed immunohistochemical analysis to deter-
mine the expression of the ERCC1 protein in such surgical specimens.
Surgical specimens from 26 patients with stage I NSCLC, not treated with
adjuvant therapy, were examined (17 adenocarcinomas, 9 squamous-cell
carcinomas). A three-gene signature discriminate 12 low-risk patients and 14
high-risk patients. Kaplan-Meier analysis of relapse-free survival showed
clear stratification of high-risk and low-risk patients (median RFS 35
mounts vs 45 mounts; log-rank P  0.05). In addiction, there was a
significant correlation between the results of immunohistochemical analysis
of ERCC1 protein and RT-qPCR analysis for such gene (Spearman’s
correlation coefficient  0.49; P  0.01). Finally, our three-gene signature
may be evaluated in larger studies for its potential effectiveness in optimizing
adjuvant therapy in stage I NSCLC-resected patients.
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A BIOLOGICAL PREDICTIVE FACTOR PANEL IN THE
GEFITINIB TREATMENT OF ADVANCED NON-SMALL
CELL LUNG CANCER (NSCLC)
M. Tiseo1, G. Rossi2, M. Capelletti3, G. Sartori2, E. Spiritelli1, A. Mar-
chioni4, C. Bozzetti1, V. Franciosi1, G. Rindi5, A. Ardizzoni1 1Medical
Oncology, University Hospital, Parma/ITALY, 2Department of Pathology, Uni-
versity Hospital, Modena/ITALY, 3Division of Medical Oncology, University
Hospital, Parma/ITALY, 4Division of Pneumology, AUSL Mirandola, Modena/
ITALY, 5Department of Pathology, University Hospital, Parma/ITALY
Background: Clinical characteristics and molecular targets related to EGFR
activation have been found to correlate with the therapeutic activity of EGFR
tyrosine kinase inhibitors, such as gefitinib, in advanced NSCLC patients (pts).
Aim of the study: To evaluate the predictive value on gefitinib activity of
clinical characteristics, EGFR and K-ras gene mutations, EGFR and HER2
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gene copy number, EGFR gene intron 1 polymorphism [intron 1 (CA)n
repeats] and EGFR expression in advanced NSCLC pts.
Methods: EGFR and K-ras mutations were detected on DNA extracted from
paraffin embedded tumors by direct sequencing. EGFR and HER2 gene copy
number was assessed by FISH. EGFR genetic polymorphism was assessed
on genomic DNA isolated from venous whole blood samples. EGFR protein
expression was quantified by immunohistochemistry. Tumor response was
assessed every 2 months by CT scan and toxicity monthly.
Results: Ninety-one pts were enrolled. A response rate of 18.7% was
observed (2 complete and 15 partial responses). EGFR and K-ras gene
mutations were successfully performed on 63 pts, EGFR and HER2 gene
copy number on 54 and 58 pts, respectively. EGFR intron-1 polymorphism
was characterised in 76 pts. EGFR protein expression was determined in the
tumour specimens of 59 pts. A statistically significant correlation was
observed between sex (p  0.005), smoking status (p  0.010), skin toxicity
(p  0.020), EGFR gene mutations (p  0.001), EGFR FISH (p  0.016)
and gefitinib response. K-RAS mutation was detected in 7 not-responder
patients. No statistically significant correlations were observed between other
factors and tumor response; about EGFR intron 1 polymorphism, a border
line statistically significant correlation was observed with allele (CA)16. The
median overall survival was of 10 months. Only EGFR intron 1 polymor-
phism shown a statistically significant correlation with overall survival (p 
0.04). Conclusions: Our data confirm the predictive role of female sex, no
smoking status, skin toxicity, EGFR gene mutations and EGFR gene copy
number and support a potential role of EGFR intron 1 polymorphism in the
gefitinib treatment of advanced NSCLC pts.
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TUMOR MARKERS IN INDUCED SPUTUM AND BLOOD
IN LUNG CANCER
H. Racil1, S. Bousnina2, S. Cheikh Rouhou3, S. Yalaoui4, A. Chabbou3
1Pavillon II, Hopital Abderrahman Mami Ariana, Ariana/TUNISIA, 2Endos-
copy and Oncology, Abderrahman Mami Hospital, Ariana/TUNISIA, 3Pa-
villon Ii, Abderrahman Mami Hospital, Ariana/TUNISIA, 4Immunology,
Abderrahman Mami Hospital, Ariana/TUNISIA
Lung cancer (LC) prognosis is gloomy with a 5-yr overall survival 20%,
mainly due to advanced stage at time of diagnosis. Biological screening tools
are promising due to advances in LC molecular biology. We examined
whether tumor marker (TM) concentrations in induced sputum (IS) were
different in patients compared to controls. Our study included 8 LC patients
(median age, 67) and 13 smoker controls (median age, 65). Blood samples
and IS were taken in both groups for assessment of CEA, CA 125 and NSE
immuno-enzymatic concentration. TM in IS reproducible. Statistical tests
using analysis of variances were performed with Epi info 2000; test signif-
icance: p0.05. Results: Mean TM concentrations in blood of LC patients
were higher than those in controls. TM levels in blood
TM CEA ng/ml CA 125UI/ml NSE ng/ml
group patients controls patients controls patients controls
Mean
level
126.6 3.2 235 27.1 64.5 20.1
CA 125 levels in IS were comparable in both groups, but CEA and NSE
levels were higher in patients. TM levels in IS
TM CEA ng/ml CA 125UI/ml NSE ng/ml
group patients controls patients controls patients controls
Mean
level
714.1 847 4665 6676 82.5 7.5
P0.0001 p 0.541NS P  0.00049
As for airway inflammation markers, TM needs validation as a discriminant
between normal and LC patients. IS could be a safe cost-effective tool for LC
detection and diagnosis. Further studies should determine the best IS pre-
dictive markers taking into account smoking history and disease stage.
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HIGH PRE-TREATMENT SERUM LEVELS OF VEGF AND
OXIDATIVE STRESS IN LUNG CANCER PATIENTS AND
THEIR CLINICAL IMPLICATIONS
A.D. Katsampeki-Katsafli1, T.S. Kerenidi2, K.T. Kostikas2, T. Kiropoulos2,
E.N. Dalaveris2, K.I. Gourgoulianis2 1Department of Respiratory Medicine,
University Hospital of Larissa, Larissa/GREECE, 2Respiratory, University
Hospital, Larissa/GREECE
Background: Vascular endothelial growth factor (VEGF) and oxidative stress
are known to play a significant role in carcinogenesis. It is demonstrated in
vitro that VEGF can be up-regulated by oxidative stress. Aim: To investigate
if there is an association between serum VEGF and oxidative stress levels
and to assess the relevance of these levels to disease outcome.
Materials and Methods: We enrolled 80 patients with primary lung cancer
(mean age 62.4 years); 51 NSCLC and 29 SCLC, 10 patients stage I, 5 stage
II, 27 stage III and 38 stage IV. We measured serum VEGF and oxidative
stress levels before any treatment and in 43 of those patients after platinum-
based chemotherapy (26 NSCLC and 17 SCLC) and in 25 normal subjects.
Serum VEGF and oxidative stress levels were analyzed by using Elisa and
D-ROM method respectively.
Results: Serum oxidative stress and VEGF levels in patients were higher
compared to normal subjects (56125.25 vs. 360.117.46 UCarr, p0.0001
for oxidative stress and 526.143.04 vs. 298.819.89 pg/mL, p0.0001 for
VEGF). Interestingly, oxidative stress presented a significant correlation with
VEGF levels before (r0.39, p0.0003) and after chemotherapy (r0.34,
p0.025). We didn’t find any difference in their levels after chemotherapy.
Although, there was no relevance of pretreatment serum oxidative stress and
VEGF levels in response to chemotherapy, there was a greater change in
oxidative stress in the responders (164.966.34 UCarr vs. -34.1460.02
UCarr, p0.03). Moreover, patients with serum oxidative stress levels higher
than the median value (561 UCarr) presented significantly shorter overall
survival than those with lower serum levels (median survival 333 days vs.
533 days respectively, p0.03, Log Rank Test).
Conclusions: VEGF and oxidative stress are significantly increased in pa-
tients with Lung Cancer and the pre-treatment oxidative stress levels may
have prognostic value. In conjunction with other clinical data, they may be
used for monitoring the patients with Lung Cancer. Additionally, the corre-
lation between these markers might implicate new aspects of the mechanisms
controlling angiogenesis and may present clinical interest in the future.
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SOLUBLE EPIDERMAL GROWTH FACTOR RECEPTOR
(SEGFR) CONCENTRATION IN SERUM IS AN INDICATOR
OF SURVIVAL IN PATIENTS WITH NON-SMALL CELL
LUNG CANCER
I. Kappers1, M.M. van den Heuvel2, C.M. Korse3, H. van Tinteren4, J.M.G.
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Institute - Antoni van Leeuwenhoek Hospital, Amsterdam/NETHERLANDS,
2Pulmonology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek
Hospital, Amsterdam/NETHERLANDS, 3Clinical Chemistry, The Nether-
lands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam/
NETHERLANDS, 4Statistics, The Netherlands Cancer Institute - Antoni van
Leeuwenhoek Hospital, Amsterdam/NETHERLANDS, 5Thoracic Oncology,
The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital,
Amsterdam/NETHERLANDS
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Background: In patients with non-small cell lung cancer (NSCLC), a re-
sponse rate of 30% can be achieved with epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) if therapy is guided by mutation
analysis or gene copy number. However, both tests are complicated and
require the availability of tumour tissue. Simple methods to predict response
to EGFR-TKIs are urgently needed. Recently, soluble EGFR (sEGFR) has
been suggested as a potential marker for epithelial cancer. This study was
designed to define sEGFR levels in NSCLC and also focused on the relation
of sEGFR to survival in patients treated with EGFR-TKIs.
Patients and Methods: Patients with stage III/IV NSCLC treated with
gefitinib or erlotinib between July 2002 and December 2005 were identified.
Univariate and multivariate analyses via Cox-regression analyses were used
to detect correlations between sEGFR and survival.
Results: One-hundred-and-two patients, 54 men and 48 women, mean age 58
years (range 35–91), were identified. Sixty-seven patients were treated with
gefitinib and 35 patients were treated with erlotinib. Mean sEGFR at baseline
was 55.9 g/l (95% CI 54.2 – 57.7 g/l). Median overall survival was 5
months (95% CI 4.3 – 6.1 months). Non-smoking status was a favourable
prognostic factor in both the univariate and multivariate analyses (HR 2.61,
95% CI 1.50–4.55). sEGFR showed a significant, negative correlation with
survival (HR 0.97, 95% CI 0.95–0.99).
Conclusion: Baseline sEGFR levels of NSCLC patients receiving EGFR-
TKIs were of prognostic value. The search for a simple reliable predictive
marker must, however, be continued.
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N1, N12-DIACETYLSPERMINE AS A TUMOR MARKER
FOR NON-SMALL CELL LUNG CANCERS
K. Sakaguchi1, K. Hiramatsu2, H. Horio3, M. Yamamoto3, K. Takahashi4, M.
Kawakita5 1Departments of Thoracic Surgery, Nagano Prefectural Suzaka
Hospital, Suzaka/JAPAN, 2Tumour Therapy Project, Tokyo Metropolitan
Institute of Medical Science, Tokyo/JAPAN, 3Departments of Thoracic Sur-
gery, Tokyo Metropolitan Komagome Hospital, Tokyo/JAPAN, 4Depart-
ments of Surgery, Tokyo Metropolitan Komagome Hospital, Tokyo/JAPAN,
5Department of Applied Chemistry, Kogakuin University, Tokyo/JAPAN
Summary: Background: N1, N12-diacetylspermine (DiAcSpm) is excreted in
the urine of healthy persons, with small individual variations in the amount.
Previous studies revealed that excretion of DiAcSpm was frequently and
markedly elevated in patients with various cancers, but Non-small Cell Lung
Cancer (NSCLC) patients have not been examined so far.
Methods; Urine samples were collected from 231 patients treated for NSCLC
(mean age; 66.99.6 year-old, Range;41–87, male;136 female;95) and 64
patients treated for benign thoracic diseases during the period from Decem-
ber 2003 to April 2007 as well as 52 healthy volunteers. DiAcSpm level was
analyzed by colloidal gold aggergation method.
Results; Patients with NSCLC (n231) had higher urinary DiAcSpm
(0.360.57mol/g creatinine, vs 0.150.05, p0.01) levels than healthy
volunteers. The mean urinary DiAcSpm level among NSCLC patients at
various pathological stages(stage IIIB and stage IV were included with
clinical stages) was 0.240.15 in IA (n104), 0.270.17 in IB (n38),
0.270.17 in IIA (n6), 0.340.25 in IIB (n16), 0.631.34 in IIIA
(n26), 0.460.48 in IIIB (n27) and 0.650.48 in IV (n14), respec-
tively. The urinary DiAcSpm level of Stage I NSCLC patients (IA and IB,
n142, 0.330.28, p0.01) was higher than healthy volunteers. The mean
level for 164 patients with adenocarcinoma and 54 patients with squamous
cell carcinoma was 0.280.25 (p0.01), and 0.550.97 (p0.01), respec-
tively. Urinary DiAcSpm levels were low in non-inflammatory thoracic
diseases (0.160.04), but high in patients with interstitial pneumonias
(n17, 0.330.27) and pleuritis (n9, 0.340.30). We traced the Receiver
Operating Characteristic (ROC) curve to assess the values of urinary DiAc-
Spm, and the area under the ROC curve was 0.74 in NSCLC and 0.88 in
squamous cell carcinoma.
Conclusions; Urinary DiAcSpm level of NSCLC patients is higher than
healthy volunteers and non-inflammatory thoracic diseases. Urine may be
readily collected non-invasively, and measurement of urinary DiAcSpm
levels is rapid and inexpensive. Urinary DiAcSpm is useful as a tumor
marker for detecting early stages of NSCLC, especially squamous cell
carcinoma.
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BIOMARKER GENE AND CANONICAL PATHWAY
DETERMINANTS OF SUNITINIB SENSITIVITY IN
NON-SMALL CELL LUNG CANCER CELL LINES
G.J. Weiss1, K. Nelson2, B. Armstrong2, M.E. Berens2 1Oncology, TGen
Clinical Research Services at Scottsdale Healthcare, Scottsdale/UNITED
STATES OF AMERICA, 2Cancer and Cell Biology, TGen, Phoenix/UNITED
STATES OF AMERICA
Background: Determination of susceptibility to tyrosine kinase inhibitors
(TKIs) can be challenging. Sunitinib is an oral multi-TKI to VEGFR2 and
VEGFR3, amongst others. We investigated putative biomarker genes and
associated canonical pathways for sunitinib sensitivity in non-small cell lung
cancer lines (NSCLC) cell lines.
Methods: Sunitinib sensitivity by Alamar Blue and VEGFR2 and VEGFR3
protein expression by Western blot were determined in six NSCLC cell lines.
Microarray gene expression data from NCBI’s GEO were normalized by ‘per
chip normalization’ and ‘per gene normalization’ using GeneSpring. Genes
were identified with statistically significant differences (p0.01) when
grouped as sunitinib “resistant” (IC50 9 uM) and “sensitive” (IC50 3
uM). Biomarker genes were validated using qRT-PCR. Ingenuity Pathway
Analysis (IPA) was queried for associated canonical pathways.
Results: H1703 and H520 were sensitive (both lacked VEGFR3 protein),
while the remaining 4 NSCLC lines were resistant (VEGFR3 protein present)
(Table). Three of 3 tested genes (FGF1, HOXC10, LHFP) correctly validated
sensitive compared to resistant NSCLC lines by qRT-PCR. By IPA, these 3
genes were not part of canonical pathways, and VEGFR was not part of
canonical pathways in resistance associated genes.
Conclusions: Lack of VEGFR3 protein and presence of the 3 biomarker
genes may predict sensitivity to sunitinib. How these 3 biomarker genes are
biologically relevant to sensitivity remains to be determined. Resistance to
sunitinib may be explained by the absence of VEGFR as a target in IPA
canonical pathways derived from overexpressed genes in the resistant
NSCLC lines. Supported by TGen Foundation. Table. Histology, protein
expression, and sunitinib IC50 of 6 NSCLC lines.
Data H1703 H520 H322C H358 A549 H157
Histology AC SCC BAC BAC AC SCC
VEGFR2
protein
Present Absent Present Present Present Present
VEGFR3
protein
Absent Absent Present Present Present Present
Sunitinib
IC50
0.5
uM
1–3 uM 9–10
uM
10
uM
10
uM
10
uM
KEY: ACadenocarcinoma; SCCsquamous cell carinoma; BAC
bronchioloalveolar carcinoma
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C-REACTIVE PROTEIN, CARCINOEMBRYONIC ANTIGEN
AND CELL-FREE PLASMA DNA AS BIOMARKERS FOR
THE DETECTION OF LUNG CANCER
C. Son1, M. Jung2 1Pulmonology, Dong-A University Hospital, Busan/KO-
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Backgrounds: C-reactive protein (CRP) is an acute-phase reactant and
several studies reported CRP levels were increased in patients with lung
cancer. Carcinoembryonic antigen(CEA) is synthesized by epithelial and
tumor cells. Cell-free DNA is present in increased amounts in the plasma of
cancer patients. We performed this study to evaluate the role of CRP, CEA
and cell-free plasma DNA for the detection of lung cancer. Methods: CRP,
CEA and cell-free DNA were measured in plasma samples from 41 lung
cancer patients and 62 healthy controls. The cell-free DNA was determined
in plasma with real-time quantitative PCR. The diagnostic accuracy of each
assay was calculated using receiver operating characteristic (ROC) curve.
Results: CRP and CEA were significantly increased in lung cancer patients
than in healthy controls (both p  0.05). However, the concentration of
cell-free DNA was not statistically significantly increased in lung cancer
patients than in controls (p  0.09). The area under the curve (AUC) of CRP
was 0.83 (95% CI, 0.739 to 0.894) and AUC of CEA was 0.82 (95% CI,
0.727 to 0.885).
Conclusions: CRP and CEA may be useful biomarkers that allow selection
of those cases requiring more intensive screening test of lung cancer. Further
studies need to be done to confirm these findings.
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BONE MARROW-DERIVED CIRCULATING LYMPHATIC/
VASCULAR ENDOTHELIAL PROGENITOR CELLS IN
PATIENTS WITH SMALL CELL LUNG CANCER
B. Dome1, K. Bogos1, J. Berta1, J. Strausz2, G. Kovacs3, G. Ostoros3, J.
Tovari1 1Tumor Biology, National Koranyi Institute of Pulmonology, Budap-
est/HUNGARY, 2Bronchology, National Koranyi Institute of Pulmonology,
Budapest/HUNGARY, 3Thoracic Oncology, National Koranyi Institute of
Pulmonology, Budapest/HUNGARY
Background: As part of the (lymph)angiogenic machinery, the newly iden-
tified bone marrow derived cell population, called lymphatic/vascular endo-
thelial progenitor cells (LVEPCs), has been shown to contribute to experi-
mental tumor growth. However, the clinical significance of these cells in the
case of small cell lung cancer (SCLC) has not yet been investigated.
Methods: 58 patients with SCLC and 12 healthy individuals were included.
Peripheral blood circulating LVEPCs labeled with CD34, CD133 and vas-
cular endothelial growth factor receptor-3 (VEGFR-3) antibodies and the
plasma levels of the key lymphangiogenic molecule VEGF-C were measured
by flow cytometry and ELISA, respectively.
Results: Mature (CD34/VEGFR3) and immature (CD133/VEGFR3)
LVEPC levels were increased in patients (vs. controls; P0.05 for both
comparisons), and there was a significant relationship between LVEPC
counts and lymph node metastasis (P0.05 for both LVEPC phenotypes).
However, we were unable to detect a significant correlation between
VEGF-C concentrations and circulating mature or immature LVEPC counts.
Conclusions: The current study demonstrates, for the first time, that the levels
of VEGFR-3 positive bone marrow–derived LVEPCs are significantly ele-
vated in patients with SCLC, and that these levels are correlated to lymphatic
progression of the disease.
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LUNG CANCER IN NON-SMOKING INDIANWOMEN: ARE
DOMESTIC COOKING FUELS RISK FACTORS?
D. Behera1, R.K. Dalai2 1Tuberculosis and Chest Diseases, LRS Institute of
Tuberculosis and Respiratory Diseases, New Delhi/INDIA, 2Medicine, SCB
Medical College, Cuttack/INDIA
Background: Indoor air pollution is an important risk factor for development
of lung cancer in non-smokers besides passive smoking, dietary factors. This
is important in women in developing countries like India as domestic
cooking is an important function of an average Indian house- wife. On an
average, an Indian woman spends about four to six hours daily for cooking.
Four different types of cooking fuels are used in this country: Biomass fuel
(Wood, Cow-dung cake, agricultural waste, coal etc.); Liquefied Petroleum
gas (LPG); Kerosene and a mixture of these. Besides a number of respiratory
problems, they contain a large number of carcinogens (Smith et al 1972;
Aggarwal et al 1972; Behera 1995). Thus these women are at increased risk
of exposure to these carcinogens. Studies from China have shown that coal
burning at home is a significant risk factor for development of lung cancer in
non-smoking females (Wu et al 1996). We have earlier published (Balamug-
esh and Behera 2005) and presented our preliminary data in the Barcelona
conference (2005) and the present communication is our data on more
number of cases.
Methods and results: This is a case control study in which 150 women with
proven lung cancer and 102 females having a non-malignant respiratory
disease were included. The patients and controls were asked about the
exposure in various cooking fuels using a questionnaire. The age in the cases
varied from 30–80 years (53.2  9.5) and in the controls the age ranged
from 31–70 years (47.8 8.6). There were 126 non-smokers and 34 smokers
in the females’ cases. Adenocarcinoma was the commonest form of malig-
nancy (n68) in the whole group and was the predominant form in the
nonsmoking females. In smoking females squamous and small cell carci-
noma was common. In the control group there were 87 non-smokers and 15
smokers. Tobacco smoking was the most important risk factor for lung
cancer with OR of 4.78 (95% CI 1.32–18.16). Among non-smokers out of all
the cooking fuels the risk of development of lung cancer was highest for
biomass fuel exposure with an odds ratio of 5.72 (95% CI 1.65–16.68). Use
of mixed fuels was associated with a lesser risk (OR  3.24, 95% CI
1.o7–8.48).). In multivariate logistic regression analysis biomass fuel expo-
sure was still significant with OR of 3.69 (95% CI 1.27–10.88) even after
adjusting for smoking and passive smoking. This study indicated that
biomass fuel exposure is an important risk factor in the causation of lung
cancer among women in addition of exposure to tobacco smoke. The study
is ongoing and we wish to gather more data. Better-ventilated kitchens and
use of smokeless chimneys should be emphasized as a measure to lessen the
risk of lung cancer in women.
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LUNGS CANCER AND COMBINATION WITH OTHER
TUMORS OF THE AMONG YOUNG PEOPLE IN EIGHT
REGIONS OF WEST UKRAINE
N.I. Kitsera1, O. Hnatejko2, Y. Shparyk3, I. Kovalchuk4, O. Tril5 1Epidemi-
ology, Institute of Hereditary Pathology, Lviv/UKRAINE, 2Director, Institute
of Hereditary Pathology, Lviv/UKRAINE, 3Chemotherapy, Lviv State Oncol-
ogy Regional Treatment and Diagnostic Centre, Lviv/UKRAINE, 4Director,
Lviv State Oncology Regional Treatment and Diagnostic Centre, Lviv/
UKRAINE, 5Cancer Registry, Lviv State Oncology Regional Treatment and
Diagnostic Centre, Lviv/UKRAINE
Analysis of the cases of malignant tumors of the lungs (C34 MCD 10) of
young people under 34 years (born in 1963–2004) and diagnosed in 1997–
2004 was made using the materials of the database of cancer registers of
Chernivtsi, Ivano-Frankivsk, Khmelnytskyy, Lviv, Rivne, Ternopil, Volyn
and Zakarpattia regions. The population of young people under 34 years of
this region is about 5,5 million per year.
During the 1997–2004 among 10178 cases of cancer in the 8 regions of West
Ukraine malignant tumors of the lungs were diagnosed in 148 cases (fre-
quency 145:10 000). This pathology was registered in males in 88 cases, and
in females - 60. The youngest among the 148 patients from these above said
8 regions were a boy aged 6 and a girl aged 16. Combination with other
tumors was observed in five females (5:10 000). For two women lung cancer
was the first tumor (2:10 000). The youngest among the patients with
combination of different tumours was the woman A. aged 26. Later in five
years at the age of 31 she was diagnosed breast cancer. Lung cancer was
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manifested in woman B. at the age of 34 and in 4 months later sarcoma of
soft tissue was detected.
Lung cancer was the second tumor for those three women. In one woman C.
aged 33 lung cancer was diagnosed, but at the age of 29 cancer of cervix
uterine was manifested. In women D. and E. aged 31 were diagnosed cancer
of placenta and cervix uterine and lung cancer in the same year.
We made retrospective analyses of cancer in Lviv region as a typical with
population about 2,5 million per year (0- 100 years) and 57397 cases cancer
was diagnosed in 1997–2004, and among them lung cancer in 7014 cases
(frequency 1222:10 000). This pathology was registered in males in 6093
cases, and in females in 921 cases. 308 patients (54:10 000) from 7014 cases
had two tumors. 63 patients (11:10 000) had lung cancer as the first tumor.
Spectrum of the second tumor was different, the most frequently - gastric in
8 cases and larynx in 5 cases.
As the combination of two tumors was rarer in the young age than in
population, its supposed that it can be explained by the worse run of this
pathology in the young age in accordance with the elder patients and
increasing of genetic load in population with age, which is reflected in
appearance of two tumors in the same person.
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LUNG CANCER IN YOUNG PEOPLE
H. Racil, S. Bousnina, S. Cheikh Rouhou, I. Chakroun, N. Chaouch, A.
Chabbou Pavillon II, Abderrahman Mami Hospital, Ariana/TUNISIA
Lung cancer (LC) is the leading cause of cancer related deaths throughout the
world. Although more frequent in elderly, it is increasing in young peop-
le.The aim is to study the epidemiologic, clinical, and therapeutic particu-
larities of LC in young patient. We retrospectively reviewed clinical data of
650 LC in the last six years, among whom 55 patients (8.4%) are aged less
than 45.The mean age of patients is 41 years (30–45). Tobacco habits are
found in 94%. All patients were symptomatic and presented in all cases with
respiratory symptoms. Diagnosis of LC was performed with endoscopy in
54.5% of cases. Epidermoid carcinoma was found in 21.8%, Adenocarci-
noma in 9% and Small cell carcinoma in 9%. In 41.8% of cases it is a non
small cell lung cancer (NSCLC) without histipathological type. Advanced
stage NSCLC was found in 82%. Surgery was performed in 18% of the case.
A curative or a palliative treatment with chemotherapy and/or radiotherapy
was indicated in 7.1%. Prognosis of patients with LC is still poor, the median
survival time was 7.8 months in all confounded stages. Chemotherapy based
on individual patients clinical and biological markers could de useful for a
better prognosis by allowing customizing chemotherapy in patients with LC.
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CHARLSON’S INDEX IN ACUTELY HOSPITALIZED
LUNG CANCER PATIENTS AS A PROGNOSTIC FACTOR
FOR LENGTH OF HOSPITALIZATION
M. Molina-Garrido, C. Guille´n-Ponce, M. Guirado-Risueño, A. Carrato
Medical Oncology, General Universitary Hospital in Elche, Elche (Ali-
cante)/SPAIN
Introduction: Charlson’s Index is a widely used measure of comorbidity.
Originally developed to predict mortality among hospitalized patients, this
index has been used to predict other patient outcomes, including treatment
and costs. The aim of this retrospective study is to determine whether or not
Charlson’s Index can help predict length of stay for hospitalized lung cancer
patients.
Methods: Social and demographic data, as well as data on physical limita-
tions, were collected from consecutive lung cancer patients who were
hospitalized from 1 December 2006 to 30 June 2007 in the General Univer-
sitary Hospital in Elche. Co-morbidity was determined on discharge from the
hospital. Results: A total of 92 patients, 86 men and 6 women, with an
average age of 67 years (SD 11.66), were included. Of these patients, 72
(78.3%) had NSCLC, and 70 (76.1%) had stage IV disease. 68.2% had
ECOG PS 2–3 (n60) and 13.6% had PS 4 (n12). Charlson’s Index scores
were 0 to 6 for 34 patients (37%) and 6 for 63% (range 2 to 13). Cause of
hospitalization: symptoms due to lung cancer, (27, 31%), symptoms of other
non-lung cancer-related comorbidities (27, 31%), toxicity of chemotherapy
(15, 17%). Using stepwise logistic regression, no risk factors were found to
be strong or independent predictors of length of hospitalization.
Conclusion: This study indicates that Charlson’s Index does not provide a
robust prediction of length of stay for hospitalized patients with lung cancer.
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IMPORTANCE OF COMORBIDITY AND PERFORMANCE
STATUS MEASURES IN PREDICTING MORTALITY
AMONG LUNG CANCER HOSPITALIZED PATIENTS
M. Molina-Garrido1, C. Guille´n-Ponce1, M. Guirado-Risueño1, A. Mora2, A.
Carrato1 1Medical Oncology, General Universitary Hospital in Elche, Elche
(Alicante)/SPAIN, 2Internal Medicine, General Universitary Hospital in
Elche, Elche (Alicante)/SPAIN
Introduction: Lung cancer remains the leading cause of cancer death in most
countries. Although multimodality treatment has been advocated, the prog-
nosis is still poor. A poor performance status has been found to have a
significant negative impact on survival in patients with stage I NSCLC.
Comorbidity can be an important predictor of survival in patients with a
variety of neoplasms.
Objective: To discover which factors could modify the survival time of
hospitalized persons with stage III or IV lung cancer.
Design: A retrospective study.
Setting: General Universitary Hospital in Elche.
Participants: Patients with lung cancer who died during hospitalization along
March 2006 and December 2006.
Methods: Data collected by chart review included age, gender, ECOG,
tumoral stage, Charlson’s index and cause of death. Survival was measured
as the number of weeks surviving from the moment of diagnosis to the date
of death.
Results: A total of 67 patients were enrolled over a 9 months period. Median
age: 66,93 years; 88,1% male; 62,7% stage IV; ECOG 0–1 55,4% (n36),
ECOG 2–3 40% (n26). Charlson’s index: 0 to 2 in 4,5% of patients (n3),
3 to 5 in 20,9% (n11), 6 to 10 in 74,6% of patients (n50) and greater than
10 in 4,5% of cases (n3). Survival: median 6,67 weeks; average 8,98 w.
Cause of death: secondary to lung cancer in 87,3% of cases (n48) and other
diverse causes in 12,7% of patients (n7). Regression analysis: ECOG
p0,046; R2corrected: 0,052, F4,156. Sex p0,618; tumoral stage
p0,370; Charlson’s index p0,722; age p0,082.
Conclusions: Performance status measured by ECOG is the only factor
which contribute to predict lenght of life in lung cancer patients stage III and
IV who are hospitalized. No age, sex or Charlson’s index do.
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ROLE OF AIR POLLUTION IN LUNG CANCERMORBIDITY
IN THE REGIONS OF UKRAINE
O. Voitko1, L. Voitko2, S. Omelchuk3 1Thoracic Surgery, Kiev city oncology
hospital, Kiev/UKRAINE, 2Medical Department 1, National O.O. Bogo-
molets Medical University., Kiev/UKRAINE, 3Public Health, Hygiene, Na-
tional O.O. Bogomolets Medical University, Kiev/UKRAINE
Research objective - how anthropogenesis air pollution influences on the
level of lung cancer (LC) morbidities among Ukrainian population in
1982–2004. In our work we have used official data of the National cancer-
register and the State committee of statistics of Ukraine.
525 713 lung cancer cases were diagnosed in Ukraine in 1982–2004.
Morbidities was authentically higher in the southeast regions than in north-
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west ones. The level of LC morbidities increased from 43,1 cases on 100 000
population in 1982 to 53,9 ones in 1991 and decreased to 37,84 ones in 2004.
24 regions from 26 ones (92,4%) had passed the LC morbidity peak till 1992.
Decreasing of morbidity in 1991–2004 was observed against the increasing
prevalence of smoking and the reduction of harmful substances emissions in
atmospheric air.
The reduction of emissions from 31,13 tone on 1 km2 in 1985 to 13,83 tone
on 1 km2 in 1994 led to the decrease of LC morbidities from 48,65 cases in
1995 to 37,84 ones on 100 000 population in 2004. The revealed dependence
was described as the same equation for all Ukrainian regions, general view -
yax3-bx2cxd (for Ukraine, as a whole, – y0.0018x3–0.0938x22,
0276x22,98:
- y – the level of LC morbidity,
- x – level of harmful substances emissions in atmospheric air for 10 years
by the time of determination of an actual morbidity,
- d – “Background” level of morbidity,
- a, b, c – factors, which, according to the authors, were caused by
ecologic-climatic conditions, specificity and features of placing of manufac-
ture, and others for each territory.
The calculations showed, that:
- If harmful substances emissions in atmospheric air had been absent (x0),
the average level of LC morbidity could have made 22,98 cases on 100 000,
- The level of morbidity, due to the harmful substances emissions in
atmospheric air, was higher than “background” morbidity in about 1,5 times
in 1982–2004.
- 1 tone on 1 km2 of emissions in atmospheric air of the region led to 1–3
(depends of time and region) “superfluous” case of LC.
Conclusions:
1. Smoking was not the only important factor which influenced on LC
morbidity amongst Ukrainian population in 1982–2004.
2. The revealed dependence allows to predict more authentically LC mor-
bidity in the regions in the future time and help to develop preventive actions.
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TO DEVELOP AND VALIDATE AN INDIGENOUS
DEVELOPED QOL FOR LUNG CANCER PATIENTS
U. Batra1, G.B. K2 1Department of Medical Oncology, Kidwai Memorial
Institute of Oncology, Bangalore/INDIA, 2Medical Oncology, KMIO, ban-
galore/INDIA
Background: lung cancer predominantly affects a large number of elderly
patients who often hail from poor socioeconomic backgrounds and have
there own unique quality of life issues. Furthermore, due to the diverse
cultural habits, quality of life issues in developing countries are different
from those of western countries. In addition, in India where there is a high
patient to Doctor ratio, the use of EORTC questionnaire is often not
feasible.
Aim: To develop a simplified Quality of life questionnaire based on local
culture and to validate the same in comparison with EORTC QLC 30.
Methods: 50 patients with histological or cytological diagnosis of locally
advanced or metastatic lung cancer were evaluated. All the patients were
given EORTC as well as the simplified questionnaire. The time taken to fill
both the questionnaire as well as the ease of completion and the mean
number of questions answered in both the questionnaire were recorded.
Results: The completion rate was high in the simplified version and the
questionnaire was well accepted by the patients. Seven scales were con-
structed (physical functioning, social functioning, emotional functioning,
financial impact, role functioning, global QOL and cognitive functioning).
The simplified questionnaire was much better in assessing the physical,
social and financial functioning of patients (p0.001) The time taken to
complete the questionnaire was also less in simplified version.
Conclusion: The simplified QOL is an easy and reliable alternative to
EORTC QOL and may be used in Indian settings.
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CRITICAL REVIEW OF META-ANALYSES ANALYZING
LUNG CANCER TREATMENT
M. Brignone1, A. Auperin1, I. Colombet2, S. Chabaud3, V. Grassi1, C.
Delbaldo4, C. Le Pechoux5, B. Besse6, J.P. Pignon7, R. Arriagada6 1Biosta-
tistics Department, Institut Gustave Roussy, Villejuif/FRANCE, 2Hospital
Informatics Department, Hoˆpital Europe´en Georges Pompidou, Paris/
FRANCE, 3Biostatistics Department, Institut Le´on Be´rard, Lyon/FRANCE,
4Oncology Department, Hopital Henri Mondor, Cre´teil/FRANCE, 5Dept. of
Radiotherapy, Institute Gustave Roussy, Villejuif/FRANCE, 6Department of
Medicine, Institut Gustave Roussy, Villejuif/FRANCE, 7Biostatistics and
Epidemiology, Institut Gustave-Roussy, Villejuif/FRANCE
Background: The number of randomized controlled trials (RCTs) on lung cancer
treatments is increasing rapidly as well as meta-analyses (MA) that synthesize
their results. Even if MA represent the highest level of evidence, their quality is
variable. This review attempted in order to identify factors which are most
associated with MA overall quality to define a simplified quality score. Second-
ary objective was to compare MA assessing the same treatment.
Methods: A systematic search was performed using multiple databases from
1990 to 2006, with the terms: lung cancer, meta-analysis and systematic
review, without language restrictions. All MA of RCTs on lung cancer
treatments published as full paper were eligible. Data on MA characteristics
(publication, size, methodsa`) were extracted by two investigators. Quality
was evaluated independently by three reviewers using the scoring method
proposed by Sacks and Auperin (27 items scored 0, 1 or 2) and clinical relevance
by two clinicians. We defined three groups of MA using the 1st and 3rd quartiles
of the score (poor, middle and high MA quality) and identified the most
important quality criteria by logistic regression. MA evaluating the same treat-
ment were compared (included trials, methods used, results).
Results: 50 articles with 69 MA were included ; all of them used overall
survival as outcome. The median numbers of RCTs and patients by MA were
11 (3–57) and 2,111 (360–11,160) respectively. Only 12% of MA were
based on individual patient data. 74% of MA concerned non-small cell lung
cancer and 70% chemotherapy evaluation. The median quality score were 25
varying from 9 to 43. Factors linked to quality were a Cochrane study,
exhaustiveness of trial search, publication of hazard ratio, estimation of
absolute benefit and use of survival curves. Fourteen therapeutic questions
were evaluated by more than one MA corresponding to 50 MA out of 69.
Conclusion: Meta-analyses publications on lung cancer treatment had a highly
variable and often low methodological quality. Our simplified quality score is
easy to use to evaluate the quality of meta-analyses of randomized trials with
survival outcome. Results of the comparison of meta-analyses on the same
treatment will be presented. Unrestricted grants from the LNCC and Sanofi-
Aventis.
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THERAPY-ORIENTED LARGE SCALE GENOMIC AND
GENE EXPRESSION ANALYSIS IN THYMOMAS,
MESOTHELIOMAS AND LUNG CARCINOIDS
F. Toffalorio1, E. Belloni2, G. Pelicci2, G. Pelosi3, F. de Braud1, T. De Pas4
1Division of Clinical Pharmacology and New Drugs Development, European
Institute of Oncology, Milan/ITALY, 2Department of Experimental Oncology,
European Institute of Oncology, Milan/ITALY, 3University of Milan School
of Medicine, University of Milan School of Medicine, Milan/ITALY, 4Divi-
sion of Clinical Pharmacology and New Drugs Development, European
Institute of Oncology, Milan/ITALY
Rare tumors are rare diseases and common strategies for their cure are still
missing. The need for a deeper knowledge of the mechanisms underlying
tumorigenesis and the definition of tumor-specific signatures become essen-
tial as the basis for novel therapeutic approaches. The role of large scale
genomic and gene expression studies has been proven decisive in enhancing
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the understanding of human diseases, with unquestioned breakthrough con-
cerning diagnosis, prognosis and treatment. In Our Institute, a collection of
rare tumor samples has started. In particular, a big effort is being directed
towards the collection of thymoma, mesothelioma, and lung carcinoid
samples, to be studied from the genomic and gene expression point of view.
These tumors are mostly characterized by high aggressiveness and resistance
to conventional treatments with radio-chemotherapy. It is therefore necessary
to find novel strategies for their cure. We have started a genetic approach to
identify specific genetic anomalies or gene expression patterns, which might
help both in acquiring new insights in the tumorigenic processes underlying
these tumors and in developing new specific antitumoral drugs. In this
context, the gene expression microarray analysis will intend in order to
identify, within the different tumor types, new categories with specific gene
signatures, which are expected to greatly improve the knowledge of the
tumors, mainly in terms of disease development and progression (aggres-
siveness). At the same time, the definition of the genomic status of the
different tumor samples, macroscopically (diploidy or aneuploidy) and
microscopically (chromosome-specific amplifications or deletions), will
highlight tumor-type or tumor- category specific genetic defects. This infor-
mation will result in a more complete knowledge of thymomas, mesotheli-
omas and lung carcinoids, allowing the choice of the best existing therapeutic
treatment, on one side, and the development of new effective approaches, on
the others. We are have already analyzed a first group of lung carcinoids,
constituted of 5 typical and 5 atypical tumors, each with its normal coun-
terparts. The data are under validation.
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HUMAN PAPILLOMA VIRUS (HPV) IN NON-SMALL CELL
LUNG CANCER (NSCLC)
A. Rezazedeh, S.J. Ghim, G. Moore, A.B. Jenson, G.H. Kloecker Hematol-
ogy/oncology, University of Louisville, Louisville/UNITED STATES OF
AMERICA
Introduction: Non-small lung cancer is commonly caused by toxic and
environmental agents. Cigarette smoking is the most common etiologic
cause. Kentucky has the highest prevalence of NSCLC and cervical cancer in
the USA. The incidence of both cancers is related to smoking. Kentucky also
has the highest rates of adult and teenage smokers in the USA. HPV is found
in 100% of cervical cancer and its role in the pathogenesis of cervical cancer
is well defined. HPV’s contribution to the risk of developing NSCLC
however is unknown. This study evaluates the incidence of HPV in NSCLC.
Methods: Random malignant FNA samples of lung masses were examined.
Formalin fixed paraffin blocks were tested using PCR MY 09/11 and G/P 5/6
primers. PCR was carried out using Taq polymerase and primers binding
DNA’s of 23 mucusotropic HPV’s. Beta-globin was separately amplified to
measure the presence of sufficient DNA as quality control. PCR products
were gel purified and DNA sequenced. Medical charts were reviewed after
the blinded PCR results were available.
Results: 23 samples of malignant lung masses were tested. By DNA se-
quencing of the PCR products, 3 needle biopsies of the lung were positive for
HPV-16, 2 for HPV 11 and 1 for HPV 22. Upon chart review, of the HPV-16
positive lung cancers one was metastatic from the cervix. The other five HPV
positive samples of 22 were found in typical NSCLC tissue. All of the
NSCLC patients were smokers.
Interpretation: HPV-11 is a well known factor causing respiratory papillo-
matosis. After radiation of the airway HPV related papillomatosis invariably
transforms to NSCLC. In a similar fashion HPV infected respiratory epithe-
lium may have a higher risk of transformation when exposed to mutagenic
cigarette smoke. The fact that five out of 22 NSCLC samples were HPV
positive supports the assumption that HPV contributes to the development of
NSCLC. P-53 mutation due to HPV in NSCLC has been recently described.
This has significant implication considering the new introduction of a HPV
vaccine and its potential effect on developing NSCLC. Studies on detection
of HPV in the respiratory tract as a tool for NSCLC screening are planned.
Analogous to HPV’s role in the prognosis of head and neck cancer, HPV’s
use for prognosis in NSCLC will be further examined.
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MEASLES VIRUS: EVIDENCE FOR ASSOCIATION WITH
LUNG CANCER
S. Ariad1, I. Lazarev1, D. Benharroch2, J. Gopas1, N. Sion-Vardi2 1Oncology,
Soroka Medical Center, Beer Sheva/ISRAEL, 2Pathology, Soroka Medical
Center, Beer Sheva/ISRAEL
Introduction: Although cigarette smoking is the principal culprit for the
development of lung-cancer (LC), only a minority of tobacco users develop
LC. Viral etiology for LC has rarely been evoked. There are reports in the
literature indicating that MV may be associated with LC. MV-phosphopro-
tein may inhibit ubiquitination of Pirh2 responsible for degrading p53, the
cell cycle regulator. In another study, Pirh2 was overexpressed in LC
biopsies compared with normal lung tissue.
Patients and methods: A retrospective, clinicopathological study on patients
with NSCLC aimed at showing whether measles antigens are present in
tumors and the prognostic importance of measles and Pirh2 in these patients.
For each case, sections were taken for immunohistochemical studies for
MV-antigens, hemagglutinin and nucleoprotein, p53, and Pirh2. The follow-
ing parameters were analyzed for association with MV: Gender, ethnicity,
place of birth, age, smoking status, histological type, tumor size, lymph node
involvement, stage, Pirh2 and p53.
Results: 65 patients with histological diagnosis of NSCLC were included;
median age-65 years (range 40–84 years); male to female ratio–2.6; Jews–
61, Bedouin-Arabs–4; Most Jewish patients were of Ashkenazi extraction
(72%); smokers-90%; Early-lung cancer (stage 1/2)–83%; adenocarcinoma–
52%, squamous cell carcinoma–32%; large cell carcinoma–15%; Positive
measles status (expression of both MV- antigens)-54%; p53–40%; Pirh2–
53%. In univariate analysis, positive MV-status correlated with age (P0.018),
and expression of Pirh2 (P0.006). Pirh2 expression correlated with positive
nodal status only (P0.024). In multivariate logistic analysis, the only indepen-
dent variables were age above 60 years (P0.01) and Pirh2 positive status
(P0.014). In Cox multivariate analysis, the only variables associated with
improved survival were Pirh2 positive status (P0.027), Africa/Asia place of
birth (p0.031), and early stage (p0.036). Conclusions: MV-antigens are
present in a large proportion of NSCLC biopsies suggesting a possible associ-
ation between MV and NSCLC. MV status was linked to older age, and to
expression of Pirh2, while Pirh2 itself indicated improved survival.
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PROTEIN EXPRESSION AND GENE AMPLIFICATION OF
EPIDERMAL GROWTH FACTOR RECEPTOR IN NON-
SMALL CELL LUNG CANCER: CORRELATION WITH
CHEMORESPONSE TO GEFITINIB THERAPY
J. Yoo1, S.H. Kim2, D.G. Cho3, M.I. Ahn4, C.H. Kim5, K.D. Cho3, H.K.
Kim5 1Pathology, Catholic University St. Vincent’s Hospital, Suwon/KO-
REA, 2Radiation Oncology, Catholic University St. Vincent’s Hospital,
Suwon/KOREA, 3Thoracic Surgery, Catholic University St. Vincent’s Hos-
pital, Suwon/KOREA, 4Diagnostic Radiology, Catholic University St. Vin-
cent’s Hospital, Suwon/KOREA, 5Internal Medicine, Catholic University St.
Vincent’s Hospital, Suwon/KOREA
Background: Gefitinib, EGFR tyrosine kinase inhibitor, has shown dramatic
effectiveness in a subset of non-small cell lung cancer (NSCLC) patients. We
evaluated the response rate of the gefitinib, and the significance of EGFR and
HER2/neu status as a predictive marker of tumor response.
Methods: EGFR and HER2/neu protein expression by immunohistochemis-
try(IHC) and gene amplification by chromogenic in situ hybridization (CISH)
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were analyzed in biopsy specimens from 46 patients with advanced NSCLC.
After failure of the first-line treatment, all had received gefitinib treatment.
Results: Partial response (PR) was achieved in 8 patients (17.4%). EGFR
overexpression was detected in 80.4% (37/46) of the tumors, and observed
exclusively in patients with PR (100% vs 75.3%; p0.076). EGFR gene
amplification was present in 47.8%(22/46). HER2/neu was overexpressed in
13%(6/46) and amplified in 17%(7/46). Overall survival was prolonged in the
female patients (p0.007), and in patients with T1 and T2 (p0.039), adeno-
carcinoma (p0.010), PR (p0.022), EGFR IHC (p0.033), EGFR IHC/
CISH (p0.010), or EGFR/HER2/neu (p0.030). In multivariate analy-
sis, gender, T and EGFR IHC/CISH remained significant predictors of survival.
Conclusions: Gefitinib showed a modest effect in the patients with chemo-
therapy-refractory advanced NSCLC. Combination of EGFR IHC and CISH
might be important in identifying patients most likely to benefit from the
gefitinib therapy.
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GLU 298 ASP NITRIC OXIDE SYNTHASE POLYMORPHISM
IN NON SMALL CELL LUNG CANCER
A. Luciani1, M.L. Biondi1, G. Ascione1, O. Turri2, S. Zonato1, S. Oldani1, A.
Baisi3, G.V. Melzi-Eril2, P. Foa1 1Medical Oncology, S. Paolo Hospital,
Milan/ITALY, 2Laboratory and Biochemistry, S. Paolo Hospital, Milan/
ITALY, 3Thoracic Surgery, S. Paolo Hospital, Milan/ITALY
Background. Nitric oxide synthase (NOS) has been implicated in tumour
angiogenesis and in the maintaining of vasodilator tone of tumour blood
vessels. NOS expression has been documented in lung tumours, and have a
potential role in induction of capillary formation and neoangiogenesis. NOS
interacts with VEGF and Metalloproteinase to form the tumour microenvi-
roment. This is a preliminary analysis of NO synthase polymorphisms and
their correlates in a population of non small cell lung cancer patients.
Patients and methods. 46 patients, 36 males (78%), 10 females (22%), were
considered. Mean age was 70 (51–90, SD 8.1). For all patients baseline
performance status (PS), medications, comorbidities and number of meta-
static sites were recorded. 40 pts (87%) had performance status 0. Stage at
diagnosis was calculated according to AJCC staging system; the distribution
was: stage I (23%, 10/46), stage II (17%, 8/46), stage III (17%, 8/46), stage
IV (43%, 20/46). 10 pts had surgery (23%), 33 pts (72%) received at least
one line of chemotherapy, 2 (4%) received adjuvant treatment. Patients and
133 controls, matched for sex and age, were genotyped for the common
eNOS polymorphisms Glu298Arg.
Results. The allele frequencies of the two polymorphisms in each group were
distributed according to the Hardy-Weinberg equilibrium. The genotype
distribution was significantly different between cases and controls (Glu/Glu
17 vs 56, Glu/Asp 18 vs 70, Asp/Asp 12 vs 7; patients vs controls;
Glu298Asp c215.27; p 0.0001) and subjects homozygous for Asp/Asp
have 6 fold higher risk lung cancer than Glu/Glu and Glu/Asp carriers (OR
6.17 CI % 2.03–19.74; p 0.0001). No correlation was observed with stage
and number of metastasis and Glu298Asp polymorphism.
Conclusion. Our preliminary results suggest that Glu298Asp polymorphism
could play a role as putative risk factor for developing lung cancer. Further
studies are necessary to determine if this polymorphism can have a role as
prognostic marker for toxicity and survival.
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OF INDUCED SPUTUM SAMPLES FOR LUNG CANCER
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Background & Objectives: Lung cancer screening studies have been per-
formed in an attempt to improve the outcome of this disease. Progress in
computer related technologies and growing knowledge of the genetic
changes involved in lung cancer, brought us new possibilities. The present
study was aimed to investigate the feasibility of computer assisted analysis
of induced sputum in identifying cells with morphological and genetic
changes indicative for lung cancer.
Methods: Induced sputum was collected from 15 lung cancer patients prior
to bronchoscopy using saline inhalation in ultrasonic nebulizer and evaluated
blindly using the “Duet” computerized cell scanning system (BioView Ltd.
Rehovot, Israel). Final diagnosis was obtained by bronchoscopy, surgery or
transthoracic fine needle aspiration. From each sample, 
 3000 cells were
fixed following cytospin, stained in Giemsa (Sigma, St Louis, MO), and
scanned by the Duet. Subsequently, cells were hybridized to a FISH mixture
of home-brew probes for chromosomes 3p22.1 & 10q22–23 and their control
centromeres, and scanned again. Two strategies of scanning were used: a)
Target scan - selection of cells with atypical morphology and analysis of the
pattern of chromosome abnormalities by FISH within these cells, and b) Area
scan - random acquisition of 500 cells and analyzing the expression of the
FISH markers in these cells.
Results: By using the target scan strategy, the average number of cells that were
analyzed in each case was 236180. The mean number of abnormal cells was
20.813.6 and 17.723.4 in 3p and 10q probes, respectively. The sensitivity of
the 3p and 10q probes was 91.7% and 58.3% and the specificity was 88.9% and
80%, respectively. In area scan the mean percentage of abnormal cells was
3.72.5 and 3.92.1 in 3p and 10q probes, respectively. The sensitivity of the
3p and 10q probes was 54.5% and 81.8% and the specificity was 80% and 82%,
respectively. The combination of both strategies yielded overall sensitivity and
specificity of 100% and 89%, respectively.
Conclusion: These results encourage us to validate this approach in high-risk
populations, to improve the computer algorithm, to allow shorter analysis
time and to make this method applicable for mass screening.
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SIGNIFICANCE OF MOLECULAR ALTERATIONS IN
ALVEOLAR CELLS IN UIP (USUAL INTERSTITIAL
PNEUMONIA) WITH OR WITHOUT LUNG CANCER
S. Lantuejoul1, A.G. Nicholson2, D. Salameire1, A. Wells3, C. Pison4, P.
Goldstraw5, D. Hansell6, G. Ferretti7, C. Brambilla4, E. Brambilla1 1Pathol-
ogy, INSERM, Grenoble/FRANCE, 2Histopathology, Royal Brompton Hos-
pital, London/UNITED KINGDOM, 3Respiratory Medicine, Royal Brompton
Hospital, London/UNITED KINGDOM, 4Respiratory Disease, INSERM,
Grenoble/FRANCE, 5Thoracic Surgery, Royal Brompton Hospital, Imperial
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Background: Incidence of lung cancer and Idiopathic Pulmonary Fibrosis
(IPF) is significantly higher than that of lung cancer alone. IPF, which is the
most common interstitial lung disease with the worse prognosis, may exhibit
histiologically a Usual Interstitial Pneumonia (UIP) or Fibrotic Non Specific
Interstitial Pneumonia (NSIP) pattern. As molecular abnormalities were
reported in atypicaland/or metaplastic alveolar cells in UIP, we hypothesized
that UIP is a predisposing condition to lung cancer.
Design: As telomere attrition, perceived as DNA damage, represents an early
genetic abnormality in carcinogenesis, preceding telomerase expression and
p53/ Rb inactivation, we looked for relative telomere length using Fluores-
cence In Situ Hybridization (Tel FISH) in alveolar cells in 5 UIP and 5
fibrotic NSIP. In addition, immunohistochemical expression of proteins
involved in proliferation or apoptosis were scored and compared in 29 UIP
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with cancer, 15 UIP without cancer, 11 Fibrotic Non Specific Interstitial
Pneumonia (NSIP) and 10 inflammatory lungs.
Results: Numerous atypical and/or metaplastic alveolar cells were found in 39%
and 43% in UIP with or without cancer, respectively, but in 9% of NSIP and
none of inflammatory cases. P53, Cyclin D1, P21 and P16 expression and a
Bax:Bc12 ratio1 were found in 70 to 100% of atypical alveolar cells from UIP
and NSIP, but not in alveolar cells from inflammatory lungs. Cyclin E was not
expressed except in tumor cells. Immunophenotype of lung carcinomas in UIP
was comparable to that reported in lung cancer alone. Using Tel FISH analysis,
alveolar cells in NSIP exhibited the same telomere length than lymphocytes and
bronchial cells considered as internal controls. In contrast, atypical and meta-
plastic alveolar cells in UIP showed short telomeres.
Conclusion: Telomere shortening in UIP suggests a deregulation of cell
division and an increased generic instability, which could favour carcino-
genesis. In contrast, the molecular abnormalities on proliferation and apo-
ptosis pathways were not so different in cancer and non cancer cases. Further
studies are required to investigate the integrity of DNA damage responses
implicated in tumorogenesis.
IMAGING
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BIENNIAL RADIOLOGICAL SCREENING OF LUNG
CANCER IN A COHORT OF ASBESTOS-EXPOSED
WORKERS: COMPARED PERFORMANCE OF CHEST
X-RAY AND HELICAL CHEST CT SCAN
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cine, Rouen University Hospital, Rouen/FRANCE
Background: The aim of this study was to compare, in a cohort of former
asbestos-exposed workers, the sensitivity and the specificity of low radiation
helical chest CT scan with that of conventional chest radiography for the
biennial screening of bronchopulmonary cancer, according to the size of
detected nodules.
Materials and methods: The study involved a cohort of 1,005 individuals
having suffered high exposure to asbestos during their professional career,
and for whom biennial chest x-ray and monodetector chest CT scan was
proposed. Excluding those for whom initial screening evidenced broncho-
pulmonary cancer, each individual included in the study benefited from at
least 2 examinations, performed at a 2-year interval. 12,30 examinations
were performed.
Results: In the studied cohort, 24 patients presented with bronchopulmonary
cancer. Chest CT scan enabled the detection of 21 cancers, 13 of which had
not been detected using conventional chest radiography. 3 cancers appeared
between 2 screening examinations. Among screened cancers, 12 were stage
I (57.14%). Sensitivity of chest X-ray and chest CT scan, for screening
bronchopulmonary cancer was respectively 33% and 83%. The specificity of
chest X-ray was 95%, whereas chest CT scan specificity was only 78%.
Calculation of the differential FP/TP ratio (false positive/true positive) and
the “ROC curve”, performed for both chest X-ray and chest CT scan,
facilitated the choice of the best possible compromise between specificity
and sensitivity, according to the chosen threshold for considering a nodule as
suspect. When considering lesions over 5mm as suspect, CT scan sensitivity
and specificity were respectively 83% and 92%, each extra case of broncho-
pulmonary cancer detected by the CT scan generating 6 further false
positives in comparison to chest X-ray.
Conclusion: The results of our study enable us to provide quantified confir-
mation of the superiority of monoslice helical chest CT scan over conven-
tional chest radiography. The differential FP/TP ratio, leads to recommend a
diameter of 5mm as the threshold for considering non-calcified lesions as
“suspect” in the surveillance of asbestos-exposed individuals.
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AFTER INDUCTION THERAPY FOR LOCALLY
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D. Lardinois1, S. Collaud2, H. Steinert3, S. Wrann4, R.A. Stahel5, W. Weder2
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Objective: Re-staging of patients with locally advanced non-small cell lung
cancer (NSCLC) is very important, since it is generally admitted that only
patients with downstaging after induction therapy will benefit from surgery.
The aim of this study was to assess the significance of new solitary focal
abnormalities located in lymph nodes or in the contralateral lung in patients
who showed a good response in the primary and in the mediastinal nodes
after induction therapy.
Material and Methods: Between January 2002 and March 2006, 603 patients
with potentially operable NSCLC underwent staging by use of whole-body
PET/CT. In 98 (16.3%) of these patients with histologically proven stage III
disease, induction was performed. Pre and postinduction PET/CT were
achieved in 31 patients and retrospectively reviewed.
Results: Re-staging PET/CT revealed a solitary new focal abnormality in
6/31 (19.4%) patients. Initial clinical stage of the disease was IIIA N2 in 4
patients and IIIB T4 in 2 patients. In each of these patients, standard uptake
value (SUV) in the primary tumor and in the initial involved mediastinal
nodes was significantly decreased after induction treatment. The new
PET/CT findings were centrally located in the upper lobe of the contralateral
lung in 2 patients, in a contralateral mediastinal lymph node in 2 patients, and
in a supraclavicular node, respectively in a cervical node in one patient each.
Clinical significance of these new lesions was unclear. In order to exclude
malignancy, explorative thoracotomy was performed in 2 patients. Histology
of the intraparenchymatous lesions showed an organized pneumonia and an
aspergilloma without any tumor. In 3 other patients, needle biopsy from a
supraclavicular and a paratracheal node revealed only inflammation. In the
last patient, clinical follow-up with PET/CT at 3 and at 6 months could
exclude tumor infiltration of the lymph nodes.
Conclusions: New solitary focal abnormalities in lymph nodes or in the
contralateral lung on PET/CT following induction treatment in patients with
locally advanced NSCLC are not rare and in our experience, not associated
with malignancy. Histology of such lesions is necessary before resection of
the primary.
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Objective: Repeat mediastinoscopy or remediastinoscopy (reMS) is a valu-
able restaging tool in non-small cell lung cancer. Not only provides a reMS
pathological evidence of mediastinal downstaging, it also selects those
patients who will benefit from a subsequent surgical resection and determines
prognosis. However, other indications for reMS exist. We reviewed our
overall experience with reMS.
Methods: From June 1994 until September 2007, 79 reMS were performed
in 75 patients (65 men and 10 women). Mean age was 67.4 years (range 35
to 85 years).
Results: ReMS was performed after induction therapy in 54 cases (68.4%),
for recurrent and second primary lung cancer in 9 cases (11.4%), for lung
cancer occurring after an unrelated disease such as sarcoidosis in 1 case
(1.2%), for an inadequate first procedure in 8 cases (10.1%) and for a
non-malignant disease such as sarcoidosis or lymphoma in 7 cases (8.9%).
ReMS was technically feasible in all patients. There was no mortality. We
encountered one haemorrhage from a bronchial artery during reMS which
was controlled by packing. In patients with lung cancer (71 patients), reMS
was positive in 29 cases (40.8%). ReMS was able to establish a definite
diagnosis in 3 patients with sarcoidosis and in 1 patient with lymphoma.
Conclusion: Although mostly performed as a restaging procedure after
induction therapy in non-small cell lung cancer, reMS can also safely be
performed for other indications providing pathological evidence of medias-
tinal involvement.
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EBUS TBNA IN PREVENTING UNNECESSARY SURGICAL
PROCEDURES
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The aim of the study Endoscopic ultrasound (EUS) –guided fine-needle
aspiration (FNA) and Endobronchia Ultrasound (EBUS)- guided transbron-
chial needle aspiration (TBNA) is accurate, safe, and minimally invasive
techniques for the analysis of mediastinal lymph nodes (LNs) The goal of
was to assess to what extent EBUS-TBNA alone and in combination with
EUS FNA could prevent surgical interventions. Patients One hundred con-
secutive patients scheduled for mediastinoscopy (75%) or thoracotomy
(25%) because of lung cancer or suspected lung cancer. In the same
anaesthesia as mediastinoscopy 100 patients underwent EBUS TBNA and 90
EUS FNA. Surgical verification occurred when mediastinoscopy and EUS
FNA was without malignancy disease. Results In 3 cases we found a false
negative mediastinoscopy and EBUS TBNA (one station 6, one metastases in
the adrenals and one in station 8). In 11 cases the mediastinoscopy were false
negative and in 4 patients EBUS TBNA were false negative. Patients with
N0 after mediastinoscopy we referred to toracotomy/thoracoscopy. 9 thora-
cotomies could therefore have been avoided with the use of EBUS-TBNA
because of false negative CT N0–1 Of the 75 patients scheduled for
mediastinoscopy 7 patients would have undergone an unnecessary primary
thoracotomy with EBUS TBNA alone. With mediastinoscopy alone the
numbers would have been 14 unnecessary thoracotomies. Because of posi-
tive EBUS TBNA 51 mediastinoscopies could be avoided The actual
guidelines recommend mediastinoscopies when EBUS TBNA is without
malignancies. Following these guidelines 49 medistinoscopies should be
performed with the results of finding 4 false negative EBUS TBNA (8%). In
90 of these patients EBUS TBNA and medistinoscopy were combined with
EUS FNA. Combining EBUS TBNA with EUS FNA results in only 2 cases
of false negative endoscopic ultrasound examinations (2%) Conclusion
EBUS TBNA as a primary procedure prevent half of the scheduled medias-
tinoscopies and EBUS TBNA alone results in less unnecessary thoracoto-
mies than mediastinoscopy alone. The combination of EBUS TBNA and
EUS FNA improves this result with only 2 false negative results.
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Docetaxel is a taxene anticancer drug with activity against a broad range of
cancers. Although pulmonary toxicity is a well-known complication ob-
served with several anticancer drugs, interstitial pneumonitis induced by
docetaxel has been rarely reported. The purpose of this study is to provide
CT findings of docetaxel-induced lung toxicity in patients with non-small
cell lung cancer. Among 53 patients with non-small cell lung cancer who had
received docetaxel, 9 patients developed pulmonary opacities on follow-up
chest CT scans. No clinical evidence of apparent infection or heart failure
was identified. Seven patients had worsened or newly developed dyspnea
with deterioration of lung function with restrictive pattern. Seven out of 9
patients with pulmonary opacities received weekly docetaxel (30–40mg/
m2), and the remaining 2 received nonweekly docetaxel (60–75mg/m2).
Among 7 patients with weekly docetaxel, four received docetaxel only
(30mg/m2), and three received docetaxel (40mg/m2) combined with cisplatin
(35mg/m2). The cumulative doses of docetaxel were between 60 and 120
mg/m2 in one, between 120 and 240 mg/m2 in four, and between 240 and
480mg/m2 in four patients. We retrospectively evaluated the CT findings of
9 patients for extent, location, density pattern of pulmonary opacities.
Ground glass opacities were found in all patients. Combined reticular
opacities (n5) and consolidation (n3) were also noted. The lesions were
focal or patchy in 7 patients and diffuse in 2 patients. The locations of the
lesions were mainly peripheral (n7) and upper lobe (n6). Four of them
received corticosteroid treatment and all patients showed symptomatic or radio-
logical improvement. In conclusion, CT findings of docetaxel-induced pneumo-
nitis are characterized by peripheral patchy ground glass opacities with upper
lobe predominance. Special concern should be given to the development of
docetaxel-induced lung toxicity as its cumulative dose increases.
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SURVEILLANCE FOR PATIENTS WITH CURATIVE-
INTENT SURGICAL RESECTION FOR NSCLC: CT
VERSUS 18F-FDG DUAL HEAD GAMMA CAMERA
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The goal of this study was to compare the utility of gamma camera with a
coincidence detection system imaging (CDET) with 18F-FDG for detecting
recurrence to CT imaging. Sixty nine patients were randomized in two
groups for follow-up after surgery from October 2000 to December 2002.
Each patient was evaluated every 3 months by clinical examination and every
6 months by CT in group A (n33) or CDET imaging techniques in group
B (n36). In two groups, brain CT was performed every 6 months. The
direct costs of each procedure were evaluated using French health care payer.
The major endpoint was detection of recurrence or new cancer in symptom-
atic or asymptomatic patients. Follow-up, disease free survival and overall
survival were calculated from the day of operation. The two groups were
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similar for clinical, pathological, staging and therapeutic characteristics. A
total of 23 patients of 69 were detected with recurrence. In group A, 9
recurrences were detected with 8 in symptomatic patients. In contrast, 16
recurrences were detected in group B using CDET imaging with 11 asymp-
tomatic patients. Overall survival was similar in the two groups. CDET
imaging was more expensive. CDET imaging provides an early detection of
recurrence in asymptomatic patients, but does not modify survival. Further
studies are necessary in selected patients to prove that incorporating PET
scanning in surveillance program is cost-effectiveness.
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Purpose: To assess retrospectively the additional value of PET/CT in the
detection of unsuspected second primary tumors in the staging of patients
diagnosed with non-small-cell lung cancer (NSCLC) and other extrathoracic
lesions including metastatic disease and physiologic variants.
Method and materials: 379 patients (342 male, age range: 28–73 y) with a
pathological proven NSCLC underwent conventional staging work-up and
PET/CT with FDG from August 2003 to February 2006. TNM metabolic
staging was established. All extrathoracic hypermetabolic lesions were
recorded (site, size and SUV) and compared with the final diagnosis obtained
from the medical records (follow-up  12 mo).
Results: Extrathoracic hypermetabolic lesions were detected in 23% of the
patients (88/379) and 75% of them (66/88) were proved to be malignant: 51
patients with metastasis (77%) and 15 patients with second primaries (23%).
Simultaneous malignancies, observed in 4% of the patients (15/379), were
more frequently colorectal tumours in an early stage (10/15) and 1 of those
patients presented a double synchronous colorectal cancer. Other primaries
included head and neck cancer (1), renal cancer (1), pancreatic cancer (1) and
lymphoma (1). Extrathoracic benign foci observed in the remaining 25% of
the patients (22/88) were localized mainly in colon and corresponded to
physiologic variants and adenomas.
Conclusion: PET/CT for staging NSCLC patients was able to assess local
involvement and detect unsuspected distant metastases and second primaries
in a single study. Most extrathoracic hypermetabolic lesions resulted malig-
nant (75%): metastasis (77%) and second malignancies (23%). The results of
our study suggest that second primary tumors can be detected in 4% of
patients with primary lung cancer and most of them are detected as an early
stage colorectal tumour.
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Background: 18FDG-PET and multislice computerized axial tomography
(CT) scan are used for diagnosis, staging and response evaluation in NSCLC
patients. In the present trial, the correlation between the response assessment
by both imaging techniques and survival was assessed in patients with
unresectable stage III NSCLC treated with induction chemotherapy followed
by consolidation radiotherapy.
Methods: 31 patients, enrolled in a phase II study evaluating the efficacy and
toxicity of a novel triplet induction chemotherapy (paclitaxel, carboplatin
and gemcitabine) followed by radiotherapy, were evaluated by CT and
18FDG-PET at baseline and after 3 cycles of chemotherapy. The correlation
between CT and 18FDG-PET response and time to progression (TTP) and
survival (S) was analyzed using the Kaplan-Meier estimates of survival and
the log-rank test.
Results: Ten patients with a complete response (CR) on had a significantly
longer TTP (median 19.9 versus 9.8 months, p0.042), and S (median 49
versus 14.4 months, p0.008) than patients with a non-CR. Twenty patients
with a partial CT response (PR) had a significantly longer TTP (median 15
versus 9.4 months, p0.001) than patients with a non-PR also a significant,
although of a lesser magnitude, benefit, in S (19.3 versus 14.4 months,
p0.029).
Conclusions: In the present trial, both CT and 18FDG-PET response corre-
lated with survival, thus confirming results of previous trials. This trial also
complements others because it is in a homogeneous patient cohort and
because it is one of the only trials to investigate the prognostic value of
18FDG-PET when induction chemotherapy is followed by consolidation
radiotherapy in patients with inoperable stage III NSCLC. 18FDG-PET is a
powerful tool in predicting patient outcome for patients with stage III
NSCLC treated with induction chemotherapy followed by radiotherapy.
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LUNG CANCER SCREENING STUDY
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Kentucky’s age adjusted cancer mortality rate is 10% higher than the national
average. LC survival is strongly dependent on pathologic stage at time of
diagnosis. A randomized study was undertaken to determine if LDCT was
better at detecting early stage LC than cxr in a community setting. Patients
were screened through pulmonary function (PFT) and risk questionaire.
Those patients between age 40–70,40 pack years, and abnormal PFT
(FEV1 80%), were offered an eligibility chest radiograph (E-cxr). Partic-
ipants were randomized to either x-ray or LDCT arms of the study. Screening
continued for 3 consecutive years. Final analysis began in Feb. 2007 (5 years
later).
Of the 1,057 who were qualified by PFT for E-cxr, 1000 were randomized
equally to both arms. The average age was 55.4 years, with an average of 62
pack years, and an average FEV1 of 63%. E-cxr detected noncalcified
nodules (NCN) in 2.46% of those taken (26/1057) with 10 were LCs, and
baseline LDCT identified 72 additional NCN (4 of which were LC). The
baseline prevalence for LC was 1.52%. Subsequent annual screenings found
5 LCs in each arm. 65.3% (633/970) of participants were accounted for at 5
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years. This study lacked the statistical power to identify disease-specific
mortality. Interestingly, on final five year analysis, lung cancer-specific
mortality was 1.04% for the LDCT arm and 2.64% for the x-ray arm.
Diagnostic Total # LC Interval Attrition
E-cxr 10 2 N1057
Base CT 4 0 N479
1 year cxr 2 1 358/491 27%
2 yrs cxr 1 2 272/491 45%
3rd cxr 2 0 165/491 66%
TOTAL
cxr
5 5 34% finish
1 year CT 1 0 446/479 7%
2 yrs CT 3 0 371/479 23%
3rd CT 1 2 187/479 61%
TOTAL
CT
9 2 39% finish
LDCT detected 28% of the baseline LCs not seen by E-cxr, 75% of which
were stage I. By the completion of the 3rd LDCT, five (16%) procedures
were benign. The attrition rate for both groups was extensive, with only 36%
of all randomized completing the three years of screening.
Baseline LDCT screening for LC resulted in a larger proportion of stage I
diagnoses than E-cxr. Attrition from study and adherence to a diagnostic
algorithm are difficult to control in a community setting.
139P
POSITRON EMISSION TOMOGRAPHY SCAN IN
SUSPECTED / CONFIRMED LUNG CANCER: AUDIT OF
EXPERIENCE IN A UK DISTRICT GENERAL HOSPITAL
S. Sangaraju1, C. Khoo2, T. Lewis3 1General Medicine, Tameside General
Hospital, Ashton Under Lyne, Ashton Under Lyne/UNITED KINGDOM,
2Chest Medicine, Prince Charles Hospital, Merthyr Tydfil/UNITED KING-
DOM, 3Chest Medicine, Withybush General Hospital, HAVERFORDWEST/
UNITED KINGDOM
Introduction: Positron Emission Tomography (PET) scan has radically mod-
ified the diagnostic and staging process in suspected / confirmed lung cancer.
The use of PET scan in lung cancer is regulated by the National Institute of
Clinical Excellence (NICE) guidelines via specialist Multidisciplinary Team
(MDT) in the United Kingdom.
Aims: To assess the compliance of using PET scans with NICE guidelines by
evaluating the indications, determine if the PET changed the radiological
staging and establish the outcomes. Methods We conducted a retrospective
analysis of 34 patients (17 male, mean age 68.3 years and range 38 -85 years)
who underwent PET scan for suspected / confirmed lung cancer between
May 2006 and April 2007.
Results: All 34 patients were reviewed in lung cancer specialist MDT
meetings. PET scan was done in 24 patients who were CT staged as surgical
candidates(Presurgery group), 5 patients for investigation of solitary pulmo-
nary nodule (SPN) and in 5 patients for evaluation of a mass lesion where
bronchoscopy and CT guided biopsy were inconclusive. In Presurgery group,
PET scan confirmed CT staging in 9/24 (37.5%) patients, up-staged 10/24
(41.7%) and down-staged 5/24 (20.8%). High uptake in the SPN was noted
in 2/5 (40%) PET scans. 3/5 (60%) SPN had low uptake and avoided surgical
procedure. PET scan done for evaluation of suspicious mass revealed
operable lung cancer in 2/5 (40%) and benign lesion in 3/5 (60%).
Conclusions: All the indications for PET scans complied with NICE guide-
lines. It changed radiological staging in 62.5% patients. PET scan was useful
in avoiding unnecessary thoracotomy in 42% of patients considered suitable
for surgery on CT staging. Our study reinforces the importance of PET scan
in the appropriate staging of lung cancer.
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POSITRON EMISSION TOMOGRAPHY AND TARGET
VOLUME IN NON-SMALL CELL LUNG CANCER:
INTERESTS AND LIMITS
N. Bourry, C. Millardet, A. Belliere, M. Lapeyre, P. Verrelle Radiotherapy,
Centre Jean Perrin, Clermont Ferrand/FRANCE
Positron Emission Tomography and Computed Tomography (PET-CT) have
an important place in the therapeutic strategy of Non-Small-Cell Lung
Cancer (NSCLC). This combination, more sensitive and specific than CT
alone, ensures a better staging which leads to a better selection of non
operable patients who can benefit from a curative radiotherapy.
The 3D radiotherapy requires an accurate definition of the target volume and
it may be interesting to integrate the metabolic information from PET into
contour delineation 3D radiotherapy.
In 22 to 100% of cases, a variation of the radiation target volume is observed.
Gross Tumor Volume can be reduced with an exclusion of atelectasis area
and on the contrary be increased by the integration of nodes which seemed
non significant with CT alone.
A better volume definition may result in a radiation dose escalation which
may lead to a better Tumoral Control Probability and decrease of Non
Tumoral Complication Probability.
The inter and intra observer variability is reduced too.
But the limits such as spatial resolution, respiratory movements, 18 FDG
distribution, Standardized Uptake Value variations, lack of correlative pa-
thology data for primary tumor sites, false positive and false negative or
practical organisation should also be evocated.
By using PET data , a new volume may be integrated : the Biological Target
Volume also called Functional Target Volume, but clinical studies are still
necessary in order to determine its place in planning treatment for Non-
Small-Cell Lung Cancer.
141P
IMAGING MANIFESTATION OF LUNG CANCERS WITH
UNUSUAL RADIOLOGICAL, HISTOLOGICAL, AND
CLINICAL FEATURES AT INITIAL PRESENTATION
M.I. Ahn1, H.K. Kim2, C.H. Kim2, S.H. Kim3, J. Yoo4, K.D. Cho5, D.G.
Cho5 1Radiology, St.Vincent’s Hospital, The Catholic University of Korea,
Suwon/KOREA, 2Internal Medicine, Catholic University St. Vincent’s Hos-
pital, Suwon/KOREA, 3Radiation Oncology, Catholic University St. Vin-
cent’s Hospital, Suwon/KOREA, 4Pathology, Catholic University St. Vin-
cent’s Hospital, Suwon/KOREA, 5Thoracic Surgery, Catholic University St.
Vincent’s Hospital, Suwon/KOREA
Although the typical imaging manifestations of lung cancers are well known,
unusual manifestations may elicit initial diagnostic error, which delay proper
timely treatment of lung cancer. The purpose of this exhibit is to illustrate
imaging findings of lung cancers with unusual radiological, clinical, and
histological features. We collected lung cancers with unusual manifestations,
and reviewed the chest radiographic, CT, and PET/CT findings of them.
Unusual radiological manifestations included adenocarcinoma (including
bronchioloalveolar cell ca. pattern) mimicking interstitial lung disease and
pneumonia, pleural dissemination type and consolidation type of small cell
lung cancer, lung cancer mimicking pulmonary tuberculosis, lung cancer
with calcification, central lung cancer with unusual postobstructive lung
change. Lung cancers with unusual histological types consisted of fetal
adenocarcinoma, carcinoma with pleomorphic, sarcomatoid or sarcomatous
elements, salivary gland tumor, and carcinosarcoma. Unusual clinical situa-
tions accompanying lung cancers were tuberculosis, complicated pneumo-
coniosis, thymoma, Poland’s syndrome, and bullous lung disease. There also
were lung cancers in teenager, and double primary lung cancers. Knowledge
of these wide imaging spectra of unusually manifesting lung cancers may
help to avoid misdiagnosis and to prevent delay in treatment of lung cancers.
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DISCORDANCE BETWEEN CT AND PET IMAGING IN
PRIMARY LUNG CANCERS
M. McNamara1, A. Khimji2, O.S. Breathnach1, L. Grogan2, P. Broe3, M.
Logan4, R. Costello5, S. O’Neill5, G. McElvaney5 1Medical Oncology, Beau-
mont Hospital Cancer Centre, Dublin/IRELAND, 2Dept. of Medical Oncology,
Beaumont Hospital Cancer Centre, Dublin/IRELAND, 3Dept. of Surgical On-
cology, Beaumont Hospital Cancer Centre, Dublin/IRELAND, 4Dept. of Radi-
ology, Beaumont Hospital Cancer Centre, Dublin/IRELAND, 5Dept. of Respi-
ratory Medicine, Beaumont Hospital Cancer Centre, Dublin/IRELAND
Purpose: To determine whether there was discordance between computed
tomography (CT) and 2-[18F]fluoro-2-deoxy-D-glucose positron emission
tomography (FDG-PET) imaging in primary lung neoplasm.
Methods: CT and PET findings from 66 patients who underwent investigation of
suspicious chest X-ray lesions in Beaumont Hospital over a period from
November 2002 – February 2006 were retrospectively reviewed. Histological
findings of primary lung neoplasm were used as the reference standard. (99m) Tc
bone scintigraphy was utilized for the detection of bone metastases.
Results: Discordance between CT and PET imaging was noted in thirteen
patients (20%) in thoracic windows; eight (12%) in tumour tissue and five
(8%) in nodal disease (in terms of location and presence). Three patients who
had increased FDG uptake in the colon; one of these had normal abdominal
CT imaging with normal rectal biopsy; another individual had a colonoscopy
and biopsy revealed a tubulovillous adenoma with moderate dysplasia; the
other subject did not have abdominal CT imaging and surgery was instigated
following PET findings. Extrathoracic discordance was also noted in three
cases involving the adrenal gland. Bone scans performed on three patients
documented bone marrow metastases. These were not identified on PET
scanning. There were two patients who had CT and PET positive identified
lung lesions, who on histological diagnosis were identified as an abscess in
one and fibrous exudate with reactive mesothelium in the other.
Conclusion: FDG PET scanning is important in the detection and evaluation
of systemic disease in addition to mediastinal adenopathy. It does not
however provide absolute diagnostic and staging information. Additional
bone and brain scanning remain imperative if clinically indicated despite a
potentially negative PET scan. Histological sampling of suspected abnormal
lung tissue should be completed to outrule non-neoplastic processes.
SCLC
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A PHASE II STUDY OF PICOPLATIN MONOTHERAPY IN
PATIENTS WITH PLATINUM REFRACTORY/RESISTANT
SMALL CELL LUNG CANCER (SCLC)
D. Bentzion1, O. Lipatov2, I. Polyakov3, R.F. MacKintosh4, H.B. Breitz5,
D.A. Karlin6, J.R. Eckardt7 1Chemotherapy Department, Sverdlovsk Re-
gional Oncology Center, Ekaterinburg/RUSSIAN FEDERATION, 2Depart-
ment of Thoracic Surgery, Republican Oncology Center under the Ministry
of Healthcare of Republic of Bashkortostan, Ufa/RUSSIAN FEDERATION,
3Department of Thoracal Oncology, Regional Clinical Hospital #1, Krasno-
dar/RUSSIAN FEDERATION4* VA Sierra Nevada Health System, Reno/
UNITED STATES OF AMERICA, 5Clinical, Poniard Pharmaceuticals, Se-
attle/UNITED STATES OF AMERICA, 6Clinical, Poniard Pharmaceuticals,
San Francisco/UNITED STATES OF AMERICA7,*, Center for Cancer Care
and Research, St. Louis/UNITED STATES OF AMERICA
Purpose: Picoplatin (Pico) is a novel chemical designed to prevent and
overcome resistance to platinum (Pt) —based chemotherapy (chemo). A
previous Phase II study of 2nd line Pico monotherapy for SCLC showed a
median overall survival (OS) of 27.0 wks in patients with Pt-refractory/
resistant SCLC. This study was designed to confirm the safety and efficacy
of Pico in patients with Pt-refractory and -resistant SCLC. Methods: SCLC
patients with: ECOG PS 0–2; measurable disease; and Pt-refractory/resistant
(no response to 1st line Pt-containing chemo / progressed within 180 days of
1st line Pt-containing chemo) were infused with Pico 150 mg/m2, q21d. OS,
progression-free survival (PFS) and tumor response (assessed every 6 wks by
CT scan using RECIST) were evaluated. Quality of life (QoL) was assessed
every cycle with the Lung Cancer Symptom Scale (LCSS) instrument.
Adverse events (AEs) were graded using the NCI CTCAE. Results: 77
patients (44 refractory, 33 resistant) were treated with Pico (mean number of
cycles 3.0, range 1–10). Median OS was 26.9 wks (95% CI 21.1–33.4).
Median PFS was 9.1 wks (95% CI 7.0–12.1). Evaluation of 68 patients
with at least 1 post-treatment CT scan indicated 7 (10%) had a PR (3
confirmed) and 29 (43%) had SD of which 15 had a minimal response. AEs
reported in15% of patients were thrombocytopenia (64%), anemia (49%),
neutropenia (39%), nausea (27%), fatigue (16%) and dyspnea (16%). Grade
3–4 toxicities in more than 10% of patients were limited to thrombocyto-
penia (48%), neutropenia (25%) and anemia (19%). There were no treatment
related deaths. QoL was preserved in patients receiving Pico. The best
overall LCSS response showed improvement in 43%, no change in 35% and
worsened in 22% of patients. In 28 patients followed for at least 4 cycles (12
weeks) there was no significant change in the Total LCSS Score.
Conclusion: Analysis of this Phase II study concluded that the clinical activity
and safety profile of Pico warranted further development. An ongoing, interna-
tional multicenter, randomized, controlled, FDA-approved Phase III study
(SPEAR, Study of Picoplatin Efficacy After Relapse) is designed to show
superiority of Pico  best supportive care (BSC) compared to BSC alone.
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BELOTECAN AND CISPLATIN COMBINATIONS
CHEMOTHERAPY FOR THE PREVIOUSLY UNTREATED
EXTENSIVE DISEASE, SMALL-CELL LUNG CANCER:
PRELIMINARY DATA OF PHASE II STUDY
S.Y. Kim1, J.E. Lee2, K.Y. Lee3, H.S. Park4, S.S. Jung2, J.O. Kim2 1Pul-
monology, Cancer Research Institute, Daejeon/KOREA, 2Pulmonology,
Cancer Institute, Daejeon/KOREA, 3Internal Medicine, Konkuk University
Hospital, Seoul/KOREA, 4Pulmonology, Cancer Instutute, Daejeon/KOREA
Belotecan and Cisplatin combinations chemotherapy for the previously
untreated extensive disease, small-cell lung cancer : Preliminary data of
Phase II study Jeong Eun Lee, M.D.1, Kye Young Lee, MD.2, Hee Sun Park,
M.D.1, Sung Soo Jung, M.D.1, Ju Ock Kim, M.D.1, and Sun Young Kim,
M.D.1 1Division of pulmonology, Department of Internal Medicine, Chun-
gnam National University & Cancer Research Institute, Daejeon, South
Korea 2Division of pulmonology, Department of Internal Medicine, Konkuk
University, Seoul, South Korea Background : Belotecan (Camtobell_, Chong
Keun Dang Corp, Seoul, Korea; CKD602) is a new camptothecin analogue.
We conducted a phase II study of belotecan combined with cisplatin to
evaluate the efficacy and toxicity of this regimen in patients with previously
untreated extensive disease small-cell lung cancer (ED-SCLC). Patients and
Methods: 14 patients with previously untreated extensive disease small-cell
lung cancer (ED-SCLC) were enrolled 14 patients until Oct. 2007 and were
treated with belotecan 0.5 mg/m2/day on days 1–4 and cisplatin 60 mg/m2/
day on day 1 every 3-week more than 4 cycles initially planned. The tumor
response was evaluated according to the WHO criteria by chest CT at every
2 cycles of chemotherapy. All 14 patients were assessable for toxicity and
response. Results: 12 patients (85.7%) showed objective tumor responses
including one complete response. The major grade 3/4 hematological toxic-
ities were neutropenia (45.7% of cycles), anemia (13.5% of cycles), throm-
bocytopenia (18.6% of cycles). But, treatment-related death was not ob-
served and hematologic toxicities were tolerable in all patients. Final data
will be followed after full number of patients enrolled. Conclusions: Com-
bination chemotherapy of belotecan plus cisplatin is an effective treatment
for extensive disease small-cell lung cancer (ED-SCLC) with acceptable
hematologic toxicities.
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CARBOPLATIN AND ETOPOSIDE WITH SEQUENTIAL
THORACIC RADIOTHERAPY IN LIMITED DISEASE
SMALL CELL LUNG CARCINOMA
U. Yilmaz1, E. Korkmaz2, H. Halilcolar1, C. Anar1, I. Unsal1, F. Cetinkaya1,
I. Unlu3 1Pulmonary Medicine Dept., Suat Seren Chest Disease and Surgery
Training and Research Hospital, I˙zmir/TURKEY, 2Radiation Oncology De-
partment, Suat Seren Chest Disease and Surgery Training and Research
Hospital, I˙zmir/TURKEY, 3Radiation Oncology Department, Suat Seren
Chest Disease and Surgery Training and Research Hospital, izmir/TURKEY
Background: There is a trend to replace cisplatin by carboplatin (C) in the
treatment of SCLC. The goal of this study is to assess the activity (response,
survival) and toxicity profile of CE with sequential thoracic radiotherapy in
patients with LD SCLC.
Methods: From 02/01 to 03/07, 57 patients (pts) with LD SCLC were treated.
Patients characteristics included pathologically diagnosed SCLC, ECOG PS
0–2, and adequate organ function. Treatment consisted of chemotherapy and
thoracic radiotherapy. Sequential CT/RT was given in 34 (63%) of patients
(RT group). Patients received C (AUC 6, d1) - E (100 mg/m2 d1–3) for 6
courses administered every 3 weeks. RT dose 50 to 60 Gy with one daily
fraction (2.0 Gy) given to the primary tumor and mediastinum, excluding the
spinal cord after 45 Gy in 5 to 6 weeks was prescribed. Prophylactic cranial
irradiation (PCI) was performed in 15 patients with complete response after
thoracic RT (PCI group). Data were prospectively collected. Results were
retrospectively analysed. Kaplan-Meier method was used for obtaining
survival rates. Log-rank test was used for univariate analyses.
Results: 54 pts were evaluated. Median age was 63 (range 40–78), 89% (48)
of pts were male. ECOG PS was 0–1 in 50 pts. Median follow-up duration
was 11,9 m (range 0,3–81,5 m). A total of of 264 cycles were administered;
median 6 (range 1–6). Response to chemotherapy in 54 pts was as follows;
complete 53.7%, partial 22.2% Response to chemoradiotherapy in 34 pts was
as follows; complete 70.6%, partial 17.6%. Median survival in RT group was
14.3 m (95% CI 12,37 – 162,2), one and two year survival were 64.9% and
24.6% , respectively. Median survival in non-RT group was 9.4 m (95% CI;
7.42–11.37) (P.001). Median survival in the PCI group was 16.2 m (95%
CI, 14.30 -18.09), One , two and three year survival were 91.7%, 42.3% and
10,6%, respectively. Median survival in the non-PCI group was 12.8 m (95%
CI; 8,4–17,1) (P.136). Three pts died of grade 4 neutropenia and one
patient died of diarrhea. Febrile neutropenia was developed in 6 pts. Grade
2 radiation pneumonitis occured in 6 of pts.
Conclusion: Sequential administration of carboplatin and etoposide chemo-
therapy followed by thoracic radiotherapy seems to be active.
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PHASE II STUDY OF IRESSA (GEFITINIB) IN RELAPSED
AND REFRACTORY SMALL CELL LUNG CANCER (SCLC)
S.W. Langer1, B.S. Pedersen2, M. Ranson3, H. Pappot4, A. Loft5, N.
Thatcher6 1Oncology, Rigshospitalet, Copenhagen/DENMARK, 2Oncology,
Herlev Hospital, Herlev/DENMARK, 3Medical Oncology, Christie Hospital,
Manchester/UNITED KINGDOM, 4Finsen Laboratory, Rigshospitalet,
Copenhagen/DENMARK, 5Clical Physiology and Nuclear Medicine, Rig-
shospitalet, Copenhagen/DENMARK, 6Medical Oncology, Christie and
Wythenshawe Hospitals, Manchester/UNITED KINGDOM
Aim: Determine the disease control rate, progression free survival, overall
survival, symptom improvement, and safety in patients with relapsed or
refractory SCLC. Additionally, to correlate the clinical outcome with a)
changes in fluoro deoxy glucose (FDG) uptake measured by FDG-PET-
scanning, and b) changes in plasma urokinase plasminogen activator receptor
(uPAR) and its cleavage products.
Patients characteristics: Twenty nine caucasian patients were enrolled from
three oncology centers (2 DK, 1 UK) with a mean age of 65 years. (44–84)
Relapsed/refractory disease: 12/17. WHO performance status 0, 1, and 2: 6,
19, and 4, respectively. Treatment: Iressa (gefitinib) 250 mg daily.
Results: Disease control (non-progression according to RECIST) was
achieved in 6 patients (21%). One patient (3%) had partial response. The
six-month progression free rate and survival was 10% and 41%, respectively.
The median progression free time was 59 days, and the overall median
survival time 20 weeks. Quality of life (FACT-L questionnaire) and lung
symptoms (LCS) were not improved during treatment. Twenty-three (79%)
patients had gefitinib related adverse events (AEs); 3 patients (10%) grade
3/4. Diarrhoea, fatigue, acne, nausea, and dry skin were the most common
AEs. The correlation between maximum FDG uptake values at baseline, at
2 weeks, and at progression/discontinuation and clinical response will be
presented as will exploratory data on uPAR and cleavage products.
Conclusion: Gefitinib showed limited antitumor activity in relapsed and
refractory SCLC, and quality of life was not improved. Exploratory data on
uPAR and split products as well as maximum FDG uptake measurements
will be presented. Sponsor: AstraZeneca.
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IRINOTECAN PLUS CARBOPLATIN CHEMOTHERAPY
FOR SMALL CELL LUNG CANCER: SINGLE
INSTITUTION EXPERIENCE OF 19 PATIENTS
H. Malhotra1, R.G. Sharma2, D.P. Agarwal3 1Medicine & Medical Oncology,
SMS Medical College Hospital, Jaipur/INDIA, 2Surgery & Sugical Oncol-
ogy, SMS Medical College Hospital, Jaipur/INDIA, 3Radiarion Oncology,
SMSMedical college and Hospital, Jaipur/INDIA
Background: Since the publication of a large randomized trial from Japan in
2002, the combination of Irinotecan and Cisplatin has become the ‘standard
of care’ for the treatment of extensive stage small cell lung cancer (SCLC).
Carboplatin is as effective as cisplatin in SCLC and has a significantly better
safety profile.
Methods: In the present paper, we report the results of a single arm, single
institution study using the combination of Irinotecan and Carboplatin in
patients with extensive stage SCLC. All the chemotherapy cycles were
adminstered on an out-patient basis.
Results: From 2003 onwards, 19 consecutive patients with extensive stage
SCLC were treated with Irinotecan 60 mg/s.m. given on D1 & D8 with
Carboplatin AUC 6 given of D1, every 3 weeks, for six cycles, followed by
External RT to residual chest disease and prophylactic cranial RT to patients
having complete response. Six (31.6%) of the 19 patients has a complete
response, 10 (52.6%) had partial response - over response rate 16/19
(84.2%). The median survival was 15.4 months and at the end of two years,
5/19 (26.3%) patients were alive. Major toxicities observed were neutrope-
nia, thrombocytopenia and diarrhea. Grade III/IV neutropenia was seen in
half the patients but neutropenic infection was seen only in three patients.
Grade III/IV thrombocytopenia was observed in 4/19 (21%) patients. Grade
III/IV diarrhea occurred in 3/19 (15.8%).
Conclusions: Irinotecan plus carboplatin is an effective combination for
extensive stage SCLC patients with acceptable toxicities and can be safely
administered in the out-patient setting.
EARLY NSCLC
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PHASE II RANDOMIZED STUDY OF MAGE-A3
IMMUNOTHERAPY AS ADJUVANT THERAPY IN STAGE
IB/II NON-SMALL CELL LUNG CANCER (NSCLC):
44-MONTH FOLLOW-UP, HUMORAL AND CELLULAR
IMMUNE RESPONSE DATA
J. Vansteenkiste1, M. Zielinski2, A. Linder3, J. Dahabreh4, E. Esteban5, W.
Malinowski6, J. Jassem7, B. Passlick8, M. Lo´pez-Brea9, C. Debruyne10
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1Respiratory Oncology Unit, University Hospital Gasthuisberg, Leuven/
BELGIUM, 2Chorob Pluc, Szpital, Zakopane/POLAND, 3Abt. Fu¨r Thoraxchiru-
rgie, Lungenklinik, Hemer/GERMANY, 4Thoracic Surgery Dept., Medical Cen-
ter, Athens/GREECE, 5Oncología Department, Hospital Central de Asturias,
Oviedo/SPAIN, 6Oddział Chirurgii Klatki Piersiowej, Szpital Kopernika,
Tuszyn/POLAND, 7Akademii Medycznej W Gdansku, Klinika Onkologii Radio-
therapii, Gdansk/POLAND, 8Department of Thoracic Surgery, University Med-
ical Center Freiburg, Freiburg/GERMANY, 9Servicio de Oncologe´a Médica,
Hospital Marque´s de Valdecilla, Santander/SPAIN, 10Gcrd - Global Clinical
R&d, GlaxoSmithKline Biologicals, Rixensart/BELGIUM
Background: Study 249553/004 is a phase II randomized trial evaluating the
administration of MAGE-A3 recombinant protein combined with GSK
proprietary immunological Adjuvant System AS02B as adjuvant treatment
for completely resected stage IB or II MAGE-A3 () NSCLC. A previous
28-month analysis showed a strong positive sign of activity. We now report
long-term follow-up and immunological assessment. Methods: Patients were
randomly assigned to postoperative MAGE-A3 or placebo (2:1) with immu-
nizations q3w x 5, followed by q3m x 8. Primary endpoint was disease-free
interval (DFI); other endpoints were safety, disease-free survival (DFS),
overall survival (OS), assessment of humoral and cellular anti-MAGE-A3
immune response (by ELISA and intracellular cytokine staining, respec-
tively). This exploratory phase II study was designed to detect a clinically
relevant HR with a 10% one-sided .
Results: 182 patients (122 MAGE-A3, 60 placebo) were randomized: Me-
dian age 63 (45–81); 87% male; 67% stage IB; 65% squamous cell
carcinoma. After a median follow-up of 44 months, 69 recurrences and 57
deaths were recorded. Group comparisons of DFI, DFS and OS gave a hazard
ratio (HR) of 0.75 (95% CI 0.46–1.23, p0.127), 0.76 (95% CI 0.48–1.21)
and 0.81 (95% CI 0.47–1.40) in favor of the MAGE-A3 group, respectively.
Treatment was well tolerated, with excellent protocol compliance. 8% of the
patients showed a baseline anti-MAGE-A3 antibody response. Induction of
anti-MAGE-A3 IgG antibody response was observed in 98% of the
patients immunized with MAGE-A3. T-cell responses were measured in 51
patients: a CD4 T-cell response to MAGE-A3 was observed in 15 of 37
(41%) immunized patients, and only in 2 of 14 (14%) patients in the placebo
group. No correlation of immune response and clinical outcome was ob-
served. Conclusions: The 44-month follow-up analysis of this randomized
Phase II study confirms the positive activity and immunogenicity of the
MAGE-A3 treatment in adjuvant NSCLC. An efficacy Phase III study
(MAGRIT) is ongoing.
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DO SUBGROUPS OF PATIENTS (PTS) WITH EARLY
STAGE NSCLC BENEFIT FROM NEOADJUVANT
CHEMOTHERAPY? AN EXPLORATORY ANALYSIS
OF LU22-NVALT 2-EORTC 08012
J.P. van Meerbeeck1, M. Nicholson2, D. Gilligan3, H.J. Groen4, M. Nankiv-
ell5, C. Pugh6, R. Stephens5 1Respiratory Medicine, University Hospital,
GENT/BELGIUM, 2Medical Oncology, Royal Hospitals Trust, Aberdeen/
UNITED KINGDOM, 3Medical Oncology, Addenbrooke’s Hospital, Cam-
bridge/UNITED KINGDOM, 4Pulmonology, UMC, Groningen/NETHER-
LANDS, 5Clinical Trials Unit, MRC, London/UNITED KINGDOM, 6Clinical
Trial Unit, MRC, London/UNITED KINGDOM
Background: LU22-NVALT 2-EORTC 08012 did not show the expected
survival benefit with neoadjuvant chemotherapy (NCT) in pts with early
stage NSCLC (Gilligan, 2007). Aim: to explore a possible benefit in the
subgroups of patients included in LU22-NVALT 2-EORTC 08012 and
categorized according to clinical stage, age, gender, histological subtype,
Performance Status, chemotherapy regimen, region and period of accrual.
Methods: unplanned exploratory analysis calculated as the number of deaths/
number of pts included for each subcategory and treatment arm and ex-
pressed as fixed hazard ratio’s (HR) with 95% confidence intervals (CI).
Results: Data are available of 519 pts. Only stage IA showed a HR,
suggestive of a significant deleterious effect of NCT (Table). HR’s of all
other variables had largely overlapping 95%CI’s, allowing no discrimination
of specific subgroups with benefit from NCT.
Variable Subgroup N pts HR 95% CI
Clinical
stage
IA 87 2.37 1.09–5.18
IB 232 0.86 0.59–1.26
II 163 1.02 0.66–1.58
IIIA 37 0.84 0.38–1.89
Conclusions: This exploratory analysis shows that of all subgroups studied,
NCT may be deleterious for pts with stage IA only.
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PREOPERATIVE VERSUS POSTOPERATIVE
CHEMOTHERAPY IN PATIENTS WITH RESECTABLE
NON-SMALL CELL LUNG CANCER: SYSTEMATIC
REVIEW AND INDIRECT COMPARISON META-ANALYSIS
OF RANDOMISED TRIALS
E. Lim1, G. Harris2, A. Patel2, I. Adachi2, L. Edmonds3, F. Song4 1Academic
Department of Thoracic Surgery, The Royal Brompton Hospital, London/
UNITED KINGDOM, 2Thoracic Surgery, Royal Brompton Hospital, Lon-
don/UNITED KINGDOM, 3Library and Knowledge Services, Papworth
Hospital, Cambridge/UNITED KINGDOM, 4Faculty of Health, University of
East Anglia, Norwich/UNITED KINGDOM
A large number of trials evaluated the efficacy of postoperative chemother-
apy after resection for lung cancer. A smaller number evaluated preoperative
chemotherapy for potentially resectable lung cancer, but no direct compar-
ison has yet been published comparing the two approaches. Methods We
conducted a systematic review of randomised trials, extracted time-to-event
data using Parmar methods (when not reported), used random effects meta-
analysis to evaluate overall and disease survival treatment effects and
performed indirect comparison using surgery (without chemotherapy) as the
common comparison. Results Data was abstracted from 31 randomised trials
involving over 10 000 participants, with 21 trials administering postoperative
and 10 trials administering preoperative chemotherapy. For overall survival,
the hazard ratio in postoperative chemotherapy trials was 0.80 (0.73 to 0.87;
P0.001) and for preoperative chemotherapy trials was 0.81 (0.68 to 0.97;
P0.024). Using indirect comparison meta-analysis, the relative hazards of
postoperative compared to preoperative treatment was 0.99 (0.81 to 1.21;
P0.900). For disease free survival, the hazard ratio in postoperative
chemotherapy trials was 0.76 (0.67 to 0.87; P0.001) and for preoperative
chemotherapy trials was 0.79 (0.63 to 1.00; P0.050). Using indirect
comparison meta-analysis, the relative hazards of postoperative compared to
preoperative treatment was 0.96 (0.74 to 1.26; P0.770). Conclusions In
patients with resectable lung cancer, the timing of administration of chemo-
therapy (post-operative versus pre-operative) yielded similar results for
overall and disease free survival.
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PILOT SPANISH CUSTOMIZED ADJUVANT TRIAL
(SCAT) BASED ON BRCA1 MRNA LEVELS IN RESECTED
STAGE II-IIIA NON-SMALL-CELL LUNG CANCER
(NSCLC) PATIENTS (P)
J.M. Sa´nchez1, J. Go´mez-Codina2, A. Carrato3, N. Reguart4, I. Maestu5, C.
Camps6, J. Oramas7, T. Mora´n8, B. Massuti9 1Oncology Service, Hospital 12
de Octubre, Madrid/SPAIN, 2Oncology Service, Hospital Universitario La
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Fe, Valencia/SPAIN, 3Medical Oncology, General Universitary Hospital in
Elche, Elche (Alicante)/SPAIN, 4Oncology Service, Institut Catala
d’Oncologia, Hospital Germans Trias i Pujol, Badalona, Barcelona/SPAIN,
5Oncology Service, Hospital Virgen de Los Lirios, Alcoy/SPAIN, 6Oncology
Service, Hospital General Universitario de Valencia, Valencia/SPAIN, 7On-
cology Service, Hospital Universitario de Canarias, Las Palmas de Gran
Canaria/SPAIN, 8Oncology Service, Institut Catala` d’Oncologia, Hospital
Germans Trias i Pujol, Badalona/SPAIN, 9Oncology Service, Hospital Gen-
eral Universitario de Alicante, Alicante/SPAIN
Background: p with low BRCA1 mRNA levels attained longer survival when
treated with cisplatin-based chemotherapy (Taron et al 2004), while p with
high BRCA1 levels attained longer survival when treated with taxanes-based
therapy (Quinn et al 2007). Early NSCLC p whose tumors had high BRCA1
levels had significantly worse survival (Rosell et al 2007). Up-regulated
BRCA1 is part of a characteristic gene signature in aggressive lung cancers
(Deeb et al 2007).
Methods: Adjuvant chemotherapy was customized based on BRCA1 mRNA
levels in 84/100 completely resected N1 and N2 NSCLC p. 11 p with high
BRCA1 levels received docetaxel (doc); 29 p with intermediate BRCA1
levels received doc/cisplatin (cis); 44 p with low BRCA1 levels received
cis/gemcitabine (gem). Results: Median survival has not been reached in p
with high or intermediate BRCA1 levels, while it is 25.6 months (m) in p
with low levels (P0.04). In a multivariate analysis for survival in all 84 p,
the hazard ratios (HR) were 5.23 for p with high BRCA1 levels (P0.07),
3.57 for p with tumor size  4 cm (P0.07). In the multivariate analysis of
42 N2 p, the HRs were 0.13 for 18 p receiving postoperative radiotherapy
(P0.04) and 22 for 15 p with intermediate or high BRCA1 levels (P0.01).
Conclusion: Interim analyses show that single-agent doc has no detrimental
effect on survival in comparison with doc/cis. In addition, high BRCA1
mRNA expression could be a poor prognostic marker. The Spanish Lung
Cancer Group has opened a phase III study of customized adjuvant chemo-
therapy based on BRCA1 mRNA levels in which p in the control arm receive
doc/cis and those in the experimental arm receive chemotherapy according to
their BRCA1 levels.
N2 p HR (95% CI) p
Postoperative
radiotherapy
Yes No
18240.12 (0.02–0.89) 1 0.04
BRCA1 mRNA
levels Low
Intermediate
/ High
24 15 1 22.43
(2.02–248.62)
0.01
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ADJUVANT CHEMOTHERAPY FOR COMPLETELY
RESECTED NON-SMALL CELL LUNG CANCER;
JAPANESE EXPERIENCE AND PERSPECTIVE
M. Tsuboi, H. Kato Thoracic Surgery & Oncology, Tokyo Medical Univer-
sity & Hospital, Tokyo/JAPAN
Current status; Several prospective randomized trials (RCT) for patients with
completely resected non-small cell lung cancer (NSCLC) have confirmed a
survival benefit with cisplatin-based adjuvant chemotherapy. However, the
strength of the data and recommendations vary by pathological stage.
Outside Japan, adjuvant chemotherapy in stage I disease is not currently
recommended as routine use. On the other hand, meta-analysis of six
Uracil-Tegafur (UFT) trials comparing surgery alone with surgery plus UFT
demonstrated that the overall pooled hazard ratio was 0.74, and its 95% CI
was 0.61 to 0.88 (P0.001), and then postoperative adjuvant chemotherapy
with UFT was associated with improved five- and 7-year survival in a
Japanese patient population composed primarily of stage I adenocarcinoma
patients. Therefore, Japanese clinical practice guideline has recommended
adjuvant chemotherapy with UFT for patients with stage IB and some IA
(tumor size: 2cm or more) disease. About 70% of patients with stage IB
disease receive UFT adjuvant treatment in practice. Perspectives; According
to previous data for UFT, Fluoropyrimidines may make a breakthrough for
the improvement of surgical outcome of NSCLC, especially stage I lung
adenocarcinoma.In Japan, several RCTs are ongoing and planned as follows;
1) WJTOG0101; This phase III trial randomized 606 patients with stage I to
IIIA NSCLC either to GEM or to UFT. Recruitment has already been
completed. 2) Setouchi Lung Cancer Trial; This phase III trial has already
started since December in 2004. 400 patients with stage IB to IIIA will be
randomized either to Carboplatin  Paclitaxel or to UFT. 3) WJTOG4107;
In this randomized phase II trial, 200 patients with stage II to IIIA will be
randomized either to Tegaful-Gimeracil-Potassium oxonate (S-1), which is a
new oral 5-FU derivative, or to Cisplatin S-1. This trial is still ongoing. 4)
JCOGPC07XX; This phase III trial will randomize 980 NSCLC stage IA
cases with 2cm or more in size,and also IB either to S-1 or to UFT. The
molecular-biological analyses, such as Thymidylate Synthase (TS), of these
clinical trials should be required this decade.
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PHARMACO-ECONOMIC EVALUATION OF 2 INDUCTION
REGIMENS PRIOR TO SURGERY FOR NSCLC
A.P. Meert1, D. Lewin2, T. Berghmans2, M. Paesmans3, J.J. Lafitte2, A.
Scherpereel2, D. Gourcerol2, T. Bosschaerts2, N. Leclercq2, J. Sculier4 1Soins
Intensifs Et Cancerologie Pulmonaire, Institut Jules Bordet, Brussels/
BELGIUM, 2-, Institut Jules Bordet, Brussels/BELGIUM, 3-, Instiutut Jules
Bordet, Brussels/BELGIUM, 4Intensice Care and Thoracic Oncology, Insti-
tut Jules Bordet, Brussels/BELGIUM
Aim: To evaluate the impact of new drugs (gemcitabine, vinorelbine) in
terms of effectiveness and cost for intitially resectable stage I-III NSCLC
treated by induction chemotherapy.
Patients and method: 129 patients were treated in a phase II randomised
study by induction chemotherapy: GNP (gemcitabine, vinorelbine, cispla-
tine) or MIP (mitomycine, ifosfamide, cisplatine).
Results: Response rate to chemotherapy (66% vs 57%; p0.29), resectability
rate (85% vs 84%; p0.91) and survival (p0.29) were similar in both arms.
As no difference in effectiveness was detectable, a cost-minimization anal-
ysis was performed. The direct medical costs (including drugs, hospitaliza-
tion, blood-sample costs. . .) were assessed in two institutions of different
countries: Belgium (Institut Bordet) and France (CHRU Lille). In both
countries, the MIP regimen was significantly less expensive: 9471€ in
comparison to 12815€ for GNP in Belgium (p0.0006), 16434€ versus
21010€ in France (p0.047). This difference can be explained by 2 factors:
the administration of a chemotherapy on day 8 and the higher cost of the
chemotherapy drugs in the GNP regimen.
Conclusion: MIP and GNP have similar effectiveness but MIP is less
expensive for induction chemotherapy before surgery for fully resectable
stage I-III NSCLC.
154P
INCREASING PREOPERATIVE NEUTROPHIL TO
LYMPHOCYTE RATIO: AN INDEPENDENT PREDICTOR
OF ADVERSE SURVIVAL AFTER PULMONARY
RESECTION OF NON-SMALL CELL LUNG CANCER
K. Sarraf1, E. Belcher1, E. Raevsky1, P. Goldstraw2, E. Lim3 1Academic
Division of Thoracic Surgery, Royal Brompton Hospital, London/UNITED
KINGDOM, 2Department of Thoracic Surgery, Royal Brompton Hospital,
London/UNITED KINGDOM, 3Academic Department of Thoracic Surgery,
The Royal Brompton Hospital, London/UNITED KINGDOM
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Introduction: Increasing neutrophil to lymphocyte ratio (NLR) has been
associated with adverse survival after resection of primary or hepatic me-
tastases of colorectal tumours. We aimed to determine the effects of overall
white cell, component cell counts and the NLR on stage adjusted survival in
patients who subsequently underwent resection for non-small cell lung
cancer.
Methods: We performed a retrospective review of patients between 1999 and
2005. Data acquisition was via patient medical records and cell counts
recorded immediately prior to surgery. Follow-up was by the National Health
Service (NHS) database searches and hospital records. Cox proportional
hazards regression was used to estimate the impact of NLR on stage adjusted
survival.
Results: Of 178 patients that underwent pulmonary resection, we excluded 1
patient with CLL. The majority were men 104 (59%) with a mean age of 63
(10) years. In total, 83 were pathologic stage I, 45 stage II, 45 stage III and
4 stage IV. The median follow up time of 29 months, and overall survival
was 83% and 54% at 1 and 5 years. In isolation, total white cell count
(P0.99), and neutrophil count (P0.49), age (P0.29), cell type (P0.49)
were not significant. On multivariable analysis, increasing NLR (HR 1.10;
1.03–1.17; P0.004) remained independent prognostic indicator after ad-
justing for stage.
Conclusions: Increasing preoperative NLR is a stage independent predictor
of adverse survival in patients undergoing pulmonary resection for primary
lung cancer, and may be a useful biomarker in addition to pTNM stage.
ADVANCED NSCLC
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SEQUENTIAL TREATMENT OF ADVANCED NON-
SMALL-CELL LUNG CANCER WITH 2 SCHEDULES OF
DOCETAXEL (D) AND CISPLATIN (C) COMBINATION,
FOLLOWED BY GEMCITABINE (G). RESULTS OF A
RANDOMIZED PHASE II TRIAL
F. Grossi1, V. Gebbia2, G. Cartenì3, T. Gamucci4, F. Ferrau`5, M. Nardi6, L.
Moscetti7, F. de Marinis8, L. Boni9, E. Galligioni10 1Medical Oncology A,
National Institute for Cancer Research, Genova/ITALY, 2Dipartimento Di
Oncologia, La Maddalena, Palermo/ITALY, 3Divisione Di Oncologia, Car-
darelli, Napoli/ITALY, 4Dipertimento Oncologico, P.O. Santissima Trinità,
Frosinone/ITALY, 5Divisione Di Oncologia, San Vincenzo, Taormina (ME)/
ITALY, 6Oncologia Medica, Bianchi Melacrino Morelli, Reggio Calabria/
ITALY, 7Divisione Di Oncologia, P.O. Belcolle, Viterbo/ITALY, 8Pulmonary
Oncology, San Camillo-Forlanini Hospitals, Rome/ITALY, 9S.s.i. Clinical
Trials, IST Tumori Genova, Genova/ITALY, 10Divisione Oncologia Medica,
Ospedale Santa Chiara, Trento/ITALY
Aim of this study was to assess the activity and toxicity of 3 courses of D and
C, followed by 3 courses of single agent G, and to investigate the weekly D/C
schedule. Untreated stage IIIB-IV NSCLC patients (pts), aged 18–70 and PS
0–1, were randomized to D/C (both 75 mg/m2 on day 1, q21) x 3 cycles
(Arm A), or D/C (both 25 mg/m2 days 1, 8, 15, q28) x 3 cycles (Arm B).
Responding or stable pts, were further treated with G (1200 mg/m2 days 1,
8, q 21) x 3 cycles. Primary endpoint was response rate. Sample size: 42 pts
per arm, considering worthy of further investigation a regimen with 14
objective responses. Between 5/2005 and 10/2006, 88 pts were enrolled and
85 of them treated (Arm A/B: 41/44). M/F ratio (76%/24%), median age (63
years), PS 0 (60%) and Stage IV disease (86%); these characteristics were
well balanced in both arms. In arm A, 90.2% of pts completed 3 cycles
instead of 72.7% of pts in arm B. After 6 cycles 61% of pts in arm A and 36%
in arm B completed therapy. Adverse experiences occurred in 2% of arm A
(1/41 pts) and in 18% of B (8/44 pts). Toxicity after 6 cycles consisted of
G3/4 neutropenia in 18.2% in arm A vs 3% in arm B, neutropenic fever was
0.5% in arm A and 0% in arm B. G3/4 thrombocytopenia was 0.5% in arm
A vs 3.6% in arm B. Beside non-haematological G3/4 toxicity consisted of
0% infections w.o. neutropenia in arm A vs 1.2% in arm B, fatigue (3.6% vs
0.6%), diarrhoea (2% vs 0.6%), pain (2.6% vs 2.4%), stomatitis (0.5% vs
1.8%) and nausea (1% vs 0%). Response rate (CRPR) after 3 cycles was
34% (95% CI: 21%–51%) in arm A and 18% (95% CI: 9%–33%) in arm B,
after 6 cycles 22% (CI 95%:10.6%–37.6%) in arm A and 14% (CI95%:
5.17%–27.4%) in arm B; and the disease control (CRPRSD) after 3
cycles were was 68% (95% CI: 52%–81%) in arm A and 36% (95% CI:
23%–52%) in arm B and after 6 cycles 36% and 19% respectively. The PFS
was 17.14 weeks (95%CI:11.29–29.71) in arm A and 13.64 weeks (95%CI:
10.57–21.43) in arm B, the OS was 12.04 months (95%CI:6.18–21.71) in
arm A and 8.09 months (95%CI:6.41–12.66) in arm B. These results
demonstrate that the three-weekly D/C combination is superior in term of
activity and disease control in comparison with weekly D/C. Both D/C
combinations appear manageable.
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A PHASE I STUDY OF GEFITINIB (IRESSA) IN
COMBINATION WITH HYPOFRACTIONATED
THORACIC RADIATION THERAPY (HRT) WITH
STEREOTACTIC BODY FRAME (SBF) IMMOBILIZATION
OF PATIENTS WITH ADVANCED NON-SMALL CELL
LUNG CANCER (NSCLC)
M. Werner-Wasik1, R. Axelrod2, M. Machtay3, G. Mallon3, L. Rose4, A.
Chapman4, A. Dicker5 1Radiation Oncology, Jefferson Medical College/
Kimmel Cancer Center, Philadelphia/UNITED STATES OF AMERICA,
2Medical Oncology, Jefferson Medical College, Philadelphia/UNITED
STATES OF AMERICA, 3Radiation Oncology, Jefferson Medical College,
Philadelphia/UNITED STATES OF AMERICA, 4Medical Oncology, Jeffer-
son Medical College, Philadelphia/UNITED STATES OF AMERICA, 5Ra-
diation Oncology, Jefferson Medical College, Philadelphia/UNITED
STATES OF AMERICA
Background: NSCLC commonly overexpresses EGFR (epidermal growth
factor receptor) and preclinical model systems demonstrate radiosensitization
following molecular inhibition of EGFR signaling. Gefitinib (Iressa) is a
small molecule selective EGFR tyrosine kinase inhibitor. HRT allows for a
shorter RT course and a potentially improved local tumor control. We report
toxicity and outcome data on a Phase I trial of gefitinib and dose-escalated
HRT in patients (pts) with advanced NSCLC.
Methods: Eligible pts were those with stage IV/recurrent/stage I inoperable/
stage III NSCLC requiring thoracic RT and not candidates for concurrent
chemoradiotherapy, all with FEV11.2 l. Gefitinib was administered orally
(250 mg/day) starting 5 days before HRT and continuing during HRT and
afterward until tumor progression or toxicity. Two HRT dose levels: I (42.0
Gy in 10 fractions) and II (50.4 Gy in 12 fractions) have completed accrual
and one pt was enrolled in level III (63 Gy in 15 fractions). The recom-
mended V15 was 25%. Pts were immobilized in a SBF and tumor
localization was verified daily with a CT scan. We report toxicity and
efficacy results of 12 pts accrued to the study. Predetermined stopping
criteria were the occurrence of grade 1 treatment-related pneumonitis in
2/6 pts or grade 2 esophagitis in 3/6 pts at any dose level.
Results: Patients in each dose level were followed for at least 2 mo from end
of RT before enrollment to the next dose level. Six pts completed HRT in
dose level I; 5 in level II, and 1, in level III. Pts characteristics: 7 women (one
non-smoker), mean age 68 years; 1 with Stage IIIB, 1 with inoperable Stage
I; 1 with recurrent NSCLC and the remainder with Stage IV; all with KPS
80–100. Gefitinib was stopped in 10 pts due to: distant progression of disease
(n8); infectious pneumonia (1) and pt’s choice (1). Two patients are alive
at 9 and 14 mo on gefitinib without progression. Pulmonary toxicities include
1 Grade 3 infectious pneumonia with reversible ARDS; 1 Grade 2 treatment-
related pneumonitis and 2 pts with grade 1 cough. Esophageal toxicities
include one lethal tracheoesophageal fistula at 11 mo in the high-dose RT
region in a pt with pre-existing esophageal diverticula; 2 pts with Grade 2,
and 1 pt with Grade 1 esophagitis. The only other significant toxicity was
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grade 3 dehydration in 1 pt. Grade 1 skin rash was seen in 5 pts and Grade
1 diarrhea, in 4. Best CT-based tumor response rate in the HRT field was
33% (3 CR, 1 PR, 3 minor responses, 1 stable disease, 1 progression and 3,
not evaluable). Mean decrease in peak irradiated tumor SUV on PET scan
was 62%. Two pts (16%) had a systemic PET tumor response. Median
progression-free survival was 5 mo (range; 2–11 mo). Median survival time
from starting gefitinib was 10 mo (range: 1–26 mo). Conclusions: Delivery
of gefitinib with HRT is feasible and is associated with excellent CT- and
PET-based responses in the irradiated tumor. Patient accrual to the third RT
level is continuing (study no IRUSIRES0122).
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PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG
CANCER (NSCLC) OBTAINING A STABLE DISEASE (SD)
AFTER TREATMENT WITH ERLOTINIB (E) OR
GEFITINIB (G) HAVE A SIMILAR PROGRESSION-FREE
SURVIVAL AND SURVIVAL COMPARED WITH THOSE
HAVING PARTIAL RESPONSE
F. Grossi, A. Brianti, C. Defferrari, M.G. Dal Bello, G. Catania, P. Pronzato
Disease Management Team - Lung Cancer, National Institute for Cancer
Research, Genova/ITALY
In the BR.21 trial (Shepherd F et al., NEJM 2005) a significant prolongation
of survival (S) in the group treated with Erlotinib was achieved despite
response rates of less than 10 percent, perhaps because a high proportion of
the patients (pts) had durable SD while receiving treatment. In another trial
(Hotta K et al., Ann Oncol 2005), investigating the prognosis of pts obtaining
SD as best response with G treatment, has demonstrated that both progres-
sion-free survival (PFS) and S were significantly longer than those in pts with
progressive disease (PD). The aim of this retrospective study was to compare
the PFS and S outcome in pts with advanced NSCLC who achieved SD or
partial response (PR) after treatment with E or G. Pooled data from 62 pts,
entered into an open label phase II program of E (n31) and a compassion-
ate-use program of G (n31), were retrospectively analyzed. E and G were
given orally at 150 and 250 mg per day respectively and were continued until
disease progression, development of unacceptable toxicity or patient’s re-
fusal. Pts characteristics: median age 69 years (42–85); females 21 pts
(34%); never/former smokers 16/38 pts (26/61%); adenocarcinoma/BAC
35/10 pts (56/16%); PS 0/1 18/38 pts (29/61%). In 16 pts (26%) E or G
were given as first-line therapy; 21 pts (34%) had received 2 prior lines of
chemotherapy. Six pts (10%) achieved a PR and 18 pts (29%) obtained SD.
TTP and OS in pts obtaining PR and SD were comparable: 7 vs 5.5 and 9.7
vs 9.1 months respectively. In progressing pts median TTP and OS were 1.7
and 3.7 months. Erlotinib and Gefitinib can prolong survival in patients with
non–small-cell lung cancer after first-line or second-line chemotherapy
through achieving disease control. Our data suggest that both overall survival
and progression-free survival in patients obtaining disease stabilization
(RPSD) are better than those with PD, whether in patients treated with
Erlotinib or in patients treated with Gefitinib. Patients obtaining a stable
disease had a similar progression-free survival and survival compared with
those having partial response.
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CLINICAL OUTCOME TO CUSTOMIZED ERLOTINIB IN
STAGE IV NON-SMALL-CELL LUNG CANCER (NSCLC)
PATIENTS (P) WITH EGFR MUTATIONS
L. Paz-Ares1, B. Massuti2, A. Insa3, G. López-Vivanco4, M.A. Moreno5, C.
Pallare´s6, C. Rolfo7, R. Bastu´s8, P. Diz9, R. Rosell10 1Oncology Service,
Hospital Virgen del Rocío, Sevilla/SPAIN, 2Oncology Service, Hospital
General Universitario de Alicante, Alicante/SPAIN, 3Oncology Service,
Hospital Clínico de Valencia, Valencia/SPAIN, 4Oncology Service, Hospital
de Cruces, Bilbao/SPAIN, 5Oncology Service, Hospital Ciudad de Jae´n,
Jae´n/SOUTH GEORGIA AND THE SOUTH SANDWICH ISLANDS, 6On-
cology Service, Hospital de Sant Pau, Barcelona/SPAIN, 7Oncology Service,
Clínica Rotger, Palma de Mallorca/SPAIN, 8Oncology Service, Mútua de
Terrassa, Barcelona/SPAIN, 9Oncology Service, Hospital de Leo´n, Leo´n/
SPAIN, 10Medical Oncology Service, Catalan Institute of Oncology, Bada-
lona, Barcelona/SPAIN
Background: EGFR-mutant “oncogene-addicted” cancers are a distinct form
of NSCLC that can be targeted with erlotinib (Paz-Ares et al. ASCO 2006).
Methods: From April 2005 to December 2007, tumor biopsies from 2312
stage IV NSCLC p from 43 centers were screened in one central laboratory
in Badalona, Spain for EGFR exon 19 D746–750 deletion and exon 21
L858R mutation. Results were available within 8 days. p with EGFR
mutations were selected for erlotinib therapy.
Results: 307 p had EGFR mutations; data available on 165/307. 48 (29.1%)
male; 112 (67.9%) never-smokers; 124 (75.2%) adenocarcinoma; 103
(62.8%) exon 19 deletion, 62 (37.6%) L858R mutation; 89 (53.9%) first-line,
76 (46.1%) second-line. Response in 111 p (73.1%); complete response in
20 p (13.2%); progressive disease in 16 p (10.5%). Odds ratio for response:
2.3 for p receiving first-line erlotinib and 2 for p with exon 19 deletion.
Median survival: 24 months (m) overall; 27 m in responders vs 10 m in
non-responders (P 0.001); not reached in females vs 16 m in males
(P0.04); 27 m for p with exon 19 deletion vs 16 m for p with L858R
mutation (P0.03). Results of the multivariate analysis are shown in the
table. Conclusion: Customized erlotinib in EGFR-mutatnt NSCLC p results
in longer survival in p with exon 19 deletion, PS 0, and no brain metastases.
The Spanish Lung Cancer Group has initiated the EUropean Randomized
Trial of TArceva vs Chemotherapy (EURTAC) trial for stage IV NSCLC p
to further clarify the prognostic and predictive relevance of EGFR mutations.
Hazard Ratio 95% CI P
EGFR mutation Exon 19 deletion
Exon 21 L858R mutation
1 (ref.) 2.12 1.10–4.53 0.03
Brain metastasis No Yes 1 (ref.) 2.8 1.16–6.76 0.02
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GEFITINIB (IRESSA) PLUS BEST SUPPORTIVE CARE
(BSC) VS PLACEBO PLUS BSC IN CHEMOTHERAPY-
NAIVE PATIENTS WITH ADVANCED (STAGE IIIB OR IV)
NON-SMALL-CELL LUNG CANCER AND POOR
PERFORMANCE STATUS: PHASE II RANDOMIZED
STUDY
R. Wierzbicki1, G. Goss2, D. Ferry3, S. Laurie2, J. Thompson4, B. Biesma5,
E. Duffield6, O. Ataman7, M. Zarenda8, A. Armour7 1Oncology, Durham
Regional Cancer Centre, Oshawa/CANADA, 2Medical Oncology, Ottawa
Regional Cancer Centre, Ottawa/CANADA, 3Oncology, New Cross hospital,
Wolverhampton/UNITED KINGDOM, 4Oncology, Birmingham Heartlands
Hospital, Birmingham/UNITED KINGDOM, 5Oncology, Jeroen Bosch Ziek-
enhuis, Hertogenbosch/NETHERLANDS, 6Research, AstraZeneca, Maccles-
field/UNITED KINGDOM, 7Research, AstraZeneca UK, Macclesfield/
UNITED KINGDOM, 8Research, AstraZeneca Canada, Missaussaga/
CANADA
Introduction: This Phase II, randomized, double-blind, multi-center, parallel-
group study compared gefitinib plus best supportive care (BSC) to placebo
plus BSC in chemotherapy-naive patients with advanced non-small-cell lung
cancer (NSCLC) and poor performance status (PS) (IRESSA NSCLC Trial
Evaluating Poor PS Patients [INSTEP]).
Methods: Chemotherapy-naive patients (18 years) with stage IIIB/IV
NSCLC, PS 2 or 3, considered unfit for chemotherapy were randomized to
gefitinib (250 mg/day) plus BSC (n100) or placebo (n101). The primary
endpoint was progression-free survival (PFS); secondary endpoints were
overall survival (OS), objective response rate, quality of life (QoL), patient-
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reported functionality, pulmonary symptom improvement, and safety. Cor-
relation of gefitinib efficacy with EGFR gene copy number assessed by
fluorescence in situ hybridisation (FISH) was explored.
Results: Hazard ratios (HRs) for gefitinib vs placebo were 0.82 (95% CI
0.60, 1.12; p0.217) for PFS and 0.84 (95% CI 0.62, 1.15; p0.272) for OS.
ORRs wew 6.0% for gefitinib and 1% for placebo (odds ratio 6.57 [95% CI
0.74, 58.17]). QoL improvement rates for gefitinib and placebo were 21.1%
and 20.0% respectively (FACT-L total score), and 15.8% and 13.8% recpec-
tively (trial outcome index [TOI]). Symptom improvement rates for gefitinib
and placebo were 32.9% and 30.8%,respectively (pulmonary symptoms). No
unexpected adverse events occured. Four (4%) gefitinib and one (1%)
placebo patient received chemotherapy post-discontinuation of study treat-
ment. In EGFR FISH patients (n32), HRs were 0.29 (95% CI 0.11, 0.73)
for PFS and 0.44 (95% CI 0.17,1.12) for OS.
Conclusions: In unselected chemotherapy-naive patients with poor PS,
improvement in PFS, OS and ORR with gefitinib versus placebo was
observed, although differences between treatments did not reach statis-
tical significance. Improvements in QoL and symptoms were similar with
gefitinib and placebo. Safety data were consistent with known safety
profile of gefitinib.
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LUNG CANCER IN THE ELDERLY: CUSTOMIZED
TREATMENT BASED ON COMPREHENSIVE GERIATRIC
ASSESSMENT (CGA)
A. Vergnenègre1, R. Corre2, H. Jullian3, H. Le Caer4 1Service De Pathologie
Respiratoire, CHU - Hôpital du Cluzeau, Limoges/FRANCE, 2Service de
Pneumologie, CHU, Rennes/FRANCE, 3Service de Pneumologie-allergolo-
gie, CH Martigues, Martigues/FRANCE, 4Service de Pneumologie, CH
Draguignan, Draguignan/FRANCE
Although two-third of patients with non-small-cell lung cancer (NSCLC)
are over 65 years of age, clinical trials specifically involving elderly
patients are rare in the field of thoracic oncology. One limitation of these
studies is that the authors select patients over age and performance status.
Indeed, the patient’s precise age and comorbid disorders, assessed
through Charlson’s score, may influence the response to chemotherapy, or
at least its tolerability. The GFPC carried out a trial devoted specifically
to elderly in 1999 which showed increased quality of life (QoL) in these
patients. Secondly, the GFPC performed two phase II trials in 2002. In
dependent patients treated with single-agent docetaxel, survival was poor
but toxicity was acceptable. In independent patients, treated with do-
cetaxel-gemcitabine, objective response was reached in 34% and con-
trolled disease in 70%; median survival was 7 months, with a 1-year
actuarial survival rate of 23.5%. Our results showed that the elderly were
a heterogeneous population. Our current challenge is to modify the
inclusion criteria, with a validated geriatric index: the comprehensive
geriatric index (CGA). We would like to test and validate this new tool
for advanced NSCLC in a phase III trial (ESSOGIA, GFPC 08 – 02)
whose patient selection is depicted in the table.
>70 years PS 0, 1, 2
Randomization
Selection on PS
age Arm A
75 years and or PS2
(75 years and or PS 0
or 1
One drug Two drugs
with platin
Selection on CGA
Arm B
Frailed Dependent
Independent
BSC One drug Two
drugs with platin
With an increase of 30% in time to treatment failure (toxicity, adverse event,
progression, death) in arm B, the number of needed subjects is 229 by arm.
Management of lung cancer in the elderly has reached a plateau. The overall
research on elderly patients needs association between this kind of manage-
ment and biological markers with the objective of treatment optimization.
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CONCOMITANT CHEMORADIOTHERAPY (CTRT) AS
INDUCTION VERSUS CONSOLIDATION TREATMENT IN
PATIENTS (PTS) WITH STAGE III UNRESECTABLE
NON-SMALL CELL LUNG CANCER (NSCLC) : A PHASE
III RANDOMIZED STUDY BY THE EUROPEAN LUNG
CANCER WORKING PARTY.
M. Paesmans1, T. Berghmans2, V. Giner3, M. Roelandts4, P. Wackenier5,
A.P. Meert6, N. Leclercq2, P. Van Houtte7, J. Sculier8 1Data Centre, Institut
Jules Bordet, Brussels/BELGIUM2,-, Institut Jules Bordet, Brussels/
BELGIUM, 3Internal Medicine, Hospital de Sagunto, Valencia/SPAIN, 4Ra-
diation Oncology, Institut Jules Bordet, Brussels/BELGIUM, 5Pneumology,
Hôpital Ambroise Pare´, Mons/BELGIUM, 6Soins Intensifs et Cancerologie
Pulmonaire, Institut Jules Bordet, Brussels/BELGIUM, 7D, Institut Jules
Bordet, Brussels/BELGIUM, 8Soins Intensifs et Cance´rologie Pulmonaire,
Institut Jules Bordet, Brussels/BELGIUM
Background: Combined treatment with chemotherapy and chest irradiation
has become a standard in the treatment of stage III unresectable NSCLC.
However, the optimal timing of administration of the two modalities is not
yet determined.
Objective: To compare concurrent CTRT given as induction treatment or as
consolidation.
Method: Pts with pathologically proven unresectable stage III non small cell
lung cancer were randomized between arm A (experimental arm): 2 courses
of adapted doses GNP chemotherapy (gemcitabine, vinorelbine, cisplatin)
given with 66 Gy chest irradiation (2 Gy per fraction) followed by two
courses with full doses GNP versus 2 GNP cycles followed by 2 GNP cycles
and chest irradiation. Planned sample size was 246 pts.
Results: The trial could never be activated in France due to ethical concerns
by French CPPRB because of the concurrent administration of gemcitabine
and chest irradiation and had to be stopped early because of poor accrual.
Fifty-five pts were randomized, 6 were ineligible (5 in arm A and 1 in arm
B). Most of the 49 eligible patients (21 in arm A and 28 in arm B) were stage
IIIB (35 pts) and with a Karnofsky index 80 or higher (44 pts). Twenty-four
pts got the whole planned treatment in arm B (86%) compared to 14 (67%)
in arm A (p0.26). Six pts (2 in arm A and 4 in arm B) never started chest
radiotherapy. Median chemotherapy relative dose intensity was 79% in arm B
and 63% in arm A (p0.001). Best antitumoral response rates, median progres-
sion free survival times and median overall survival times were respectively in
arms A and B 57% and 79% (p 0.13), 7.3 months and 13.3 months (p0.26),
17.0 months and 23.9 months (p0.19). At 2 years, survival rates were
respectively 38% and 50% (median follow-up is 51 months and 7 pts, 3 in arm
A and 4 in arm B are alive without documented progression). Acute grades
III-IV toxicities were acceptable in both treatment arms, without detectable
differences, except for leucopenia which occurred more frequently in arm A
(55% versus 21%). Assessment of late toxicities is ongoing.
Conclusion: Although our study had to be stopped prematurely due to accrual
concerns and suffers obviously from a lack of power, our results do not
support that giving early concomitant CTRT is beneficial to the pts probably
due to a lack of compliance to further chemotherapy.
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A TRIAL OF CONCOMITANT CHEMORADIOTHERAPY
VS CONCOMITANT CHEMORADIOTHERAPY FOLLOWED
BY CONSOLIDATION PACLITAXEL FOR LOCALLY
ADVANCED NSCLC
W. Arafat1, A. Yossef2 1Clinical Oncology, University of Alexandria, Alex-
andria/EGYPT, 2Pulmnoary, Alexandria University, Alexandria/EGYPT
The use of combined modality therapy in locally advanced stage III NSCLC
is an area of intense investigation. The optimal Chemoradiotherapy approach
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for this group of patients needs to be defined. In this regard, the preliminary
results of clinical trials addressing the role of induction chemotherapy
followed by concomitant chemoradiotherapy did showed no survival benefit
but added toxicity. In this trial we tested concomitant chemoradiotherapy
followed by extended adjuvant chemotherapy.
Material and Methods: 56 patients with locally advanced NSCLC (patholog-
ically or cytologically confirmed) were randomized to either, concomitant
chemoradiotherapy using platinum and vp16 (A) or to the same regimen
followed by 4 cycles of paclitaxel (B). Both groups received radiotherapy 64
Gy/6.5 weeks and Pentoxifylline 400mg BID during the concomitant phase.
Results: From 12/2005–1/2007, a total of 56 patients were randomized.
There was no significant difference between groups in age, sex, stage, or
performance status. The response rates were 57% (A) and 64% (B). Median
progression-free survival was 6.0 (A) and 6.7 (B) months. Median overall
survival was 13 (A) and 14 (B) months. The overall survival was higher in
group B but did not reach statistical significance (p0.08). Toxicities were
comparable between the two groups, with esophagitis grade 3 (10%) and
9.6% in group A and neutropenia grade 3 (23.1% in group A, 45% in group B).
Conclusion: Concomitant chemoradiotherapy followed by consolidation pac-
litaxel might have a survival advantage over concomitant chemoradiotherapy
alone. However, this advantage at the cost of toxicity which was higher in the
consolidation arm. The slightly higher response and survival in this study
compared to our previous findings could be attributed to Pentoxifylline,
which was received by both groups.
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EFFICACY, SAFETY AND PHARMACOKINETIC (PK)
RESULTS OF A PHASE II STUDY WITH THE TRIPLE
ANGIOKINASE INHIBITOR BIBF 1120 IN PATIENTS
SUFFERING FROMADVANCED NON SMALL CELL LUNG
CANCER (NSCLC)
J. von Pawel1, R. Kaiser2, C. Eschbach3, J. Love4, A. Staab5, M. Freiwald5,
R. Bruno6, P. Stopfer5, U. Gatzemeier7, M. Reck8 1Center for Pneumologie
and Thorax Surgery, Asklepios Fachkliniken Mu¨nchen-Gauting, Gauting/
GERMANY, 2Clinical Research / Oncology, Boehringer Ingelheim Pharma
GmbH & Co. KG, Biberach/GERMANY, 3Eißendorfer Pferdeweg 52, Askl-
epios Krankenhaus Hamburg-Harburg, Hamburg/GERMANY, 4900 Ridge-
bury Road, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield/UNITED
STATES OF AMERICA, 5Drug Metabolism and Pharmacokinetics, Clinical
Pharmacokinetics/pharmacodynamics, Boehringer Ingelheim Pharma
GmbH & Co. KG, Biberach/GERMANY, 6Mountain View, Pharsight Cor-
poration, Cary/UNITED STATES OF AMERICA, 7Oncology, Krankenhaus
Großhansdorf/Hamburg, Hamburg/GERMANY, 8Department of Thoracic
Oncology, Krankenhaus Großhansdorf/Hamburg, Hamburg/GERMANY
Background: BIBF 1120 is a novel, oral, potent angiokinase inhibitor blocking
the VEGFR 1/2, FGFR 1/3 and PDGFR / tyrosine kinases at nanomolar
concentrations. This randomized, double-blind, multicentre Phase II study eval-
uated the efficacy, safety and PK of two doses of BIBF 1120 in patients with
advanced NSCLC. Methods: Patients were continuously treated with BIBF 1120
until disease progression or limiting toxicity. The primary endpoints were PFS
and objective tumour response (RECIST). At various visits, trough samples for
PK analysis were taken and at two visits sparse absorption profiles were
determined. PK analysis was performed utilizing NONMEM.
Results: 73 patients with an ECOG score of 0–2 with locally advanced or
metastatic (stage IIIB/IV) relapsed NSCLC after failure of 1st or 2nd line
chemotherapy were randomly assigned to 250 mg bid (n36) or 150 mg bid
(n37) of BIBF 1120. PK information was available from 71 patients (736
plasma samples). A one-compartment model with first-order absorption (ka)
and elimination rate described the PK data. The median PFS of all patients
(n73) was 1.6 months and the stable disease rate was 48%, without
significant difference between both treatment arms. Patients with an ECOG
score of 0–1 (n57) had a median PFS of 2.9 months without any difference
between both treatment arms. The stable disease rate was 59%. The median
overall survival of all patients was 22 weeks (ECOG 0–2) and 38 weeks in
patients with ECOG performance status 0 or 1. 20 patients showed tumour
shrinkage as best response, with tumour shrinkage close to partial response
(PR) in 5 patients. 1 confirmed PR was observed. The most frequent AEs
irrespective of relatedness were of CTCAE Grade 1 or 2 and included nausea
(63%), diarrhoea (56.2%), vomiting (47.9%), anorexia (39.7%) and fatigue
(32.9%). Grade 3 and 4 toxicities included diarrhoea (9.6%), reversible ALT
elevations (9.6%), nausea (8.2%), fatigue (5.5%), and vomiting (4.1%).
Conclusions: BIBF 1120 showed an acceptable safety profile and promising
efficacy data in advanced NSCLC patients. BIBF 1120 plasma concentra-
tions were described by a one-compartment model.
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COMMUNITY HAZARDS OF TOBACCO INDUCED-
CANCER –EFFORTS TO HELP QUIT TOBACCO BY A
DEVELOPING NATION NGO IN RURAL INDIA
P.D. Shankpal Community Care, HAOI, Dhule/INDIA
Objectives: Our project [Phase-II] aims at [1] 890 participants about behav-
ioural-traits of those willing to QUIT but FAILED to QUIT Tobacco[2]
Non-availability of behavioural therapists in rural/tribal areas.
Methods: Our NGO-volunteer team studied/analysed total 890 subjective re-
sponses of tobacco users. 83% males, 17% females. Of these 68% farmers, 11%
factory workers, 18% college students, 3% jobless people. Subject evaluation
Performa included behavioural aspects, educational parameters, family-cultural-
economic influence on efforts to Quit-Tobacco. Concurrent substance/drug
abuse & tobacco smoking patters additionally added to profile.
Results: 83% smokers using tobacco for  5 years, 32% for  3 years & 15%
for  6 months. 90% were using  one packet per day. 84% did try to quit
tobacco for three times in two-years. However 23% succeeded in reducing no
of cigarettes per day by 30%. Relapse is very common in age group 20 to 30
years. Desire to QUIT 71% in females compared to 39% in males.
Reasons for desire to QUIT; [1] 54% recurrent health problems [2] 12%
social & family pressure [3] 24% fear of cancer-related-dealth[4]8% eco-
nomic reasons.
RELAPSE due to; [1] 70% withdrawals [2] 22% peer pressure [3] 8%
improper follow-up counselling.
Conclusion: High [70%] relapse in efforts to QUIT due to absence of
de-addiction centres/methods & nicotine-intradermal-patches. Absence of
counselling & behavioural therapy techniques still major hurdle in efforts in
making smoke-free society. Weak motivation [ or  92% in chronic
smokers] common in farmers/students. Shockingly 34% health care set-up
personal consumed chewable tobacco. 24% seek help of traditional faith
healers & sooth-sayers to quit. Future interventional strategies need material
& manpower assistance from centres of developed nations. Behavioural
therapy must for mass population. NGOs can collaborate at Geneva-2008
conference to train oncology workers in behavioural therapy for better
cancer-control in resource-poor settings.
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SOLITARY ADRENAL METASTASIS FROM NON-SMALL
CELL CANCER: A MULTIMODALITY THERAPY
M. Conti1, B. Silva Moura2, L.M. Benhamed3, A. Wurtz3, H. Porte3 1Clin-
ique de Chirurgie Thoracique, Hôpital Calmette - CHRU Lille, Lille/
FRANCE, 2Clinique de Chirurgie Thoracique, CHRU Lille - Hôpital
Calmette, Lille/FRANCE, 3Clinique de Chirurgie Thoracique, CHU Lille -
Hôpital Calmette, Lille/FRANCE
Objectives: Metastatic disease from non-small cell lung cancer (NSCLC)
remains associated with poor prognosis. Nevertheless, patients presenting a
solitary metastasis can be successfully treated by multimodality therapy
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including surgery. We report here our 19 years of experience in the man-
agement of patients referred to us with resectable lung cancer in whom we
discovered a solitary adrenal metastasis. Methods: All patients with resect-
able lung cancer underwent extensive investigations including brain, bones
and adrenal glands. When an adrenal gland mass was discovered, a Magnetic
Resonance Imaging (MRI) followed by CT guided fine needle aspiration
(FNAB) or a PET scan were performed to confirm the diagnosis of adrenal
metastasis. If the metastasis was solitary, the patients underwent a complete
bifocal resection. For all patients who had previously undergone potentially
complete resection but in whom a solitary mass was discovered on follow-
up, the same management was carried out.
Results: Of the 2990 patients with resectable or resected NSCLC referred to
our surgical unit between January 1988 and August 2007, 22 presented a
solitary adrenal metastasis. There were 13 patients with synchronous and 9
with metachronous metastasis. All patients underwent radical (R0) surgery of
primary and metastatic sites. Post-operative radiotherapy in to the adrenal
bed and chemotherapy were administered in 10 patients (45.5%). Recurrence
of metastatic disease occurred in 14 patients (63.3%). The most frequent site
was the brain (7 patients); recurrence in adrenal bed occurred in 2 patients.
There was no local recurrence in patients who underwent radiotherapy in the
adrenal bed. The overall median survival time was 13.5 months (SE 35.6),
and a long-term survival of more than 5 years was observed in 4 (18.2%)
patients. Conclusions: Solitary adrenal metastasis from NSCLC is a rare
event but should be the focus of a more careful consideration, since there are
fair chances of long-term survival if patients are surgically treated. Adjuvant
radiotherapy and chemotherapy should be considered as ancillary treatment
since they have proven their usefulness in the treatment of brain metastasis.
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DIFFERENT IMPACT OF ERCC1 IN MALE AND FEMALE
PATIENTSWITH INOPERABLE NON-SMALL CELL LUNG
CANCER (NSCLC) TREATED WITH CARBOPLATIN AND
GEMCITABINE – A RETROSPECTIVE STUDY
B. Holm1, A. Mellemgaard1, B.G. Skov2 1Dept. of Oncology, Herlev Hos-
pital, Herlev/DENMARK, 2Dept. of Pathology, Gentofte Hospital, Hellerup/
DENMARK
Platinum-based chemotherapy improves survival in inoperable (NSCLC).
Excision repair cross-complementation group 1 (ERCC1) is a key component
of the platinum-DNA repair mechanism responsible for nucleotide excision
repair. High expression has been associated with shorter survival when
cisplatin was used as adjuvant therapy after resection of NSCLC. In this
retrospective study we included inoperable patients treated with carboplatin
AUC 5 and gemcitabine 1000 mg/m2. Paraffin-embedded histologic material
from 163 patients from a single center (50% males, 50% females. 57%
adenocarcinoma, 29% squamous cell carcinoma and 14% other NSCLC. St.
IIB 1%, IIIA 10%, IIIB 33%, IV 47%, unknown and other 9%) were
immunohistochemically stained using monoclonal antibody against ERCC1
(clone8F1). Staining frequency and intensity were scored semiquantitatively.
Different cut-off values for positivity were tested: Any vs no positive reaction in
any tumor cell gave the best separation of the material (70 positive and 93
negative tumors). Median survival for ERCC1 negative patients was 366 days as
compared to 249 days for ERCC1 positive patients (p0.023). Using the
definition of a positive tumor as in (NEJM, 355, p.983, 2006) (10 positive and
153 negative tumors) median survival for ERCC1 negative patients was 364
days compared to 198 days for ERCC1 positive patients (p0.0173). Using any
positive tumor cell as the definition of a positive tumor and divided by sex,
median survival was as shown in the table.
ERCC1 pos. median
survival (days)
ERCC1 neg. median
survival (days) P value
Males 239 360 0.0053
Females 375 382 0.6967
In conclusion, survival is significantly shorter in ERCC1 positive patients treated
with carboplatin compared to ERCC1 negative patients. When patients are
divided by sex survival is significantly shorter in carboplatin treated males with
an ERCC1 positive tumor compared to an ERCC1 negative tumor, whereas the
expression of ERCC1 has no effect on survival in females.
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INDUCTION CHEMO-RADIATION BEFORE SURGERY IN
PATIENTS WITH STAGE IIIA/B NON SMALL CELL LUNG
CANCER
A. Cyjon1, I. Bar2, J. Sandbank3, D. Stav4, A. Sella5 1Oncology Dept., Assaf
Harofe Hospital, Zrifin/ISRAEL, 2Thoracic Surgery, Assaf Harofe Hospital,
Zrifin/ISRAEL, 3Pathology, Assaf Harofe Hospital, Zrifin/ISRAEL, 4Pul-
monology, Asaf Harofe Hospital, Zrifin/ISRAEL, 5Oncology, Assaf Harofe
Hospital, Zrifin/ISRAEL
Introduction: Induction treatments are active in advanced NSCLC, with high
response rates, leading to increased resection rates and improved survival.
However, prognosis of these patients (pt’s) is still poor with median survivals
in the range of 14–20m. The best results obtained by adding taxane-based
consolidation chemotherapy following local treatment. To improve this
outcome we adopted a triple modality approach of chemotherapy combined
with radiation followed by surgery.
Patients/methods: Thirty-nine consecutive pt’s treated from 1/03–7/07. Pt’s
characteristics: m/f 30/9, median age 60 (45–83) yrs, stage IIIA 11 (28%)
pt’s and selected IIIB (no pleural effusion) 28 (72%) pt’s. Therapy included
3 cycles of paclitaxel 225mg/m2 and carboplatin AUC6 q 3 weeks and
concomitant radiation (60 Gy/6w) starting with cycle 2. Responding pt’s
underwent surgery when feasible.
Results: Response rate: CR- 2 (5%), PR- 22 (56%), SD- 8 (21%), PD- 4 (10%)
and 3 pt’s not evaluated. Nineteen (49%) pt’s underwent surgery. Lobectomy
was performed in 9 (47%) and pneumonectomy in 10 (53%) of operated pt’s.
Pathological findings: CR in 4 (21%) and with viable disease in 15 (79%) of
specimens, 6 of the latter showed only microscopic residual tumor. Seventeen
(44%) pt’s relapsed: systemic relapse - 12 (71%) pt’s, local - 2 (12%) pt’s and
local with systemic - 3 (18%) pt’s. Within a median followup of 16m 20 (51%)
pt’s are alive. Median survival of all pt’s is 20m. Grade III-IV toxicity:
neutropenia - 9 (23%) pt’s, 2 with neutropenic fever, radiation esophagitis - 7
(18%) pt’s. No pt developed severe radiation pneumonitis. Surgical complica-
tions: one pt died from respiratory failure and another developed a transient
broncho-pleural fistula both following pneumonectomy.
Conclusions: In pt’s with advanced NSCLC aggressive induction treatment
is active and achieves a resectability rate of approximately 50% with
acceptable toxicity. Morbidity and mortality after surgery are low. The
median survival of these pt’s compared favorably with the best published
results of induction treatments in advanced NSCLC. The use of taxanes in
induction chemoradiation should be considered and the need for consolida-
tion chemotherapy should be reasessed.
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INDUCTION CHEMOTHERAPYWITH A NOVEL TRIPLET
REGIMEN BEFORE CONSOLIDATION RADIOTHERAPY
IN UNRESECTABLE STAGE III NON-SMALL CELL LUNG
CANCER (NSCLC): MATURE RESULTS OF A PHASE II
STUDY
D. Schallier1, L. De Coster1, B. Neyns1, C. Fontaine1, B. Ilsen2, M.
Meysman3, S. Bral4, H. Everaert1, J. De Gre`ve1 1Medical Oncology, UZ
Brussel, Brussel/BELGIUM, 2Radiology, UZ Brussel, Brussel/BELGIUM,
3Pneumology, UZ Brussel, Brussel/BELGIUM, 4Radiotherapy, UZ Brussel,
Brussel/BELGIUM
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Background: Induction doublet chemotherapy (IC) followed by radiotherapy
(RT) is a validated treatment option for patients (pts) with unresectable stage
III NSCLC. Efficacy and long-term outcome may be enhanced by using more
active drugs or regimens. In the present phase II study a novel triplet regimen
preceding radiotherapy was evaluated. Methods: 3 cycles of paclitaxel
(175mg/m2 by 3 hour infusion on day 1), carboplatin (AUC 5mg/ml.min. by
IV bolus on day 1) and gemcitabine (1000mg/m2 by IV bolus on day 1 and
8) (PACCAGE) were administered q3 weeks in pts with a Karnofsky
Performance Score (PS) of  80 and normal baseline laboratory. Toxicity
was assessed every week during cycle 1 and on day 1 and 8 in cycles 2 and
3. Response assessment was performed before and after 3 cycles of induction
chemotherapy. Radiotherapy (66 Gy, 2Gy/session) started 4 weeks after the
last chemotherapy administration.
Results: 64 pts (25 stage IIIA and 39 stage IIIB) received a total of 179
cycles. Eight pts did not receive the scheduled 3 cycles because of tumour (4)
and treatment (4) related early events precluding further chemotherapy. Full
dose RT was administered in 47 pts, a reduced dose in 11 and no RT in 6.
Haematological toxicity grade 3/4 during IC occurred most often on day 15
of cycles. Worst grade 3/4 toxicity during cycle 1: leucopenia; neutropenia;
thrombocytopenia; anaemia. One complete (CR) and 35 partial responses
(PR) were observed (ORR55% c.i. 42.5 to 66.9%) (Stage IIIA: 72% c.i. 44
to 89.6%; stage IIIB 44% c.i. 28 to 59%; p0.06). The median time to
progression (TTP) and survival (S) of all pts was 10.9 and 17.0.month
respectively.
Conclusion: 3 cycles of IC with the novel PACCAGE regimen in pts with
unresectable stage III NSCLC is active and well tolerated. Myelotoxicity on
day 15 of the cycle constituted the main toxicity but was manageable.
Whether the triplet is superior and offers a better cost-effectiveness com-
pared to the currently used platinum-doublets as induction chemotherapy
should be evaluated in a randomised study.
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THE FAVORABLE PROGNOSTIC SIGNIFICANCE OF
ATELECTASIS IN PATIENTS WITH ADVANCED
NON-SMALL CELL LUNG CANCER. RESULTS OF A
PROSPECTIVE OBSERVATIONAL STUDY
M. Dediu1, E. Crisan2, M. Radut3, A. Tarlea4, D. Median1, A. Alexandru1, G.
Vremes1, C. Gal1 1Medical Oncology, Institute of Oncology Bucharest,
Bucharest/ROMANIA, 2Bronchology, National Pneumology Institute, Bu-
charest/ROMANIA, 3Radiology, Institute of Oncology Bucharest, Bucharest/
ROMANIA, 4Radiation Therapy, Institute of Oncology Bucharest, Bucharest/
ROMANIA
Purpose: The TNM staging system for lung cancer, included atelectasis (At)
as a negative prognostic factor, within the T category. However, according to
our clinical experience, we observed the opposite. The aim of the study was
to evaluate the influence of At on patient outcome for unresectable stage III
and IV non-small cell lung cancer (NSCLC).
Patients and Methods: We prospectively evaluated the patient survival data,
in correlation with the presence, At(), or absence, At(-), of At. A distinct
analysis according to stage was preplanned. Univariate and multivariate
analysis were performed to refine the prognostic significance of At.
Results: We evaluated 1352 consecutively treated patients, during 1997–
2004. Sixty eight patients (5%) were identified with At, of which 46/592
(8%) were in stage III , and 22/760 (3%) were in stage IV. The survival data
were significantly better for patients At() vs. At(-) ; median overall survival
(OS): 21 vs. 10 months (p0.001), median progression free survival (PFS):
17 vs. 7 months (p0.001), and the 2 year survival rate (2 y SR): 45% vs.
10% (p0.001). The most consistent difference was noted for patients with
stage III; OS: 24 vs. 14 months (p0.001), PFS: 19 vs. 8 months (p0.001)
and the 2 y SR: 56% vs. 14 %(p0.001). In stage IV, we noted a non
significant trend toward improved survival in patients At(); OS: 16 vs 9
months (p0.21), PFS: 8 vs 6 months (p 0.12) and the 2 y SR : 19% vs 7
% (p0.52). The multivariate analysis showed that At (HR0.56, p0.008),
stage (HR1.39, p0.01),and ECOG performance status (HR1.22,
p0.05) were independent predictors for survival.
Conclusion: At predicts a better survival in patients with advanced NSCLC. The
predictive value is more powerful for stage III patients. Inclusion of At as a
negative prognostic factor in the TNM staging system warrants further evaluation.
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CAN PATHOHYSTOLOGY PREDICT RESPONSE TO
CISPLATIN-BASED CHEMOTHERAPY IN STAGE IIIB-IV
NSCLC PATIENTS YOUNGER THAN 50 YEARS OF AGE?
Z. Andric, S. Kostic, V. Kovcin, Z. Murtezani Oncology, Clinical Center
Bezanijska kosa, Zemun/SERBIA AND MONTENEGRO
Background: Approximately 5–10% of newly diagnosed NSCLC patients are
younger than 50 years of age. Some previous studies suggested that younger
patients with NSCLC have a more aggressive disease course and a worse
prognosis than older patients. Other investigators have reported that no
differences were observed in two age groups. Response to first line therapy
is strong predictor of overall survival in stages IIIB and IV.
Objective: To determine if the pathohistology can predict response to standard
cisplatin-based chemotherapy in patients younger than 50 years of age.
Material and method: All clinicopathological data were obtained from
medical histories of patients with NSCLC stage IIIB and IV diagnose at
Clinical Center Bezanijska kosa in period 2001–2002. All patients were
treated according ESMO minimal clinical recommendations for treatment of
NSCLC. Results: There were 50 patients with NSCLC, diagnosed at age 
50 at Clinical Center Bezanijska kosa in period 2001–2002, 38 men and 12
women. Among them 19 (38%) were with non-squamous and 31 (62%) with
squamous histology. All patients were treated with cisplatin based chemo-
therapy, 32% stage IIIB in non squamous and 39% stage IIIB in squamous
histology group (p0,05). Distribution of response rates were as follow: in
non squamous histology group- response rate 47%, stabile disease 16%, and
37% of patients progressed at first evaluation, in squamous histology group-
48% responded to therapy, 26% were with stabile disease, and 26% were
with progressive disease (p0,05). Despite the fact that first line chemother-
apy response rates were no different in two histology groups, median overall
survival was a bit higher in squamous group (14,8 vs 19,9 months), but
without statistically significance (p0,353).
Conclusion: According the results of study, there is no evidence that
pathohystological subtype imact to both response to first line chemotherapy
and overal survival in NSCLC patients younger than 50 years of age. Largest
series are needed to confirm those results.
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LONG-TERM BENEFIT IS OBSERVED IN A RANDOMIZED
PHASE III TRIAL OF SEQUENTIAL CHEMO-
RADIOTHERAPY VERSUS CONCURRENT CHEMO-
RADIOTHERAPY IN LOCALLY ADVANCED NON SMALL
CELL LUNG CANCER (NSCLC) (GLOT-GFPC NPC 95–01
STUDY)
P. Fournel1, M. Bozonnat2, G. Robinet3, M. Grivaux4, P. Souquet5, H. Lena6,
A. Vergnenegre7, E. Dansin8, D. Paillotin9, F. Mornex10 1Medical Oncology,
Institut de Cance´rologie de la Loire, Saint-Priest en Jarez Cedex/FRANCE,
2Clinical Research, University hospital, Montpellier/FRANCE, 3Thoracic
Oncology, University Hospital, Brest/FRANCE, 4Pneumology, General Hos-
pital, Meaux/FRANCE, 5Pneumology, University Hospital, Lyon/FRANCE,
6Pneumology, University Hospital, Rennes/FRANCE, 7Pneumology, Univer-
sity Hospital, Limoges/FRANCE, 8Oncology, Centre Oscar Lambret, Lille/
FRANCE, 9Pneumology, University Hospital, Rouen/FRANCE, 10Radiother-
apy, University Hospital, Lyon/FRANCE
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Background: Preliminary results of GLOT-GFPC NPC 95–01 study are in
favor of concurrent chemo-radiotherapy versus sequential administration in
stage III unresectable NSCLC (JCO 2005; 23: 5910–7). The objective is to
confirm this survival benefit by long-term analysis.
Patients and method: From 10/96 to 05/00, 205 patients (pts) with unresect-
able locally advanced NSCLC, stage IIIAN2/IIIB, from 30 centers, were
randomized in a phase III trial which compare a sequential chemo-radiother-
apy (arm A) to a concurrent chemo-radiotherapy (arm B). The pts were age
18–70 years, PS (ECOG) 0–1, with normal renal, cardiac, hepatic and
hematologic function. In arm A, pts received an induction treatment by
Cisplatin (C) 120 mg/m2 on day 1, 29 and 57 and Vinorelbine (V) 30 mg/m2/
week from day 1 to 78, followed by a thoracic radiotherapy (TRT) as 66 Gy in
33 fractions, 5 days per week for 6.5 weeks. In arm B, the same TRT started on
day 1 with 2 concurrent cycles of C 20 mg/m2/d and Etoposide 50 mg/m2/d
(d1–5 and d29–33); after this chemo-radiotherapy, pts received C 80 mg/m2 on
day 78 and 106 and V 30 mg/m2/week from day 78 to 127.
Results: Survival data of 205 pts are available (arm A: 104; arm B: 101). Grade
3–4 toxicities (193 pts analyzable) by WHO criteria (arm A/arm B)were:
neutropenia: 88%/77%; oesophagitis: 3%/32%; pneumonitis: 11%/5%. 6 (5.6%)
toxic deaths occured in arm A and 10 (9%) in arm B. On 01/01/07, after a
median follow-up of 8.5 years, median overall survival was 14.4 months in arm
A and 16.1 months in arm B (p0.13; Log-Rank test). 5-yr/7-yr survival rates
were 8.8%/5.8% in arm A and 18.5%/15% in arm B. The overall survival benefit
appears constant at 5 and 7 years, around 9%. Between 01/04/03 and 01/01/07,
the main cause of death was progression disease (29/10 pts). One pt died of
pulmonary infection and one of cardiac failure.
Conclusions: Although not statistically significant, our study shows a long-term
survival benefit in favor of concurrent chemo-radiotherapy as compared with
sequential strategie. This survival benefit around 9% in clinically relevant.
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COMBINEDMODALITY THERAPY FOR LIMITED-STAGE
SMALL-CELL LUNG CANCER: AN EXPERIENCE
OF ONCE DAILY THORACIC RADIOTHERAPY
CONCURRENTLY WITH PLATIN CHEMOTHERAPY
AND ETOPOSIDE
L. Cartier1, N. Remini2, J. Tslabard2, P. Fournel3 1Radiothe´rapie, Institut de
Cance´rologie de la Loire, Saint Priest en Jarez/FRANCE, 2Radiothe´rapie,
Institut de Cance´rologie de la Loire, Saint Priest en Jarez/FRANCE, 3Pneu-
mologie, CHU Saint-Etienne, Saint-Etienne/FRANCE
Objective: The aim of this study was to evaluate our results in activity and
toxicity for patients with limited stage small-cell lung cancer (LS-SCLC)
treated with concurrent thoracic radiotherapy in combination with platin
chemotherapy and etoposide.
Patients and methods: We retrospectively reviewed the medical records of
patients with LS-SCLC diagnosed between January 1999 and December
2006. Twenty one patients with median age of 56.1 years (42 – 74) entered
the study. Chemotherapy consisted of 4 to 6 cycles with ciplatin (80 mg/m2
day 1) and etoposide (100 mg/m2 day 1–3) each 3 weeks or carboplatin
(AUC 6 day 1–2) and etoposide (150 mg/m2 day 1–2). Thoracic irradiation
was given concurrently with chemotherapy to the third cycle. It was admin-
istred once-daily for a total dose of 60 Gy in 30 fractions in tumor
documented volume and lymph nodes involved fields. Results: The median
follow-up time for all patients was 13.6 months. Overall survival (OS) at 1
and 3 years was 56.1% and 40.2%, respectively, with a free disease survival
of 10 months and a median overall survival of 14.2 months. Toxicities were
evaluated according to NCI-CTC v3.0 criteria. Grade 3–4 toxicities were:
neutropenia in 61.9% but no infection, thrombocytopenia in 28.6%, and
anemia in 23.8%. There were no toxic deaths. Grade 3 acute esophagitis
occurred in 14.3% and grade 2 pneumonitis occurred in 14.3%, but there
were no cases of grade 3 or greater pneumonitis. One case (4.8%) of grade
3 neurologic toxicity was observed.
Conclusion: Thoracic radiotherapy (once daily – 60 Gy) delivery concur-
rently with platin and etoposide is feasible and can be given in a non selected
population with outcomes comparable litterature series. However esophagitis
remains a limiting toxicity.
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TOLERANCE OF THE TREATMENT WITH
CHEMOTHERAPY AND/OR RADIOTHERAPY
(CH/RXT) IN OLDER PATIENTS WITH ADVANCED
LUNG CANCER
N.G. Pilnik De Mareca1, O. Mareca2, G. Kevorkof3, M. Ibero1, D. Carri4
1Oncology, Hospital Transito, Cordoba/ARGENTINA, 2Public Health, Cor-
doba University, Cordoba/ARGENTINA, 3Neumonology, Hospital Transito,
Cordoba/ARGENTINA, 4Oncology, Hospital Transito, Cordoba/ARGENTINA
Background: Lung cancer represents the first cause of death by cancer in
older people. Two thirds of the population with lung cancer are 65 yrs or
older. Cancer represents a major clinical problem in the elderly. Elders are
also more likely to present multiple comorbid conditions and use three times
more medications than younger pts. Besides, age affects the pharmacokinet-
ics of antineoplasic agents and increases the susceptibility to complications.
Purpose:To study the most common toxicities To compare the level and
types of toxicities.To evaluate survival, and QoL Methods : 110 lung cancer
patients with PS (0,12,) were included in this study. Patients had stages III
and IV.PtS selection was conducted using General Geriatric Assessment
(Katz’ score). Pfeiffer’s questionnaire was used for cognitive status.The pts
underwent Ch/Rxt after diagnosis. All pts had adequate cardiac, hepatic,
renal and bone marrow functions. Comorbidities studied were: hypertension,
diabetes, EPOC, arrhythmia, coronary disease and gastrointestinal disease.
Toxicities were studied following the WHO criteria according to age, BADL,
PS, WL comorbidities, and the use of more than 3 drugs (Polypharmacy). In
addition to Ch/ Rxt. QoL was studied through the evaluation of BADL, and
PS evolution. Pts were grouped in two groups (GI  70 and GII  70 ys).
Statistical Methods used: Pearson’s Chi-Square, Kaplan Meier’s Survival test.
Results: The most frequent level in the whole sample according to type and
grade was Grade I. Toxicities between the two groups were similar, no
significant differences were found. There was no correlation between age and
the most common toxicities.No relationship was found between toxicities
and age, irrespective of type and level.Toxicity level was found to be higher
in patients who used more than 3 other medications. Pts with PS 0–1 had
lower toxicity level than pts with PS 2. Statistically significant association
was found between comorbidities and toxicity levels.
Conclusion: Older lung cancer patients in good general condition and with
controlled comorbidities may receive Ch/ Rxt, if this treatment modality results
in improvement of their QoL.The reason why the majority of patients had low
toxicities may be attributed to the fact that all of them were properly selected for
treatment. Treatment options should be tailored to older patients based on the
same selection process and benefits seen in the population as a whole.
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IS PLATINUM-BASED CHEMOTHERAPY NECESSARY
FOR ELDERLY PATIENTS WITH ADVANCED
NON-SMALL CELL LUNG CANCER (NSCLC)?
H. Daga1, K. Takeda2, H. Kiyota2, S. Tokunaga2, S. Nanjo3, M. Sumitani3,
S. Shoji4 1Clinical Oncology, Osaka City General Hospital, Osaka/JAPAN,
2Clinical Oncology, Osaka City General Hospital, Osaka/JAPAN, 3Pulmo-
nary Medicine, Osaka City General Hospital, Osaka/JAPAN, 4Pulmonary
Medicine, Osaka City General Hospital, Osaka/JAPAN
Purpose: Single-agent chemotherapy as a first-line treatment is currently
considered the standard approach for elderly patients with advanced NSCLC.
Since platinum-based combination chemotherapy is the standard treatment
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for younger patients with advanced NSCLC, it may also be more effective
for the elderly. We reviewed the chart records of elderly advanced NSCLC
patients treated with any chemotherapy in our hospital.
Methods: We undertook retrospective reviews in 178 elderly advanced
NSCLC patients 70 years old receiving any chemotherapy in our hospital
from 1996 to 2005. Survival curves were constructed using the Kaplan-Maier
method and compared using the log-rank test. Multivariate analysis was
performed with the Cox proportional hazards model.
Results: 178 elderly patients: 109 (61.2%) aged 70–74 years old; 69 (38.8%)
aged 75 years or older. There was no difference in backgrounds gender,
histology (adenocarcinoma or nonadenocarcinoma), and ECOG PS (0–1 or
2), between the two groups. However, there was a significant difference in
the treatment regimens (platinum-based combination or non-platinum single
agent) administered. Platinum-based chemotherapy was selected more in
patients aged 70–74 (65 pts; 59.6%) than in those aged 75 years or older (16
pts; 23.2%), while single-agent chemotherapy was selected more often for
patients aged 75 years or older. There was no statistical difference in median
overall survival between those receiving platinum-based group and those
receiving non platinum-based chemotherapy (10.4 months vs 9.9 months,
P0.3647). The prognostic factors in the multivariate analysis were PS 0–1
and female, but platinum-based chemotherapy was not a good prognostic
factor. Furthermore, patients aged 75 years or older did not have poor
survival.
Conclusion: Platinum-based chemotherapy was not necessary for elderly
patients with advanced NSCLC in this review. While retrospective studies
have several limitations, a prospective randomized controlled trial comparing
platinum-based chemotherapy with single-agent chemotherapy for elderly
patients with advanced NSCLC is being conducted in Japan.
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PLATINUM-BASED DOUBLET CHEMOTHERAPY IN
VERY ELDERLY INOPERABLE NSCLC PATIENTS ABOVE
75 YEARS COMPARED TO YOUNGER PATIENTS: EQUAL
ACTIVITY BUT HIGHER HEMATOLOGIC TOXICITY
J.B. Sorensen, S. Wallerek Dept. Oncology, Finsen Centre/National Univer-
sity Hospital, Copenhagen/DENMARK
Purpose: To examine tolerability and activity of platinum-based doublet
chemotherapy in very elderly inoperable NSCLC patients (pts) aged 75
years compared to younger pts.
Patients and Methods: Chemotherapy naïve inoperable NSCLC pts aged 
18 years with no upper age limit received Carboplatin AUC 5 and Vinorel-
bine (VNB) 25 mg/m2 day 1 and VNB 80 mg/m2 orally day 8 q 3 weeks for
maximum 6 courses without g-CSF. They were divided in group A being
70 years, group B 70–75 years, and group C  75 years.
Results: A total of 135 pts received 530 treatment courses (group A 70 pts,
group B 40 pts, and group C 25 pts). There were no differences in
pre-treatment characteristics such as gender, histologic subtype, performance
status, weight loss, or stage. The median age (with range), and frequencies of
performance status 2, stage IV, and subsequent 2nd line chemotherapy were
in group A 61 years, (36–69), 19%, 69%, and 30%, in group B 72 years,
(70–75), 25%, 60%, and 18%, and in group C 78 years, (76–84), 20%, 60%,
and 0%, respectively. Number of treatment courses and time spent on
treatment were similar for all three groups, as were the case for all toxic
effects except leucopenia. The frequency of grade 4 leucopenia was 16% in
group C and 1% in group A (p0.01), and the frequency of febrile
leucopenia higher in C (12%) than in A (1%) (p0.05) with group B being
intermediate. There were no toxic deaths. Response rates were 33%, 35%,
and 56% for groups A, B, and C, and median survivals (with range) were 35
weeks (1–115), 38 weeks (2–104), and 41 weeks (8–108), respec-
tively (not significant). Median times to progression were 19, 29, and 16
weeks, respectively.
Conclusions: Very elderly pts aged 75 years had similar treatment duration
and levels of toxicities except for leucopenia and febrile leucopenia episodes
which were both considerably more frequent than in younger pts. The
activity of Carboplatin and VNB was statistically similar between age
groups, though with a remarkable trend towards higher response rate and
longer survival among the vey elderly. Platinum-based chemotherapy is
feasible and highly active in very elderly NSCLC pts but may require close
hematologic monitoring.
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DOCETAXEL COMPARED WITH VINORELBINE IN
ELDERLY OR POOR PERFORMANCE STATUS (PS)
PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG
CANCER (NSCLC): A RANDOMIZED PHASE II HELLENIC
ONCOLOGY RESEARCH GROUP TRIAL
S. Agelaki, A. Karampeazis, L. Vamvakas, X. Tsiafaki, A. Kalykaki, V.
Bozionelou, I. Gioulbasanis, V. Markos, Z. Giannousi, N. Androulakis
(horg), Hellenic Oncology Research Group, Athens/GREECE
Background: We conducted a randomized phase II trial to evaluate single-
agent docetaxel or vinorelbine in the first-line treatment of elderly and PS
2–3 pts with advanced NSCLC.
Methods: Chemo-naïve pts 65 years, with histo- or cyto-logically docu-
mented stage IIIB/IV NSCLC or pts of any age and PS 0–3 were randomly
assigned to docetaxel 38mg/m2 (days 1 and 8) or vinorelbine 25mg/m2 (days
1 and 8), every 21 days. Treatment was continued for a maximum of six
cycles and was interrupted in case of disease progression or unacceptable
toxicity. The primary end point was overall survival and secondary endpoints
were response rate, time to progression (TTP) and toxicity analysis.
Results: Seventy-six pts received docetaxel and 77 vinorelbine. Grade 3/4
neutropenia was significantly lower in the docetaxel arm (30% versus 14%;
p 0.0001). Other toxicities were mild, well tolerated and similar for both
groups with the exception of asthenia grade 2/3 (9% for docetaxel; 25% for
vinorelbine; p0.012). There was no significant difference between do-
cetaxel and vinorelbine with respect to median overall survival (5.6 months
vs 3.7 months; p0.083), overall response rate (9% vs 10%; p0.806) and
median TTP (2.2 months vs 1.6 months; p0.260). In the subset of elderly
pts with PS 0–1, docetaxel was associated with a significantly longer
survival compared to vinorelbine (8.9 months vs 4.3 months; p0.006) while
there was no statistical difference among elderly pts with PS 2–3 (2.5 months
vs 2.5 months; p0.746). In addition among elderly pts treated with
docetaxel a significantly higher survival was recorded for those with PS 0–1
compared to PS 2–3 (8.9 months vs 2.5 months; p0.002) while no
statistical difference was recorded in the vinorelbine arm (4.3 months vs 2.5
months; p0.580). Similar efficacy results were obtained when the analysis
according to PS included all pts enrolled into the study.
Conclusion: Docetaxel and vinorelbine are effective in the treatment of
elderly or poor PS pts with NSCLC. Docetaxel is associated with improved
survival over vinorelbine in good PS elderly pts. Both regimens are well
tolerated.
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POOLED ANALYSIS OF ELDERLY PATIENTSWITH NON-
SMALL-CELL LUNG CANCER TREATED WITH FRONT
LINE DOCETAXEL/GEMCITABINE REGIMEN: THE
HELLENIC ONCOLOGY RESEARCH GROUP EXPERIENCE
A. Pallis, A. Polyzos, I. Boukovinas, A. Agelidou, M. Agelidou, V. Chan-
drinos, S. Kakolyris, N. Kentepozidis, N. Androulakis, S. Agelaki (horg),
Hellenic Oncology Research Group, Athens/GREECE
Introduction: Thirty to 40% of patients with non-small cell lung cancer
(NSCLC) are older than 70 years and rarely are enrolled in clinical trials.
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Moreover, in clinical practice,  75% of patients older than 65 years with
metastatic NSCLC never received any kind of chemotherapy.
Purpose: To retrospectively evaluate the impact of age on efficacy and
toxicity of chemotherapy regimens in patients with advanced NSCLC treated
with the docetaxel-gemcitabine combination.
Patients-Methods: Pooled data from six clinical trials of the Hellenic Oncol-
ogy Research Group were analysed. According to their age, patients were
divided into two groups: those with age70 years and those with 70 years.
Results: A total of 858 patients were included in this analysis. Six hundred
sixty-six patients (77.6%) were younger than 70 years, while 192 (22.4%)
where 70 years old. Overall response rate was 30.3% and 30.2% for
patients 70 years and 70 years, respectively (p0.974). The median time
to tumor progression (TTP) was 4.1 and 4.5 months for patients 70 years
and 70 years, respectively (p0.948). Median OS was 9.9 and 9.2 months
for patients70 and 70, respectively (p0.117). The multivariate analysis
revealed PS (p0.0001) and stage (p0.0001) as independent factors with
significant impact on the hazard of death. Chemotherapy was well tolerated,
but the incidence of grade III/IV mucositis was significantly higher in elderly
patients (0.2% vs 1.5% for patients 70 vs 70 years, respectively;
p0.011).
Conclusion: The docetaxel/gemcitabine regimen has a comparable efficacy
and tolerance in young (70y) and elderly (70y) patients.
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EFFECT OF SMOKING ON THE CHEMOTHERAPY
COMPLICATION RATES IN PATIENTS OF STAGE
IIIB - IV NON SMALL CELL LUNG CANCER
S.V. Attili1, P.P. Bapsy2, K. Govinda Babu3, L. Dasappa3 1Medical Oncol-
ogy, Yashoda Group of Hospitals, Hyderabad/INDIA, 2Medical Oncology,
KMIO, Bangalore/INDIA, 3Medical Oncology, KMIO, Bangalore/INDIA
Background: Smoking is one of the major risk factors for the carcinoma
Lung globally. It leads to significant comorbidity in majority of patients. In
view of the poor prognosis of the advanced stage disease, it is often difficult
for the physician to convince the patient for cessation of smoking. The
avialable data suggest a higher rates of complications in patients recieving
radiation. However same was not studied with chemotherapy from our
region. Aim: This study was undertaken to evaluate the toxicity profile of
patients with Stage IIIb /IV non small cell lung cancer recieving chemother-
apy and to assess the effect of continuing smoking on the overall toxicity
Methods: All the patients with histologically or cytologically proven Stage
III B / IV non small cell lung cancer attending the Medical Oncology OPD
at Kidwai Memorial Institute of Oncology, Bangalore from 2005–2007 July
were enrolled. The details were collected from the case records and only those
with definite history of smoking were evaluated. Pateints were councelled for
cessation of smoking and those who stopped smoking were evaluated as cases
and the remaining as controlls. All patients recieved either Etoposide with
Cisplatinum, or Gemcitabine with either Cisplatinum or carboplatinum as the
chemotherapy. Stratification was done according to the chemotherapy recieved
for the final analysis. Toxicity was measured by NCI CTC version 3.0. Medcalc
VErsion 7.0 for windows was used for statistical Analysis.
Results: Total of 106 patients were evaluated and final analysis was done on
the 70 patients among which 35 continued smoking and remaining didnot.
The overall toxicity rate was 64% and there is no statistically significant
difference in the overall incidence of toxicity in either groups. However
Smokers experianced more grade III/ IV toxicities and more febrile episodes
compred to the non smokers. The trend was uniform irrespective of the
chemotherpay recieved.
Conclusion: Continuation of smoking was associated with more sever tox-
icity and more febrile episodes, though overall incidence of toxicities are
similar in both groups. Therefore it is advisable to stop smoking atleast
during the period of chemotherapy. Howwever there is no differences in the
survival among the two groups.
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PEMETREXED AS SECOND-LINE TREATMENT IN
ADVANCED NSCLC: EXPERIENCE WITH 131 PATIENTS
A. Bearz1, I. Garassino2, R. Cavina2, A. Favaretto3, R. Talamini4, M.
Boccalon5, S. Spazzapan1, C. Simonelli1, L. Fratino1, U. Tirelli1 1Oncologia
Medica, Centro di Rifermento Oncologico, Aviano/ITALY, 2Medical and
Hematology Department, IRCCS Humanitas, Rozzano/ITALY, 3Medical On-
cology, IOV, Padova/ITALY, 4Epidemiology Unit, CRO-IRCCS, Aviano/
ITALY, 5Medical Oncology, General Hospital, Pordenone/ITALY
Background: Pemetrexed has been registered as a second-line option for
advanced Non Small Cell Lung Cancer (NSCLC). We collected data on 160
patients treated in second- or further-line therapy for advanced NSCLC in a
post-registrative phase after progression to a previous treatment. We have
already reported the data in Bearz A. et al (Lung Cancer in press), with
overall survival and progression-free survival of 12 and 3 months respec-
tively. Herein we analyze the data on 128 patients receiving second-line
therapy only, where we added data from 3 more patients.
Patients and Methods: From May 2005 to March 2007, 131 patients with
advanced NSCLC in progression to first-line platinum-based therapy were
treated with Pemetrexed 500 mg/m2, q 21, in several Italian institutions;
M/F 95(72.5%)/36 (27.5%); median age 65.4 yrs (41–82); adeno, squa-
mous and other carcinoma 67(51%), 26(19.8%), 38(29%) respectively; PS
0–1 in 120 (91.6%), 2 in 11 patients (8.4%). Median overall survival and
progression-free survival were assessed by the Kaplan-Meier method.
Results: Analysis was performed up to October 31st 2007. Median overall
survival was 12 months, the same as reported in the previous analysis; median
progression-free survival was 3.1 months.
Conclusion: Our findings confim the data observed with patients receiving n
second and further lines of therapy and the promising overall survival
reported for Pemetrexed in the post-registrative phase. Progression-free
survival is mildly improved when only patients receiving second-line therapy
are considered.
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RESPONSE TO GEMCITABINE-PLATINUM
CHEMOTHERAPY BY SINGLE NUCLEOTIDE
POLYMORPHISMS (SNPS) OF RRM1 AND ERCC1 GENES
IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
(NSCLC)
Y. Kim1, K. Kim1, I. Oh1, S. Ahn2, K. Na3, Y. Kim4, K.Y. Lee5, K. Lee6, E.
Jeong7, Y. Jeon8 1Lung & Esophageal Cancer Clinic, Chonnam National
University Hwasun Hospital, Hwasungun, Jeonnam/KOREA, 2Radiation
Oncology, Chonnam National University Hwasun Hospital, Hwasun-Gun/
KOREA, 3Thoracic Surgery, Chonnam National University Hwasun Hospi-
tal, Hwasun-Gun/KOREA, 4Medical Imaging, Chonnam National University
Medical School, Gwangju/KOREA, 5Internal Medicine, Konkuk University
Hospital, Seoul/KOREA, 6Medicine, Yeungnam Universith Medical School,
Daegu/KOREA, 7Medicine, Wonkwang University Medical School, Iksan/
KOREA, 8Medicine, Keimyung University Medical School, Daegu/KOREA
Background: RRM1, the regulatory subunit of ribonucleotide reductase, is
involved in carcinogenesis, and the response to gemcitabine. Two SNPs
(RR37 and RR524) in the promoter region of RRM1 gene impacted promoter
activity, and were associated with prognosis. ERCC1, the excision repair
cross-complementation group 1, is associated with platinum resistance. A
SNP in codon 118 (exon 4) of ERCC1 gene was reported as a prognostic
marker in platinum treated NSCLC.
Methods: SNPs were analyzed with real time-PCR using genomic DNA
extracted from peripheral blood of 121 patients. The patients (male 93,
female 28, mean age 62 years) had advanced stage NSCLC treated with
gemcitabine and platinum(GP) as a first line chemotherapy.
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Results: Responses to GP were classified as responders (n60, CR 3, PR 57)
and non-responders (n57, SD 28, PD 29). Patients were classified into 4
groups with RRM1 and ERCC1 allelotypes.
Group 1 (RRM1-AC-CT and ERCC-CC) showed highest response rate
(64.7%), compared to Group 2 (RRM1-AC-CT and ERCC-CT/TT, 63.2%),
Group 3 (RRM1-CC-TT and ERCC-CT/TT, 52.2%), and Group 4 (RRM1-
CC-TT and ERCC-CT/TT, 38.2%)(p0.05).
Conclusion: We observed tendency of different responses to GP regimen
according to SNPs of RRM1 and ERCC1 gene. The allelotype with the
lowest predicted expression of both genes was associated with the best
patient outcome, although not significant.
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OUTCOMES OF SECOND LINE TREATMENTS IN
PLATINUM-RESISTANT NON SMALL CELL LUNG
CANCER (NSCLC)
D. Tassinari1, C. Santelmo1, E. Tamburini1, C. Possenti1, M. Papi1, L.
Lazzari Agli2 1Oncology, City Hospital, Rimini/ITALY, 2Pneumology, City
Hospital, Riccione/ITALY
Background: To assess the role of second line treatments in platinum-
resistant NSCLC.
Methods: A systematic review of literature in MEDLINE and EMBASE
from 2000 to 2007 was performed independently by two authors (DT and
ET). All the randomized phase III trials comparing chemotherapy or target
therapies with placebo were considered eligible and included into the
analysis. 1-year survival rate (1YSR) was the primary outcome of the
analysis, time-to-progression (TTP) the secondary one. A sub-analysis in-
cluding only the target therapies (TT) was secondarily performed. Hetero-
geneity between the trials was analysed using the Mantel-Haenszel test; the
outcome analysis was performed using a random effects model and an alpha
error lower than 5%.
Results: 3 trials met the selection criteria and were included into the analysis.
One trial compared docetaxel with placebo, 1 trial erlotinib with placebo and
1 trial gefitinib with placebo. The outcomes of 2627 patients (104 treated
with docetaxel, 488 with erlotinib, 1129 with gefitinib and 906 with placebo)
were compared in the pooled analysis. A trend in favour of heterogeneity
between the trials was documented (p0.08). A significant advantage in
favour of the treatments was observed for 1YSR (Odds Ratio0.77,
p0.021). Data about TTP were detailed only in the 2 trials with the TT. A
significant heterogeneity was observed in the TT subgroup (p0.047) with a
trend in favour of the treatment for 1YSR (Odds Ratio0.79, p0.057), and
a significant improve for TTP (Odds Ratio0.71, p0.022).
Conclusion: Our data seem to suggest a significant advantage for second line
treatments in platinum resistant NSCLC; nevertheless, the significant side effects
of chemotherapy and the controversial results with target therapies probably
suggest that only patients with good performance status or a significant predic-
tive profile (no smokers patients, patients with adenocarcinoma, female patients
for TT) have to be treated. Further trials focused on the predictive parameters for
second line treatments are probably needed to significantly improve the outcome
of second line treatments in platinum resistant NSCLC
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SEVERE BRONCHIOLITIS OBLITERANS ORGANIZING
PNEUMONIA (BOOP) AFTER TWO CYCLES OF
DOCETAXEL AS FOURTH LINE CHEMOTHERAPY FOR
ADVANCED NON SMALL CELL CARCINOMAOF THE LUNG
J. Hasskarl1, A. Ru¨ckert1, A. Frydrychowicz2, H. Becker1, M. Neagu3, G.
Kayser4, C. Waller1 1Hematology & Oncology, University of Freiburg Med-
ical Center, Freiburg/GERMANY, 2Abteilung Ro¨ntgendiagnostik, University
of Freiburg Medical Center, Freiburg/GERMANY, 3Gastroenterology, Uni-
versity of Freiburg Medical Center, Freiburg/GERMANY, 4Pathology, Uni-
versity of Freiburg Medical Center, Freiburg/GERMANY
Bronchiolitis obliterans organising pneumonia (BOOP) is an inflammatory
process of the bronchioles that can lead to destruction of small airways and
surrounding lung tissue. Although the majority of cases are idiopathic,
certain chemicals and drugs can induce BOOP. Here, we report of a 54-year
old male patient with advanced non small cell lung cancer (NSCLC) who
developed therapy-associated BOOP. He had undergone several rounds of
other treatments before receiving docetaxel as monotherapy (75 mg/m2).
Treatment was initially well tolerated, but after the second cycle of do-
cetaxel, he developed increasing shortness of breath. A computed tomogram
(CT) for staging after the second cycle showed tumour regression and bilobar
diffuse interstitial infiltration, highly suggestive for acute pulmonary fibrosis.
Bronchoscopy revealed signs of chronic bronchitis and watery discharge
from both lungs. Bronchioalveolar lavage and transbronchial needle biopsy
was performed, and based on histopathologic examination, the diagnosis of
BOOP was confirmed. After immediate cessation of docetaxel and high-dose
steroid treatment, the pulmonary infiltrates rapidly improved. Unfortunately,
after reduction of steroids, clinical symptoms reoccurred and the CT scan
demonstrated BOOP-deterioration. Review of the literature revealed that only
two reports of docetaxel-induced BOOP have been piublished, also producing
severe respiratory insufficiency and simulating tumour progression. Our patient
developed rapid onset of BOOP after initially well tolerated docetaxel chemo-
therapy. This suggests that taxane-induced BOOP might occur more often than
presumed. With histologically confirmed BOOP diagnosis, our patient was
switched to vinorelbine chemotherapy, thereby remaining in stable disease
concerning his NSCLC and showed further improvement of respiratory symp-
toms. We suggest that patients receiving docetaxel treatment that develop
moderate to severe respiratory symptoms should also be suspected with and
carefully evaluated for chemotherapy-induced BOOP.
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RESOURCE UTILIZATION IN ADVANCED NON-SMALL
CELL LUNG CANCER: RESULTS FROM THE EUROPEAN
SAMPLE OF THE RANDOMIZED, PHASE III TRIAL OF
PEMETREXED/CISPLATIN VERSUS GEMCITABINE/
CISPLATIN
C. Manegold1, J. Douillard2, F. de Marinis3, L. Paz-Ares4, M. O’Brien5,
A.M. Liepa6, L. Simms7, G.V. Scagliotti8 1Department of Surgery, Thoracic
Oncol., Heidelberg University, Mannheim/GERMANY, 2Boulevard J.
Monod, Centre R Gauducheau, Saint-Herblain/FRANCE, 3Pulmonary On-
cology, San Camillo-Forlanini Hospitals, Rome/ITALY, 4Medical Oncology,
Hospital Universitario Virgen del Rocio, Seville/SPAIN, 5Medicine, Royal
Marsden Hospital, Sutton/UNITED KINGDOM, 6Global Health Outcomes,
Eli Lilly and Company, Indianapolis/UNITED STATES OF AMERICA,
7Statistics, Eli Lilly Canada, Toronto/CANADA, 8Department of Clinical and
Biological Sciences, University of Torino, Orbassano/ITALY
Background: Results from the multinational phase III trial of pemetrexed/
cisplatin (PC) versus gemcitabine/cisplatin (GC) demonstrated non-inferior
efficacy in the overall population and superior efficacy for the non-squamous
population for PC (Scagliotti et al, Proc IASLC 2007). In the overall
population, hematological and non-hematological toxicities, with a few
exceptions, favored PC; in addition, some resource utilization also favored
PC. Given that delivery of oncology services differs by country, we explore
resource utilization data by European country.
Methods: Patients who received treatment were included in the analysis. At each
cycle, adverse events (AEs) were assessed using Common Toxicity Criteria
(version 2) and concomitant medications, transfusions and AE-related hospital-
izations were recorded. Resource utilization and drug-related AEs were summa-
rized by country and compared between arms with Fisher’s exact test.
Results: Of 1725 randomized patients, 1669 (PC: n839; GC: n830) received
treatment. For the overall population, grade 3/4 neutropenia was 15.1% vs 26.7%
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(p.001), anemia was 5.6% vs 9.9% (p.001) and thrombocytopenia was 4.1%
vs 12.7% (p0.001); toxicity results by country were generally consistent with
the overall population. Select resource utilization data for Germany and Italy are
presented in the table. Data for Spain (n88), France (n54) and the United
Kingdom (n43) were also analyzed and will be presented. Antibiotic and
antiemetic use was similar between arms both in the overall population and in
each of the countries. Resource utilization by country, PC vs GC
All
Germany
(n199)
Italy
(n120)
Transfusions 16 vs 29%;
p0.001
25 vs 30%;
p0.43
6 vs 13%;
p0.21
Erythropoietin 10 vs 18%;
p0.001
5 vs 2%;
p0.28
10 vs 22%;
p0.09
G-CSF 3 vs 6%;
p0.004
4 vs 7%;
p0.54
6 vs 22%;
p0.01
Hospital 32 vs 35%;
p0.28
45 vs 37%;
p0.31
31 vs 31%;
p1.0
Conclusions: Differences in resource utilization between PC and GC within
European countries were generally consistent with the overall population.
Although use of specific medical resources may differ across countries, the
between-arm differences were consistent.
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TO ANALYZE THE EFFICACY, TOLERABILITY,
TOXICITY PROFILE, AND PHARMACO-ECONOMICS
OF PACLITAXEL-CARBOPLATIN VS CISPLATIN-
ETOPOSIDE IN PATIENTS WITH ADVANCED NSCLC
K.V.S. Saini, K. Lakshmaiah, U. Batra, K. Sajeevan, A. Jain, T. Singh, C.
Sathish Department of Medical Oncology, Kidwai Memorial Institute of
Oncology, Bangalore/INDIA
Aim: To analyze the efficacy, tolerability, toxicity profile, and pharmaco-
economics of Paclitaxel-Carboplatin vs Cisplatin-Etoposide in patients with
advanced NSCLC. Methods: 46 patients with Stage IIIB or IV histologically
proven Non Small Cell Lung Cancer (NSCLC), absence of known metastasis
to the brain, and an ECOG performance status of 0 or 1 were randomly
assigned to receive either 6 cycles of Paclitaxel-Carboplatin (TP) or Cispla-
tin-Etoposide (EP) chemotherapy. We then analyzed the overall survival,
toxicity profile, and the pharmaco-economics of both therapy arms. Phar-
maco-economic analysis took into account the cost of chemotherapy drugs
and supportive care, duration and cost of hospital stay, and laboratory tests.
Lost wages during hospitalization were not included in this assessment.
Treatment: Chemotherapy was administered as follows: TP (n22): Pacli-
taxel 175 mg/m2 and Carboplatin AUC 5, repeated 3 weekly; EP (n24):
Cisplatin 100 mg/m2 and Etoposide 120 mg/m2 repeated 3 weekly.
Results: Characteristics like patient age, sex distribution, tumor stage, and
histology were comparable in both the arms. Results:
TP EP
Number of patients 22 24
Delay 1 week in completing planned protocol 12 7
Patients requiring G-CSF support 9 2
Overall Survival at 6 months 15 14
Grade 3 or 4 toxicity 17 11
Monthly cost in INR (to nearest 1000 INR) 68000 14000
Conclusion: In a resource-restricted country like India, cost effectiveness is
of considerable importance in the decision making process of patients outside
the ambit of effective health insurance coverage. Although TP regimen had
a slightly higher OS as compared to EP, it was associated with a higher
incidence of toxicity, increased duration of hospital stay, and a much higher
cost of therapy. This study provides an economic rationale to continue EP
regimen as the first choice treatment of advanced NSCLC in a developing
country like India.
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BENEFITS OF USING INDIVIDUAL PATIENT DATA
IN META-ANALYSIS: EXAMPLE OF DOCETAXEL
COMPARED WITH VINCA-ALKALOIDS IN THE
FIRST-LINE TREATMENT OF NSCLC
M. Buyse1, S. Laporte2, P. Squifflet3, J. Pujol4, V. Georgoulias5, F. Fossella6,
S. Kudoh7, K. Kubota8, J. Douillard9, A. Monnier10 1Dept. of Statistics,
IDDI, Ottignies Louvain-la-Neuve/BELGIUM, 2Dept. of Clinical Pharma-
cology; Ea3065;, University Hospital, Saint-Etienne/FRANCE, 3Dept. Of
Statistics, IDDI, Ottignies Louvain-La-Neuve/BELGIUM, 4Hopital Arnaud
De Villeneuve, Montpellier Academic Hospital, Montpellier/FRANCE, 5Hel-
lenic Oncology Research Group (horg), University General Hospital of
Iraklion, heraklion/GREECE, 6Md Anderson Cancer Ctr, University of
Texas, Houston/UNITED STATES OF AMERICA, 7Dept. of Respiratory Med-
icine, Osaka City General Hospital, Osaka/JAPAN, 8Thoracic Oncology Divi-
sion, National Cancer Center Hospital, Kashiwa Chiba/JAPAN, 9Boulevard J.
Monod, Centre R Gauducheau, Saint-Herblain/FRANCE, 10A Bouloche Hospi-
tal, Centre Hospitalier Belfort-Montbe´liard, Montbeliard/FRANCE
Background: Meta-analyses are often performed with published data. Al-
though such meta-analyses are easy to perform, they may yield biased results
and may not be adequate to address important clinical questions that require
individual patient data (IPD).
Material and methods: We performed a meta-analysis of randomized trials
comparing docetaxel with vinca-alkaloids in the first-line treatment of
NSCLC. We compared the results of analyses based on summary statistics
from the literature (SSL) with those based on IPD. Study search and results
based on SSL have been described elsewhere [Douillard JY et al. J Thorac
Oncol 2007]. Clinical outcomes were overall survival (OS) and progression-
free survival (PFS) or, when PFS was not reported, time to progression
(TTP). We also investigated whether PFS could be considered a valid
surrogate for OS in this setting.
Results: A total of 7 RCTs were included (2867 patients). For overall
survival, the pooled estimates of the OS hazard ratio were close whether
calculated on SSL or on IPD (Table). In contrast, the pooled estimates of the
PFS hazard ratio were quite different when calculated on SSL or on IPD, in
part because the relevant information was published for only 2 of the 7 trials.
In our investigation of the surrogacy of PFS for OS, we could not estimate
the correlation between PFS and OS based on SSL, but found a moderate
correlation between these endpoints based on IPD (R20.68). Finally, the
correlation between the effects of treatment on PFS (or TTP) and OS was quite
low when based on SSL (R20.09), but quite high when based on IPD
(R20.83).
Summary Stat.
from the Literature
(SSL)
Individual
Patient Data
(IPD)
OS HR0.88
[0.81;0.96]
HR0.90
[0.83;0.98]
PFS HR0.85
[0.71;1.02]
HR1.01
[0.92;1.11]
Correlation between the hazard
ratios of PFS and of OS
R20.09 R20.83
[0.62;1.05]
Conclusions: The meta-analysis based on individual patient data confirmed
the survival benefits found with published data. All other analyses were
either impossible or misleading when performed on published data.
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THE IMPACT OF NUMBER AND SITE OFMETASTASES ON
SURVIVAL IN STAGE IV NON-SMALL CELL LUNG CANCER
D. Colak1, B. Yilmaz2, H. Sakalli2, Z. Calikusu2, H. Mertsoylu2, Z. Akcali1,
B. Demirhan3, O. Ozyilkan1 1Medical Oncology, Baskent University, Anka-
ra/TURKEY, 2Medical Oncology, Baskent University, Adana/TURKEY, 3Pa-
thology, Baskent University, Ankara/TURKEY
Purpose: In our study, we aimed to evaluate the impact of number and site
of the metastases at the time of diagnoses on survival in stage IV non-small
cell lung cancer (nsclc).
Patients and methods: From January 2001 to January 2006, 408 lung cancer
patients (334 nsclc and 74 small-cell lung cancer) had been received in our
department. Of them, 171 were stage IV. Thirty of these patients were
excluded from the study with different causes (second primary, active
tuberculosis, refusal of any treatment etc), and 141 patients with stage IV
nsclc were reviewed.
Results: Of the patients included in the study, 11 were women, 130 were men
and mean age was 61.8 years. Median survival time (MST), 1- and 2-year
survival rates was 9 months, 34.8% and 10.6% respectively. MST for men was
9 months (%95 CI 6.8–11.2) and for women was 9.1 months (%95 CI 2.8–15.5)
(p0.99). MST for patients who received first-, second-, third- and fourth-lines
chemotherapies were in order 6.5 months (%95 CI 5.1–7.9), 10.8 months (%95
CI 8.2–13.4), 17 months (%95 CI 14.2–19.8) and 20.6 months (p0.0034).
Metastases was in one body site in 80 (%56) patients. For the patients with
metastases in one body site MST was 12.6 months (%95 CI 10.3–14.9) and for
the others with multipl metastatic body sites it was 6.5 months (%95 CI 5–8)
(p0.0006). MST was 4.7 months (%95 CI 3.7–5.7) for the patients with liver
metastases, and 10.5 months (%95 CI 8.1–12.9) for the others (p0.0000). The
site of metastases other then liver had no statistical impact on survival. Cox
regression analysis also showed number of metastatic sites (p0.048) and liver
metastases (p0.033) to be significantly associated with survival.
Conclusion: Metastasis in more than one body site and liver metastases are
bad prognostic factors.
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DOWN-STAGING OF EGFRMUTATION-POSITIVE STAGE
IV LUNG CARCINOMA BY GEFITINIB PROVIDES AN
OPPORTUNITY FOR SURGICAL TREATMENT OF THE
DISEASE: REPORT OF 2 CASES
E. Levchenko1, V. Moiseyenko2, D. Matsko3, A. Iyevleva4, A. Ivantsov3, S.
Yargnian1, V. Anisimov1, E. Imyanitov4 1Thoracic Surgery, N.N. Petrov
Institute of Oncology, St.-Petersburg/RUSSIAN FEDERATION, 2Therapy,
N.N. Petrov Institute of Oncology, St.-Petersburg/RUSSIAN FEDERATION,
3Pathology, N.N. Petrov Institute of Oncology, St.-Petersburg/RUSSIAN
FEDERATION, 4Tumor Growth Biology, N.N. Petrov Institute of Oncology,
St.-Petersburg/RUSSIAN FEDERATION
Stage IV lung cancer is known to be an inoperable disease. Here we present the
experience of successful down-staging of two EGFR mutation-positive lung
adenocarcinomas, that eventually allowed to perform surgery for these patients.
Patient 1, female non-smoker, 62 years old, was diagnosed with the right-sided
adenocarcinoma of the upper lobe with multiple metastases to the middle lobe.
Based on the presence of tyrosine kinase inhibitor (TKI) sensitizing deletion in
the EGFR gene, gefitinib was administered as a front-line treatment at conven-
tional dose (250 mg daily). Adverse effects were limited to grade 1 skin rash and
grade 1 diarrhea. After 2 months of treatment, only single lesion in the upper
lobe (2 cm in diameter) remained detectable; the effect was classified as partial
response. The surgery included upper bilobectomy with mediastinal lymph
nodes dissection. Comparison of pre-treatment biopsy and surgical material
revealed decrease of Ki-67 count from 7% to 3% as well as dystrophic changes
in the tumor parenchyma. Patient 2, male smoker, 48 years old, entered the
hospital with the life-threatening condition (ECOG performance status 3,
marked hemoptysis, fever). Clinical examination revealed large adenocarcinoma
of the lower lobe of the right lung and a single metastasis to the right adrenal.
Similarly to the above case, EGFR intragenic deletion was detected and 250 mg
daily gefitinib was administered. Dramatic symptomatic improvement (disap-
pearance of hemoptysis and fever; normalization of performance status up to
grade 2) was observed by the day 5. Gefitinib toxicity manifested in grade 2 skin
rash and grade 1 diarrhea. After 3 months of treatment, the adrenal metastasis
was no longer detectable, and the primary tumor was reduced up to 1.5 cm in
diameter (partial response). Surgery included right lower lobectomy with medi-
astinal lymph nodes dissection and left adrenalectomy. Although long-term
outcomes for these 2 patients remain to be seen, this initial experience justifies
EGFR testing for lung adenocarcinoma patients and consideration of surgical
treatment in case of pronounced tumor response.
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TREATMENT OF PATIENTS WITH ADVANCED
NON-SMALL-CELL LUNG CANCER (NSCLC) WITH
ERLOTINIB: RESULTS FROM CLINICAL PRACTICE
M. Faehling1, S. Kuom2, M. Leschke3, M. Geissler4, T. Kamp5, R. Eckert5
1Klinik fu¨r Kardiologie und Pneumologie, Klinikum Esslingen/Thoraxzentrum
TESS, Esslingen/GERMANY, 2Klinik fu¨r Kardiologie, Pneumologie und Angi-
ologie, Kliinikum Esslingen/Thoraxzentrum TESS, Esslingen/GERMANY,
3Klinik fu¨r Kardiologie, Pneumologie und Angiologie, Klinikum Esslingen,
Esslingen/GERMANY, 4Klinik fu¨r Onkologie, Klinikum Esslingen, Esslingen/GER-
MANY, 5Onkologie, Onkologische Schwerpunktpraxis, Wendlingen/GERMANY
Background and objective: “Targeted therapies” provide new options for the
treatment of inoperable non-small cell lung cancer. The “small molecule”-based
EGFR-tyrosine kinase inhibitor erlotinib has been approved as 2nd and 3rd line
therapy of NSCLC. So far, it is not entirely clear who benefits most from this
therapy. Post-hoc subgroup analyses of randomized phase II and III studies
suggest that nonsmokers, women, and patients with adenocarcinoma histology
may have a superior response to treatment. We performed a retrospective
analysis to answer the question, whether these 3 response criteria can be used in
routine clinical practice for patient selection for therapy with erlotinib.
Methods: Twenty-six consecutive patients with inoperable NSCLC who were
treated with erlotinib (150 mg/d) for at least 4 weeks after at least one preceding
chemotherapy were analysed. In addition, one patient on hemodialysis unfit for
conventional chemotherapy was treated with erlotinib as 1st line therapy.
Results: In our series, 10 of 26 patients (38.5%) with advanced pretreated
NSCLC demonstrated an objective response, in another 5 patients, erlotinib
resulted in disease stabilization. The patient on hemodialysis tolerated
erlotinib well and showed stable disease after 3 months of treatment. In 4
patients, the response lasted for more than a year. All of these patients were
never-smoking women with adenocarcinoma. In contrast, none of the current
smokers responded to erlotinib.
Discussion: Obviously, the physicians had performed a clinical preselection:
Eleven patients were never smokers, whereas only 4 patients were current
smokers. Twenty-two patients (84.6%) had an adenocarcinoma, only 4
patients (15.4%) had squamous cell carcinoma. In contrast to our results, in
the randomized clinical trial (BR.21), which was performed without this
patient selection, erlotinib showed an objective remission of only 8.9%. This
may indicate that the above clinical criteria may be valid for response
prediction to erlotinib. However, our retrospective data need to be confirmed
with larger patient numbers (e.g. from registries) in order to define the
clinically and economically appropriate method of patient selection.
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RESULTS OF A PHASE I DOSE-ESCALATION STUDY OF
SUNITINIB (SU) PLUS DOCETAXEL (D)
A. Sandler1, A.M. Traynor2, J.H. Schiller3, J. Ilagen4, W. VerMeulen5, G.
Liu2, L. Verkh6, X. Huang6, R. Chao6, F. Robert7 1Department of Hematol-
ogy/oncology, Vanderbilt University Medical Center, Nashville/UNITED
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STATES OF AMERICA, 2Paul P. Carbone Comprehensive Cancer Center,
University of Wisconsin, Madison/UNITED STATES OF AMERICA, 3De-
partment of Internal Medicine - Hematology-Oncology, University of Texas
Southwestern, Dallas/UNITED STATES OF AMERICA, 4Department of
Clinical Study and Data Management, Pfizer Global Research and Devel-
opment, La Jolla/UNITED STATES OF AMERICA, 5Clinical Trials Pro-
gram, Vanderbilt University Medical Center, Nashville/UNITED STATES
OF AMERICA, 6Department of Clinical Pharmacology, Pfizer Global Re-
search and Development, La Jolla/UNITED STATES OF AMERICA, 7Com-
prehensive Cancer Center, University of Alabama at Birmingham, Birming-
ham/UNITED STATES OF AMERICA
Background: SU is an oral multitargeted tyrosine kinase inhibitor of VEG-
FRs, PDGFRs, KIT, RET, CSF-1R and FLT3. Xenograft models of human
breast cancer and non-small cell lung cancer (NSCLC) show enhanced
antitumor activity of SUD. The maximum tolerated doses (MTDs), phar-
macokinetic (PK) profile, safety and antitumor activity of SU given in
combination with D was assessed in patients (pts) with lung cancer and other
advanced solid tumors.
Methods: Successive cohorts of pts received oral SU at 25, 37.5, or 50 mg
daily for 4 wks of a 6-wk cycle (Schedule 4/2) or for 2 wks of a 3-wk cycle
(Schedule 2/1) plus D at 60 or 75 mg/m2 every 21 days (q21d) in this
dose-finding study. MTD was defined as the highest dose at which 0/3 or 1/6
pts experienced dose-limiting toxicities (DLTs) during cycle 1. Safety/
tolerability were evaluated by adverse events and clinical laboratory tests.
Antitumor activity was assessed by objective response (RECIST). Results 48
pts were enrolled (Sep 2007), including 18 pts with lung cancer. Of 10 pts
who received SU on Schedule 4/2, 1 had NSCLC. Of 38 pts on Schedule
2/1, 16 had NSCLC and 1 had small cell lung cancer. DLTs were
observed in 2 pts on Schedule 4/2 at D 60 mg/m2/37.5 mg SU: Grade (G)
3 bilateral weakness and febrile neutropenia. Neutropenia (with or with-
out fever; maximum G4), the most commonly observed DLT (n5) on
Schedule 2/1 [D 60 mg/m2/25 mg SU (n2/9), D 75 mg/m2/50 mg SU
(n2/2) and D 75 mg/m2/37.5 mg SU (n1/21)] was manageable/
reversible. Other DLTs included G3 GI hemorrhage (n1/21). The MTD
on Schedule 2/1 was SU 37.5 mg with D 75 mg/m2. Most common
non-hematological G3 adverse events on Schedule 2/1 at the MTD
included fatigue (24%), stomatitis/oral discomfort (10%) and pyrexia
(10%). No clinically significant drug– drug interaction was observed with
the D 75 mg/m2/37.5 mg SU combination; on Schedule 4/2, 1 NSCLC pt
had stable disease (SD). On Schedule 2/1, partial responses were ob-
served in 2 pts (NSCLC and breast cancer) and SD in 10 pts (27%),
including 3 NSCLC pts in this previously treated pt population.
Conclusions: The combination of oral SU 37.5 mg/day  D 75 mg/m2 IV
q21d (Schedule 2/1) has a manageable safety profile, demonstrated clinical
activity in lung cancer, and was selected for further study.
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A PHASE II STUDY OF ERLOTINIB AS A FIRST-LINE
THERAPY FOR NON-SMALL-CELL LUNG CANCER
PATIENTS WITH FAVORABLE CLINICAL PREDICTORS
D.H. Lee, J. Hong, Y.H. Han, Y.M. Lee, S. Kim, C. Suh, J. Lee Department
of Internal Medicine, Asan Medical Center, Seoul/KOREA
Background: Many studies of EGFR TKIs suggest positive and negative
predictors for response and survival. We conducted the study to evaluate the
efficacy of erlotinib as a first-line therapy for patients with non-small cell
lung cancer (NSCLC) who have favorable clinical predictors, such as
never-smoking, adenocarcinoma or female gender. Methods: The eligible
patients should have at least two of three favorable clinical predictors,
including female gender, adenocarcinoma, and never-smoking history. Ad-
ditional inclusion criteria were as follows; stage IIIB or IV, ECOG PS of
0–2, adequate organ functions, and measurable lesions. Neither prior che-
motherapy or targeted therapy nor radiotherapy to measurable disease was
allowed. Treatment consisted of erlotinib 100mg to 150 mg orally given once
daily till disease progression, unacceptable toxicity or patient’s refusal.
Objective tumor responses were assessed one month after the commence-
ment of erlotinib and then every two months.
Results: Between 10/2006 and 6/2007, all 38 patients enrolled (median age:
54 years; M/F 1/37; ECOG PS 0/1/2 2/29/7; stage IIIB/IV 3/35, never/current
smoker 36/2) were evaluable for response. Among them, 26 reached a PRs
while there were 6 SDs and 6 PDs, giving overall response rate of 68.4%
(95% CI, 52.5% to 81.0%) and disease control rate of 84.2% (95%CI, 69.2%
to 92.9%). Out of 6 patients identified to have an EGFR gene mutation before
initiating treatment, 5 reached a PR but 1 PD while out of 6 patients with
wild type of EGFR, there were 2 PRs, 1 SD, and 3 PDs. After a median
follow-up of 6.9 months, 15 progressive diseases and 3 deaths were ob-
served. The most common toxicity was skin rash, which was manageable.
Retrospective biological study of tumor tissue and blood is still being
analyzed and will be presented at the meeting.
Conclusions: Erlotinib showed promising response rate as a first-line therapy
for patients who have favorable predictors, and could be a treatment of
choice in this clinical setting.
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A PHASE I STUDY OF CONCURRENT WHOLE BRAIN
RADIOTHERAPY (WBRT) AND ERLOTINIB FOR BRAIN
METASTASES FROM NON-SMALL CELL LUNG CANCER
F.J. Lagerwaard1, J.S.W. Lind2, S. Senan3, E.F. Smit4 1Radiation Oncology,
VU University Medical Center, Amsterdam/NETHERLANDS, 2Pulmonary
Diseases, VU University Medical Center, Amsterdam/NETHERLANDS,
3Department of Radiation Oncology, VU University Medical Centre,
Amsterdam/NETHERLANDS, 4Pulmonary Diseases, VU University Medical
Center, Amsterdam/NETHERLANDS
Background: WBRT is the standard treatment for multiple brain metastases
from NSCLC, but results in a median survival of 4 months, with 50% of
patients dying from intracranial progression. A two-step dose-escalation
phase I study (NCT00536861) of WBRT with concurrent and maintenance
erlotinib was performed to assess the safety of this approach. Methods
Eligible pts had untreated brain metastases from pathologically confirmed
NSCLC. Erlotinib was started 1 week prior to WBRT (cohort 1: 100mg/day;
cohort 2: 150mg/day), and continued during WBRT (30 Gy/10 fx). Mainte-
nance erlotinib (150mg/day) was continued until disease progression or
unacceptable toxicity. Serial neuro-imaging was performed at 3-monthly
intervals. Primary end-point was toxicity; secondary end-points were sur-
vival and time to disease progression.
Results: Of 13 pts enrolled between May 2006-Dec 2007, 2 withdrew
prior to WBRT due to clinical progression. Median duration of erlotinib
treatment in the 11 remaining patients (M:F 6:5, median age 65 years)
was 78 days (range 38 –523). No treatment-related grade 3 toxicity was
seen in cohort 1 (4 pts). In cohort 2 (n7 pts) grade 3 toxicity was
grade 3 acneiform rash (n1); grade 3 fatigue (n1); fatal interstitial
lung disease (ILD) (n2). No treatment-related neurotoxicity was ob-
served. Median overall survival was 130 days (range 42–557), with 3 pts
alive at the time of analysis. Median time to disease progression was 96
days (range 38 –523) and only extracranial progression was seen (n 6
pts). In the 6 pts with follow-up neuro-imaging, the intracranial response
was PR in 4 and SD in 2. Four pts without disease progression had died
at the time of analysis: erlotinib-induced ILD (n2); COPD exacerbation
(n1); cardiac failure (n1). All 3 pts surviving 150 days had devel-
oped an acneiform rash.
Conclusions: Concurrent erlotinib (150mg/day) and WBRT (30 Gy/10 fx)
was well tolerated in most patients with brain metastases from NSCLC, but
fatal ILD was seen in 2 pts during maintenance erlotinib. The notable
absence of progression in intracranial symptoms indicates that further study
of concurrent WBRT and erlotinib is indicated.
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PROSPECTIVE EVALUATION OF ERLOTINIB IN
PATIENTS WITH ADVANCED NON-SMALL CELL LUNG
CANCER (NSCLC) HARBORING A MUTANT EGFR GENE
(FIELT STUDY)
J. De Greve1, D. Schallier1, J. van Meerbeeck2, C. Keppens1, V. Meert3, N.
Fontaine1, P. In tVeld3, J. Vansteenkiste4, E. Teugels5 1Medical Oncology,
UZ Brussel, Brussels/BELGIUM, 2Thoracic Oncology, University Hospital
Ghent, Ghent/BELGIUM, 3Pathology, UZ Brussel, Brussels/BELGIUM, 4Re-
spiratory Oncology Unit, University Hospital Gasthuisberg, Leuven/BEL-
GIUM, 5Medical Oncology, UZBrussel, Brussels/BELGIUM
Background: EGFR gene tyrosine kinase (TK) domain mutations increase
sensitivity of the receptor both for the effects of ligand and small molecule
tyrosine kinase inhibitors (TKI). Retrospective and limited prospective data
have indicated impressive activity in patients with advanced EGFR mutant
lung cancer. The FIELT study is a single arm multicenter phase II study
evaluating first-line erlotinib in patients with advanced NSCLC with a
documented EGFR mutation.
Patients and Methods: Because of the anticipated low prevalence of EGFR
mutations in Caucasians and the large recruitment base needed, 24 clinical
centers in Belgium and Luxemburg cooperate in the trial. Patients are
pre-selected on phenotype: adenocarcinoma with no or little smoking history.
Diagnostic formalin-fixed biopsy samples are examined by DGGE and
sequencing of exons 18–24 of the EGFR gene. In addition EGFR IHC and
FISH are performed. Patients with a TK domain mutation are prospectively
treated with erlotinib (150mg/day) until progression. The primary endpoint
of the study is PFS at 3 months (hypothesis  70%). Secondary endpoints are
RECIST and early metabolic response, and duration of response and survival.
Results: Thus far, 81 patients have been screened. 21 patients had inconclu-
sive mutation analysis (insufficient tissue quality). Various EGFR mutations
were found in 20 (25%) (33% of evaluable) cases. Fourteen of these patients
have initiated first-line erlotinib treatment. All mutations were found in
never-smokers. Results of mutation analysis were returned to the participat-
ing investigator within 2 weeks. IHC was positive in 68/79 (86%) of cases
and 24/74 (32%) had increased gene copy number. Updated (march 2008)
response, progression free survival and survival data will be provided.
Current results support the initial hypothesis.
Conclusions: Pre-selection of NSCLC patients on phenotypic basis leads to
a satisfactory mutation detection rate in EGFR. It is feasible to perform a
mutation analysis before selecting first-line treatment in a multicenter con-
text, although diagnostic tissue samples are insufficient in 25% of cases.
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GEFITINIB SHOWS PROMISING RESULTS IN THE FIRST-
LINE TREATMENT OF EGFR MUTATION-POSITIVE
LUNG CANCER
E. Imyanitov1, V.M. Moiseyenko2, E.V. Levchenko3, S. Procenko2, R.
Orlova2, A. Iyevleva1, K. Buslov1, Y. Ulibina1, D.E. Matsko4, F. Moiseenko5
1Molcular Oncology, N.N. Petrov Institute of Oncology, Saint-Petersburg/
RUSSIAN FEDERATION, 2Biotherapy and Bmt, N.N. Petrov Institute of
Oncology, Saint-Petersburg/RUSSIAN FEDERATION, 3Thoracic Oncology,
N.N. Petrov Institute of Oncology, Saint-Petersburg/RUSSIAN FEDERA-
TION, 4Pathomorphology, N.N. Petrov Institute of Oncology, Saint-Peters-
burg/RUSSIAN FEDERATION, 5Biotherapy and Bmt, N.N. Petrov Cancer
Research Institute, Saint-Petersburg/RUSSIAN FEDERATION
Probability of clinical benefit from epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitors (TKI) in previously treated non-small cell lung
cancer (NSCLC) patients is strongly associated with the presence of the
somatic mutations in EGFR gene. However, the experience of gefitinib
application in the first-line therapy to mutation-positive NSCLC remains
limited. Upon prospective screening of chemonaive non-squamous meta-
static and locally advanced NSCLC cases, we identified 6 patients whose
tumors contained TKI-sensitizing deletion in the exon 19 (all stage IV
adenocarcinomas; median age 59 years; males/females: 4/2; ECOG perfor-
mance status 1/2/3: 2/3/1). Gefitinib was administered at conventional dose
(250 mg daily). All patients experienced symptomatic improvement upon the
treatment. Adverse events were rash (grade 1–2: 4/6; grade 3: 1/6) and
diarrhea (grade 2: 1/6). Clinical examination revealed partial response in 4
(67%) patients and the disease stabilization in the remaining 2 (33%) cases
(RECIST criteria). Median time to tumor progression was 8.3 months (2
- 18 months). The results of the study suggest that gefitinib is superior to
cytotoxic therapy in the front-line treatment of EGFR mutation-positive
NSCLC, with respect to both efficacy and safety profile. Given the relative
simplicity of the EGFR mutation detection, this test has reasonable chances
to become an integral part of NSCLC therapy planning.
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DESCRIPTION OF ERLOTINIB-RELATED SKIN
TOXICITY MANAGEMENT IN DAILY CLINICAL
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Introduction: The most common side effect of Tarceva™ (Erlotinib, Erl) is
skin toxicity. However, there is still no consensus on its management. The
French PRECEDE study (PRise En Charge des Effets Dematologiques sous
Erlotinib) describes the current attitude towards the management of Erl-
related skin effects (ERSE) in lung cancer patients (pts).
Methods: Data were retrospectively collected from the medical files of lung
cancer pts treated with Erl in 7 cancer centers from January 2005 to
December 2007. The frequency, management and evolution of ERSE were
recorded when available.
Results: Among 234 patients identified 152 (65,0%) presented with ERSE: NCI
CTC grade 1&2: 30.3%, grade 3: 2%, grade not available: 67.8%. 6 patients
(3.8%) had persistent ERSE despite treatment, for 21 (10%), data were lacking,
and in 131 pts (86.2%), ERSE improved or resolved, either spontaneously (46
pts, 35.1%) or under treatment (85 pts, 64.9%). Those patients who responded to
treatment received a mean of 2.1 drugs, for a total of 178 drug-prescriptions.
Table 1 illustrates the different drugs used to treat ERSE. Table 1
Type of treatment Prescriptions
N %
Topical/Emollient 64 36,0
Oral ATB 57 32,0
Topical ATB 36 20,2
Topical CS 8 4,5
Topical Antiseptic 4 2,2
Topical ATF 4 2,2
Topical Retinod 2 1,1
Topical Anti-Inflammatory 1 0,6
Topical IS 1 0,6
Oral CS 1 0,6
Total 178 100,0
ATB: Antibiotics; CS: Corticosteroids; ATF: Antifungals; IS: Immunosup-
pressants Oral ATB included Doxycycline, Minocycline, Erythromycine,
Levocetirizine, Ceftriaxone, Tetracycline, Gentamicin, Clindamycin, Spira-
mycine; Local ATB were Erythromycin and Fucidin; Local ATF, Ketocon-
azole and Metronidazole, and Local IS was Tacrolimus. Erl dose reduction
was recorded in 6.6% of patients Conclusion: ERSE is frequent but rarely
severe and tends to improve in most cases, spontaneously or with treatment.
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The wide variety of drugs used illustrates the lack of consensual treatment.
Further studies are needed to evaluate the real efficacy of the treatments and
to determine which patients should be treated in order to establish therapeu-
tical guidelines for ERSE management.
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The survival benefit of TKIs in advanced non small lung cancer (NSCLC) is
modest and gefitinib and erlotinib are usually considered drugs with similar
efficacy.
We performed a pooled analysis in order to assess the efficacy of these drugs
alone or in combination.
An electronic search focused on randomized controlled trials assessing
efficacy or activity of TKIs alone or associated with chemotherapy in
NSCLC was performed. A pooled analysis was accomplished and Hazard
Ratio (HR) with 95% confidence interval was derived. Only six papers were
considered for analysis. Overall, there was a 3% (HR: 0.97, 95% CI
0.91–1.03) mortality reduction and a 10% reduction in event rate (HR: 0.90,
95%CI 0.85–0.95). Results differed when analysing II line therapies vs. I
line therapies, in which TKI was added to chemotherapy. In first line
chemotherapy there was a consistent lack of effect, while in II line there was
a 18% reduction in mortality (HR: 0.82, 95%CI 0.73–0.92) and a 24%
reduction in event rate (HR: 0.76, 95%CI 0.68–0.83) with a greater effect
showed for erlotinib therapy (test for heterogeneity between studies, p0.04
and 0.007 for OS and PFS respectively).
From our results erlotinib and gefitinib seem to be drugs with different efficacy;
although structurally related and with the same ability to interfere with the
EGFR- mediated cascade, erlotinib and gefitinib have some pharmacological
differences which could account for the observed differences in activity. Erlo-
tinib is for example less susceptible to the metabolism mediated by cytochrome
P450 3A than gefitinib and this could account for the lower clearance (compared
to gefitinb) observed for erlotinib. In addition, erlotinib inhibits the activity of
wild type EGFR at lower concentrations than those necessary with gefitinib.
A combination of higher circulating levels of erlotinib plus a stronger potency in
inhibiting wild type target activity could at least in part explain the differences.
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ON A COMPREHENSIVE EGFR SOMATIC MUTATION
DATABASE
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Background: The presence of somatic mutations of EGFR (epidermal growth
factor receptor) in patients with non-small cell lung cancer (NSCLC) has
been evaluated in numerous studies as a potential predictive factor of
response to tyrosine kinase inhibitors (TKIs).
Methods: Using a comprehensive online analytical database of somatic EGFR
mutations in NSCLC (www.egfr-mutations.org) we identified studies reporting
on the association between mutations and response to ant-EGFR TKIs. Studies
were deemed eligible if they reported on the treatment (monotherapy TKI) of
unselected patients with advanced NSCLC. Between-study heterogeneity was
assessed with the I2 statistic; small study effects were assessed using Begg’s and
Egger’s tests. In the absence of large between-study inconsistency (I250%),
RRs were pooled using the Mantel-Haenszel method.
Results: Out of a total 202 studies reporting on somatic EGFR mutations in
NSCLC, 30 studies (1,437 patients; 482 with somatic mutations) were consid-
ered eligible. Assessment of the association of mutational status with response to
gefitinib (28 studies; 1365 patients) and erlotinib (2 studies; 72 patients) was
conducted. No evidence of between-study inconsistency (I2 30.5%) was
evident, however, there was strong evidence of differential small study effects
(p-values for Begg’s and Egger’s tests 0.01). The presence of any somatic
mutation in EGFR correlated highly with response, RR6.4 (5.17–7.91). Eth-
nicity did not alter this association: non-Asians, RR7.92 (5.31–11.82); Asians,
RR6.00 (4.68–7.70); interaction p-value 0.25. Mutational status was a predic-
tor of response both to gefitinib, RR6.38 (5.14–7.91) and erlotinib, RR7.29
(2.12–25.09); interaction p-value 0.84.
Conclusions: This pooled analysis provides large-scale empirical evidence that
EGFR mutations are predictive of response to monotherapy TKI of advanced
NSCLC. The effect of mutations appears to be independent of ethnicity. We
encourage a consortium effort to perform a meta-analysis of patient-level data
that would provide a thorough evaluation of the interaction of clinico-patholog-
ical characteristics, mutational status and treatment efficacy.
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Background: SU is an oral multitargeted tyrosine kinase inhibitor of VEG-
FRs, PDGFRs, KIT, RET, FLT3, and CSF-1R, approved multinationally for
the treatment of advanced RCC and imatinib-resistant/intolerant GIST.
Aberrant VEGF and PDGF signaling is implicated in NSCLC with elevated
VEGF expression associated with decreased survival. SU demonstrated
antitumor activity in NSCLC preclinical models and single-agent activity in
advanced, platinum-refractory NSCLC (Socinski et al. JCO In Press).
Materials and methods: This phase II study evaluated the safety and efficacy of
SU in platinum-refractory, advanced NSCLC. The primary endpoint was objec-
tive response rate (RECIST). Secondary endpoints included progression-free
survival (PFS), overall survival (OS), 1-year survival, and safety. Eligible
patients (pts) had stage IIIB/IV NSCLC, were ineligible for, or failed, a
platinum-containing combination chemotherapy regimen EGFR inhibitor, and
had an ECOG PS 1. Two separate pt cohorts received either 37.5 mg oral SU
bid in 4-wk continuous daily dosing (CDD) cycles or 50 mg oral SU bid for 4
wks, followed by 2 wks off treatment (Schedule 4/2) in 6-wk cycles.
Results: 110 pts were treated: 47 on the CDD schedule and 63 on Schedule
4/2. Across both schedules, most pts (89%) had stage IV disease and
adenocarcinoma (53% CDD; 64% 4/2). On the CDD schedule, 1 pt (2%) had
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a PR, 9 pts (19%) had SD of 8 wks, median PFS was 12.3 wks, and median
OS was 38.1 wks. On Schedule 4/2, 7 pts (11%) had PRs, 18 pts (29%) had
SD of 8 wks, median PFS was 12.0 wks, and median OS was 23.4 wks.
1-year survival was 40.5% (CDD schedule) and 20.2% (Schedule 4/2). Both
regimens were generally well tolerated. Non-hematological grade 3/4 AEs of
all causality included fatigue/asthenia (17% CDD; 29% 4/2), pain/myalgia
(2% CDD; 17% 4/2), dyspnea (11% both schedules), and nausea/vomiting
(2% CDD; 10% 4/2). Hematological grade 3/4 AEs included thrombocyto-
penia (0% CDD; 5% 4/2) and neutropenia (9% CDD; 5% 4/2). No cases of
febrile neutropenia were observed.
Conclusions Both SU regimens showed promising single-agent antitumor activ-
ity with manageable tolerability in heavily pretreated NSCLC pts. Further
evaluation of the CDD schedule in NSCLC is ongoing, including a phase III trial
of SU (37.5 mg CDD) plus erlotinib vs erlotinib alone (SUN1087).
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KINASE INHIBITORS AS A FIRST-LINE THERAPY FOR
NEVER SMOKERS WITH ADENOCARCINOMA OF THE
LUNG AND ASYMPTOMATIC SYNCHRONOUS BRAIN
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Background: As routine initial evaluation with improved neuroimaging
technique increases incidence of brain metastases in advanced/metastatic
non-small cell lung cancer, we have to face a dilemma to choose initial
treatment for patients with asymptomatic brain metastasis. On the other hand,
EGFR TKIs, such as gefitinib and erlotinib, reportedly have high response
rates for patients who have never smoked and have adenocarcinoma histol-
ogy. Based on those findings, we studied the efficacy of the EGFR TKIs as
a first-line therapy for never-smokers with metastatic adenocarcinoma of the
lung and asymptomatic synchronous brain metastases.
Methods: The eligible patient should be a never smokers with adenocarcinoma
of the lung and asymptomatic synchronous brain metastases. Additional inclu-
sion criteria were as follows; ECOG PS of 0–3, adequate organ functions, and
measurable disease in both extracranial and intracranial sites. Neither prior
chemotherapy nor radiotherapy including stereotactic radiosurgery was allowed.
Treatment consisted of gefitinib 250 mg or erlotinib 150 mg orally given once
daily till disease progression, unacceptable toxicity or patient’s refusal.
Objective: tumor responses were assessed every two months or clinical indicated.
Results: Between 1/2005 and 8/2007, all 23 patients (median age: 60 years;
M/F 1/22; ECOG PS of 0–1/2–3 11/12) were enrolled. Among them, 11 had
no extrathoracic metastasis except brain. There were 15 PRs (65.2%; 95%
CI, 44.8% to 81.3%) while there were 3 SDs (13.0%) and 5 PDs (21.7%),
giving disease control rate of 79.3%. With a median follow-up of 9.0 months,
the progression-free and overall survival was 6.4 months and 18.6 months,
respectively. Among 17 patients showing progressive disease, 9 had to
receive whole brain radiotherapy due to development of neurologic symp-
toms or signs.
Conclusions: EGFR TKIs showed promising response rate as a first-line therapy
for never-smokers with adenocarcinoma of the lung and asymptomatic synchro-
nous brain metastases in both intracranial and extracranial site, suggesting that
these agents can be a treatment of choice in this clinical setting.
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Introduction: In approximately 30–40% of patients (pts) with advanced LC,
bone mets develop that can weaken the structural integrity of bone. With
therapeutic advances, pts may survive for a prolonged time at risk for
potentially debilitating skeletal-related events (SRE) such as pathologic
fractures. Bone mets may be asymptomatic in the early stage; therefore,
waiting until bone pain develops may result in underdiagnosis and incorrect
staging. Currently, guidelines for detection of bone mets in pts with LC are
limited and inconsistent. However, the gap in screening guidelines can be
bridged by insight from clinical experience. Methods: Current management
guidelines for pts with advanced LC were reviewed by an international panel
of experts, and consensus recommendations for diagnosis of bone mets from
LC were suggested based on the panel’s collective experience and evidence
from current literature.
Results: Current guidelines for diagnosis of bone mets usually support bone
scans in early LC pts with symptoms or clinical characteristics consistent
with bone mets and in pts with advanced LC who have symptoms of bone
involvement. However, failure to detect bone mets can result in inconsistent
or incomplete staging and less effective treatment strategies. Therefore, a
panel of lung cancer specialists suggests screening for bone mets at initial
diagnosis and staging—preferably by whole-body positron emission tomog-
raphy (PET), if available, or by skeletal scintigraphy with appropriate
follow-up—rather than limited to symptomatic pts. Screening is important
for pts who are candidates for potentially curative surgery or radical chemo-
radiotherapy (eg, 1 positive node and/or tumors T2 with unknown M
state) to rule out the possibility of distant mets. Moreover, elevated bone
marker levels or documented metastatic disease correlates with an increased
likelihood of bone mets.
Conclusions: Screening for bone mets is warranted early in the course of
disease in pts with LC to facilitate more accurate staging and to provide the
opportunity for initiation of bone-targeted therapy such as zoledronic acid (4
mg via 15-minute infusion every 3 to 4 weeks) to minimize the risk of SREs.
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Introduction: Recent retrospective analyses of the phase III clinical trial of
ZOL vs placebo (PLA) in pts with bone metastases from NSCLC or other
solid tumors (N773) have shown that elevated urinary NTX levels are
associated with poor survival. We reported that, in addition to the prevention
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of skeletal-related events (SREs), ZOL significantly prolonged survival vs PLA
in NSCLC pts with high baseline NTX in a multivariate analysis of the phase III
study (Hirsh V, et al. J Thorac Oncol. In press). However, the role of ongoing
NTX assessments in the NSCLC setting has not yet been established.
Methods: Pts with NSCLC and bone marker assessments (n263) in the
phase III ZOL trial were retrospectively categorized as low or high (64
nmol/mmol creatinine) by baseline and on-study NTX levels. Associations
between bone marker levels and death or any SRE were assessed by Cox
regression and Anderson-Gill, respectively.
Results: Among PLA-treated pts, 
50% had high baseline and on-study
NTX. High baseline NTX was associated with a 2.4-fold increased risk of
death (P  .001) and a trend for a 64% increased risk of SREs (P  .068)
compared with low NTX; on-study NTX assessments also correlated with
SRE and death risks throughout the study. In contrast, although NTX levels
were also high in 56% of the ZOL group at baseline, 
10% or fewer pts at
each on-study assessment had high NTX after ZOL treatment. Among
ZOL-treated pts, high baseline NTX was associated with a significant 81%
increased risk of SREs (P  .012) but not death vs low NTX. However, high
NTX during ZOL treatment correlated with a significantly increased risk of
both death (P  .001) and SREs (P  .016) vs low NTX.
Conclusions: ZOL effectively normalizes NTX levels in pts with NSCLC,
and transition from high-risk to lower-risk NTX states may have contributed
to the survival benefit of ZOL observed in NSCLC pts with high baseline
NTX. High NTX levels—in general and despite ZOL therapy—indicate a
poor prognosis. Furthermore, these analyses suggest that bone metastases
contribute significantly toward overall prognosis in NSCLC pts and NTX
may be useful in monitoring ZOL efficacy.
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LLC, Bethesda/UNITED STATES OF AMERICA, 2Health Economics, No-
vartis, Florham Park/UNITED STATES OF AMERICA
Objectives: Zoledronic acid (ZOL) reduces the risk of skeletal-related events
(SREs) in lung cancer patients with bone metastases. The present analysis
compared the economic impact of ZOL therapy in lung cancer patients with
bone metastases in the UK and Germany.
Methods: A literature-based model was developed to compare the estimated
direct costs and quality adjusted life years (QALY) experienced by lung
cancer patients with bone metastases receiving placebo or ZOL. Survival,
SRE incidence, and number of infusions administered were obtained from a
randomized clinical trial comparing patients receiving 4 mg ZOL to patients
receiving placebo every three weeks for up to 21 months. Drug acquisition
and administration costs were estimated using published sources. The cost of
an SRE avoided in Germany was estimated by pooling SRE data from four
separate studies of Dutch and Portuguese patients. Corresponding costs in the
UK were obtained from the literature. Consistent with similar economic
analyses, it was assumed that quality of life decreased for 1 month after each
SRE experienced. Results: The remaining average projected life expectancy
was at 8.50 months (median, 5.89 months) in both groups. During this survival
period, patients receiving placebo were projected to experience 2.07 SREs on
average vs 1.32 SREs among ZOL patients. QALYs were estimated at 0.3523
per patient (pp) and 0.3350 pp in the ZOL and placebo groups, respectively.
ZOL drug-related costs were estimated at €22,01 in Germany and £1,473 pp in
UK. The use of ZOL was associated with a reduction of €2,676.72 pp in SRE
costs in Germany and £1,562 pp in UK. Overall, therefore, ZOL saved €476 pp
in Germany and £89 pp in UK. The use of ZOL resulted in a net increase of
0.0173 QALYs pp compared to no therapy. In sensitivity analyses, ZOL was
cost effective under a wide range of assumptions.
Conclusions: ZOL leads to fewer SREs, better estimated quality of life, and
lower estimated costs relative to placebo in German and UK lung cancer
patients with bone metastases. The use of ZOL in these populations therefore
provides cost savings and is highly cost effective.
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FUNCTIONAL STATUS IN LUNG CANCER PATIENTS?
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Montreal/CANADA, 2Cancer Nutrition and Rehablitation Program, McGill
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Background: Reduced survival in patients (pts) with an aberrant systemic
inflammatory response to cancer is well recognized and is a principal cause
of the anorexia cachexia syndrome (CACS). Numerous studies have dem-
onstrated that high levels of C-reactive protein (CRP) and white blood cells
(WBC) translate into poorer survival. However, very little is known about the
correlation between inflammatory response in advanced lung cancer patients
and their functional capacity. We sought to determine the association
between inflammatory markers (CRP and WBC) and functional capacity in
patients with lung cancer.
Methods: A retrospective cohort of NSCLC pts who performed the six-
minute walk (6MWT), and had CRP and WBC determinations at the first
visit to the McGill Cancer Nutrition and Rehabilitation program was ana-
lyzed. All participants were assigned a prognostic index (PI) score as an
indicator of cancer-related inflammatory state, if CRP 10mg/L and WBC
 11x109/L, then PI 0; if one of the markers was elevated PI 1; or PI
2 if both were elevated (ASCO 2005, 17035). Furthermore pts were catego-
rized into 2 groups based on their performance of 6MWT; level I400m and
level II 400m. 2 was used to analyze the significance level.
Results: 47 pts (F 25, M 22) aged 63 (10–38–81) years were studied. 38 pts
had locally advanced and/or metastatic disease. The median CRP was 10.34
(0.6 to 108.3), WBC 7.3 (range: 2.3 to 26.5) and 6MWT 370 (range: 82.5 to
675). Twenty-one pts were PI  0, 21 pts PI  1 and 5 pts PI  2.
Twenty-six pts walked 400m and 18 pts walked 400m on the 6MWT.
Three pts were unable to perform the test due to cancer symptoms. The
presence of high inflammatory markers (PI0) was associated with poor
performance on 6MWT (Fisher exact test, p0.026037).
Conclusion: NSCLC pts have a high prevalence of an aberrant inflammatory
response as demonstrated by PI0. The presence of elevated inflammatory
markers (PI0) was associated with a poor performance on 6MWT.
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BORTEZOMIB IN PATIENTS WITH STAGE IIIB/IV
NON-SMALL-CELL LUNG CANCER
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Background: Preliminary results indicated that bortezomib (Velcade*) as a
single agent may have activity in pretreated non-small-cell lung cancer
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(NSCLC) patients (pts) with similar or lesser toxicity compared to chemo-
therapy. This phase II study was initiated to determine the efficacy and
toxicity of single-agent bortezomib in chemonaïve pts with advanced
NSCLC. Here we report feasibility and toxicity data.
Methods: Pts received bortezomib (1.5 mg/m2) twice a week for 2 consec-
utive weeks (Days 1, 4, 8, and 11) followed by a 10-day rest period. The
primary endpoint was non-progression rate (NPR) after 6 wks of treatment.
Secondary endpoints included response, progression-free survival, overall
survival, and safety. Results: 18 pts were enrolled from 06/06 to 02/07 from
3 institutions. Demographics: male/female 15/3; median age 66 (54–79); PS
0/1/2, 3/12/3; pathology: adenocarcinoma 11, squamous cell 5, large-cell 2;
smoking status current/former/never 7/10/1; stage IIIB/IV 2/16. The number
of cycles by pts ranged from 0 to 8, 16/18 pts received 2 cycles or more. The
most frequent toxicity was fatigue (17 pts). Twelve pts (71%) had a grade 3
toxicity : 4 haematological, 1 infection, 3 anorexia, 1 nausea, 1 stomatitis, 9
fatigue. No grade 4 events. 13 grade 1/2 neuropathy, no grade 3.
Conclusions: Bortezomib is feasible and tolerable at recommended single-
agent doses in chemonaïve pts with advanced NSCLC.
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ACUTE TOXICITIES FOLLOWED BY MANAGEMENT
OF LOCALLY ADVANCED NON-SMALL CELL LUNG
CANCER – TGF-B1 AS A PREDICTOR AND ROLE OF
AMIFOSTINE
J. Stejskal1, M. Kubecova´2, D. Dvor˘a´kova´3, V. Ulrych3, I. Kola´r˘ova´1, J.
Vanˇa´sek1, M. Kheck4 1Radiation Oncology, Regional Hospital Pardubice,
Pardubice/CZECH REPUBLIC, 2Radiation Oncology, University Hospital
Prague, Praha/CZECH REPUBLIC, 3Radiation Oncology, Ragional Hospi-
tal Pardubice, Pardubice/CZECH REPUBLIC, 4Pathology, Regional Hos-
pital Jihlava, Jihlava/CZECH REPUBLIC
Purpose: Locally advanced non-small cell lung cancer (LA NSCLC) repre-
sents a disease with an extremely poor prognosis. The use of more aggressive
radiation regimens included dose escalation and the addition of cytotoxic
chemotherapy (CT) to radiotherapy (RT) have yielded conflicting results.
This management can be limited by toxicities, especially radiation pneumo-
nitis (RP) and acute esophagitis (AE). Cytokine TGF-1 is high sensitive
predictor for RP. Amifostine could reduce the incidence of induced acute and
late toxicities. Descriptions Between 2000 - 2005, a total of 30 patiens with
LA NSCLC (IIIA, IIIB) were treated. Patients were treatment with neoad-
juvant CT (4 cycles: paclitaxel 175 mg/m2  cisplatin 75 mg/m2 , day 1,
every 3 weeks) followed by the same concurrent radiochemotherapy (2
cycles) – group A (n15) and group B (n15). Group A plus amifostine i.v.
infusion 500 mg daily during RT. All patients were treated using 3D
conformal radiotherapy (3D CRT). Lung tissue for histopathologic evalua-
tion had been sampled from two different sites: Amax and Bmax (area of
PTV2) vs Aref and Bref (outside the PTV1). Changes in plasma TGF-1
levels were obtained before CT, before RT, in the middle of course RT, and
after RT. Summary RP grade 3/4 and AE grade 3 (CTC v 2.0) occurred in
5 and 3 patients in group A vs 9 and 8 patients in group B. The median dose
of 3D CRT to GTV was 67,4 Gy (range 63,8–72,8 Gy). The median of gross
tumor mass was 166,13 cm3 (range 63,40–284,26 cm3). Plasma level
TGF-1 were significant elevated (p 0,001) in the middle of course RT in
group A (14,9 ng/ml) vs group B (31,3 ng/ml). Histological examination of
the thickness of alveolo-capillary space showed significant differences (p
0,0001) between groups Amax (8,8 m) vs Bmax (49,8 m).
Conclusions The incidence of RP and AE was lower for patients receiving
amifostine than for patients receiving chemoradiotherapy alone. These re-
sults suggest that plasma TGF-1 levels during treatment may be useful to
determine which patients are at high risk of developing radiation pneumo-
nitis. Significant differences of the thickness of alveolo-capillary space may
represent the effect of amifostine as a protector of the alveolocapillary
integrity.
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INTRATUMORAL CISPLATIN AS AN ADJUNCT TO
ENDOBRONCHIAL BRACHYTHERAPY
D. Nader Thoracic Oncology, Cancer Treatment Centers of America, Tulsa/
UNITED STATES OF AMERICA
Therapeutic radiation therapy for NSCLC has included Cisplatin as a
radiosensitizer. Fourteen patients with stage IIIB or IV NSCLC were treated
with intratumoral cisplatin (ITC) as an adjunct to endobronchial brachyther-
apy with endoscopically observed benefits. Fourteen patients were selected,
which had geater than 75% endoluminal obstruction of a main or lobar
airway to recieve intratumoral injection at the same setting as placement of
brachytherapy catheter. Cisplatin (1mg/ml) was administered to the entire
endoscopically visible tumor through a flexible 21 gauge retractable needle
placed through the bronchoscope. Cisplatin was injected with volumes of 0.5
to 4.0 ml each setting in which a brachytherapy catheter was placed. All
patients recieved weekly brachytherapy of 500 cGy at one cm diameter in
four sessions. All patients were re-evaluated bronchoscopically 4 to 6 weeks
following their last brachytherapy. 13/14 patients had complete clearing of
endobronchial disease grossly and confirmed cytologically. One patient had
residual necrotic tisssue occupying less than 10% of the airway lumen which
was cytologically negative for neoplasia. Follow-up (median 13 months,
range 3 to 25 months) revealed 4 deaths (11, 10, 9 and 3 months) all related
to progression of distant disease. One patient had recurrent endobronchial
disease at a site not previously treated. No patient exhibited local or systemic
toxicity beyond what is seen with brachytherapy alone. Intratumoral admin-
istration of cisplatin, as an adjunct to brachytherapy, was shown to be a safe
and potentially useful modality to assist in management of tumoral endo-
bronchial obstruction. Further studies assessing benefits of this management
compared with brachytherapy without ITC will be required. ITC may be a
useful adjunctive therapy with endobronchial brachytherapy in the manage-
ment of NSCLC endobronchial obstruction.
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COMPARISON OF WEEKLY AND EVERY-3-WEEK
DOSING REGIMENS OF NAB PACLITAXEL FOLLOWED
BY CARBOPLATIN AS FIRST-LINE THERAPY IN
PATIENTS WITH ADVANCED NON-SMALL CELL LUNG
CANCER (NSCLC)
M. Socinski1, G. Manikhas2, A. Makhson3, S. Cheporov4, S. Orlov5, P.
Yablonsky6, P. Bhar7 1Medicine, University of North Carolina at Chapel
Hill, Chapel Hill/UNITED STATES OF AMERICA, 2Oncology, St. Peters-
burg Oncology Center, St Petersburg/RUSSIAN FEDERATION, 3Oncology,
City Oncology Hospital #62, Moscow/RUSSIAN FEDERATION, 4Medicine,
Yaroslavl Regional Oncology Center, Yaroslavl/RUSSIAN FEDERATION,
5Medicine, St. Petersburg Pavlov State Medical University, St Petersburg/
RUSSIAN FEDERATION, 6Medicine, City Multifield Hospital #2, St Peters-
burg/RUSSIAN FEDERATION, 7Biostats, Abraxis Bioscience, Inc, Los An-
geles/UNITED STATES OF AMERICA
Background: Nanoparticle albumin-bound–paclitaxel (nab-pac; Abraxane)
demonstrated a 38% response rate and overall survival of 10.3 months as
monotherapy treatment for patients with advanced NSCLC in a phase I/II
study (Rizvi et al. J Clin Oncol. 2006;24:7105). Carboplatin AUC6 com-
bined with solvent-based paclitaxel every 3 weeks (q3w) demonstrated a
17% response rate in patients with advanced NSCLC. This study aimed to
identify the dose and schedule of nab-pac to combine with carboplatin AUC6
q3w as 1st-line therapy for patients with advanced NSCLC.
Methods: Patients (18 years with untreated stage IIIB/IV NSCLC) in this
open-label, phase II trial were enrolled sequentially into 7 cohorts of 25
patients each. All cohorts received carboplatin AUC6 q3w. The first 4
cohorts received nab-pac q3w (225 mg/m2, 260 mg/m2, 300 mg/m2, or 340
mg/m2); the last 3 cohorts received nab-pac 140 mg/m2 weekly 2 of every 3
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weeks, 100 mg/m2 weekly, or 125 mg/m2 weekly. Primary objectives were
antitumor activity (objective response [OR], total response [TR; OR or stable
disease 16 wks]) and safety.
Results: A total of 175 patients were enrolled and evaluable for efficacy.
Patients who received nab-pac weekly dosing had higher OR and TR (47%,
56%) compared with nab-pac q3w (30%, 46%). Incidences of peripheral
neuropathy (PN), myalgia, arthralgia, and alopecia were significantly lower
in patients who received weekly vs q3w nab-pac (P  0.001). Median time
to improvement of PN was 18 days. Although patients who received the 100
mg/m2 weekly dose were among patients with the highest median doses
(1420 mg/m2), incidences of grade 3 PN and grade 4 thrombocytopenia were
lowest in patients in this cohort.
Conclusions: Nab-pac and carboplatin therapy is an effective therapy for
NSCLC. Based on the favorable efficacy and toxicity profile of the weekly
schedule, a phase III, randomized, multicenter study comparing 100 mg/m2
weekly nab-pac and carboplatin AUC6 q3w to solvent-based paclitaxel and
carboplatin has been initiated.
207P
PHOTODYNAMIC THERAPY ON THE CENTRAL LUNG
CANCER
Y.A. Ragulin1, M.A. Kaplan2, V.N. Medvedev3, V.N. Kapinus2, V.V.
Peters4 1Thoracic Department, Medical Radiological Research Center
RAMS., Obninsk/RUSSIAN FEDERATION, 2Laser and Photodynamic Ther-
apy Department., Medical Radiological Research Center RAMS., Obninsk/
RUSSIAN FEDERATION, 3Thoracic Department., Medical Radiological
Research Center RAMS., Obninsk/RUSSIAN FEDERATION, 4Endoscopy
Department., Medical Radiological Research Center RAMS., Obninsk/RUS-
SIAN FEDERATION
Background: Photodynamic therapy (PDT) is a novel method for treatment
of malignancy. It is effective method for palliation of lung cancer and can
improve results of combined treatment. Therapeutical improvement in this
field may result from use of new photosensitizers. The aim of this study is to
estimate direct results of photodynamic therapy with chlorine photosensitiz-
ers on the central lung cancer.
Methods: The photodynamic therapy with chlorine photosensitizers (Photol-
on(R), Photoditazin(R)) on 41 patients with central lung cancer is carried out.
37 males, 4 females, aged 42–81 years (mean 61.5) with advanced inoper-
able bronchogenic cancer and endobronchial luminal obstruction were stud-
ied. Most patients were at the stage IIIb-IV. The histology of the tumors was:
non small cell in 36 and small cell in 5 patients. The pre/post-treatment
protocol consisted of: clinical, radiological and bronchoscopic examination,
pulmonary function testing. Intravenous injection of chlorine photosensitiz-
ers (1.5–2.4 mg/kg body weight) was given, 2–3 h later the tumor was
illuminated with 662 nm laser light. We use a flexible fibreoptic broncho-
scope for visualization and placement of the optical fibre, which was passed
through the biopsy channel of the instrument to the target tissue. For 3 days
after the procedure the patients were under special light conditions.
Results: Positive radiological dynamics in the form of the sanction atelektasis
elimination of ventilating infringements was observed in 66.7% cases. In a
month after the PDT bronchoscopy was done (37 patients) complete response
was observed in 23 (62.2%) cases, partial response in 12 (34.4%), in 2
patients reductions of a tumor is not revealed. Vital capacity (VC) after PDT
increase from 3% up to 33% (mean 20%). Reduction of cough and hae-
mophtisis was noted in 55% patients. Dyspnoea was reduced in 47.4%
patients. Complications: pneumonia - 4 patients, bronchitis - 5. There was no
treatment related mortality. The complications caused by the photosensitizers
were not observed.
Conclusions: Photodynamic therapy with chlorine photosensitizers is effec-
tive in palliation of inoperable lung cancer and the low rate of complications.
After treatment patients have been followed up, quality of their life and
survival rate are estimated.
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INDUCTION OF GEMCITABINE (GCB)-RELATED GENES
BY PEMETREXED (MTA): ASSESSMENT OF THE BEST
ADMINISTRATION TIME OF GCB AFTER MTA
T. De Pas1, R. Danesi2, F. Toffalorio3, E. Giovannetti2, G. Pelosi4, F. de
Braud3 1Division of Cliniccal Pharmacology and New Drugs Development,
European Institute of Oncology, Milan/ITALY, 2Department of Internal
Medicine, University of Pisa, Pisa/ITALY, 3Division of Clinical Pharmacol-
ogy and New Drugs Development, European Institute of Oncology, Milan/
ITALY, 4University of Milan School of Medicine, University of Milan School
of Medicine, Milan/ITALY
Background: Both MTA and GCB are active drugs in non-small cell lung
cancer (NSCLC). Many molecular events induced by MTA support the
synergic interaction between the two drugs and explain why the sequence
MTA  GCB is more active than GCB  MTA. Of major interest, MTA
induces the expression of deoxycytidine kinase (dCK), the rate-limiting
enzyme of GCB activation, and of the human equilibrative nucleoside
transporter-1 (hENT1), the key transporter for the intracellular penetration of
GCB. Even if the optimal sequence is well established, no information on the
best administration time between the two drugs is available.
Methods: To evaluate if there is a reproducible timing of maximum dCK and
hENT1 expression by MTA, we measured these targets in patients with
advanced NSCLC after administration of MTA 500 mg/m2 q2wks. All
patients were not pre-treated with MTA or GCB. Gene-expression was
measured in normal lymphocytes by quantitative real-time PCR (qRT-PCR),
at various interval (up to 48 hrs) after each of the first 3 chemotherapy cycles.
Results: Between September and January 2008, 16 out of the 19 planned
patients were enrolled in the present study. Up to now, dosages from 63
samples / 9 cycles of chemotherapy are available. In all treatment cycles,
qRT-PCR analysis revealed an increase of hENT1 and/or dCK genes at least
in one time-point. With respect to gene expression levels at basal time, dCK
increased both early (1h: 3 out of 9 valuable cycles;  4–6 hrs: 4 out of
9 cycles) and late ( 24–48 hrs: 5 out of 9 cycles); hENT1 increased poorly
at 1h (1 out of 6 valuable cycles) but consistently at  4–6 hrs (5 out of
6 cycles) and late (24–48 hrs: 6 out of 6 cycles). The increase of dCK and
hENT1 gene expression was from 15% to 285% and from 21% to 380%,
respectively.
Conclusion: MTA induces GCB-related genes both at early and late time
points. The most rationale interval between the two drugs administration will
be valuated at the completion of the study.
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GEFITINIB (GEFITINAT) – A MOLECULAR TARGETED
THERAPY IN ADVANCED NON SMALL CELL LUNG
CANCER IN INDIAN PATIENTS, A FOLLOW-UP STUDY
D. Behera1, R. Aggarwal2, A.N. Aggarwal2, D. Gupta2, S.K. Jindal2, S.C.
Sharma3, R. Kapoor2, A. Jaiswal1 1Chest Diseases, Lala Ram Sarup Institute
of TB and Respiratory Diseases, New Delhi/INDIA, 2Pulmonary Medicine,
Postgraduate Institute of Medical Education and Research, Chandigarh/
INDIA, 3Radiotherapy, Postgraduate Institute of Medical Education and
Research, Chandigarh/INDIA
Recent clinical trials suggest that epidermal growth factor receptor (EGFR)-
targeted agents could benefit many patients with lung cancer (Rocha-Lima
2007). A number of growth-factor-receptor-targeted agents have been tried
with encouraging results in patients with advanced NSCLC (Noble et al
2006). Women, non-smokers, adenocarcinoma and Asians respond better.
We use Gefitinib in Indian patients over a long time now and the data has
been presented in various conferences earlier (Behera et al, 2007). This
communication presents our experience in more number of cases.
Histologically proven advanced (stage IIIB or IV) non-small cell lung cancer
patients earlier treated with chemotherapy received gefitinib (Gefitinat)
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250mg daily orally. There were 35 females (36–57 yrs) and 78 males (42–67
yrs). Sixty four were non-smokers and the remaining were smokers. 75 had
adenocarcinoma and 38 had squamous cell carcinoma. The disease was of
stage IIIB (n76) and stage IV (n47). The duration of gefitinib therapy
varied from 24 weeks to 58 weeks with median of 29weeks. The disease
remained static in 81 (72%) with stabilization or improvement in the
Kornofsky performance scales in the remainder. The mean performance
status improved from 70 to 90 in 48 cases, deteriorated in 24 and in the
remaining remained static at 90. There was no radiological progression in 52
cases, while 34 cases showed radiological progression. The median survival
(calculated after completion of chemotherapy and start of gefitinib) was 33.5
weeks with 26 patients surviving beyond 1 year. The drug was well tolerated
by all. Thirtyeight patients complained of mild skin rash (three fixed drug
eruption). 33 patients had grade 1–2 diarrhoea.
We found gefitinib as beneficial. The drug is well tolerated by Indian
patients. This may be due to a different pharmacogenomic property of
gefitinib in this population.
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EGFR-TKI AND LUNG ADENOCARCINOMA WITH CNS
RELAPSE: INTEREST OF MOLECULAR FOLLOW-UP
A. Ruppert1, M. Beau-Faller2, M. Legrain3, A. Neuville4, B. Mennecier5, E.
Gue´rin3, A. Voegeli3, M. Gaub3, E. Quoix5 1Respiratory Diseases, Hoˆpitaux
Universitaires de Strasbourg, Strasbourg/FRANCE, 2Departement of Molec-
ular Biology, Hoˆpitaux Universitaires de Strasbourg, Strasbourg/FRANCE,
3Biologie Mole´culaire, Hoˆpitaux Universitaires de Strasbourg, Strasbourg/
FRANCE, 4Anatomopathologie, Hoˆpitaux Universitaires de Strasbourg,
Strasbourg/FRANCE, 5Department of Respiratory Diseases, Hoˆpitaux Uni-
versitaires de Strasbourg, Strasbourg/FRANCE
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI),
gefitinib or erlotinib, improve survival of lung cancer. However, after an
initial response, most patients will recur, especially within the central
nervous system (CNS). We report the case of a 27-year-old non smoking
man presenting a metastatic lung adenocarcinoma with a EGFR exon 19
deletion, associated to sensitivity to EGFR-TKI. Gefitinib, followed by
chemotherapy and finally erlotinib resulted in a prolonged disease control,
until multiple liver metastases were detected. After stopping EGFR-TKI,
brain metastases with carcinomatous meningitis were diagnosed. A second-
ary T790M mutation, associated to resistance to EGFR-TKI, was found on
the liver biopsy, but not in the cerebrospinal fluid. Erlotinib was reintroduced
and allowed a quick neurological improvement, even though the extr-a-
cranial disease remained resistant to erlotinib. This report underscores the
interest of molecular monitoring the lung cancer. Persistent cerebral TKI
sensitivity should be considered in patients presenting an early CNS relapse
after stopping EGFR-TKI, even with a T790M resistant mutation in non
cerebral metastases. Questions remain open concerning the selection of
sub-clones during EGFR-TKI therapy, which could be different according to
metastatic sites, especially the CNS.
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A MULTICENTER STUDY OF DOCETAXEL AND
OXALIPLATIN WITH BEVACIZUMAB AS FIRST LINE
TREATMENT IN CHEMOTHERAPY NAÏVE SUBJECTS
WITH UNRESECTABLE LOCALLY ADVANCED AND/OR
RECURRENT (STAGE IIIB) OR METASTATIC (STAGE IV)
NON SQUAMOUS-CELL HISTOLOGY NON-SMALL CELL
LUNG CANCER (NSCLC)
L.E. Raez1, W. Babcock2, T. Webb3, R. Brito4, R. Asbury5, R. Lilenbaum6,
M. Karr7, J. Wade8, C. Faison9, E. Santos10 1Sylvester Comprehensive
Cancer Center, University of Miami Miller School of Medicine, Miami/
UNITED STATES OF AMERICA, 2South Carolina Oncology Associates,
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tology and Medical Oncology, Boynton Beach/UNITED STATES OF AMER-
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Miami Miller School of Medicine, Miami/UNITED STATES OF AMERICA,
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Background: Platinum-based doublets are the standard of care for advanced and
metastatic NSCLC. Studies have shown acceptable toxicity and encouraging
activity for the combination of docetaxel with oxaliplatin in NSCLC. This study
aims to determine the safety and efficacy of this doublet with bevacizumab, as
first-line treatment of NSCLC in chemotherapy-naïve patients (pts).
Methods: Newly diagnosed pts 18 yrs with histologicaly proven non-
squamous NSCLC and ECOG PS  2 received 6 cycles of docetaxel (70
mg/m2), oxaliplatin (100 mg/m2), and bevacizumab (15 mg/kg) q3w, fol-
lowed by single-agent bevacizumab (15 mg/kg) q3w (for 1 yr of therapy).
Primary efficacy endpoint is progression-free survival; secondary endpoints
are objective response rate (RR) and overall survival. Results: A total of 39
pts have been enrolled to date; full demographics and safety data are
available for 14 pts and response data for 29 pts. Of the 14 pts, 2 (14.3%)
were female. Median age was 61.0 yrs; 9 (64.3%) were 65 yrs. Disease
stage distribution was: IIIB: 2 pts (14.3%) and IV: 12 pts (85.7%). ECOG
performance status distribution was: 0 in 10 pts and 1 in 4 pts; there were no
pts with performance status1. The most frequently (22% of pts) reported
adverse events (AEs) of any grade were: pain (64.3%); asthenia (57.1%);
dysgeusia (50%); skin-related AEs (rash or flushing) (42.9%), as well as
diarrhea, nausea, anorexia, and vomiting (35.7% each). Fourteen grade 3/4
AEs were seen in 7 pts, including: neutropenia 4 (of which 1 was febrile);
pneumonia 2; sepsis 1; gastrointestinal AEs 4; hypertension 1; fatigue 1; and
broncho-esophageal fistula 1. From 39 enrolled pts, 29 were available for
response evaluation. Eleven (38%) pts had partial response (PR), 10 (34.5%)
stable disease (SD), and 7 (24%) disease progression. One pt had unknown
response status. Disease control rate (PRSD) was 72.5%.
Conclusions: These data support the tolerability of this regimen with accept-
able safety features, and will be updated at the time of presentation.
Additional RR data will be presented.
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ERLOTINIB (E) WITH OR WITHOUT SUNITINIB (SU) IN
THE TREATMENT OF METASTATIC NON-SMALL CELL
LUNG CANCER (NSCLC): A PHASE II STUDY
G.R. Blumenschein, Jr1, F. Robert2, O. Melnyk3, E. Wang4, P. Selaru4, R.
Chao4, F. Fossella5 1Md Anderson Cancer Center, University of Texas,
Houston/UNITED STATES OF AMERICA, 2Department of Medicine - He-
matology/Oncology, University of Alabama at Birmingham, Birmingham/
UNITED STATES OF AMERICA, 3Department of Medical Oncology/Hema-
tology, Bay Area Cancer Research Group, Concord/UNITED STATES OF
AMERICA, 4Department of Clinical Pharmacology, Pfizer Global Research
and Development, La Jolla/UNITED STATES OF AMERICA, 5Md Anderson
Cancer Center, Department of Thoracic/Head and Neck Medical Oncology,
University of Texas, Houston/UNITED STATES OF AMERICA
Background: SU is an oral, multitargeted tyrosine kinase (TK) inhibitor of
VEGFRs, PDGFRs, KIT, FLT3, CSF-1R and RET, approved internationally
for the treatment of advanced RCC and imatinib-resistant or -intolerant
GIST. NSCLC xenograft data indicate that SU augments the efficacy of E, an
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EGFR TK inhibitor approved to treat NSCLC. This ongoing trial investigates
the activity and safety/tolerability of E  SU in patients (pts) with platinum-
refractory NSCLC.
Materials and methods: In this double-blind, multicenter, phase II trial, pts
(stage IIIB/IV NSCLC, ECOG PS 0–1), who had received prior treatment
with a platinum-based regimen are randomized to receive either SU  E or
placebo  E. Prior to initiating the phase II portion, a lead-in study was
conducted to assess the safety of SU 37.5 mg/d (continuous daily dose) and
E 150 mg/d; full pharmacokinetic (PK) profiles were also performed. If 3
dose-limiting toxicities (DLTs) or 4 DLTs including dyspnea were re-
ported during a 28-day treatment period with E  SU, then the randomized
study could proceed. Additional pts could be added to the lead-in study if6
pts completed full PK sampling.
Results: In the lead-in cohort, 12 pts were treated with SU 37.5 mg/d  E
150 mg/d in 4-wk treatment cycles and were observed for DLTs: mean age
62.6 yrs (range 47–75); n6 male; n11 adenocarcinoma; n11 Stage IV;
n8 smokers. A median of 2 (range 1–9) treatment cycles were started. Two
pts developed a DLT (Grade [G] 3 fatigue 7 d). Most AEs were mild-to-
moderate in severity (G 1 or 2). The most common G 3 AEs were diarrhea
(n4) and fatigue (n2). As of Sept 2007, 2 pts had a durable partial
response and 2 pts had stable disease for 16 weeks. Preliminary PK data
indicate E levels were comparable to those reported in the literature,
suggesting SU has no effect on E exposure.
Conclusions: SU 37.5 mg/d given on a continuous daily dosing schedule with
150 mg/d E is tolerable in this pt population. Preliminary data indicate
promising activity and no PK interaction of SU on E. The randomized phase
II portion of this study is ongoing.
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ERLOTINIB (TARCEVA) IN PATIENTS WITH
ADVANCED NON-SMALL-CELL LUNG CANCER
(NSCLC) - THE SINGLE INSTITUTION EXPERIENCE
M. Tomísˇkova´1, J. Skr˘icˇkova´2, I. Vasˇutova´1, B. Kadlec3, J. Kaplanova´3, L.
Babicˇkova´3, P. Turcˇa´ni3, T. Nebeský4, L. Kr˘en5, L. Buresˇova´6 1Department
of Respiratory Diseases and Tb, University Hospital Brno, Brno/CZECH
REPUBLIC, 2Department of Tb and Respiratory Disease, University Hos-
pital Brno, Brno/CZECH REPUBLIC, 3Department of Respiratory Diseases
and Tb, University Hospital Brno, Brno/CZECH REPUBLIC, 4Department
of Imagines Methods, University Hospital Brno, Brno/CZECH REPUBLIC,
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Background: Erlotinib (Tarceva) is a potent oral non-cytotoxic antraquin-
olone. It is the active and selective EGFR-TKI (epidermal growth factor
receptor tyrosine kinase inhibitor). Our study evaluates the outcome of the
first 38 patients with advanced NSCLC (stage III/IV) treated with erlotinib
between December 2005 and July 2007 in the University Hospital Brno.
Patients and Methods: Thirty-eight eligible patients had failed to prior
chemotherapy (94.7%), or were unsuitable for chemotherapy (5.3%). Erlo-
tinib was administered orally 150 mg/day until disease progression or
unacceptable toxicity. Twenty (52.6%) patients were male and 18 (47.4%)
female, median age was 59.7 years, 18.4% patients were non-smokers,
60.5% stop-smokers and 21.1% current smokers. The outcomes include:
response, survival and symptom improvement (fatigue, dyspnea, cough).
Results: Erlotinib was used as 1st line therapy in 5.3%, as 2nd line in 57.9%
and as 3rd line in 36.8% patients. At the start of treatment, one patient was
PS 0, 68.4% were PS 1, and 29% were PS 2. 25% stage IIIB, 75% stage IV.
Adenocarcinoma was confirmed in 60.6%, squamous-cell carcinoma in
26.3% and other histologies in 27.1% patients. PR (partial response) was
confirmed in 29.0% patients, SD (stable disease) in 48.4% and progressive
disease (PD) in 22.6%. 77.8% patients had a decrease in dyspnoea and in
fatigue and 66.7% had a decrease in cough. We found the statistically
significant better response in females (p0.001) and in patients with adeno-
carcinoma (p0.054). Major toxicities were skin toxicity (88.3%) and
diarrhoea (11%). Treatment was discontinued due to toxicity grade 3–4 in
10.5% patients. Median survival was 7.5 months. In the group of patients
with PR and SD, median survival was 9.4 months, and in the group of PD,
it was 1.5 month (p0.001).
Conclusions: Erlotinib was well tolerated with evidence of antitumor activity
in 2nd and 3rd line of therapy in patients with advanced NSCLC. The results
were statistically significant better in the subgroups of females and adeno-
carcinomas and in patients attaining PR and SD.
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GEFITINIB MONOTHERAPY AS FIRST-LINE
TREATMENT IN PATIENTS WITH ADVANCED
NON-SMALL-CELL LUNG CANCER
X. Zhang, L. Li Lung Cancer Center, Pulmonary Medicine, Peking Union
Medical College Hospital, Chinese Academy of Medical Sciences, Beijing/
CHINA
Background: The result of current standard first-line treatment for advanced
NSCLC is poor, particularly for patients with poor performance and elderly
patients. Gefitinib, an oral EGFR-TKI was generally well tolerated with
clinically meaningful anti-tumor activity in previously treated patients. The
aim of the study was to evaluate the efficacy of gefitinib as first-line
treatment for a series of Chinese patients with advanced NSCLC.
Methods: from October 2002 to March 2005, 26 patients received gefitinib
250mg once daily treatment. No systemic anticancer treatment was permitted
during the study. Objective tumor response and adverse events were assessed
according to RECIST criteria and National Cancer Institute CTC 2.0.
Logistical regression were used to identify baseline factors independently
predict tumor response. Median PFS and OS were calculated using the
Kaplan-Meier method.
Results: Of the 26 patients, 12 patients were male and 19 patients were
non-smokers. 18 patients had adenocarcinoma, and 22 patients were over 70
years or with PS over 2. The most frequently reported adverse events were
skin disorders (72.0%) and diarrhea (36.0%) The majority of these events
were mild with grade 1 to grade 2. Other adverse events included nausea
(8.0%), oral ulcer (4.0%) and elevation in hepatic enzymes (4.0%). No
patient withdrew due to adverse effect. Of the 26 patients, 23.1% achieved
partial response and 38.5% achieved stable disease with DCR 61.5%. The
odd of disease control was 12 times higher for patients with adenocarcinoma
than patients with nonadenocardinoma. For all patients, The median PFS was
6 months and the median OS was 12 months. The 1-year survival rate was
50%. Median PFS and OS were improved among patients with adenocarci-
noma and patients who had objective tumor response or disease control.
Conclusion: Oral dose of gefitinib 250mg/day as first-line treatment was well
tolerated and provides significant anti-tumor activity in patients aged over 70
or with poor performance with advanced NSCLC.
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ERLOTINIB: A PLAUSIBLE TREATMENT FOR
ADVANCED/METASTATIC NON-SMALL CELL LUNG
CANCER (NSCLC)?
M.R. Couto, M. Ferreira, N. Afonso, M. Soares, I. Azevedo, A. Arau´jo
Medical Oncology Department, Portuguese Institute of Oncology, Porto/
PORTUGAL
Background: Erlotinib is an orally available, quinazoline derivate, selective
and reversible EGFR tyrosine kinase inhibitor. It’s approved as monotherapy
for the treatment of pts with locally advanced/metastatic NSCLC after failure
of at least one prior chemotherapy (CT) regimen.
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Aim: Review our clinical experience with erlotinib on locally advanced/
metastatic NSCLC.
Material and methods: Retrospective analysis of consecutive patients with
locally advanced/metastatic NSCLC treated with erlotinib in a single insti-
tution. Clinical data were obtained from pts medical records of the Portu-
guese Institute of Oncology – Porto Centre. Data were analyzed using
statistical package SPSS 13.0. Survival curves were calculated by the
Kaplan-Meier method.
Results: A total number of 42 pts were evaluated. Gender: 71.4% males.
Median age at diagnosis: 55-years-old (range: 30 to 81). Sixty four percent
of pts were current or former smokers. Histology: 59.5% adenocarcinoma,
28.6% squamous, 11.9% other. Stage at diagnostic: 21.4% - I, 2.4% - II,
7.1% - IIIA, 31% - IIIB, 38.1% - IV. Initial treatment: 59.5% CT, 16.7%
surgery, 23.7% combined modalities. Number of prior regimens of CT: 69%
- 2, 23.8% - 3, 4.8% - 1 and 2.4% - 0. Prior exposure to taxanes – 92.9%,
platinum - 95.2%, gemcitabine – 52.4% and to pemetrexed – 52.4%. Median
overall survival was 40 months. Median time to progression since erlotinib
was 3.4 months. The main grade 3 and 4 adverse effects occurred were: rash
- 11.9%, anemia - 4.8%, diarrhea -2.4% and fatigue - 2.4%. Four pts needed
dose reduction during erlotinib therapy to 100 mg id. No unexpected
toxicities have been observed.
Conclusion: Erlotinib is a good option for NSCLC in second or third line of
therapy. With a relatively safe profile it extends survival in our clinical daily
setting of pts.
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SUNITINIB PLUS ERLOTINIB, A NOVEL VEGFR–EGFR
CO-INHIBITION TREATMENT STRATEGY IN PATIENTS
(PTS) WITH METASTATIC NON-SMALL CELL LUNG
CANCER (NSCLC)
R. Govindan1, G. Blumenschein2, H.J.M. Groen3, A. Szczesna4, J. Strausz5,
J. Montesinos6, R. Chao7, G.V. Scagliotti8 1Department of Medicine, Alvin J.
Siteman Cancer Center at Washington University School of Medicine, St.
Louis/UNITED STATES OF AMERICA, 2Md Anderson Cancer Center,
University of Texas, Houston/UNITED STATES OF AMERICA, 3Department
of Respiratory Disease, University Medical Center Groningen, Groningen/
NETHERLANDS, 4Department of Lung Disease and Oncology, Regional
Lung Diseases Hospital, Otwock/POLAND, 56th Department, Koranyi Na-
tional Institute for Pulmonology, Budapest/HUNGARY, 6Department of
Medical Oncology, Corporacion Sanitaria Parc Tauli, Sabadell Barcelona/
SPAIN, 7Department of Clinical Pharmacology, Pfizer Global Research and
Development, La Jolla/UNITED STATES OF AMERICA, 8Department of
Clinical & Biological Sciences, University of Torino, Orbassano/ITALY
Vascular endothelial growth factor receptor (VEGFR), a major regulator of
angiogenesis (AG), and human epidermal growth factor receptor (EGFR/HER1)
are two important targets in NSCLC. VEGFR and EGFR share common
downstream signaling pathways (SP) exerting direct and indirect effects on
tumor vasculature. Because complex SP exist, resistance to single-target agents
may result by bypassing inhibited SP via parallel, overlapping SP. Rational
combinations inhibiting multiple SP may be less prone to drug resistance. EGFR
is implicated in AG via its expression on tumor vasculature endothelial cells in
preclinical models and its association with increased microvessel density. EGFR
inhibition appears to down-regulate VEGF, and VEGFR inhibition appears to
inhibit EGFR signaling. Co-inhibition of VEGFR and EGFR in preclinical
models showed significantly greater anti-tumor activity over inhibition of either
SP alone, and clinical data support this co-targeting. Sunitinib (SUTENT; SU)
is an oral, multitargeted tyrosine kinase inhibitor of VEGFRs, PDGFRs, KIT,
RET, and FLT3 that has shown single-agent anti-tumor activity in refractory
NSCLC. SU  E is a novel VEGFR–EGFR treatment strategy that may confer
additive/synergistic clinical benefit in pts with advanced NSCLC. Two trials are
assessing the efficacy/tolerability of SU at 37.5 mg/d (continuous daily dosing
[CDD]) E 150 mg/d vs placebo E 150 mg/d in pts with platinum-refractory
(PR) NSCLC. SUN1058 is a randomized, multicenter, phase II trial evaluating
SU  E. To date 2/12 pts had durable PR and SU  E was well tolerated.
SUN1087 is a global, randomized, multicenter, pivotal phase III trial in pts with
PR NSCLC. 956 pts will be randomized to either SU 37.5 mg/d CDD  E 150
mg/d or placebo  E 150 mg/d given in 4 week cycles. Pts 18 yrs with stage
IIIB/IV disease, ECOG PS 0–1, prior treatment with 1–2 chemotherapy regi-
mens, including a platinum-based regimen are eligible. The primary endpoint is
overall survival; progression-free survival, objective response rate, 1-yr survival,
duration of confirmed response, safety, and pt reported outcomes are secondary
endpoints. Enrollment is ongoing.
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A PHASE II STUDY OF THE COMBINATION
CHEMOTHERAPY OF DOCETAXEL AND CARBOPLATIN
IN ADVANCED NON-SMALL CELL LUNG CANCER
B. Kim, S. Nam, Y.M. Ahn, Y.H. Roh Internal Medicine, Seoul Veterans
Hospital, Seoul/KOREA
Background: To evaluate the efficacy and safety of induction chemotherapy
with docetaxel and carboplatin in advanced lung cancer.
Methods: Between January 2005 and January 2007, 54 patients were enrolled
and evaluable. Patients were treated with Docetaxel 75 mg/m2 and Carbo-
platin AUC 5 on day 1 every 21 days.
Result: The median age was 66 (range 23–78) years old. Among the 54
patients, 51 were male. Pathologically, 21 patients had adenocarcinoma, 23
patients had squamous carcinoma and 5 patients had large cell carcinoma and
5 patients had poorly differentiated carcinoma. Complete responses (CR)
were in 2 (3.7%) patients and partial responses (PR) in 14 (25.9%) patients.
The overall response rate was 29.6% and the median response duration was
5 (range, 1 to 12.7) months. The median overall survival for all patients was
14.8 (range, 1.4 to 23.8) months. One-year survival rate was 45.3%.
During a total 253 cycles, anemia greater than CTC grade 2 occurred in 51
cycles (20.1%), leukopenia occurred in 22 cycles (8.7%) and thrombocyto-
penia occurred in 19 cycles (7.5%). The grade 3 stomatitis and neuropathy
occurred in one patient, respectively. Non-hematologic toxicities were minor
and easily controlled.
Conclusion: The combination chemotherapy of docetaxel and carboplatin has
moderate efficacy with acceptable toxicities in patients with advanced NSCLC.
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PROGNOSTIC ROLE OF BASELINE LEVELS OF
CHEMOKINE IL-8 IN METASTATIC LUNG CANCER
PATIENTS
I. Gioulbasanis, L. Vamvakas, A. Karampeazis, N. Androulakis, K. Kalbakis,
S. Agelaki, A. Kalykaki, A. Kotsakis, V. Georgoulias, D. Mavroudis De-
partment of Medical Oncology, University General Hospital of Heraklion,
Heraklion/GREECE
Background – Task: Chemokine IL-8 participates in the development of
inflammatory responses and cancer-related cachexia and promotes cell pro-
liferation and tumor angiogenesis in lung cancer but its role as a prognostic
factor remains inconclusive. The aim of this study was to determine the
relation between baseline chemokine IL-8 levels and malnutrition, response
to treatment and overall survival.
Material – Methods: All patients with metastatic lung cancer referred to our
hospital during the past 18 months were eligible. Chemokine IL-8 levels in
the blood were measured before the onset of chemotherapy. Demographic
(sex, age, smoking status) and baseline characteristics (performance status,
histologic type, blood chemistry, C-reactive protein, ferritin) were recorded.
Patients’ nutritional status was evaluated with the Mini Nutritional Assess-
ment (MNA) (www.mna-elderly.com). Response to first-line chemotherapy,
time to tumor progression, subsequent chemotherapy lines and overall
survival were also recorded.
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Results: A total of 173 patients (median age SD 65.3 10.1) have been
evaluated. Demographic and baseline characteristics are tabulated as follows:
Sex males females
153 20
Smoking status Current never- / ex-smokers
126 16 / 31
PS 0–1 2
107 66
Histology NSCLC SCLC
139 34
1st line chemotherapy Platinum-based Nonplatinum-based
45 128
From the studied parameters IL-8 levels were significantly correlated with
smoking history, MNA-score, albumin and ferritin. Although baseline IL-8
levels could not predict response to treatment, they were correlated with
overall survival (p0.046). Conclusions: In this exploratory analysis, base-
line chemokine IL-8 levels were significantly correlated with smoking
history, malnutrition and overall survival in lung cancer patients.
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MALIGNANT PERICARDIAL EFFUSION IN LUNG
CANCER PATIENTS
T. Adzic, A. Blanka, D. Jovanovic, D. Trifunovic Institute for Lung Diseases
and Tuberculosis, Clinical Centre of Serbia, Belgrade/SERBIA AND MON-
TENEGRO
Introduction: Malignant pericardial effusion is most frequently observed in
patients (pts) with advanced lung and breast cancer, leukemia,lymphoma and
malignant melanoma.
Patients and methods: We analyzed 29 lung cancer (LC) pts with malignant
pericardial effusion and cardiac tamponade who were diagnosed and treated
at the Institute of lung diseases and tuberculosis in Belgrade, during three-
year period (2005–2007).
Results: Amog the affected 18(63%) were males with mean age of 52 years
and 11(37%) were females with mean age of 53 years. The diagnosis was
confirmed by bronchology examination in 17(58%) pts, and percutaneus
biopsies of lungs and lymph glands in 12(42%) pts. Adenocarcinoma was
found in 17(58%) pts, squmous-cell carcinoma in 7(26%) pts, while small-
cell carcinoma was found in 5(16%) pts. At the time of diagnosis malignant
pericardial effusion was established in 26 (89%) pts with average 1000 ml of
hemorrhagic fluid, and in 3(11%) pts in LC relapse with average 1300 ml of
fluid. Pericardiocentesis was performed in all the patients, while positive
malignant cells in pericardial fluid were found in 18(63%) pts. Intrapericar-
dial addmition of cytotoxic agents were in 15(53%) pts. Systemic chemo-
therapy was applied in 18(63%) pts, combined chemo and radio therapy in
5(16%) pts, while symptomatic in 6(21%) pts.
Conslusion: Our results support the opinion that malignant pericardial
effusion singificantly reduced survival in LC pts (up to seven months) in
advanced stage of disease.
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LUNG CANCER IN ELDERLY PATIENTS (OVER 70):
SAFETY DATA FROM OBSERVATIONAL CLINICAL
TRIAL IN A SINGLE INSTITUTION EXPERIENCED
A. Butera1, L. Vizzini2 1Medicina, A.O. S. Giovanni di Dio, Agrigento/
ITALY, 2Oncologia, A.O. S. Giovanni di Dio, Agrigento/ITALY
Background: Lung cancer (NSCLC) can be considered a typical cancer of
advanced age.
More than 50% of NSCLC patients are diagnosed at  65 years of age and
one-third of all patients are  70 years of age. More recent studies with a
special focus on elderly patients demonstrate that these patients indeed
benefit from chemotherapy.These patients are not often considered eligible
for aggressive cisplatin-based chemotherapy.
In advanced disease, single-agent chemotherapy proves to be active and
well-tolerated, and compared with better supportive care, improves survival
and quality of life.
Methods: In our experience, from January 2006 to February 2007 we treated 55
patients with advanced NSCLC over 70-years-old and 10 patients over 80, all in
good clinical conditions. Patients with good performance and without comorbid
conditions treated with combination chemotherpy, carboplatin based regimen
(carboplatin/vinorelbine;carboplatin /gemcitabine). PS 1–2 (ECOG) patients
treated with single agent chemotherapy with Vinorelbine or Gemcitabine.
Results: dverse event were experienced by 40 % of patients, but were
generally mild (grade 1–2). In particular, among the non emathological
toxicity, fatigue was reported by 15%,mild nausea by 25 %, no patients
experienced febrile neutropenia. Dose reduction was never required. No
patients experienced CR; RP reported in 14/55 (25%), 26/55 (47%) reported
a SD with clinical benefit. 15/55 (27%) patients reported a PD. Median time
to progression and overal survival were 5,2 and 10 months. 32 patients
among 55 have received a second line of chemotherpy.
Conclusions: The available data and our experience suggest that patients
should be evaluated for chemotherapy based on their performance status and
comorbidities rather than only for age. For elderly patients judged fit to receive
combination chemotherapy, carboplatin-based regimens (carboplatin and vi-
norelbine or gemcitabine) are a reasonable option in patients with ECOG 0–1.
In elderly patients with less than optimal performance status or significant
comorbid conditions single-agent therapy may be more appropriate.
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ANALYSIS OF CLINICAL FACTORS IN RELATIONSHIP
TO TREATMENT EFFECTS OF ERLOTINIB IN NON
SMALL CELL LUNG CANCER PATIENS
M. Tomísˇkova´1, J. Kaplanova´2, J. Skr˘icˇkova´3, L. Babicˇkova´2, I. Vasˇutova´4,
B. Kadlec2, T. Nebeský5 1Depth. of Tb and Respiratory Diseases, University
Hospital Brno, Brno/CZECH REPUBLIC, 2Department of Respiratory Dis-
eases and Tb, University Hospital Brno, Brno/CZECH REPUBLIC, 3Depart-
ment of Tb and Respiratory Disease, University Hospital Brno, Brno/CZECH
REPUBLIC, 4Department of Respiratory Diseases and Tb, University Hos-
pital Brno, Brno/CZECH REPUBLIC, 5Department of Imagines Methods,
University Hospital Brno, Brno/CZECH REPUBLIC
Introduction: Erlotinib is the tyrosin kinase inhibitor of epidermal growth
factor receptor (EGFR). We have had an opportunity to use erlotinib in 47
patients with advanced NSCLC from the year of 2005. Methods. This is a
retrospective analysis of the group of 47 patients with advanced NSCLC,
who started the treatment with erlotinib from December 2005 to October
2007. We compared groups of patiens with PR and SDPD and tried to find
clinical parametres that could predict treatment response and increase median
survival. Characteristics of patients: There were 25 men (53,2%) and 22 women
(46,8%). Mean age was 58,4 years (27,3–80,4). Ten patiens (21,3%) were
neversmokers, 29 (61,7%) formersmokers and 8 (17,0%) smokers. Adenocar-
cinoma was diagnosed in 28 patiens (59,6%), bronchoalveolar carcinoma (BAC)
in 3 (6,4%), squamous cell carcinoma in 10 (21,3%), NSCLC without further
details in 5 (10,6%) and large cell carcinoma in 1 (2,1%). Performance status
(PS) at the start of treatment was 0 in one patient (2,1%), 1 in 33 (70,2%) and
2 in 13 patients (27,7%). Erlotinib treatment was started after failure of preceding
chemotherapy in almost all patients (97,8%).
Results: Only 38 from 47 patients (80,8%) were evaluable for statistical
analysis. Best objective response was PR in 10 patiens (21,3%) and SD in 17
(36,2%). Progression of the disease was found in 11 patients (23,4%).
Average duration of treatment in patiens with PR was 9,4 months. Partial
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response was significantly more frequent in women than men (10 to 0).
Treatment response did not differ significantly between adenocarcinoma and
other histological cancer types, but there was a trend to better response in the
former one (p0,067). Better treatment response was noticed in never
smokers (PR 40%) than in formersmokers and smorkers (PR 21,4%), but this
difference was not statistically significant. Second line erlotinib treatment
was linked with significantly better response (PR 40,9%) than first line (PR
0) and third line (PR 6,7%) treatments.
Conclusions: We found female sex, histology of adenocarcinoma, never
smoker status and second line treatment as potential factors of better
response to erlotinib treatment in NSCLC patiens.
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RADIOTHERAPY USING DEEP INSPIRATION BREATH
HOLD (DIBH) TECHNIQUE FOR LOCALLY ADVANCED
NON SMALL CELL LUNG CANCER (NSCLC)
L. Vicenzi1, P. Blanchard1, I. Ferreira1, J. Brahim1, B. Besse2, J.J. Bretel1,
R. Arriagada2, C. Le Pechoux3 1Radiotherapy, Institut Gustave Roussy,
Villejuif/FRANCE, 2Department of Medicine, Institut Gustave Roussy, Villejuif/
FRANCE, 3Dept. of Radiotherapy, Institute Gustave Roussy, Villejuif/FRANCE
Objective: To compare dosimetric parameters of a 3D-conformal external
radiotherapy planning with/without DIBH technique for treatment of locally
advanced NSCLC.
Patients and methods: Between 2005 and 2007, 16 patients (pts) had
conformal radiotherapy with a spirometer-monitored technique at our insti-
tution. All tumours were staged IIIA-IIIB except one (stage IA). Thirteen
patients underwent neoadjuvant chemotherapy. 12 received concomitant
chemoradiotherapy, and 4 pts received radiotherapy alone. All pts underwent
3 planning-CTs: one in free breathing condition (FBC) and two in breath-
hold condition (BHC). Gross, Clinical, Internal and Planning Target Vol-
umes (GTV, CTV, ITV and PTV) and Organs at Risk (OAR: heart, lungs,
esophagus and spinal cord) were delineated on each scan. Two different
treatment plans were created using FBC or BHC. Detailed dosimetric
parameters for target coverage and OARs were recorded for each treatment
plan. Median dose: 66 Gy/33fr on the PTV, using 4 to 6 coplanar 6 MV
beams. Treatment toxicity was evaluated using the RTOG scale.
Results: Median follow-up: 8.5 months. Currently, 9 patients are dead (local
disease progression: 6, distant metastases: 2, unknown cause: 1) and 7 patients
are alive (6 without evidence of disease progression). The most significant
comparative dosimetric parameters are: - no difference in target coverage - heart:
relative reduction in V30 and V40 of 29% and 21% (V30 from 17% to 12% and
V40 from 14% to 11% in FBC and BHC respectively) - esophagus: V50
presented a reduction of 24,4% in BHC; no significant differences in LR50 and
LR60 values - lungs: relative reduction in D5, V5 and V35 of 10%, 16% and 30%
in BHC compared to FBC; mean dose, V20, V25 presented a reduction of 21%,
28% and 30%, respectively Treatment toxicity was moderate: 1 grade 3 oesoph-
ageal toxicity and no grade3 lung toxicity was observed.
Conclusions: The external radiotherapy with DIBH is feasible, well tolerated
and allows a reduction of dosimetric parameters that should decrease the
OAR toxicity in the treatment of advanced NSCLC. This could enable dose
escalation without increasing the OAR toxicity. However, the best respira-
tory gating technique is an open issue.
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TREATMENT OUTCOMES OF STAGE III NON-SMALL
CELL LUNG CANCER
A.F. Korcum1, G. Aksu1, M. Ozdogan2, C. Sen1, M. Samur2 1Department of
Radiation Oncology, Akdeniz University, School of Medicine, Antalya/TUR-
KEY, 2Division of Medical Oncology, Akdeniz University, School of Medi-
cine, Antalya/TURKEY
Background: Concomitant or sequential chemotherapy (CT) and radiotherapy
(RT) have become the standard of care for patients with unresectable Stage III
non-small-cell lung cancer (NSCLC). However, both local and distant metasta-
ses remain substantial problems. The aim of this study was to analyze the
prognostic factors for overall survival and evaluate the efficacy of different
treatment approaches in patients with unresectable stage III NSCLC.
Material and Method: We performed a retrospective review of 104 patients
with unresectable NSCLC who were treated with RT and CT between
1999–2007. All patients had histologically confirmed NSCLC. Median age
was 57 (range 32–82), males / females 99/5, stage IIIA/ IIIB 24/80. Patients
were classified into following three groups: The patients in the group 1 (n 
23) were treated only with concurrent chemoradiotherapy (CCRT). In the
group 2 (n  41), before the CCRT, induction CT was administered. In the
group 3 (n  40), after induction CT, RT was used alone. There was no
difference for age, sex, stage among the groups. Fifty-eight patients com-
pleted at least 4 cycles planned chemotherapy. All patients were treated with
median 63 Gy in 1.8–2.0 Gy daily fractions. Age, sex, tumor and lymph node
stage, clinical stage, KPS, presence of co-morbidity and number of total CT
cycles were investigated as prognostic factors.
Results: Median follow-up was 13.6 months (range 4–57). At the time of
analysis, 65 patients had died, 39 were alive. Median disease free survival
(DFS) and overall survival (OS) for this study were 15.5 months (95% CI
14–17 mos) and 13.3 months (95% CI 11–15 mos), respectively. Median
DFS and OS were 10.1, 17.6, 12.7 months and 15.8, 16.2, 21.3 months for
groups 1, 2, 3, respectively. There was no statistical difference in median OS
and DFS among three groups. Univariate and multivariate analysis demon-
strated that only the number of received CT cycles were statistically signif-
icant predictors of survival.
Conclusion: This study demonstrated that patients completed at least 4 cycles
CT were significantly associated with better survival. Although there is not
statistically significant difference among three approaches, induction CT
followed by CCRT prolonged survival.
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FIRST-LINE TREATMENTWITH PLANNED SEQUENTIAL
ADMINISTRATION OF GEMCITABINE FOLLOWED BY
DOCETAXEL IN ELDERLY ADVANCED NON-SMALL-
CELL LUNG CANCER (NSCLC) PATIENTS: A
MULTICENTER PHASE II STUDY
E. Vasile1, C. Tibaldi2, A. Antonuzzo3, R. Di Marsico4, G. Tartarelli5, A.
Fabbri6, M. Lo Dico2, E. Mazzoni2, M. Andreuccetti2, A. Falcone7 1Oncology,
University of Pisa, Pisa/ITALY, 2Division of Medical Oncology, Civil
Hospital Livorno, Livorno/ITALY, 3Division of Medical Oncology, Civil Hospi-
tal Piombino, Piombino/ITALY, 4Division of Medical Oncology, Civil Hospital
Cecina, Cecina/ITALY, 5Division of Medical Oncology, Civil Hospital Viareg-
gio, Viareggio/ITALY, 6Division of Pneumology, Civil Hospital Pistoia, Pistoia/
ITALY, 7Oncology, University of PIsa, Pisa/ITALY
Background: Single-agent chemotherapy (as gemcitabine) is currently a
standard of care for elderly advanced NSCLC patients. The addiction of
docetaxel to gemcitabine was active but not well tolerated in this subset
(Hainsworth et al, Clin Lung Cancer 2003). A possible approach to reduce
the toxicity of the combination consists of administering the two drugs in a
sequential manner. A modified schedule of weekly docetaxel was active and
well tolerated in pre-treated elderly advanced NSCLC patients (Tibaldi et al,
Clin Lung Cancer, 2006). The main purpose of this study was to evaluate the
activity and the toxicity of a sequential regimen of gemcitabine followed by
weekly docetaxel in elderly advanced NSCLC patients. Methods: Chemo-
naïve elderly patients (70 years old) with confirmed stage IV NSCLC and
a performance status (PS) 0–2 were treated with gemcitabine 1200 mg/m2 on
Day 1 and 8 every 3 weeks for 3 cycles followed by, in case of partial
response or stable disease, docetaxel 37.5 mg/m2 on Day 1 and 8 every 3
weeks for further 3 cycles.
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Results: Fifty-six patients were enrolled into the study; 46 were male and 10
female; PS was 0 in 7 patients, 1 in 38, 2 in 11; the median age was 76 years
(range 70–84) and the median number of major comorbidities was 2.
Toxicity was acceptable; afebrile grade 3 neutropenia was observed in 3
patients (5.4%), grade 3 thrombocytopenia in 2 (3.6%), grade 3–4 fatigue in
5 (8.9%), and diarrhoea and mucositis in 2 patients each (3.6%). According
to intention-to-treat analysis, the objective response rate was 16.0% (95%
C.I. 7.6%–28.3%); stable disease was obtained in 23 patients (41.0%) while
24 patients (43%) experimented progression of the disease. Five patients who
had a stable disease after three courses of gemcitabine obtained a conversion
to partial response by docetaxel. Median time to progression was 4.8 months
(95% C.I 3.6–6.0 months) and median duration of survival was 8.0 months
(95% C.I 5.6–10.5 months), with a 1-year survival rate of 34%.
Conclusion: Sequential chemotherapy with gemcitabine and docetaxel seems
a well-tolerated and effective regimen in elderly advanced NSCLC patients.
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DOCETAXEL-INDUCED ISCHAEMIC COLITIS IN A
WOMAN WITH LUNG CANCER
S. Bensliman Pneumology, IRIS hospitals, Brussels/BELGIUM
Case report: A 69 years old woman was diagnosed with locally advanced
squamous cell lung carcinoma (cT1N2M0), stage IIIA in September 2007.
She received an induction chemotherapy consisting in cisplatine (60 mg/m2
day 1) plus docetaxel (75 mg/m2 day 1). On day 5 of her first cycle of
therapy, she was admitted to hospital for diarrhoea, severe abdominal pain
and rectorragia. Her white blood count and platelet count was normal. Computed
tomography of the abdomen showed inflammation and swelling of the colon.
The colonoscopy revealed severe colitis with necrotic area. The patient’s clinical
condition deteriorated the following days with worsening of the abdominal pain
and acute abdomen at the physical examination. She underwent emergency
exploratory laparotomy with subtotal colectomy with ileostomy. The postopera-
tory evolution was favourable and the patient regained her domicile three weeks
later. I report here the rare case of an ischemic colitis induced by docetaxel
chemotherapy in a patient with lung cancer.
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IMPROVING QUALITY OF SEXUAL LIFE AMONG
PATIENTS WITH LUNG CANCER IN DEVELOPING
COUNTRIES: DISPELLING THE MYTHS!
S. Sharma1, D.P. Agarwal2, O.P. Sharma3, R. Sharma3, N. Somani4 1Radi-
ation Oncology, SMS Hospital, Jaipur/INDIA, 2Radiarion Oncology, SMS
Medical College and Hospital, Jaipur/INDIA, 3Radiation Oncology, SMS
Medical College and Hospital, Jaipur/INDIA, 4Medical Oncology, BM-
CHRC, Jaipur/INDIA
Sex is a legitimate part of normal life but might be last thing on mind as one
start thinking about cancer.Sensuality is, and has always been, the primitive
need. Patient needs affection, tenderness and physical contact until they die,
because these are inborn urges and man remains human until his death.In-
dividual’s sexual identity, function and relationship is dramatically wounded,
physically and emotionally, by changes and challenges that one faces when
lung cancer disrupts life, patient’s struggle with hopelessness around poor
prognoses, guilt over smoking. Loved ones are often left with the question
“What if?” those two words can tear people and families apart. Side effects
of treatment affects individual’s sexual self-image and make them feel
unattractive.In our sexually silent society, a sex talk is culturally labeled as
shameful, Cultural issues in our society, such as the myth that patients are no
longer interested in intimacy, and the presumption that issues of survival
overshadow sexuality, provide barriers to open communication about sexu-
ality. The very privileged relationship that oncologist have with their patients
should help in dispelling these myths and permit them to assist patient with
this aspect of health and recovery. Sexuality is, by dogma, satisfaction par
excellence which certainly does not mean lying in the arms of scantily-clad
women, mouths reddened by desire, and terminating in one prodigious
orgasm it is largely a function of breadth of activities in ones repertoire and
the degree to which one is open to learn and explore. Methods include
educating patients about the phases of sexual functioning, masturbation often
regarded as the most secret sexual pleasure can be a good foreplay, turning
lights off during sex, changes in coital positions like spoon position; advice
on how to mitigate the effects of physical handicaps, and self-help strategies
to overcome specific sexual problems may help in alleviating suffering from
this aspect of the silent killer known as lung cancer, as this “life robber” does
not discriminate between men or women, doctors or lawyers, firefighters or
homemakers, rich or poor. It is an equal opportunity disease and killer, and
one which we can, and must, defeat!
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BRAIN METASTASES AT INITIAL PRESENTATION
OF NSCLC: NORTHERN CENTRE FOR CANCER
TREATMENT (NCCT) EXPERIENCE
F. Azribi, J. Adam, J. Gardiner Medical Oncology, NCCT, NEWCASTLE
UPON TYNE/UNITED KINGDOM
Objectives: Brain metastases are common at presentation in patients with non
small cell lung cancer(nsclc), and surgery(s), radiotherapy(rt) and chemo-
therapy (ct) are all used for treatment. To investigate survival patterns of
nsclc patients seen at ncct, clinical data on patients treated sequentially over
a period of 6 months was collected.
Patients and methods: nsclc patients with brain metastases at presentation
reffered to ncct from 1/7/2005–31/12/2005 were identified. We collected the
following data: age, ecog performance status (ps), extent of distant metas-
tases, number of brain metastases, treatment modalities and survival.
Results: of 394 nsclc patients referred to ncct, 39 patients (22 males and 17
females) had brain metastases at presentation. Mean age was 65.3 years (sd
8.6, range 48 to 80 yrs) and the majority (24, 62%) were ps 0–2. 14
patients (36%) had only brain metastases, while 21 patients (54%) in addition
had extracerebral metastases. Only 3 patients received surgery as part of their
treatment, 16 had rt alone, 9 patients had rt and ct in combination, 4 patients
had ct, and 7 patients received only best supportive care (bsc). Median
survival (ms) for the whole group was 3 months (m). Survival was better in
good ps patients (4m for ps0–2 versus 1 m for ps3–4). As per radiation
therapy oncology group recursive partitioning analysis (rpa); patients were
divided into the 3 prognostic classes; rpa class 1(6 patients, 15%), 2 (18
patients, 46%) and 3(7 patients, 18%). Ms was 6 m, 4 m and 1 m
respectively. Patients receiving both ct and rt (regardless of order) had ms of
5m, ms in the ct or rt alone group was 3 m, while patients receiving only best
supportive care had a ms of 1m.
Conclusion: patient numbers were small in this study so any conclusions are
limited,but, fit nsclc patients presenting with brain metastases should be
considered for both chemotherapy and radiotherapy. Surgery may also have
a role in selected cases.more research is required to find better treatment and
treatment combinations.
Variable : patient nos ecog ps 0–2: 24 3–4: 7 not clearly stated: 8 extent of
distant metastasis brain only: 14 brainother sites: 21 not known: 3 treat-
ment modality bsc: 7 rt: 16 ct: 4 rt/ct: 9 rt/s: 1 rt/s/ct: 2.
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EFFECTIVENESS OF EPOETIN BETA 30,000 IU ONCE
WEEKLY (QW) FOR TREATMENT OF CHEMOTHERAPY-
INDUCED ANEMIA IN LUNG CANCER (LC)
K. Chouahnia1, D. Spaeth2, E. Quoix3, J. Kleisbauer4, F. Lebas5, P. Sou-
quet6, G. Deplanque7, G. Des-Guetz,1 A. Jenabian8, J. Morere9 1Medical
Oncology, Avicenne Hospital, Bobigny/FRANCE, 2Oncology, Gentilly Cen-
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ter, Nancy/FRANCE, 3Department of Respiratory Diseases, Hôpitaux Uni-
versitaires de Strasbourg, Strasbourg/FRANCE, 4Oncology, Sainte-Margeu-
rite Hospital, Marseille/FRANCE, 5Oncology, Le Mont Hospital, Le Mont/
FRANCE, 6Pneumology, University Hospital, Lyon/FRANCE, 7Medical
Oncology, Hopital Saint Joseph, Paris/FRANCE, 8F.Hoffman-la Roche,
F.Hoffman-la Roche, Neuilly-sur-Seine/FRANCE, 9Medical Oncology, Ho-
pital Avicenne, Bobigny/FRANCE
Background: Anemia is the most frequent haematological complication of
cancer. Epoetin beta (E), an effective treatment of chemotherapy-induced
anemia in patients (pts) with solid tumors was administred three-times
weekly. This study was to evaluate efficacy and safety of E 30 000 IU in pts
with LC.
Methods: This study was an open-label, single-arm, multicenter trial between
December 2003 and August 2005. Eligibility criteria were: informed consent,
age 18 yrs, WHO performance status 0/2, malignant non-myeloid malig-
nancies, on-going chemotherapy and anemia: hemoglobin (Hb) 12 g/dl. E
30 000 IU QW was administered SC for up to 16 weeks. Follow-up visits
were scheduled after each chemotherapy cycle. Primary endpoint was Hb
response defined as an Hb increase of 2 g/dl (whatever the baseline Hb
level) and/or an achievement of Hb level of 12 g/dl or 13 g/dl with Hb
levels 11 g/dl or 11 g/dl at baseline respectively). Time to Hb response,
transfusion requirement, mood and cognitive functions were also assessed.
Here, we focus specifically on the subgroup of pts with LC Results: In total, 102
pts with LC were included. Characteristics of the population are the following:
63% of pts were male and 28% above 70 years old, 69% of pts received 1st line
chemotherapy (75% were platinum-based regimen). Median Hb level at baseline
was 10.4 g/dl [7.9–12.3]. At endpoint, median Hb level increased to 13.2 g/dl
[9.3–15.0]. Hb response rate (RR) was: 54% (IC95: 44–64%), 57% (IC95:
43–70%) in pts treated with platinum based regimen and 61% (IC95 : 39–84%)
in pts treated without platinum. E treatment was well tolerated. No difference
according to age, number of lines of treatment and the type of chemotherapy.
Thromboembolic events related to treatment occurred in 2.9% of pts.
Conclusion: Epoetin beta 30 000 IU once weekly is effective and well
tolerated in anemic pts with lung cancer treated with platinum based
chemotherapy. Once weekly treatment offers a convenient therapy which
will improve patient compliance.
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CLINICAL STUDY OF CRYO-ABLATION FOR CENTRAL
ADVANCED NON-SMALL-CELL LUNG CANCER
L. Ji-Fu1, X. Bo2 1Thoracic Surgery, General Hospital of Beijing Unit,
Beijing/CHINA, 2Department of Thoracic Surgery, General Hospital of
Beijing Unit, Beijing/CHINA
Objective: To investigate the clinical feasibility and effects of cryo-care
system (CCS, USA) for central advanced non-small-cell lung cancer
(NSCLC).
Methods: 50 patients with central advanced NSCLC, including adenocarci-
noma (25), squamous cell carcinoma (22), large cell carcinoma (3). cTNM:
stage IIIa (14), IIIb (20), VI (16). Under local anesthesia, transcutaneous 1–4
cryoprobes were inserted into the tumor area, treated by CCS, guided and
monitored by real-time larger aperture CT. One cycle of cryotherapy was
first frozen below -130°f, continued 15–20, cryofield covered the tumor
area, and then warming up 20–30°f. The freezing and thawing was 2 cycles
for the tumor area. 2–3 weeks after the cryotherapy, bronchial arterial
intensive chemotherapy and assisted chemotherapy were administered to
patients. If the patients had complicated intracranial metastatic tumors by
Y-ray radiotherapy. The curative effects were estimated by X-ray chest film,
chest CT scan and Karnofsky score. Follow-up was 2–48 months.
Results: Pneumothorax rate was 23.5%. No–hemothorax occurred and no
perioperative deaths. 2 weeks after the cryotherapy, respiratory tract symp-
toms, such as chest distress, chest pain, cough, breathlessness and general
symptoms, such as good appetite, got force and weight, showed significant
improvement. Karnofsky score was raised from 20 to 40. Median survival
was 16 months. One month after cryotherapy, tumor shrinkage was 10–20%.
There was partial remission rate of 78% after 3 months.
Conclusion: CCS treatment of central advanced NSCLC was safe and
effective in the target area. It was able to improve the general condition and
the respiratory tract symptoms of the patients.
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COMPLEX TREATMENT OF ANOREXIA – CACHEXIA
SYNDROME PATIENTS WITH LUNG CANCER
A. Snegovoy1, L. Manzuk1, A. Saltanov2, V. Selchuk3 1Research of New
Anticancer Drugs, N.N. Blokhin Russian Cancer Research Center, Moscow/
RUSSIAN FEDERATION, 2Icu Department, N.N. Blokhin Russian Cancer
Research Center, Moscow/RUSSIAN FEDERATION, 3Head Chair of Oncol-
ogy, N.N. Blokhin Russian Cancer Research Center, Moscow/RUSSIAN
FEDERATION
Background: Decrease in total body mass is one of the major symptoms of
presence or development of tumor. Tumor cachexia is suspected in cancer
patients (pts) with weight loss 5% for 6 months, especially if the weight
loss is associated with loss of muscle tissue. In cancer pts, it is mandatory to
note that tumor cachexia is combined with anorexia, leading to anorexia-
cachexia syndrome.
Materials and Methods: 10 pts with locally advanced and metastatic disease,
undergoing out-patient chemotherapy (CT) with different regimens. A me-
dian decrease in body mass of 13–15 kg, anorexia stage 1–2, asthenia,
low-grade fever, depression, alimentary failure, nausea, foul taste, anemia,
hypoprotenemia, pain syndrome (2–3 points) and thrombocytosis were
observed. Additionally, PG-SGA, QLQ C-30, VAS and ‘ABC’ (in-house
design) scales were used. The treatment scheme ‘step by step’ (in-house
design) included four levels. The pts were divided into 2 groups according to
the duration of complex treatment use: in the 1st group (n12) the treatment
was conducted only for a period of 7 days before every cycle of CT, whereas
in the 2nd group (n11) the treatment was also resumed on the 7th-8th day
after administration of CT for a period of 5 days. The interval between the
cycles of CT was 15–21 days. Evaluation was performed after 2 cycles of
CT.
Results: As a result of complex treatment use, improvement was observed
in both groups, however stabilized body mass, increased physical activity
and increased appetite were observed in 72% of pts from the 2nd group.
Similar results were observed only in 18% of pts from 1st group (Student’s criteria
3,1 p.
231P
ERLOTINIB AS THIRD-LINE THERAPY IN ADVANCED/
METASTATIC NON SMALL CELL LUNG CANCER
(NSCLC): RESULTS FROM A SINGLE-CENTRE
EXPERIENCE
A. Rozzi, C. Nardoni, M. Corona, F. Petricola, R. Restuccia, G. Lanzetta
Oncology Unit, Istituto Neurotraumatologico Italiano, Grottaferrata
(Rome)/ITALY
Background: In recent studies Erlotinib demonstrated its substantial efficacy
in NSCLC after failure of chemotherapy. In this study we evaluated the
efficacy in terms of radiographic and symptomatic response of Erlotinib in
patients with advanced/metastatic NSCLC progressed during/after second-
line chemotherapy. Patients and methods: From March October 2006 to
November 2007 we consecutively recruited twenty pts with unselected
advanced/metastatic NSCLC progressed during/after second-line chemother-
apy. Mean characteristics of pts were as follows: M:F12:8, median ECOG
PS 2 (range 1–2), median age 62 yrs (range: 45–76), median number of
metastatic sites 2 (range: 0–3). All pts received consecutively first-line
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(platinum-based regimen) and second- line (docetaxel or pemetrexed) che-
motherapy. Erlotinib, at dose of 150 mg/daily p.o., was administered until
appeareance of unacceptable toxicity or progressive disease. At least one
month on treatment was required to consider evaluable each patient enrolled.
Radiographic response was evaluated using WHO criteria while symptom-
atic response was defined using FACT-L scale.
Results: To date, eighteen pts are evaluable for efficacy and toxicity. No CR was
observed. Two pts (11%) had PR, three (17%) SD while thirteen pts (72%)
progressed. Time to progression (TTP) was 7,8 weeks (range 3–14) with a
median overall survival (MOS) of 5,9 months (range 2–9). Using FACT-L scale
the symptom improvement rate was 39% and median duration of benefit was 2,3
months (range 1–4). Erlotinib was well tolerated: no G3–4 haematological
toxicities were recorded. Acne-like cutaneous rash was G3 in three pts (17%),
G2 in five pts (28%), G0–1 in ten pts (55%). Diarrhoea was easily managed: one
patient developed G3 diarrhoea and G2 diarrhoea was observed in three pts
(17%). Other toxicities were G1–2 and required any intervention.
Conclusion: Erlotinib showed an expected satisfactory profile of toxicity
with an interesting activity in terms of amelioration of the most frequent
lung-cancer related-symptoms. Due to its efficacy in symptom improvement,
administration of Erlotinib as third-line therapy should be considered beyond
the appeareance of radiographic response in advanced/metastatic NSCLC.
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ERLOTINIB TREATMENT AFTER FAILURE OF
GEFITINIB IN PREVIOUSLY RESPONDING PATIENTS
WITH ADVANCED NON–SMALL-CELL LUNG CANCER
(NSCLC)
E. Vasile1, C. Tibaldi1, A. Chella2, M. Lo Dico1, E. Mazzoni1, A.
D’Incecco1, N. Ambrosino2, A. Falcone3 1Division of Medical Oncology,
Civil Hospital Livorno, Livorno/ITALY, 2Division of Pneumology, Cisanello
Hospital Pisa, Pisa/ITALY, 3Oncology, University of Pisa, Pisa/ITALY
Background: Gefitinib (G) and erlotinib (E) are two orally active EGFR
tyrosine kinase inhibitors (TKI). G was the first EGFR TKI to become
available in Europe in an expanded access program in pre-treated advanced
NSCLC. When E granted approval for its demonstrated survival advantage
versus placebo in the BR.21 phase III trial, there were many patients who had
progressed after receiving G and different lines of chemotherapy with no
further treatment options; the clinical results suggested that E could be more
efficacious than G and that there could be significant differences in the
mechanisms of sensitivity between these two agents, and so there was a
potential rationale to evaluate the activity of E after the failure of G.
Methods: This analysis includes heavily pretreated advanced NSCLC pa-
tients who had previously obtained a partial response (PR) or a stable disease
(SD) with G 250 mg/day treatment. After progression of disease (PD),
patients received E at the daily dose of 150 mg until PD or unacceptable
toxicity. Patients accrual was early stopped because of the closure of the G
expanded access program after the results of ISEL study. Results: Eight
patients were enrolled; 4 patients were female and histology was adenocar-
cinoma in 4 cases, and bronchoalveolar carcinoma and unspecified NSCLC
in 2 cases each. Median age was 70 years (range 53–85). The median number
of previous treatment regimens was 3. Seven patients had never smoked and
one was a former smoker. With E treatment, we obtained 2 PRs (25%) and
3 SDs (37.5%) with a median duration of response of 8 months; 3 patients
experienced PD. The median time to progression (TTP) to E was 5.75
months. Although all patients has achieved tumor control with G, at an
exploratory analysis those patients who obtained PR or SD with E had
showed a longer TTP to previous G (21 and 16 months, respectively) than
those who progressed under E treatment (6.5 months).
Conclusion: E seems to be a potential therapeutic option for the treatment of
selected advanced NSCLC patients after the failure of G. Further studies are
warranted to evaluate the molecular mechanisms behind this evidence and to
clarify how to select patients for one or more treatment with EGFR TKIs.
MESOTHELIOMA
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EXTRAPLEURAL PNEUMONECTOMY AFTER
CISPLATIN/GEMCITABINE OR CISPLATIN/
PEMETREXED INDUCTION FOR MALIGNANT PLEURAL
MESOTHELIOMA
I. Opitz1, A. Schramm1, P. Kestenholz1, D. Lardinois2, T. Rordorf3, R.A.
Stahel4, W. Weder5 1Thoracic Surgery, University Hospital Zurich, Zurich/
SWITZERLAND, 2Division of Thoracic Surgery, University Hospital Basel,
Basel/SWITZERLAND, 3Ondology, University Hospital Zurich, Zurich/
SWITZERLAND, 4Clinik and Policlinic of Oncology, University hospital of
Zuerich - USZ, Zurich/SWITZERLAND, 5Division of Thoracic Surgery,
University Hospital Zurich, Zurich/SWITZERLAND
Objective: To evaluate overall survival and time to recurrence with induction
chemotherapy of two different regimens followed by extrapleural pneumonec-
tomy for patients with malignant pleural mesothelioma (MPM). Material and
Methods: Eligible patients had MPM with clinical stage T1–3 N0–2 M0 disease
considered to be completely resectable. Neoadjuvant chemotherapy consisted of
a combination of cisplatin and gemcitabine (cis/gem) or cisplatin and pem-
etrexed (cis/pem). Surgery included extrapleural pneumonectomy, resection of
pericardium and diaphragm. Postoperative radiotherapy was optional.
Results: From May 1999 to July 2007, 128 patients were included in the
multimodality treatment concept for MPM; 51% received the combination
cis/gem and 49% cis/pem. 87 patients underwent extrapleural pneumonectomy
corresponding to a resectability rate of 68%. Postoperative morbidity was 57%,
whereas 90-day mortality was 6.9%. The median survival of the operated
patients was significantly longer with 23 months (95% CI: 19.9; 26.0) for a
median follow-up time of 20 months (95% CI: 3.0; 87.6) in comparison to 9.5
months (95%CI: 8.0; 10.9) of the patients without EPP (p0.0001). Median
time to recurrence of patients that underwent EPP was 11.3 months (95% CI:
8.8; 13.8). There was a trend for a longer median survival in the cis/pem group
(26.9 (95%CI: 19.6; 34.2) vs. cis/gem (22.9 (95% CI: 19.6; 26.1) but not
statistically significant (p0.7). Significant prognostic factor for longer survival
were histological subtype (epithelial) (p0.01) and lymph node involvement
(p 0.0001). The time to recurrence was prognostically influenced by the
following factors: stage of disease (T-factor: p0.0009, N-factor: p0.001),
extend of resection (p0.00001). Cox-regression analysis revealed histological
subtype only as independent prognostic factor for survival (p0.004).
Conclusion: Induction chemotherapy with cis/gem or cis/pem followed by
EPP for MPM results in a median survival time of 23 months. Although not
compared by randomization there was no difference in survival between the
two chemotherapy regimens applied.
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EVOLUTION OF LUNG FUNCTION PARAMETERS IN
A TRI-MODALITY PROTOCOL FOR MALIGNANT
PLEURAL MESOTHELIOMA (MPM): HOW SAFE IS
INTENSITY-MODULATED RADIOTHERAPY?
Y. Lievens1, P. Nafteux2, B. Vanstraelen3, J. Moons2, K. Nackaerts4 1Radiation
Oncology, Universitaire Ziekenhuizen Leuven, Leuven/BELGIUM, 2Thoracic Sur-
gery, Universitaire Ziekenhuizen Leuven, Leuven/BELGIUM, 3Radiation Phys-
ics, Universitaire Ziekenhuizen Leuven, Leuven/BELGIUM, 4Respiratory On-
cology, Universitaire Ziekenhuizen Leuven, Leuven/BELGIUM
Purpose: To evaluate and compare the lung function parameters of MPM
patients after hemi-thoracic radiotherapy with 3D conformal radiotherapy
(3D-CRT) and intensity modulated radiotherapy (IMRT). Materials and
methods: Out of 43 patients included in a tri-modality protocol between
3–2003 and 12–2007, 22 patients have been referred for radiotherapy (RT)
after 3 cycles of cisplatin-based induction chemotherapy and extrapleural
pneumonectomy. Of them, 20 patients completed the full course of RT
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(54Gy/1.8Gy) to the entire hemithorax, while 4 patients received an addi-
tional boost of 10Gy/2Gy to areas of incomplete resection. All patients were
evaluated for lung function changes (FEV1 - forced expiratory volume at 1
second and DLCO - diffusion capacity).
Results: Of the 20 patients completing radiotherapy, 4 have not yet reached
6 months follow-up. Two patients died within 6 months after RT: one due to
metastatic disease, one - treated with 3D-CRT - due to overwhelming BOOP
after RT. One patient was followed elsewhere and did not perform lung
function tests. The 13 patients with a follow-up of at least 6 months after RT
were included in this analysis: 8 patients were treated with IMRT (all but one
had a right-sided mesothelioma) and 5 with 3D-CRT (all except one were
left-sided). The mean lung dose and the percentage of lung volume receiving
more than 20 Gy (Vlung20) were 9.96 Gy and 9.17% in the IMRT patients
compared to 2.98 Gy and 2.09% in the 3D-CRT patients (p 0.0001 and p
0.03 respectively). The table shows the evolution (in percentile means 
standard deviations) of the lung function tests for the periods post-surgery
and six months post-radiotherapy. Paired student t-test showed no significant
differences over time.
FEV1
post surgery
FEV1
6 months post RT P 
3D-CRT 42.6  0.6 38.0  6.2 0.133
IMRT 40.7  8.4 45.5  6.0 0.112
DLCO
post surgery
DLCO
6 months post RT
P 
3D-CRT 40.3  4.1 45.0  5.5 0.512
IMRT 36.4  6.1 46.4  7.3 0.746
Conclusion: Although IMRT (necessary to limit the dose to surrounding
organs, especially the liver) delivered a significantly higher dose to the
remaining lung, this did not translate in a worse pulmonary outcome in our
MPM patient population.
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ERCC1 - PROGNOSTIC MARKER FOR MALIGNANT
PLEURAL MESOTHELIOMA
I. Opitz1, A. Soltermann2, A. Schramm1, M. Abaecherli1, P. Vogt1, H.
Moch2, N. Probst-Hensch3, R.A. Stahel4, W. Weder5 1Thoracic Surgery,
University Hospital Zurich, Zurich/SWITZERLAND, 2Institute of Pathology,
University Hospital Zurich, Zurich/SWITZERLAND, 3Institute of Pathology,
Universitary Hospital Zurich, Zurich/SWITZERLAND, 4Clinik and Policlinic
of Oncology, University Hospital of Zuerich - USZ, Zurich/SWITZERLAND,
5Division of Thoracic Surgery, University Hospital Zurich, Zurich/SWIT-
ZERLAND
Background: Malignant pleural mesothelioma (MPM) is a highly aggressive
tumour with poor prognosis and limited response to therapy. Expression of
the excision repair cross-complementation group 1 (ERCC1) protein predicts
response to platinol-based chemotherapy and survival in lung cancer pa-
tients. The relevance of ERCC1 expression in MPM has not yet been studied.
Patients and Methods: In the present tissue microarray-based study, quad-
riple punches of 341 MPM were studied for the expression of ERCC1 by
immunohistochemistry using monoclonal antibody 8F1. Staining intensity
was semi quantitatively scored (0–3) and percentage of positive stained cells
(0–100%) was measured. A final H-score was calculated by multiplication of
intensity with percentage. This H-score was correlated to overall survival.
Results: Clinical data from 206 patients were available. 105 patients were
stage T4 and 92 patients presented with regional and mediastinal lymph node
metastasis. ERCC1 was expressed in 80% of these cases. Median H-score
was 0.26. Survival time was correlated to marker expression in 126 cases
with complete follow-up data. Univariate analysis revealed age ( 62 vs.
62 years) (p0.02), histological subtype (epithelial vs. biphasic vs. sarco-
matoid) (p0.01), treatment (none with trimodality therapy) (yes vs. no) (p
0.0015) and H-Score (0.26 vs. 0.26) (p0.0004) as prognostic marker.
Median survival of patients with ERCC1-H-score 0.26 was 8.8 (95% CI
7.1; 10.5) in comparison to patients with H.score 0.26 15.5 months (95%
CI 8.0; 22.9). Cox-regression analysis of all factors revealed ERCC1 H-score
as the only independent marker for overall survival.
Conclusion: Loss of ERCC1 expression seems to be an independent prognostic
marker for poor overall survival of mesothelioma patients. The exact predictive
value of this marker especially in the context of platinol-based chemotherapy
needs to be further analysed in a prospectively documented data-base.
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HUMAN MESOTHELIOMA CELL PROLIFERATION IS
DE-REGULATED BY P38 MAP KINASE ISOFORMS AND
C/EBP-BETA EXPRESSION
J. Zhong1, M. Cornelson-Gencay2, D. Lardinois3, M. Tamm4, M. Roth1
1Department of Biomedicine, Pulmonary Cell Research, Basel/SWITZER-
LAND, 2Department of Biomedicine, Pulmonary Cell Research, Basel/
SWITZERLAND, 3Division of Thoracic Surgery, University Hospital Basel,
Basel/SWITZERLAND, 4University Hospital Basel, Pneumology, Basel/
SWITZERLAND
Malignant mesothelioma is characterized by uncontrolled cell proliferation and
local invasion rather than metastatic spread. Tumour growth and invasion
depends on mesothelioma cell proliferation and digestion of extracelluar matrix
(Zhong et al J Cell Physiol. 2006; 207: 540–52). Activation of p38 mitogen
activated protein kinase (MAPK) is an important signalling pathway involved in
mesothelioma cell proliferation. However, the role of p38 MAPK-isoforms and
their substrate the transcription factor CCAAT/enhancer binding protein (C/
EBP) -b in this process is unknown. C/EBP-b belongs to the family of C/EBP
isoforms which have either anti- or pro-proliferative actions. C/EBP-b has been
shown to exhibit pro-proliferative actions on tissue structural cells. Therefore we
characterised the expression, activation and interaction of Erk1/2 and p38
MAPK-isoforms, and C/EBP-b in human mesothelioma and non-malignant
mesothelial cell lines by immuno-blotting, immunohistochemical straining, RT-
PCR, and cell count assessment. Serum (5%) or platelet-derived growth factor
(PDGF)-BB (20 ng/ml) rapidly activated Erk1/2 MAPK and C/EBP-b, in all cell
lines and increased proliferation significantly. In mesothelioma cells, contrast to
mesothelial cells, total p38 MAPK was constitutively activated. In mesothelial
cells p38a and p38b MAPK were translocated into the nucleus upon PDGF-BB
stimulation, while in mesothelioma cells p38a MAPK remained in the cytosol,
p38b MAPK was shifted into the nucleus, and p38g MAPK was only detected
in the nucleus. The expression of C/EBP-b was controlled by different p38
MAPK-isoforms in mesothelial and mesothelioma cells. In mesothelioma cells
the down-regulation of Erk1/2, p38b and p38g MAPK, or of C/EBP-b inhibited
PDGF-BB-stimulated proliferation. In conclusion inhibition of specific p38
MAPK or C/EBP-b may serve as novel targets for mesothelioma therapy.
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NOVEL STRATEGIES IN MOLECULAR TARGETING
THERAPY OF MESOTHELIOMA
S. Korfee1, T. Gauler2, C. Po¨ttgen3, D. Cortes-Incio4, P. Schu¨tt4, T. krbek5,
H. Teschler6, W.E.E. Eberhardt4 1Dept. Internal Medicine (Cancer-Re-
search.), West German Cancer Centre Essen, Essen/GERMANY, 2Internal
Medicine (Cancer-Research), University Duisburg-Essen, Essen/GER-
MANY, 3Dept. of Radiation Oncology, West German Cancer Centre, Essen/
GERMANY, 4Department of Internal Medicine, West German Cancer Center,
Essen/GERMANY, 5Department of Thoracic Surgery, Ruhrlandklinik, Essen/
GERMANY, 6Department of Pulmology, Ruhrlandklinik, Essen/GERMANY
Background: The number of patients with malignant mesothelioma is ex-
pected to increase in the industrialized world within the next years. Although
few anticancer drugs like gemcitabine, pemetrexed and cisplatin have shown
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proven activity in this specific tumor entity, overall survival following
systemic therapy is still unsatisfactory. New therapeutic strategies are ur-
gently needed. In a well characterized mesothelioma cell-line model we have
analyzed the in-vitro cytotoxic activity of several novel molecular targeting
agents. Materials and methods: Individual mesothelioma cell-lines (MSTO-
211H, NCI- H2052, NCI-H2452, NCI-H28) were exposed to several novel
molecular targeting agents. Cellular growth was evaluated by MTT assay.
Results: 17-AAG - an inhibitor of HSP90 - and Bortezomib - a proteasom
inhibitor - were found to be the most effective agents among the panel of
compounds and drugs we have tested so far. For 17-AAG we have observed
IC50 values  1 M. For Bortezomib we have observed IC50 values between
0,002 and 0,01 M. A strong expression of HSP90 and its client proteins EGFR,
VEGFR2, c-met and Akt was detected in majority of the cell-lines.
Conclusion: Our results indicate that 17-AAG and bortezomib are inhibiting the
growth of mesothelioma cell-lines in vitro. Our findings in this model demon-
strate some evidence, that mesothelioma represents a molecular profile that is
vulnerable for targeting HSP90. We are also continuing to analyse the molecular
mechanisms behind the high efficacy of bortezomib against mesothelioma cell-lines.
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CISPLATIN AND VINORELBINE FIRST LINE
CHEMOTHERAPY IN NON-RESECTABLE MALIGNANT
PLEURAL MESOTHELIOMA (MPM)
J.B. Sorensen1, H. Frank2, T. Palshof3 1Dept. Oncology, Finsen Centre/
National University Hospital, Copenhagen/DENMARK, 2Dept. Oncology,
Aalborg Hospital, Aalborg/DENMARK, 3Dept. Oncology, Aarhus University
Hospital, Aarhus/DENMARK
Purpose: To evaluate the activity of cisplatin and vinorelbine in previously
untreated, inoperable patients (pts) having histologically verified Malignant
Pleural Mesothelioma (MPM).
Patients and Methods: Previously untreated inoperable MPM pts without
upper age limit, and with normal organ function and performance status 0–2.
Treatment was cisplatin 100 mg/m2 i.v.day 1 and vinorelbine 25 mg/m2 i.v.
weekly every four weeks with hydration and standard prophylactic anti-
emetic treatment. The study was approved by the health authorities and the
local ethical committees. Patients gave written informed consent.
Results: Characteristics of 54 consecutive patients were: Males 85%, epi-
thelial subtype 74%, IMIG stages III and IV 35% and 46%, performance
status 0, 1, and 2 26%, 69%, and 6%, and median age 63 years (31–78 years).
CTC grade 3 or 4 toxicity occurred with respect to leucocytopenia (48% of
pts, grade 4 in 13%), nausea (13%), neurotoxicity (11%), nephrotoxicity
(4%), and other toxicities (9%). There were no toxic deaths. Median no. of
cycles was 4. The fraction of patients alive at 1-, 2-, and 3-yrs were 61%,
31%, and 4%, respectively. Median survival and median time to progression
were 16.8 months (0.5–46.4months) and 7.2 months (1.6–40.6 months),
respectively. There were two CRs and 14 PRs (response rate 29.6%).
Conclusions: Cisplatin and intraveneous vinorelbine is a feasible and highly
active regimen in MPM with a response rate and survival comparable to the
most active regimens so far reported.
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ALTERATIONS IN NF2 SIGNALING PATHWAY IN
MALIGNANT PLEURAL MESOTHELIOMA
C. Thurneysen1, I. Opitz2, S. Kurtz3, R.A. Stahel4, W. Weder5, E. Felley-
Bosco6 1Molecular Oncology/Internal Medicine, University Hospital of Zu-
rich, Zurich/SWITZERLAND, 2Thoracic Surgery, University Hospital Zu-
rich, Zurich/SWITZERLAND, 3Molecular Oncology/Internal Medicine,
University Hospital of Zurich, Zurich/SWITZERLAND, 4Clinik and Poli-
clinic of Oncology, University Hospital of Zuerich - USZ, Zurich/SWITZER-
LAND, 5Division of Thoracic Surgery, University Hospital Zurich, Zurich/
SWITZERLAND, 6Molecular Oncology, Dpt. Internal Medicine, University
Hospital of Zurich, Zurich/SWITZERLAND
Cytogenetic analysis of mesothelioma has revealed that the single most
consistent numerical chromosomal change concerns chromosome 22. The
tumor suppressor merlin is encoded by the neurofibromatosis type 2 gene
NF2 which is located on chromosome 22q12 and mutations in this gene have
been found in 40% of mesothelioma. Mutations including deletions and
insertions lead to truncated and inactivated merlin. Experimental animal
models indicate that disruption of NF2 signaling pathway, together with
deficiency in lnk4a, is essential for mesothelioma development. We made the
hypothesis that in mesothelioma without detectable NF2 alterations, regula-
tors of NF2 activity such as CPI-17, would be altered. CPI-17 is an oncogene
inhibiting merlin phosphatase which is necessary to maintain merlin active.
Elevated levels of CPI-17 are expected to inhibit merlin activity. Tumor
samples were resected from 37 MPM patients and were used for primary
culture or RNA extraction. 7 normal pleura and 2 inflamed pleura samples
were obtained from patients with unrelated pathologies. Primary cultures
were characterized by mesothelin and N-cadherin and p14 (lnk4a) expression
analysis. NF2 transcripts were amplified by PCR in conditions allowing the
detection of NF2 transcripts variants. Unexpected PCR fragments, correspond-
ing to deleted NF2 transcript, were analyzed by sequencing. CPI-17 expression
was determined using real-time PCR. All samples expressed N-cadherin and
mesothelin and lacked p14 expression. Truncated NF2 transcripts were observed
in 8 MPM samples. In all other samples NF2 isoform 1 only or isoforms 1 and
2 were detected. 17 MPM and 2 normal pleura samples expressed also splicing
variant 7. Unexpected variants in addition to wild type were identified in 21
MPM samples but not in controls. CPI-17 expression was significantly increased
in tumor samples without deleted NF2 compared to normal pleura and tumor
expressing deleted NF2 transcripts. Taken together these results support the
hypothesis that disruption of NF2 signaling in a p14 deficient background is
essential for mesothelioma development.
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GENETIC POLYMORPHISMS WITHIN XENOBIOTIC
METABOLIZING ENZYMES, OXIDATIVE PROTECTIVE
ENZYMES AND GENOME STABILITY GENES AND RISK
OF PLEURAL MESOTHELIOMA
F. Bottari1, S. Landi1, F. Gemignani1, S. Bonassi2, M. Neri2, M. Ceppi2, R.
Filiberti2, P. Scaruffi2, G.P. Tonini3, L. Mutti4 1Biology, University of Pisa,
Pisa/ITALY, 2Molecular Epidemiology, Epidemiology and Biostatistics, Na-
tional Cancer Research Institute, Genoa/ITALY, 3Translational Paediatric
Oncology, ASl11, Genoa/ITALY, 4Laboratorio di Oncologia Clinica, ASL11,
Vercelli/ITALY
Background: Malignant pleural mesothelioma (MPM) is a rare and aggres-
sive cancer. Asbestos fibres exert their well-recognized causative effect on
MPM through direct or indirect mechanisms. They could modify the mitotic
spindle during mitosis, causing chromosome abnormalities, and activate or
inactivate a variety of genes by phosphorylation (EGFR, INSR, INK4a/ARF,
p16, NF2, genes). Moreover, they could cause changes in the expression of
TNF and its receptor TNFR1 in mesothelial cells. However, the most
acknowledged carcinogenic mechanism is the DNA damage mediated by
iron-related oxygen-free radicals produced by the asbestos fibres that directly
penetrated and persisted within the lung, engraving the mesothelial surface
and causing prolonged cycles of tissue and DNA damages, repair, and local
inflammation. There are few previous studies investigating the role of
polymorphisms associated with the risk of MPM. Some investigated poly-
morphic enzymes within the pathways protecting cells against oxidative
damages (the oxidative protective enzymes, OXPE), whereas very few
investigated the role of polymorphisms within the xenobiotic metabolizing
enzymes (XME) and within the genes involved in the maintenance of the
genome stability (GS). In this work, we performed a case-control association
study focusing on three main groups of genes: the XME, the OXPE, and the
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GS genes. Thus, an explorative case–control association study on 120 MPM
patients and an appropriate number of referent subjects is described. We
studied 114 single nucleotide polymorphisms (SNP) within XME, 24 SNPs
in OXPE genes and 167 SNPs in GS genes in relation to the risk of MPM.
Methods: The polymorphisms were analyzed by a micro-array technique
based on the arrayed-primer extension (APEX) principle.
Results: When the three groups of genes were compared, the highest share of
associations were found within the GS and OXPE genes, whereas very few
association were found for the XME genes. Thus, the present results seem to
corroborate the original hypothesis.
Conclusions: Future studies are warranted in order to replicate our findings
on GS and OXPE genes.
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DETERMINATION OF MTD AND PHARMACOKINETICS
FOR PEMETREXED PLUS CISPLATIN WITH VITAMIN
SUPPLEMENTATION
T.H. Fink1, M. Thomas2, J.E. Latz3, A.M. Hossain3, L. Musib3, N. Dick-
greber4 1Pneumologie, Klinikum Nurnberg Nord, Nurnberg/GERMANY,
2Oncology, Thoraxklinik-Heidelberg, Heidelberg/GERMANY, 3Oncology,
Eli Lilly and Company, Indianapolis/UNITED STATES OF AMERICA,
4Oncology, Hannover Medical School, Hannover/GERMANY
Background: The currently established dose for the combination of pem-
etrexed (PEM) plus cisplatin (CIS) was identified before folic acid and
vitamin B12 were added to the treatment regimen. We evaluated the toxicity
and pharmacokinetics (PK) of higher doses of PEM, in combination with CIS
at a fixed dose, administered with vitamin supplementation.
Methods: This dose escalation study included patients with malignant pleural
mesothelioma (MPM) or non-small cell lung cancer (NSCLC). The starting
dose was PEM 500 mg/m2 plus CIS 75 mg/m2 on Day 1 of a 21-day cycle.
The PEM dose was increased in increments of 100 mg/m2 for subsequent
cohorts. Folic acid and vitamin B12 were administered according to label
recommendations. Blood samples for quantitation of total and free platinum
(PLAT) derived from CIS and for quantitation of PEM were collected during
cycle 1 and evaluated using noncompartmental methods.
Results: Twenty-one patients received a combined total of 84 cycles of PEM
at doses from 500 mg/m2 to 900 mg/m2 plus CIS 75 mg/m2. The MTD was
PEM 900 mg/m2  CIS 75 mg/m2. Dose limiting toxicities at this dose level
included G3 anemia, G3 bronchopneumonia, G3 neutropenia, and a death
secondary to SAEs (G4 febrile neutropenia and G5 sepsis considered
possibly related to study drug). PEM 800 mg/m2  CIS 75 mg/m2 was
identified as the recommended dose. PEM PK were consistent across dose
levels. PEM did not appear to affect PLAT pharmacokinetics (total or free).
PEM, total PLAT, and free PLAT PK were consistent with previous studies.
Conclusions: PEM  CIS with vitamin supplementation was tolerated at
higher doses than the currently established PEM 500 mg/m2  CIS 75
mg/m2. The toxicities seen in this study were not unexpected, were manage-
able and were consistent with the known safety profile of this combination.
Based on this study, the recommended dose would be PEM 800 mg/m2 
CIS 75 mg/m2. However, considering these results together with the efficacy
results from recently completed studies evaluating higher single-agent PEM
doses in patients with NSCLC and PK/PD exposure-response analyses for
PEM 500 mg/m2  CIS 75 mg/m2 in patients with MPM, the currently
established dose remains the recommended dose.
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PHARMACOKINETICS OF PLATINUM DERIVED FROM
CISPLATIN ADMINISTERED ALONE AND WITH
PEMETREXED
P.M. Specenier1, T. Ciuleanu2, J.E. Latz3, L. Musib3, C.L.S. Darstein4, J.B.
Vermorken5 1Department of Medical Oncology, University Hospital Ant-
werp, Edegem/BELGIUM, 2Department of Medical Oncology, Ion Chiricuta
Cancer Institute, Cluj/ROMANIA, 3Oncology, Eli Lilly and Company, Indi-
anapolis/UNITED STATES OF AMERICA, 4Oncology, Eli Lilly, Indianap-
olis/UNITED STATES OF AMERICA, 5Oncology, University Hospital Ant-
werp, Edegem/BELGIUM
Background: Pemetrexed (PEM)  cisplatin (CIS) is an established first-line
treatment (tx) for malignant pleural mesothelioma. This study evaluated total
and free platinum (PL) pharmacokinetics (PK) following CIS administered
alone and with PEM.
Methods: An open-label, uncontrolled, 2-arm, cross-over Phase 1 study was
conducted in patients with head and neck cancer. PK evaluations were
conducted in the first 2 tx cycles. Tx Arm A: PEM 500 mg/m2  CIS 75
mg/m2 during Cycle 1, CIS alone during Cycle 2. Tx Arm B: CIS alone
during Cycle 1, PEM 500 mg/m2  CIS 75 mg/m2 during Cycle 2. Both
groups received PEM  CIS for up to 4 additional cycles. Patients received
folate and vitamin B12 supplementation. PK parameters were computed
using noncompartmental methods. The 90% confidence interval (CI) of the
ratio of least square geometric means (R-LSGM) for Cmax and AUC of total
and free PL were used to assess drug interaction. Adverse events were graded
according to the Common Terminology Criteria for Adverse Events scale
(CTCAE, Version 3). Investigator assessment of best tumor response was
documented.
Results: Thirteen patients were evaluated. The R-LSGM and 90% CI for
the comparison of PL PK for PEM  CIS versus CIS alone were:
Cmax0.97 (CI: 0.88, 1.06) and AUC0.87 (CI: 0.81, 0.93) for total PL,
and Cmax  1.08 (CI: 0.92, 1.27) and AUC0.93 (CI: 0.82, 1.06) for
free PL. PK of total PL, free PL, and PEM were consistent with previous
studies. Four patients had 9 Gr 3/4 CTCAE laboratory toxicities, 7
considered by the investigator to be related to study drug. Four patients
had 12 Gr 3/4 CTCAE nonlaboratory toxicities, 5 considered to be related
to study drug. Four patients had 19 SAEs, 10 considered to be related to
study drug. One patient accounted for 11 of 21 Gr 3/4 toxicities and 13
of 19 SAEs. No patients died during study tx. Of 13 patients, 10 had a
best response of stable disease, 2 had progressive disease, and 1 response
was unknown.
Conclusions: There was no evidence of a drug interaction. No clinically
relevant alterations in free and total PL PK for PEM  CIS relative to CIS
alone were observed. In addition, CIS coadministration did not alter PEM
PK. Toxicities were expected, manageable and consistent with the estab-
lished safety profile for PEM  CIS.
243P
PHASE II STUDY OF VINORELBINE INTRAVENEOUSLY
(DAY 1) AND ORALLY (DAY 8) WITH CARBOPLATIN AS
1ST LINE TREATMENT IN INOPERABLE MALIGNANT
PLEURAL MESOTHELIOMA
J.B. Sorensen1, P. Sorensen2, H. Frank3 1Dept. Oncology, Finsen Centre/
National University Hospital, Copenhagen/DENMARK, 2Dept. Oncology,
Odense University Hospital, Odense/DENMARK, 3Dept. Oncology, Aalborg
Hospital, Aalborg/DENMARK
Purpose: Platinum-based combination chemotherapy improves survival and
quality of life in Malignant Pleural Mesothelioma (MPM). Vinorelbine
(VNB) is among the most active drugs and may be administered orally (p.o.)
or intravenously (i.v.). Thus, the combination of Carboplatin with VNB was
explored.
Methods: Chemotherapy-naïve inoperable MPM patients (pts) with perfor-
mance status (PS) 0–2, normal renal function, no major comorbidity, and no
upper age limit received Carboplatin AUC 5 and VNB 25 mg/m2 i.v. day 1
and VNB 80mg/m2 p.o. day 8 q. 3 weeks for 4–6 courses. CT-scans were
done initially and for every 2 courses. Modified RECIST criteria were used
for response assessment. The study was approved by the National Health
Authorities and the regional ethical committees. Pts gave written informed
consent. Results: Median age of 41 pts included was 66 years (range 42–79),
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there were 90% males, 68% had epithelial subtype, 59% had IMIG stage
stage IV, and PS 1 and 2 occurred in 59% and 20%, respectively. Median no.
of courses were 4 (range 1–6) and median time on treatment was 15 weeks.
Toxicity was modest, only grade 4 toxicity encountered was leucopenia
(15% of pts). There were 3 episodes of febrile leucopenia (7%), no bleeding
episodes and no toxic deaths. Dose reductions were necessary in 16 pts
(39%). Partial remission occurred in 10 pts (24%); there were no complete
remissions. Median times to progression and overall survival were 25 weeks
and 41 weeks, respectively.
Conclusions: This regimen of Carboplatin with VNB i.v. and p.o. was
feasible and safe in this population of MPM pts including poor-prognosis and
frail pts with PS2 and age 70 years. The activity is similar to that of other
regimens combining a platinum with drugs such as Pemetrexed, Raltitrexed,
Gemcitabine, or Epirubicin in such patient populations.
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FATAL TUMOR LYSIS SYNDROME IN MALIGNANT
PLEURAL MESOTHELIOMA AFTER PEMETREXED/
CARBOPLATIN CHEMOTHERAPY
K.Y. Lee Internal Medicine, Konkuk University Hospital, Seoul/KOREA
Tumor lysis syndrome (TLS), resulting from the rapid destruction of malig-
nant cells and release of their intracellular components into the systemic
circulation, is a potentially fatal complication of chemotherapy. TLS usually
develops in hematologic malignancies, while its incidence in solid tumors is
rare. There is no report about TLS occurring in malignant mesothelioma
which was usually refractory to conventional chemotherapy before the
advent of pemetrexed. We herein report the first case of TLS in a 74-year old
male patient with bulky malignant pleural mesothelioma after pemetrexed/
carboplatin combination chemotherapy. On the 3rd day after the 1st cycle of
pemetrexed/carboplatin chemotherapy, the typical findings for TLS in serum
electrolytes and chemistry developed and reached in peak in 7th day, with
dramatic resolution in symptoms and chest X-ray. Unexpected TLS in the 1st
cycle of chemotherapy was well overcomed with supportive treatment.
However, in the 2nd day of the 2nd cycle of chemotherapy, TLS redeveloped
in spite of prophylactic hydration and urine alkalinization. On 5th day of the
2nd cycle, pulmonary edema and oliguria developed and finally the patient
died due to cardiac arrest. We suggest that pemetrexed/platinum chemother-
apy might provoke potentially fatal TLS in malignant mesothelioma.
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CLINICAL STUDY OF TREATMEAT WITH
COMBINATION OF PACLITAXEL AND CARBOPLATIN
IN ELDERLY PATIENTS WITH ADVANCED NON-SMALL
CELL LUNG CANCER
G. Ding Cancer Center, Renji Hospital, Shanghai/CHINA
Objective: To assess the efficacy and safety of the combination of paclitaxel
and carboplatin in elderly patients with advanced non-small cell lung
cancer(NSCLC).
Methods: The patients were divided into three groups by aged: group A70,
group B 60age70 and group C60. Paclitaxel 135mg/m2 were given
intravenously one day1, combined with caboplatin AUC5 6 one day1, with
21–28 days as a cycle.
Result: The RR one-year survival CCR and TTP in group A,B and C were
31.5% 35.2% 78.1% and 5.2months 32.4% 36.4% 81.2% and 6.1months
32.8% 35.6% 79.8 and 5.7months,respectively. There were no significant
differences among three groups.Hematological, renal, hepatic,gastro-intesti-
nal toxicities were similar in three groups.
Conclusion: The regimens of TC for elderly patients with advanced NSCLC
is effective and well-tolerable.
RADIOTHERAPY
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DOSE ESCALATION STUDY ON INTENSITY
MODULATED RADIOTHERAPY (IMRT) IN LOCALLY
ADVANCED NON-SMALL CELL LUNG CANCER
(LA-NSCLC): IS THE OESOPHAGUS THE BOTTLENECK?
Y. Lievens1, A. Nulens2, A. Mousa3, W. De Wever4, S. Stroobants5 1Radi-
ation Oncology, Universitaire Ziekenhuizen Leuven, Leuven/BELGIUM,
2Radiation Physics, Universitaire Ziekenhuizen Leuven, Leuven/BELGIUM,
3Radiation Oncology, National Cancer Institute, Cairo/EGYPT, 4Radiology,
Universitaire Ziekenhuizen Leuven, Leuven/BELGIUM, 5Nuclear Medicine,
Universitaire Ziekenhuizen Leuven, Leuven/BELGIUM
Purpose: To analyse the potential dose escalation with IMRT compared to
3D-conformal radiotherapy (3D-CRT) in LA-NSCLC patients and to determine
organs at risk (OAR) interfering with increased dose delivery. Materials and
methods: CT scans of 35 LA-NSCLC patients with pathologically proven
mediastinal involvement were retrospectively retrieved from our database. In-
volved nodal areas were redefined on CT and PET by visual correlation, target
definition was restricted to PET-positive regions. Eclipse software with pencil
beam algorithm was used for treatment planning. Reference 3D-CRT plans were
made with at least 3 coplanar static 10 megavolt (MV) beams. Prescribed dose
(PD) was 66Gy/2Gy except in case of endpoint (EP) violation. Primary EP was
tumour coverage (95% coverage on 95% of the PD). Secondary EP were doses
to the spinal cord (Dmax50Gy), lung (mean lung dose19Gy; V2037%) and
heart (V40100%; V5067%; V6033%). For oesophagus tolerance,
Dmax66Gy and D2cm3 60Gy were defined. 3D-CRT plans were escalated to
reach maximal PD based on secondary EP constraints and de-escalated within
defined oesophageal tolerance. IMRT plans with the same primary and second-
ary EP, consisted of 6 coplanar 10MV beams, delivered with sliding window
technique. They were escalated to achieve an equal mean lung dose as the
reference 3D-CRT plan (comparison 1), to reach secondary EP constraints
(comp. 2) and de-escalated for oesophageal tolerance (comp. 3).
Results: The table shows differences in mean PD and oesophageal Dmax and
corresponding p-values.
3D-CRT IMRT P value
Comp. 1
PD 64.3 Gy 72.9 Gy 0.0001
Comp. 2
PD 80.7 Gy 94.9 Gy 0.0001
Dmax 79.1 Gy 93.1 Gy 0.0001
Comp. 3
PD 62.3 Gy 63.8 Gy 0.16
Dmax 60.9 Gy 61.9 Gy 0.03
If oesophageal tolerance was considered a secondary EP, oesophageal dose
was the first limiting factor for dose escalation in 86 and 91% of the 3D-CRT
res. IMRT plans.
Conclusion: IMRT has the potential to significantly increase PD in LA-NSCLC
compared to 3D-CRT if the oesophagus is not considered limiting OAR. If it is,
the advantage is lost. These findings may be important to consider when using
concomitant chemo-radiotherapy schedules in these patients.
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ADAPTIVE RADIOTHERAPY PLANNING DURING
IMAGE-GUIDED CONCURRENT CT-RT FOR LUNG
CANCER: PRELIMINARY ANALYSIS OF A PROSPECTIVE
CLINICAL STUDY
J.R. Pantarotto, F.O.B. Spoelstra, S. Senan Department of Radiation Oncol-
ogy, VU Medical Center, Amsterdam/NETHERLANDS
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Introduction: The standard treatment for locally advanced lung cancer is
concurrent chemo-radiotherapy (CT-RT), which increases acute and sub-
acute toxicity. Reducing field sizes and toxicity is possible using image-
guided approaches such as respiratory-gated radiotherapy (RGRT), but
smaller fields may lead to ‘target miss’ if volumetric changes or baseline
shifts in tumor position occur over a 4–6 week treatment course. An
IRB-approved prospective study was performed to evaluate the need for
‘adaptive modification’ of RGRT treatment plans during CT-RT.
Methods: Locally advanced lung cancer patients eligible for concurrent
CT-RT and RGRT delivery underwent a repeat 4DCT planning scan after 15
fractions. All initial treatment plans aimed to achieve a conformal 95%
isodose volume around the 4D planning target volume (PTV), while mini-
mizing lung and spinal cord dose. The repeat 4DCT scan was co-registered
with the initial scan and a new PTV was generated based on a standard
expansion of the gross tumor seen after 15 fractions. Coverage of the repeat
PTV was evaluated by applying the original treatment plan to the second
scan and recalculating the dose. Plan modification was triggered by obvious
geometric miss, a 5% reduction in the PTV volume included within the 95%
isodose volume, or unacceptable rise in a critical organ dose.
Results: Of the first 12 patients analyzed, 7 had a reduction in PTV after 15
fractions, with reductions exceeding 20% in 2 patients. Of the 5 remaining
patients, 4 had stable disease and only 1 experienced an increase in PTV
(magnitude 7.7%). Good coverage of repeat PTVs was seen using the initial
plan, with 3 patients maintaining 100% coverage by the 95% isodose volume
and others showing only slight deviations (maximum volume not covered of
1.4%). Consequently, no treatment plans were modified. Lung and cord
doses were not significantly different on the repeat scan.
Conclusion: The changes in PTV after 15 fractions of CT-RT do not appear
to be clinically significant in terms of geometric or dosimetric miss. Our
preliminary results suggest that ‘adaptive radiotherapy’ has a limited role
when RGRT is used to reduce toxicity.
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DOSE ESCALATED, HYPOFRACTIONATED
RADIOTHERAPY USING HELICAL TOMOTHERAPY
FOR INOPERABLE NON-SMALL CELL LUNG CANCER
J.B. Adkison, S.M. Bentzen, D. Khuntia, G.M. Cannon, W.A. Tome, H.
Jaradat, W. Walker, M.P. Mehta Department of Human Oncology, Univer-
sity of Wisconsin, Madison/UNITED STATES OF AMERICA
Purpose: To improve local control for inoperable NSCLC, a dose escalation
phase I study for locally advanced and medically inoperable patients was
devised to escalate the dose to tumor while limiting the dose to organs at risk
including the esophagus, spinal cord, and residual lung.
Methods: Forty-six patients judged not to be surgical candidates with Stage
I-IV NSCLC were enrolled for definitive radiotherapy. Concurrent chemo-
therapy was not allowed. Radiotherapy was delivered via helical tomo-
therapy and limited to the primary site and clinically proven or suspicious
nodal regions without elective nodal irradiation. Patients were placed in 1 of
5 dose-per-fraction bins, all treated for 25 fractions, with dose per fraction
ranging from 2.28 to 3.22 Gy. Bins were calculated to yield normalized
tissue dose (NTD) equivalents in 2 Gy fractions of 60–100 Gy, with starting
doses determined by the relative normalized tissue mean dose predicted
for  20% Grade 2 pneumonitis. Dose escalation upper limit constraints
were spinal cord maximum NTD of 50 Gy, oesophageal maximum NTD 
64 Gy to 0.5 cc volume, and oesophageal effective volume of 30%.
Results: No grade 3 RTOG acute pneumonitis (NCI-CTC v.3) or oesopha-
geal toxicities (CTCAE v.3.0 and RTOG) were observed. Pneumonitis rates
were 17% grade 0, 70% grade 1, and 13% grade 2. Multivariate analysis only
identified lung NTDmean (p0.012) and administration of adjuvant chemo-
therapy following radiotherapy (p0.015) to be independent risk factors for
grade 2 pneumonitis. Only 7 patients (15%) required narcotic analgesia
(RTOG gr. 2 toxicity) for esophagitis, with only 2.3% average weight loss
during treatment. Best in-field response rates were 17% complete response,
43% partial response, 26% stable disease, and 6.5% in-field thoracic pro-
gression. The out-of-field thoracic failure rate was 13%, and distal failure
rate was 28%. The median survival was 18 months with 2-year overall
survival of 46.8%  9.7% for this cohort, 50% of whom were stage IIIB and
30% stage IIIA.
Conclusions: Dose escalation can be safely achieved in NSCLC with lower
than expected rates of pneumonitis and esophagitis using image-guided
IMRT. The maximum tolerated dose has yet to be reached.
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FRAMELESS STEREOTACTIC BODY RADIOTHERAPY
FOR NON-SMALL CELL LUNG CANCER USING 4D
CONE-BEAM CT GUIDANCE
J. Sonke1, J. Belderbos2, M. Rossi1, J. Wolthaus1, E. Damen1, J. Lebesque1,
M. Van Herk2 1Radiation Oncology, The Netherlands Cancer Institute /
Antoni van Leeuwenhoek Hospital, Amsterdam/NETHERLANDS, 2Radio-
therapy, The Netherlands Cancer Institute, Amsterdam/NETHERLANDS
Background: Stereotactic-body-radiotherapy (SBRT) is a treatment regime
for stage I lung cancer patients showing high local control rates. To limit
toxicity, PTV margins need to be minimized requiring high precision
treatment techniques. We investigated the accuracy of frameless 4D-CBCT
guided SBRT.
Methods Patients: with peripheral tumors 5 cm were treated with SBRT
without a body frame to 54 Gy in 3 fractions within 8–10 days. For treatment
planning, a 4DCT scan was acquired. From this 4D dataset, a single 3D CT
was extracted with the anatomy in their time averaged position. Organs-at-
risk (OAR) were delineated and automatically expanded by 1 cm to validate
that corrections up to 1 cm can be safely executed during treatment delivery
without violating fixed dose constraints. Before each treatment fraction, the
linac integrated CBCT scanner was used to acquire a new 4D data set. A
local rigid registration technique was used to measure the tumor trajectory
after which the time averaged tumor misalignment is calculated and cor-
rected with a couch shift. At the end of the treatment fraction another
4D-CBCT scan is acquired to determine intrafraction stability.
Results: For 58 patients treated with SBRT in our institution 4D CBCT
guidance was feasible and patient friendly. The time from the patient
entering until leaving the treatment room was on average 50 min. The
residual inter-fraction group mean, systematic and random errors for all
directions were  1mm. The required PTV-margin wasa calculated to
account for delineation uncertainties (2 mm SD), patient specific tumor
motion, residual setup errors and intrafraction stability (systematic and
random  2 mm (1 SD)). Even at large tumor amplitudes, margins were
relatively small due to accurate guidance, shallow penumbra in lung and low
prescription iso-doses (typically 80%). For example at a 1 cm tumor
amplitude, a margin of only 0.7 cm was required. For all patients, post
treatment scans did not show unacceptable deviations.
Conclusion: Frameless SBRT can be accurately performed using 4D-CBCT
guidance. Even with considerable tumor motion the PTV-margins can safely
be kept relatively small allowing patients with larger tumor volumes to
benefit from the advantages of SBRT.
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INTERIM TOXICITY ANALYSIS OF RTOG 0236 USING
STEREOTACTIC BODY RADIATION THERAPY TO
TREAT MEDICALLY INOPERABLE EARLY STAGE LUNG
CANCER PATIENTS
R. Timmerman1, R. Paulus2, J. Galvin3, J. Michalski4, W. Straube4, J.
Bradley4, A. Fakiris5, A. Bezjak6, G. Videtic7, H. Choy8 1Radiation Oncology,
University of Texas Southwestern, Dallas/UNITED STATES OF AMERICA,
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2Statistical Unit, Radiation Therapy Oncology Group Headquarters, Phila-
delphia/UNITED STATES OF AMERICA, 3Medical Physics, Thomas Jeffer-
son University, Philadelphia/UNITED STATES OF AMERICA, 4Radiation
Oncology, Washington University, St. Louis/UNITED STATES OF AMERICA,
5Radiation Oncology, Indiana University, Indianapolis/UNITED STATES
OF AMERICA, 6Radiation Oncology, Princess Margaret Hospital, Toronto/
CANADA, 7Radiation Oncology, Cleveland Clinic Foundation, Cleveland/
UNITED STATES OF AMERICA, 8Radiation Oncology, Southwestern, Dal-
las/UNITED STATES OF AMERICA
The Radiation Therapy Oncology Group (RTOG) 0236 protocol utilized
stereotactic body radiation therapy (SBRT) with ablative prescription dose to
treat early stage non-small cell lung cancer patients (pts). A secondary
endpoint of this study was to determine treatment related toxicity. All pts
were required to have documented severe comorbid medical conditions
precluding lobectomy. Pts with peripheral (greater than 2 cm from the central
bronchial tree) T1-T3, N0, M0 tumors were eligible. The prescription dose
was 20 Gy per fraction times 3 fractions (60 Gy total dose) assuming all
water density. Subsequent analysis with proper tissue heterogeneity correc-
tion showed the actual dose to be only 54 Gy total. Early stopping rules
required that the rate of treatment related grade 3 and higher toxicity be less
than 25%. Rigorous central accreditation and quality assurance assessments
were used to insure pts were treated according to protocol guidelines. The
study opened May 2004 and closed October 2006 after accruing a total of 59
pts. Of 55 evaluable pts, 44 had T1 and 11 had T2 tumors. The majority of
pts were female (62%) and had a Zubrod score  1 (64%). Contouring and
dose/volume compliance of 22 (40%) of the pts indicated the majority (91%)
were treated per protocol or with only minor deviations. The criteria for early
stopping due to toxicity was not met in each of 3 interim toxicity assess-
ments. With median follow-up of 14.7 months (range 5.2–31.2 months),
there was one (2%) grade 4 and 7 (13%) grade 3 protocol defined pulmonary/
upper respiratory adverse events reported as related to treatment. Of these 8
pts, 3 pts reported pulmonary function test decreased, 1 pt reported cough/
dyspnea, 1 pt reported hypoxia, 1 pt reported pneumonitis, 1 pt reported
cough/forced expiratory volume, and 1 pt reported pneumothorax. There was
also 2 grade 3 dermatitis, a grade 3 syncope, a grade 3 rib fracture, and a
grade 3 fatigue reported as related to protocol treatment. No treatment related
deaths have been reported. SBRT using an ablative total dose of 54 Gy in 3
fractions appears to be associated with acceptable treatment related morbid-
ity in a population of frail pts with medically inoperable early stage
non-small cell lung cancer with peripheral lesions. Further toxicity follow-up
and assessment of the effect of pretreatment comorbidity is ongoing. Pts
continue to be followed for the primary endpoint of 2-year local control.
Supported by grant numbers (RTOG U10 CA21661, CCOP U10 CA37422,
Stat U10 CA32115) from the National Cancer Institute and the ATC grant
(U24 CA 81647).
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ANATOMICAL CHANGES DURING RADIOTHERAPY OF
LUNG CANCER PATIENTS
M. Van Zwienen1, S. Van Beek1, J. Belderbos2, S. Van Kranen2, C. Rasch2,
M. Van Herk2, J. Sonke2 1Radiotherapy, Netherlands Cancer Institute,
Amsterdam/NETHERLANDS, 2Radiotherapy, The Netherlands Cancer Insti-
tute, Amsterdam/NETHERLANDS
Purpose: Cone-beam CT (CBCT) guided radiotherapy (RT), allows repeti-
tive imaging of the anatomy in 3D. During RT for lung cancer, tumor
progression or regression may be seen as well as other anatomical changes
within the thorax requiring re-planning. The purpose of this study is to
quantify the occurrence of anatomical changes during conventional RT with
curative intent.
Materials and Methods: In this study, 114 consecutive lung cancer patients
(pts) were included, treated with conventional RT with a dose of 45 Gy to 88
Gy over 5–6 weeks. Tumor stage ranged from T1N0 to T4N3. Pts received
repetitive CBCT scans for an off-line setup correction protocol. To assess the
tumor volume a radiation oncologist delineated the tumor on the planning CT
and one CBCT each treatment week. The occurrence or dissolving of
atelectasis, and pleural effusion were scored qualitatively.
Results: Forty-seven pts (41%) manifested considerable anatomical changes
in at least one of the categories. Tumor regression was observed in 37 pts
(32%), while only one pt (1%) showed tumor progression during therapy.
Changes in atelectasis were found for 26 pts (23%), in 20 dissolving (18%)
and in 6 increasing (5%), pleural effusion in 13 pts (11%). The tumor volume
on the CBCT’s in the group with regression is listed in Table 1. At the end
of treatment 10 pts showed a tumor size decrease of  50%, 17 pts: 25 –
50%, and 10 pts:  25%. In nine pts a reduction of  25% was seen in the
3rd week and in 19 in the 4thweek. Larger volume reductions were associ-
ated with reducing atelectasis. Clinically, the CBCT information led to
re-planning for 6 pts, mainly in case of atelectasis changes.
Conclusions In one third of the lung cancer pts, tumor regression was seen
over the 5–6 week course of conventional RT. A protocol is needed to
monitor anatomical changes during treatment and quantify whether the
delivered dose meets the treatment intent. Further research on CTV coverage
of re-planning following regression is required before clinically introduction.
Planning
CT
Day
1
Day
2
Week
2
Week
3
Week
4
Week
5
Week
6
Tumor volume (cc)
Mean 143 147 151 130 117 98 80 64
SD 102 99 104 89 83 71 57 56
Change 1.00 1.11 1.14 1.02 0.83 0.70 0.63 0.56
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IMRT-BASED 4D STEREOTACTIC RADIOTHERAPY FOR
EARLY STAGE INOPERABLE LUNG CANCER: UPDATED
OUTCOMES AND INITIAL CLINICAL VALIDATION OF A
RADIOBIOLOGIC MODEL
G.M. Cannon1, C.W. Hodge1, W.A. Tome1, D. Khuntia1, T. Weigel2, K.
Palazzi-Churas1, I. Tan1, M.P. Mehta1 1Department of Human Oncology,
University of Wisconsin, Madison/UNITED STATES OF AMERICA, 2De-
partment of Surgery, University of Wisconsin, Madison/UNITED STATES
OF AMERICA
Purpose/Objective(s): We have previously described the predictive Tome´-
Fenwick model which will hypothetically provide for rational selection of a
safe and effective hypofractionated dose schedule to treat early stage,
medically inoperable non-small cell lung cancer (NSCLC). We report the
updated clinical outcomes from a treatment regimen generated by the model.
Methods and materials: Twenty-three patients with stage IA/B NSCLC were
treated with SBRT between December 2003 and April 2006. All lesions were
2cm distal to the proximal tracheobronchial tree. Patients were immobi-
lized using a full BodyFix mold, abdominal pillow, and 80 millibar vacuum
to minimize respiratory excursion. Four dimensional CT imaging was used to
define a motion envelope. The motion-defined GTV was uniformly expanded
by 6mm to generate a planning target volume. Eleven patients were treated
using linear accelerator based IMRT and 12 patients were treated using
helical IMRT. The prescription was 60 Gy in 5 fractions with a median
normalized tumor dose (NTD) of 122.4 Gy10.
Results: The median age was 73 years (range 58–89). Initial staging was IA-
78% and IB- 22%. Median follow-up is 20.8 months for all patients (range
2–45.5 months) and 30.6 months for all living patients (range 17.8–45.5
months). Radiographic follow-up of 20 evaluable lesions demonstrates a
major response rate of 80%, including a complete response rate of 50%. Two
year actuarial overall, cause-specific, and disease free survival, and local
control are 63, 79, 75, and 88%, respectively. The crude incidence of grade
2 acute toxicity is 9%, and grade 3 chronic toxicity is 13%. In-field
recurrence occurred in 1/23 patients (4.3%). Conclusion: IMRT-based SBRT
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using a 12 Gy x 5 dose fractionation scheme yields a rate of local control and
survival concordant with other series which treat to much higher NTDs,
providing early clinical support for the Tome´-Fenwick model. NTDs on the
order of 120 Gy10 may be adequate for local control of stage I lung cancers,
implying that higher doses may not be necessary if appropriate volume and
targeting considerations are addressed. The procedure is well tolerated, with
minimal toxicity.
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HYPOFRACTIONATED RADIOTHERAPY WITH
STEREOTACTIC LOCALIZATION IN EARLY STAGE
NON SMALL CELL LUNG CANCER (NSCLC)
F. Salvi1, E. Donini1, L. Vicenzi1, A. Baldissera1, F. Monari1, O. Martelli1,
P. Chiovati2, M. Palombarini2, F. Spagnolli1 1Radiotherapy, Bellaria Hos-
pital, Bologna/ITALY, 2Physics, Bellaria Hospital, Bologna/ITALY
Purpose: To evaluate the response rate, survival and the toxicity of hypo-
fractionated radiotherapy (50–55 Gy/5 fractions) in patients affected by early
stage NSCLC treated in a dedicated frame with stereotactic fiducials.
Materials: From June 2002 to July 2007, 58 patients (pts), with T1N0 (50 pts)
and T2N0 (8 pts) NSCLC, not eligible to surgery, were treated with
hypofractionated stereotactic radiotherapy (SRT): 57 pts recived 50 Gy/5fr
and 1 pt 55 Gy/5fr. Mean age was 73,4 years.
Methods: Staging included CT scan and in 48 pts 18 FDG PET scan. Pts
were positioned in a dedicated frame developed by Elekta: “stereotactic body
frame”. A spiral CT scan of the chest was performed under shallow
breathing, with a reconstructed slice thickness of 3 mm. For 3D planning the
Precise Plan (Elekta) was used. Gross tumor volume (GTV) and organ at risk
were contoured in each section. Mean Clinical target volume (CTV), ob-
tained expanding the GTV of 5 mm in each directions was CTV: 32 cc.
Planning target volume (PTV) comprised the CTV with an expansion axial
of 5 mm and a longitudinal of 9 mm (mean PTV: 75,4 cc). We used a
mechanical device to reduce the movements of the diaphragm in lower lobes
tumors. Irradiation was given on 5 consecutive daily fractions with 4–6 fixed
non coplanar and coplanar beams of 10 MV photons, shaped with a MLC
aiming to encompass the PTV with 80% isodose. Mean dose to PTV was
4933 cGy.We considered lung mean dose and V12 as possible factors of
complication risk.
Results: Mean follow up was 23 months (range: 1–60). Response was evaluated
with chest CT scan and/or PET scan. 28 pts alive (22 without evidence of disease
progression); death cancer related:16/28 pts. 5 Isolated local disease progressions
in the site of treatment. 2 pts lost at the follow up, without progression of disease
after 13 and 18 months respectively from the end of treatment. Distant metas-
tases were the first cause of failure. Acute and late toxicity more then grade 2,
scored according to RTOG criteria were never observed.
Conclusions: Hypofractionated SRT in early stage NSCLC gives a high
response rate with acceptable toxicity but further follow up is necessary to
determine if this observation is related to an improvement of survival rate.
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QUALITY OF LIFE AFTER RADIOTHERAPY AND
STEROIDS IN PATIENTS WITH INOPERABLE BRAIN
METASTASES FROM NON-SMALL CELL LUNG CANCER:
THE QUARTZ TRIAL
P. Mulvenna1, R. Barton2, C.A. Pugh3, R. Stephens3 1Northern Centre For
Cancer Treatment, Newcastle General Hospital, Newcastle Upon Tyne/
UNITED KINGDOM, 2Oncology, Princess Royal Hospital, Hull/UNITED
KINGDOM, 3Cancer Division, MRC Clinical Trials Unit, London/UNITED
KINGDOM
For patients with multiple inoperable brain metastases the standard therapy
is a combination of steroids and whole brain radiotherapy (WBRT). How-
ever, WBRT causes side effects and has never been shown to correlate with
an improved quality or length of survival. Therefore, it is uncertain whether
those clinicians who treat this group of patients should continue to include
WBRT within the package of optimal supportive care (OSC) offered via the
multidisciplinary team. The QUARTZ trial compares OSC with OSC plus
WBRT in the treatment of patients with inoperable brain metastases from
NSCLC (where OSC includes dexamethasone titrated to clinical effect to the
lowest dose possible). The two arms will be compared in terms of quality of
life (using QUALYs as the primary outcome measure), overall survival, and
side-effects. Hence QUARTZ is addressing a clinical area where significant
uncertainty continues to exist. QUARTZ is now open to recruitment with 46
recruiting centres, including 3 centres from TROG (Trans Tasman Radiation
Oncology Group in Australia), with a further 24 centres organising ethics and
R&D submissions. Data for the QUARTZ trial are collected via weekly
telephone assessments between the patient (and carer if consented for
participation) and their nurse using a questionnaire including the EQ-5D,
EQ-VAS and a list of symptoms. Updated recruitment and compliance with
the weekly collection of data will be presented, which to date has proved
very successful. For more details or to register your centre’s interest please
contact QUARTZ@ctu.mrc.ac.uk.
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HYPOFRACTIONATED RADIOTHERAPY WITH IMAT
TECHNIQUE IN ADVANCED STAGE OF NSCLC
N. D’Abbiero Radioterapia Oncologica, Arcispedale Santa Maria Nuova,
Reggio Emilia/ITALY
Purpose: Hypofractionated radiotherapy technique may overcome repopula-
tion in rapidly proliferating tumor such as non small cells lung cancer
(NSCLC) without or with modest normal tissue complications. This study
reports our experience on patient with medical or stage inoperable IIIA and
IIIB NSCLC treated with hypofractionated Intensity Modulated Arc Therapy
(IMAT) technique.
Material and methods: From January 2006 to August 2007, 30 patients with
IIIA-IIIB NSCLC were treated with hypofractionated IMAT radiotherapy
after standard chemotherapy. 22 patient was IIIB and 8 patient was IIIA.
Radiotherapy started after three cicles of chemotherapy and consisted in 25
Gy in 5 fraction, in 1 week. All patient was studied with TC-PET and
planning TC with slow scan ; GTV was identified by lung window and on
PET images by appling a therehold value (40%) of the maximum uptake
value. GTV included primary and also nodal disease and PTV was generated
by adding 1 cm margin to GTV. Treatment planning was performed with
IMAT technique and dose was prescribed at 70% isodose surface with
internal dose gradient about 30%. We did not use any approce to reduce
respiratory motion but the entity respiratory motion of GTV was identified
with PET scan.
Results: All patient concluded the treatment and we observed only G1–2, in
accord to RTOG scale, acute toxicities in 10 patients.
Conclusion: IMAT technique hypofractionated at a dose of 25Gy in 5 daily
fraction is safe, well tolerated and relative easy radiation treatment. It is
shorter then traditional treatment (50 Gy in 25 fr) and my be improve quality
of life.Obviously, further studies are needed to compare similar technique
with standard treatments modalities.
SURGERY
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MINIMALLY INVASIVE RADICAL LYMPHADENECTOMY
FOR EARLY STAGE LUNG CARCINOMA
B. Witte1, W. Neumeister2, M. Huertgen1 1Lung Centre, Thoracic Surgery,
Katholisches Klinikum Koblenz, Koblenz/GERMANY, 2Lung Centre, Pneu-
mology, Katholisches Klinikum Koblenz, Koblenz/GERMANY
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Objectives: To assess the feasibility and radicality of a combined thoraco-
scopic and mediastinoscopic approach to mediastinal lymphadenectomy
compared to thoracoscopy only for minimally invasive management of early
stage lung carcinoma.
Methods: Prospective observational study of patients undergoing anatomical
thoracoscopic lung resection for lung carcinoma in our department in 2007.
Mediastinal lymphadenectomy was performed either thoracoscopically
(VATS group) or by a combination of videoassisted mediastinoscopic
lymphadenectomy (VAMLA) and thoracoscopy (VAMLAVATS group).
Inclusion criteria for the study were: stage Ia on CT scan, no central tumour
at bronchoscopy, and no contraindications against lobectomy or segmentec-
tomy. Additional criteria for VAMLA were: preoperatively confirmed his-
tology, and no contraindications against multimodality treatment.
Results: Eighteen VAMLAVATS and 14 VATS patients were studied. For
histology, pTNM stage, type of resection, semiquantitative assessment of the
fissure and vascular dissection plane, conversions, blood loss, operation time,
adverse events and drainage time, no differences between the two groups
were observed. In the VATS group, there was a slight preponderance of
women, and right-sided tumours. In the VAMLAVATS group, both the
number of dissected mediastinal lymph node stations (6.4 vs 3.6 stations) and
the weight of the mediastinal specimen (10.7 vs 5.6 gr.) were significantly
higher than in the VATS group (p0.005).
Conclusions: A combined approach by VATS and VAMLA improves
radicality of minimally invasive mediastinal lymphadenectomy without in-
crease in operation time, morbidity, and drainage time.
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COMPLETE THORACOSCOPIC LOBECTOMY IN LUNG
CANCER
A.M. Bosch1, E. Belgers2, J. Siebenga3, E. Bollen3 1Surgery, Atrium Medical
Center Heerlen, Heerlen/NETHERLANDS, 2Surgery, University Hospital
Maastricht, Maastricht/NETHERLANDS, 3Surgery, Atrium Medical Center,
Heerlen/NETHERLANDS
Introduction: One surgical treatment of lung cancer is a lobectomy and
lymph node dissection cq. lymph node sampling. In contrast to thoracotomy,
at the thoracoscopic resections, there is no need to spread the ribs. Thora-
coscopic lobectomy has shown good results since the 90’s. 50 lung resections
a year are performed in our hsopital by 2 lung surgeons. After a careful
period of preparation, we initiated completely thoracoscopic performed
lobectomies.
Technique and methods: A team of two lung surgeons and a third surgeon
perform the operation. Four ports (2 cm) usually meet the demands for
optimal preparation. One port is larger (5–7 cm) in order to palpate the
tumour and to extirpate it at the end of the operation. Demographic data of
patients, tumours, operations, admission to the hospital and pain scores were
analyzed. The minimal follow-up is 30 days.
Results: Since March 2006, 27 thoracoscopic lobectomies have been per-
formed (16 males). The mean age was 65 years. There was an equal
distribution of the tumours in the upper and lower lobes. Tumours with a
diameter of 6.5 cm were excised. Two patients received neoadjuvant
therapy. The median operating time was 210 minutes. It seems we will reach
a plateau in operating time at 150 minutes. There was no post-operative
mortality. In one operation, post-operative bleeding occured in the thoracic
wall, which was managed conservatively. One operation required a long-time
drainage of 7 days. With another operation thoracoscopy was converted to a
thoracotomy because the patient could not be ventilated on one lung. The
painscore (VAS) “in action” was zero at day three (three times 1 to 3).
Median admission time was five days. Conclusion: Our results confirm the
positive results in the literature. The complete thoracoscopic lobectomy is
safe and the benefits for the patient are impressive. There is hardly any pain
after the operation and recovery is prosperous. The use of the correct
instruments is essential. The oncological technique of the thoracoscopic
resection is identical to the thoracotomic resection and we expect the same
survival rate. The technique is awkward and the learning curve is substantial.
It is the responsibility of the lung surgeon to obtain sufficient experience and
to offer the patient a thorascopic lobectomy.
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INDUCTION CHEMOTHERAPY FOLLOWED BY
PARENCHYMA-SPARING SURGERY IN MEDICALLY
INOPERABLE NSCLC - RESULTS OF A FEASIBILITY
STUDY
M. Pless1, F. Gambazzi2, P. Stillhart3, T. Lieb4, M.H. Brutsche4 1Oncology,
Kantonsspital Winterthur, Winterthur/SWITZERLAND, 2Thoracic Surgery,
University Hospital Basel, Basel/SWITZERLAND, 3Oncology, University
Hospital Basel, Basel/SWITZERLAND, 4Pneumology, University Hospital
Basel, Basel/SWITZERLAND
Purpose: Feasibility trial to test the toxicity and outcome of three cycles of
induction chemotherapy followed by limited surgery in medically inoperable
early stage NSCLC patients.
Patients and Methods: Thirteen patients with NSCLC (stage I-IIIB) with
insufficient cardio-respiratory reserves for the oncologically required lung
resection, received three cycles of induction chemotherapy with cisplatin
(100mg/m2) and docetaxel (85 mg/m2) followed by parenchyma sparing lung
surgery. Operability was evaluated with pulmonary function tests, perfusion
scintigraphy and cardiopulmonary exercise testing. In selected patients
coronary angiography or myocardial perfusion scintigraphy was performed.
Rate of R0-resections was taken as primary outcome.
Results: Twelve of 13 patients received the 3 cycles of chemotherapy as
planned. The main grade 3/4 hematological toxicity was neutropenia (62%),
non-hematological toxicity was neutropenic fever (23%) and cough/dyspnea
(31%). Complete, partial and stable responses to chemotherapy were seen in
1, 10 and 2 patients, respectively - the overall response rate was 85%. No
patient had tumor progression. Eleven/13 (85% [CI95% 54, 97] %) patients
underwent surgery (4 lobectomies, 2 segmentectomies, 5 wedge resections),
all had a pathologically complete resection of the tumor. There was one
postoperative death due to myocardial infarction. The median disease-free
and overall survival were 57(CI95% 36–78) and 66 (CI95% 40–92) months,
with a median follow up time of 58 months. The one, two and four year OS
was 85%, 85% and 67% respectively. There were no significant changes in
any lung function parameter compared to the preoperative assessment. The
FEV1 showed a trend for improved values after surgery.
Conclusion: Induction chemotherapy in medically inoperable patients fol-
lowed by parenchyma sparing surgery is feasible and yields very promising
results.
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SYSTEMATIC RADICAL LYMPHADENECTOMY: IS IT
JUSTIFIED IN TYPICAL AND ATYPICAL CARCINOID
TUMOURS OF THE LUNG?
M. Conti1, L.M. Benhamed2, B. Silva Moura3, R. Akkad1, A. Wurtz2, H.
Porte2 1Clinique de Chirurgie Thoracique, CHU Lille - Hoˆpital Calmette,
Lille/FRANCE, 2Clinique de Chirurgie Thoracique, CHU Lille - Hoˆpital
Calmette, Lille/FRANCE, 3Clinique de Chirurgie Thoracique, CHRU Lille -
Hoˆpital Calmette, Lille/FRANCE
Study objective: To report our experience in lung carcinoid tumours surgery
in order to determine the frequency and the location of lymphatic spread in
patients who underwent resection with systematic radical lymphadenectomy
(SRL) and the benefit and risk of SRL.
Methods: We prospectively followed up all patients who underwent lung
resection associated to SRL for carcinoid tumour, starting from 1998. All
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cases were classified as typical (TC) or atypical carcinoid (AC) according to
1999 WHO criteria.
Results: From January 1998 to June 2007, 53 patients underwent lung
resection associated to SRL; there were 43 TC and 11 AC; mean age was 45
 16.1 years. Procedure included an anatomical resection in 31 patients
(58.5%) and an enlarged resection associated with bronchoplastic procedure
in 22 (41.5%), including 18 sleeve lobectomy, 1 sleeve pneumonectomy and
1 left main bronchial sleeve resection. Only one patient underwent standard
pneumonectomy. All the 53 patients underwent SRL, with a mean of 18 
8.23 nodes (range 7 to 44) per patient. In the TC group, 2 patients (4.7%)
presented an involvement of the ipsilateral hilar lymph nodes (N1 disease),
and 4 patients (9.5%) showed N2 disease. In AC group, 2 patients presented
N1 (18.1%) and 1 patient N2 disease (9%). No in-hospital mortality was
observed. Seven patients (13.20%) experienced postoperative complications
related to SRL: chylothorax (n1, 1.88%), transient left recurrent nerve
palsy (n  6, 11.3%). One patient (1.88%) presented bronchostenosis after
sleeve lobectomy, treated by endotracheal stent. Follow-up was complete for
all patients (median, 52 months; range 6 to 119 months). Mediastinal
lymphnodes involvement was statistically correlated with tumor size 3 cm
(p0.004) and age 35 years (p0.004). There was no correlation with
histological type and topography (peripheral or central tumor).
Conclusions: SRL do not increase morbidity and surprisingly show high fre-
quency of lymph node invasion not predicted by the preoperative investigations.
Nodal involvement was correlated with a young age and with the tumour size.
Long term follow-up is required to evaluate the impact of SRL on survival.
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SURGICAL TREATMENT OF COMPRESSION SYNDROME
IN PATIENTS WITH CENTRAL LUNG CANCER AND
MEDIASTINAL NEOPLASMS
V. Boyko1, A. Krasnoyarugskiy2, K. Smolyanyk2 1Department of Oncology,
Institute of General and Urgent Surgery, Kharkiv/UKRAINE, 2Thoracic
Surgery Department, Institute of General and Urgent Surgery, Kharkiv/
UKRAINE
Treatment of compression syndrome due to central lung cancer and medi-
astinal neoplasms is difficult and warrants special preoperative assessment.
Aim: To improve the results of treatment of compression mediastinal
syndrome.
Patients and Methods: 511 patients with central lung cancer and mediastinal
neoplasms were operated on in the Institute in 1997 – 2007. Compression
syndrome was revealed in 287 patients. Among them there were 82 patients
with thymomas, 138 patients with central lung cancer, 4 patients with
neurinomas of posterior mediastinum, 63 patients with mediastinal cysts of
various morphology and location. All patients underwent thoracic X-ray,
contrast-enhanced CT, transthoracic ultrasound, echocardiography with eval-
uation of volume blood flow in superior caval vein, aorta, heart chambers.
Results: In 68 cases of invasive growth aortography and cavagraphy were
performed with temporal stenting of superior caval vein in severe cava-
syndrome. 14 patients with compression syndrome of breathing pathways
and high risk of intraoperative tracheobronchial obstruction underwent stent-
ing of occluded structure preoperatively. Superselective intraarterial neoad-
juvant chemotherapy and irradiation therapy were performed in 72 patients
with malignant mediastinal tumors that resulted in reduction of tumor and
decrease of compression mediastinal syndrome. In 210 patients with malig-
nant tumor removal of tumor with lymphatic dissection were performed
(pulmonectomies - 177, thymectomies - 33). If invasion of mediastinal
structures was found various methods of reconstruction were performed:
superior caval vein reconstruction - 6, prosthesis reconstruction of pulmo-
nary artery with bypass application - 4, trachea and bronchi resection - 4,
oesophageal resection - 3.
Conclusions: Surgical strategy in patients with mediastinal tumors depends
on histologic type of tumor and severity of compression syndrome. Bypass
with reconstructive operations on major vessels and other mediastinal struc-
tures together with superselective intraarterial neoadjuvant chemotherapy
and irradiation therapy improve the duration of life in patients earlier
considered non-resectable.
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EVALUATION OF THE TUMOR REGRESSION GRADE
(TRG) IN LYMPHATIC METASTASES OF LUNG CANCER
AFTER NEOADJUVANT THERAPY
J. Klein1, C. Neoral1, V. Kolek2, T. Bohanes1, M. Szkorupa1, T. Tichy3, T.
Janaskova4 1The 1-st Department of Surgery, University Hospital Olomouc,
Czech Republic, Olomouc/CZECH REPUBLIC, 2Dep. of Pneumology, Uni-
versity Hospital Olomouc, Czech Republic, Olomouc/CZECH REPUBLIC,
3Dep. of Pathology, University Hospital Olomouc, Czech Republic, Olo-
mouc/CZECH REPUBLIC, 4Dep. of Pneumology, Hospital Ostrava-Vítkov-
ice, Ostrava/CZECH REPUBLIC
Objectives: The outcome of surgery for higher stages of non-small cell lung
cancer (NSCLC) is poor. Only 13% of patients in stage IIIA survive 5 years
after the diagnosis determination. The goal of a neoadjuvant (inductive)
therapy is to eliminate haematogenous and lymphogenous metastases and to
cause cytoreduction in the primary tumor before the resection. Especially
verification of lymphogenous metastases is the leading factor in the indica-
tion of the pre-operative chemotherapy, but this therapy is frequently indi-
cated according to CT finding without any bioptic verification.
Method: A biopsy of the lymph nodes was performed as a part of the staging
via mediastinoscopy. If the metastasis was proved, the lymph node was
labeled with a metal clip and the patient was treated by 3 cycles of the
inductive chemotherapy. If no progression was found, the labeled lymph
node was removed during the subsequent lung resection and lymphadenec-
tomy. In two cases of progression in the mediastinum, the lymph nodes were
biopsied by re-mediastinoscopy or videothoracoscopy. The evaluation of
TRG in the lymphatic metastases of lung cancer after the inductive chemo-
therapy and its comparison with the pre-operative bioptic findings have
quantificated the chance of the inductive therapy to eliminate lymphatic
micrometastases.
Results: The clinical down-staging was found in 21 cases (36,8%), but the
viable malignant cells rested in the majority (50, 87,7%) of the taken labeled
lymph nodes (57,100%) even after the neoadjuvant therapy. On the other
hand, the satisfactory tumor regression changes (TRG I-III) were proven in
49 (86%) lymphatic metastases. Conclusion: The results of the study may
modify the judgment in the staging and monitoring of the inductive therapy
in advanced stages of lung cancer.
OTHERS
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THE VALUE OF RECLASSIFICATION OF
NEUROENDOCRINE TUMORS (NE): IMPROVED
SEPERATION OF CARCINOIDS AND IMPACT ON
SURVIVAL
B.G. Skov1, M. Krasnik2, S. Lantuejoul3, E. Brambilla3 1Pathology, Herlev
Hospital, div. Gentofte, Copenhagen/DENMARK, 2Thoragic Surgery, Gen-
tofte Hospital, Copenhagen/DENMARK, 3Département D’Anatomie et Cy-
tologie Pathologiques, University Hospital Grenoble, Grenoble Cedex 09/
FRANCE
NE are rare tumours and a central database is desirable to learn more about
these tumours including the value of TNM classification in relation to
survival. Reliable histopathological diagnoses are crucial for such a database.
As a contribution to the proposed IASLC-database for NE tumours, we
retrieved 110 surgical resected tumours. All tumours were reclassified
according to the WHO classification of 2004 and the following parameters
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were registered: age by diagnosis, sex, TNM stage, endobronchial compo-
nent, treatment, recurrence and survival. By reclassification, the diagnoses on
48 tumours (44%) were changed, most of these (23 cases) were changed
from “carcinoid NOS” to typical carcinoid (TC) (19 cases), atypical carci-
noid (AC) (3 cases) and no diagnosis (too small for rediagnosis). Eight cases
were originally diagnosed as “malignant carcinoid” and rediagnosed as AC
(5 cases), large cell neuroendocrine carcinoma (LCNEC) (2 cases) and SCLC
combined (1 case). The median age was 60 years (range15–83 years).
Forty-five % were men, and LCNEC and SCLC combined were significantly
more common in men than in women whereas TC and AC were more
common in women. The median tumour size was 25 mm (range 10–100
mm). An endobronchial component was observed in 54% of TC, 31% of AC
and 11% of LCNEC. Sixty-nine of the patients were in stage I (43 TC, 9 AC,
15 LCNEC, 2 SCLC), 8 were in stage II (1 TC, 2 AC, 3 LCNEC, 2 SCLC),
15 were in stage III (2 TC, 3 AC, 7 LCNEC, 3 SCLC) and 1 patient was in
stage IV (AC). N1/N2 nodes were removed from 80/58 patients and metas-
tases were detected in 15/13 of these (3/2 TC, 4/4 AC, 6/4 LCNEC, 2/3
SCLC). Median follow-up was 4.4 years (range 0.5–20 years).The reclassi-
fication separated the tumours better than the original diagnoses in relation to
overall survival. In conclusion, all tumours must be rediagnosed before
entering a central database as the classification of lung tumours has changed
over the last 20 years. Furthermore these tumours are rare and an expert
panel should reclassify at least a subset of tumours. Information regarding
age, sex, endobronchial relation, tumour size and pleural relation, stage,
treatment, recurrence and survival should be included in a central database.
263O
RECURRENCE OF EUROENDOCRINE TUMOURS AFTER
SURGERY
M. Krasnik1, B.G. Skov2 1Thoracic Surgery Gentofte, Heartcenter Copen-
hage, Gentofte/DENMARK, 2Pathology, Herlev Hospital, div. Gentofte,
Copenhagen/DENMARK
Background: Neuroendocrine tumours (typical and atypical carcinoid, large cell
neuroendocrine carcinoma and small cell carcinoma) cover a wide spectrum of
diseases with very different pognosis. The aim of this study was to analyse the
characteristics of patients with recurrence after surgery for these tumours.
Material: 110 surgical resected tumours were retrieved from the pathology
database at Herlev Hospital, Denmark in the period 1 Jan 1989 to 15 Nov 2007.
All tumours were reclassified according to the WHO classification of 2004.
Results: Twenty patients developed recurrence - 8 in the lung, 7 in the liver,
2 multiple organs, 2 in cerebrum and 1 in the mediastinum. Six% of the
typical carcinoids, 50% of the atypical carcinoids, and 15% of the large cell
neuroendocrine tumours developed recurrence (partly detected by autopsy)
of the the disease. Not all patient that died had undergone an autopsy why the
real number of recurrence might be even higher.
Conclusion: Due to the high rate of recurrence especially for atypical
carcinoids, special attention to the follow up this group of patient is
important. As therecurrences is very frequent in the liver and the lung, the
follow up should be concentrated on these organs.
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BRONCHIAL CARCINOID 10 YEARS SINGLE
INSTITUTION EXPERIENCE
A.M. Abdelrahman1, R.M. Gaafar2, I.A.M. Mourad3, A.M. Ali3, S.A. Sherif3
1Surgery, National Cancer Institute, Cairo, Cairo/EGYPT, 2Medical Oncol-
ogy, National Cancer Insititute, Cairo/EGYPT, 3Surgery, National Cancer
Institute, Cairo/EGYPT
Purpose : Broncho-pulmonary carcinoids are reported to represent 10% of all
carcinoid tumors and 1–6% of all lung tumors. This work was conducted to
study bronchial carcinoid tumor regarding age and sex distribution, incidence
rate, surgical techniques and patients’ survival.
Patients and Methods: Between 1995–2004, 29 pateints with broncho-
pulmonary carcinoid were included. Evaluation of the patients included, C.T
scan of the chest and upper abdomen and fiber optic bronchoscopy. Pulmo-
nary function tests were ordered for all patients. Bronchoscopic biopsy was
obtained in 21 patients, transthoracic needle biopsy in 5 and the diagnosis
was reached postoperatively in the remaining 3 patients.
Results: There were 13 males and 16 females, the mean age was 33 years, all
male patients were smokers and non of female patients ever smoked. Twenty
five patients were symptomatic, the tumor was discovered accidentally in the
remaining 4. Bronchial carcinoid represented 22.4% of all carcinoid tumors
and 8.2% of lung cancer patients referred to our institution during this period.
Operative procedures performed were; lobectomy in 8 ,bi-lobectomy in 2,
pnemonectomy in 3 and 16 sleeve resections. Postopertaive pathology
revealed 27 patients with typical and 2 with atypical carcinoid. The mean
tumor size was 2 X 3.5 cm with a range of 1.5 X 1.8 cm. – 3 X 4.5 cm.
Postoperative TNM staging was: 12 patients with stage IA (T1 N0), 13 IB
(T2 N0), 2 IIA (T1 N1, T3N0), 2 IIIA (T2 N2). Morbidity was encountered
in 11 patients, in the form of arrhythmia in 5, pneumonia in 3 and prolonged
air leak in 3 patient with no operative related mortality. Follow up data were
available for 27 patients as 2 patients were lost to follow up. One patient with
atypical carcinoid died 8 months postoperatively from disseminated disease,
the remaining 26 patients are alive disease free. Follow up duration ranged
from 7 -97 months. Overall survival rate was 81.5%.
Conclusion: Bronchial carcinoid is of low malignant potential with excellent
survival following complete resection. Great effort should be carried out to
resect this special type of lung tumor as surgery is considered the only line
of treatment, due to low malignant potential, bronchoplastic procedures
should be encouraged whenever indicated.
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ENHANCEMENT OF THE ANTITUMOR ACTIVITY
OF IONIZING RADIATION BY NIMOTUZUMAB, A
HUMANIZED MONOCLONAL ANTIBODY TO THE
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR),
IN NON-SMALL CELL LUNG CANCER CELL LINES OF
DIFFERING EGFR STATUS
Y. Akahi1, I. Okamoto1, T. Iwasa1, T. Yoshida1, M. Suzuki2, T. Satoh1, M.
Fukuoka1, K. Ono2, K. Nakagawa1 1Medical Oncology, Kinki University
School of Medicine, Osaka-Sayama/JAPAN, 2Radiation Oncology Research
Laboratory, Research Reactor Institute, Kyoto University, Osaka/JAPAN
The expression and activity of the epidermal growth factor receptor (EGFR)
are determinants of radiosensitivity in several tumor types, including non–
small cell lung carcinoma (NSCLC). However, little is known of whether
genetic alterations of EGFR in NSCLC cells affect the therapeutic response
to monoclonal antibodies to EGFR in combination with radiation. We
examined the effects of nimotuzumab, a humanized monoclonal antibody to
EGFR, in combination with ionizing radiation on human NSCLC cell lines
of differing EGFR status. Flow cytometry revealed that H292 and Ma-1 cells
expressed high and moderate levels of EGFR on the cell surface, respec-
tively, whereas H460, H1299, and H1975 cells showed a low level of surface
EGFR expression. Immunoblot analysis revealed that EGFR phosphorylation
was inhibited by nimotuzumab in H292 and Ma-1 cells but not in H460,
H1299, or H1975 cells. Nimotuzumab augmented the cytotoxic effect of
radiation in H292 and Ma-1 cells in a clonogenic assay in vitro, with a
dose enhancement factor of 1.5 and 1.3, respectively. It also enhanced the
anti-tumor effect of radiation on H292 and Ma-1 cell xenografts in nude
mice, with an enhancement factor of 1.3 and 4.0, respectively. Nimotu-
zumab did not affect the radioresponse of H460 cells in vitro or in vivo.
Nimotuzumab enhanced the anti-tumor efficacy of radiation in certain
human NSCLC cell lines in vitro and in vivo. This effect may be related
to the level of EGFR expression on the cell surface rather than to EGFR
mutation.
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OSTEOBLASTIC RESPONSE AS A HEALING REACTION
TO CHEMOTHERAPY MIMICKING PROGRESSIVE
DISEASE IN PATIENTS WITH SMALL-CELL LUNG CANCER
T.C. Gauler1, S. Hahn2, S. Mu¨ller3, S.C. Ladd2, M. Forsting2, J. Stattaus4,
W.E.E. Eberhardt5 1Internal Medicine (Cancer Research), University Hos-
pital of Essen, Essen/GERMANY, 2Diagnostic and Interventional Radiology
and Neuroradiology, University Hospital of Essen, Essen/GERMANY, 3Nu-
clear Medicine, University of Du¨sseldorf, Essen/GERMANY, 4Diagnostic
and Interventional Radiology and Neuroradiology, University of Du¨sseldorf,
Essen/GERMANY, 5Department af Internal Medicine, West German Cancer
Center, Essen/GERMANY
Background: The osteoblastic response (OR) phenomenon as a healing
reaction during successful chemotherapy, showing an increase in the quantity
or density of bone lesions has been described for breast and prostate cancer.
The purpose of this retrospective study was to verify the existence of this
phenomenon, mimicking progressive disease, in patients with small-cell lung
cancer (SCLC) and therefore to establish rules for interpretation of follow-up
computer tomography (CT) examinations.
Methods: Twenty-four patients with newly diagnosed SCLC and bone metas-
tases were included in this trial. The behavior of bone lesions in CT examina-
tions was compared with bone scintigraphy and magnetic resonance imaging, if
available. In target lesions the CT density in Hounsfield units (HU) was
measured at baseline and during follow-up visits. Cancer remission was estab-
lished with tumor measurements based on RECIST guidelines.
Results: New osteoblastic lesions occurred during follow-up in 17 patients. OR
was proven in 4 patients and considered most likely in 11 patients; mean density
increase in target lesions was 153 HU. OR remained doubtful in 2 patients.
Conclusion: Osteoblastic response as a healing reaction occurs in the ma-
jority of patients with SCLC and bone metastases and should not be
misinterpreted as progressive disease. Medical oncologists, pneumonologists
and radiologists should be aware of this phenomenon.
267O
AN ALGORITHM THAT PREDICTS OUTCOME FOR EGFR
TKI THERAPY HAS NO PROGNOSTIC ASSOCIATION IN
SURGICALLY TREATED ADENOCARCINOMA LUNG
CANCER PATIENTS
A. Spreafico1, R. Dziadziuszko2, H. Roder3, M. Duncan4, J. Grigorieva3, M.
Tsypin3, S. Hunsucker4, J. Jassem5, P.A. Bunn, Jr.6, F.R. Hirsch6 1Medical
Oncology, University of Colorado Health Science Center, Aurora/UNITED
STATES OF AMERICA, 2Medical Oncology, University of Gdansk, Gdansk/
POLAND, 3Biodesix, Biodesix, Steamboat Springs/UNITED STATES OF
AMERICA, 4Pediatrics, University of Colorado Health Science Center,
Aurora/UNITED STATES OF AMERICA, 5Akademii Medycznej W Gdansku,
Klinika Onkologii Radiotherapii, Gdansk/POLAND, 6Medicine-Oncology,
University of Colorado Cancer Center, Aurora/UNITED STATES OF
AMERICA
Background: EGFR-TKIs can improve the outcome of patients (pts) with
NSCLC. EGFR mutations have shown to be both prognostic and predictive,
whereas EGFR gene copy numbers only predictive for EGFR TKIs. How-
ever, these techniques require biopsy. Our previous publication (JNCI, 2007)
reported the predictive value of an algorithm based on MALDI ToF MS
analysis of pretreatment serum of unselected pts to identify who would
benefit from EGFR-TKIs treatment. The aim here is to confirm that the
algorithm is not prognostic by testing a cohort of surgically treated adeno-
carcinoma pts not treated with EGFR TKIs. Methods: Mass spectra were
acquired in linear mode using a Voyager DE-PRO mass spectrometer. Forty
spectra were collected from 20 unique locations within the perimeter of each
MALDI spot to generate an average spectrum comprised of 800 separate
spectra for each serum specimen. Samples were randomly spotted on 3
different targets and 3 spectra were collected for each sample. Spectra were
externally calibrated using a mixture of proteins standards.
Results: Forty-seven sera were analyzed. Pts characteristics were: males/
females: 33/14; histology: 47 adenocarcinoma; never/former/current smok-
ers: 3/13/31. The same algorithm predictive for response to EGFR TKIs in
the previous study, VeriStratTM (Biodesix Inc.), based on 8 distinct mass-
to-charge (m/z) features, was used to analyze the spectra. Results from
unselected surgically treated pts showed that the classifier did not predict
outcomes (OS). The results (TTP, OS) from this new selected group, who did
not receive EGFR-TKIs will be presented at the meeting.
Conclusion: If the study confirms that the MALDI algorithm, which has
proven predictive for EGFR TKIs, is not prognostic in surgically treated
adenocarcinoma pts, the finding strengthens the predictive clinical applica-
tion of the VeriStratTM algorithm for pts treated with EGFR TKIs.
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PHASE II TRIAL OF CAMTOBELL, A NEW
CAMPTOTHECIN ANALOGUE, IN PATIENTS WITH
IRINOTECAN SENSITIVE RELAPSED SMALL CELL
LUNG CANCER
B.C. Cho1, S. Kim2, K.C. Keum3, J.H. Kim1 1Medical Oncology, Yonsei
Cancer Center, Seoul/KOREA, 2Head and Neck Surgery, Yonsei Cancer
Center, Seoul/KOREA, 3Radiation Oncology, Yonsei Cancer Center, Seoul/
KOREA
Background: CKD-602 (Camtobell, Chong Kun Dang Pharm, Seoul, Ko-
rea) is a new camptothecin analogue. The objective of this phase II trial was
to investigate the safety and efficacy of CKD-602 in patients with irinotecan
sensitive relapsed SCLC.
Methods: Eligibility included patients with previously treated small cell lung
cancer patients who responded to first-line irinotecan containing regimen and
progressed after response duration of 90 days or more. Patients were required
to have measurable disease, Eastern Cooperative Oncology Group (ECOG)
performance score over 2, and adequate organ function. Treatment consisted
of CKD-602 on days 1 to 5 of a 3-week cycle. At the first cycle, all patients
received 0.5 mg/m2/day of CKD-602. From the second cycle, the daily dose
of CKD-602 was adjusted to one of three dose levels, 0.4, 0.5, or 0.6
mg/m2/day, based on the toxicities after the each cycle.
Results: A total of 21 patients, 9 in ED and 12 LD at diagnosis, were enrolled
onto this study. Median age was 63 years. The dose level of CKD-602 was
0.4 mg/m2/day in 23 cycles, 0.5 in 54, and 0.6 in 15. A total of 92 cycles of
CKD-602 were delivered with a median of 6 cycles. All patients were
assessable for toxicity and for response. There was no treatment-related
death. The most frequent grade 3/4 toxicities were related to myelosuppres-
sion including neutropenia in 91% of patients and thrombocytopenia in 43%.
Grade 3/4 non-hematological toxicities didn’t occur. There were 5 partial
responses. Overall objective response rates were 24% (95% CI, 3.9 – 43.6);
11.1% for ED and 33.3% for LD. Response rates were not significantly
different according to age, gender, performance status and stage at diagnosis.
With a median follow-up duration of 6.3 months, 2 of 5 responded patients
progressed after a mean response duration of 2.2 months. Five patients died
and median survival for all enrolled patients wasn’t reached.
Conclusions: CKD-602, a new camptothecin analogue, was active in irrino-
tecan sensitive relapsed SCLC patients and showed reversible myelosuppres-
sion as the main toxicity. This promising result warrants further investigation
of CKD-602 versus topotecan Phase III trial.
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THIRD LINE THERAPY IN TREATMENT OF THYMIC
CELL CARCINOMA
V. Radosavljevic, D. Bozic, A. Stojanovic Pulmology, KBC Bezanijska kosa,
Belgrade/SERBIA AND MONTENEGRO
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Thymic cell carcinoma is a relatively rare diagnosis. The first choice of
therapy is surgical therapy, followed by radiotherapy. The aim of the study
was determining the best third line therapy. MATERIAL AND METHODS
6 patients were included in the study (5M, 1F) with pathological diagnosis of
thymic cell carcinoma. They had undergone radical surgery and were
irradiated with 64 Gy in the first subsequent year. Secondary deposits in the
lung were diagnosed in the third year (after 38 months, 4 patients) and the
fourth year (after 50 months, 2 patients). Chemotherapy was performed with
the ADOC protocol in standard doses. All patients had stable disease: 4
patients for 12 months, and 2 patients out of 6 for 18 months. After the first
relapse the question of further treatment was considered. In three cases, the
chosen treatment was surgical intervention. In the remaining three cases no
further therapy was applied due to a bad Karnofski index and joint diseases.
In patients who received surgical treatment the median survival was 3–6
months. A similar median survival was observed in the group which did not
receive surgical treatment. CONCLUSION It is hard to give a definite
answer to the question of choice of third line therapy after observing such a
small group of patients. However, surgical treatment as third line therapy did
not show any benefits to the median survival of patients. The question of best
treatment possibilities in this respect remains open.
270P
LUNG METASTASIS OF THYROID CARCINOMA:
MISUNDERSTANDING OF EXISTING PATHOLOGY
M. Gorobeiko, O. Larin, S. Cherenko Surgery, Ukrainian Scientific and
Practical Centre for Endocrine Surgery, Kyiv/UKRAINE
More 6.5 thousand operations on thyroid were performed during 1995–2007
years in our Centre. There were 2474 patients (38%) - cases of differentiated
thyroid cancer among these patients (including 521 cases of microcarci-
noma). After operations 1821 of them were examined by radioiodine-131,
752 patients were treated by radioiodine therapy. Metastases to lungs were
detected in 99 cases (4% of all thyroid carcinomas). Nevertheless, after chest
X-ray examination, the apparent metastases were detected in 31 cases (31%
of verified lung metastases). At the same time, in another hospitals, after
routine chest x-ray exams in 12 cases was uncorrected made diagnosis lung
cancer, 4 patients of them were operated (3 lobectomy, 1 pulmonectomy).
Correct diagnosis of thyroid cancer was ascertained only after path exami-
nation. Moreover, the lung metastases of thyroid cancer were often evaluated
as a fibrosis or petrificates. For improvement such situation, from our point
of view, in cases of detection of focal lesions in lungs, it is necessary to
provide thyroid examination (including US scan and if any lesions are found,
FNA biopsy). And after surgical treatment of thyroid cancer, the whole body
scanning by 131-iodine is absolutely necessary.
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MAMMALIAN TARGET OF RAPAMYCIN (MTOR)
SIGNALING ACTIVATION PATTERNS IN
NEUROENDOCRINE TUMORS OF THE LUNG
S. Novello1, M. Volante2, L. Righi2, F. Ardissone3, G.V. Scagliotti1, P.
Ceppi4, M. Giaj Levra1, M. Longo1, E. Capelletto1, M. Papotti2 1Thoracic
Oncology Unit, University of Turin, Orbassano/ITALY, 2Pathology Unit San
Luigi Hospital, University of Turin, Orbassano/ITALY, 3Thoracic Surgery
San Luigi Hospital, University of Turin, Orbassano/ITALY, 4Clinical and
Biological Sciences, University of Turin, Orbassano/ITALY
Background: Adjuvant therapeutic strategies in metastatic lung neuroendo-
crine tumors (NETs) are still incompletely settled and are mostly planned on
the degree of differentiation of the tumor. Clinical trials testing the efficacy
of mTOR inhibitors in lung NETs are ongoing, despite little is known about
mTOR activation patterns in this spectrum of neoplasms.
Method: We analyzed the expression of phosphorylated-mTOR and of its
major targets p70-S6K and 4EBP-1 by means of immunohistochemistry in a
large series of 162 surgically resected lung NETs with complete clinical and
follow up information available; the series included 53 typical carcinoids
(TC, of which 16 with metastases), 50 atypical carcinoids (AC), 33 large cell
neuroendocrine carcinomas (LCNEC) and 26 small cell carcinomas (SCC).
Results: Higher levels of mTOR were detected in well differentiated lung
NETs (TC and AC), as compared to poorly differentiated LCNEC and SCC
(Mann Whitney test p0.01), whereas 4EBP-1 was more expressed in poorly
differentiated tumors (p0.02). A strong correlation between mTOR and
p70-S6K expression was observed (Spearman test p0.0001) whereas
4EBP-1 was unrelated to mTOR expression (p0.89), possibly due to the
fact that 4EBP-1 antibody does not recognized specifically the phosphory-
lated form. Low mTOR expression was correlated to the presence of lymph
node metastases in AC tumor group (Chi-square test p0.018) and to
residual/recurrent disease and disease-related deaths in the poorly differen-
tiated tumor group (p0.03) However, mTOR did not correlate with adverse
outcome both in well differentiated and poorly differentiated tumor groups at
univariate survival analysis. 4EBP-1 and p70-S6K were both unrelated to
specific clinical features.
Conclusion: Peculiar mTOR activation patterns are present within the spec-
trum of lung NETs, with possible clinico-prognostic implications. The
definition of mTOR pathway activation profile in lung NETs is of potential
interest to test its predictive value in patients treated with mTOR-targeted
therapies.
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INTIMAL PULMONARY ARTERY SARCOMA: A CASE
REPORT
N. Bourry1, P. Chabrot2, G. Jeannin3, M. Filaire4, C. Charpy5, J.O. Bay6, J.L.
Kemeny7, D. Caillaud8, G. Escande4, L. Boyer9 1Radiotherapy, Centre Jean
Perrin, Clermont Ferrand Cedex 1/FRANCE, 2Radiology, CHU Gabriel
Montpied, Clermont Ferrand/FRANCE, 3Pneumology, CHU Gabriel Mont-
pied, Clermont Ferrand/FRANCE, 4Thoracic Surgery, CHU Gabriel Mont-
pied, Clermont Ferrand/FRANCE, 5Pathology, CHU Gabriel Montpied,
Clermont Ferrand/FRANCE, 6Oncology, Centre Jean Perrin, Clermont
Ferrand Cedex 1/FRANCE, 7Pathology, CHU Gabriel Montpied, Clermont
Ferrand/FRANCE, 8Pneumology, CHU Gabriel Montpied, Clermont Fer-
rand/FRANCE, 9Radiology, CHU Gabriel Montpied, Clermont Ferrand/
FRANCE
Primary pulmonary artery sarcoma is a rare tumor often misdiagnosed with
pulmonary thromboembolism.
We present a case of intimal sarcoma arising from right pulmonary artery and
left lower pulmonary vein.
A 44-year-old man with no particular medical history had been presenting a
non productive cough for few weeks.
A right hilar mass and a ipsilateral pleural effusion were revealed by the two
first chest radiographs.
Contrast-enhanced Computed Tomographic scans and Magnetic Resonance
Imaging with gadolinium showed a seven centimeters tumor filling the right
pulmonary artery extending to the lobar arteries with a heterogeneous
enhancement after injection, in favour of a vascular tumor instead of
thromboembolism; a similar filling defect was observed into the left lower
pulmonary vein.
The subsequent biopsy confirmed this hypothesis.
Because of this double location, surgery could not be performed and the
patient received a palliative treatment composed of tree cycles of chemo-
therapy (adriamycin, ifosfamide, dacarbazine) followed by radiotherapy
treatment.
Twelve months after diagnosis the patient was still alive and well. Last CT
scans imaging showed a partial response, less than 50% of the tumor size in
the right pulmonary artery and a progression of the left lower pulmonary vein
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disease. The patient will benefit of a new radiotherapy concentrated on this
specific area.
Pulmonary vascular sarcoma may look like pulmonary embolism, but en-
hancement of the filling defect is quite specific.
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INCREASE INCIDENCE OF VENOUS
THROMBOEMBOLIC EVENTS (VTES) IN NON SMALL
CELL LUNG CANCER PATIENTS TREATED WITH SU?
A. Rahal1, C. Massard2, P. Girard3, J. Domont2, A. Le Cesne2, B. Escudier2,
J. Soria4, B. Besse5 1Medical Oncology, INSTITUT GUSTAVE ROUSSY,
Villejuif/FRANCE, 2Medical Oncology, Institut Gustave Roussy, Villejuif/
FRANCE, 3Pneumology, Institut Mutualiste Montsouris, Paris/FRANCE,
4Medical Dpt (7), Institut Gustave-Roussy, Villejuif/FRANCE, 5Depart-
ment of Medicine, Institut Gustave Roussy, Villejuif/FRANCE
Background: Sunitinib (SU) is multi target tyrosine kinase inhibitor approved
by FDA and EMEA in Renal Cell Cancer (RCC) and Gastric intestinal
stromal tumor (GIST). SU has not been reported to increase the rate of VTEs
in RCC, GIST. As VTEs incidence is higher in NSCLC pts treated with
chemotherapy (CT) compared to other tumor type, we investigate whether
VTEs rate was similar in RCC, GIST and NSCLC pts treated with SU.
Methods: RCC, GIST and NSCLC pts treated with SU in prospective
clinical trials at Institut Gustave Roussy (IGR) were analyzed to assess
the risk of VTEs rate and identify predisposing factors. SU was given at
50 mg/d 4 wks out of 6, as a 2nd or 3rd line in GIST, as maintenance
therapy after 4 cycles of paclitaxel-carboplatin in NSCLC and in RCC pts
after cytokine failure. Key exclusions criteria of these trials were: pts
with history of thrombosis within 6 months, brain metastasis, PS WHO
1, or squamous cell lung cancer. Diagnoses of symptomatic pulmonary
embolism (PE) confirmed by CT pulmonary angiography were centrally
reviewed.
Results: Between Aug.05 and Oct.06, 72 pts were included (21 GIST, 8
NSCLC, 43 RCC). Baseline characteristics were (RCC/GIST/NSCLC):
female 23%/57%/50%, mean age 54/54/51yrs, PS 0: 84%/57%/38%,
indwelling central venous catheters (ICVC) 0%/0%/100%, bone metas-
tases: 11%/0%/75%, liver metastases: 76%/28%/37%. None has history
of previous cancer or surgery within 1 yr. Five pts (6.9%, 95%CI:
3.0 –15.2%) developed symptomatic PE., 3 in NSCLC pts (37%), 1 in
RCC (2%) and 1 in GIST (5%). PE occurred early after sunitinib
initiation (4 wks in 2 pts, 6 wks in 2 pts, 10 wks in 1 pt). In case of PE,
SU was interrupted in NSCLC but continued in GIST and RCC pts. All
5 PE were treated with low molecular weight heparin (LMWH). In 1 pt
(GIST), LMWH was discontinued after 4 months due to a grade 3
oesophageal hemorrhage (peptic esophagitis) but SU was maintained for
3 additional months untill disease progression. In 1 pt (RCC), LMWH and
SU were maintained for up to 24 months.
Conclusions: Incidence of VTEs may be higher in NSCLC pts treated with
SU, compared with GIST & RCC pts. Concomitant SU and LMWH treat-
ment is feasible but might expose to severe hemorrhage.
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NET OF THE LUNG (NON SC): TEN YEARS EXPERIENCE
OF E. MORELLI HOSPITAL OF SONDALO AND
PROPOSAL OF AN ITALIAN REGISTRY
G. Valmadre1, R. Delfanti2, M. Robustellini2, G. Rossi2, C. Della Pona2, R.
Epis1, A. Pastorini1, S. Artale3, S. Baio4, C. Capella5 1Internal Medicine and
Hematology, E.Morelli Hospital AOVV, Sondalo/ITALY, 2Thoracic Surgery,
E.Morelli Hospital AOVV, Sondalo/ITALY, 3Medical Oncolofy “falck”, Ni-
guarda Hospital, Milan/ITALY, 4Nuclear Medicine, European Institute of
Oncology, EIO,Milan/ITALY, 5Pathological Anatomy, “Ospedale di Cir-
colo”, University of Insubria, varese/ITALY
Background: pulmonary NETS are typical carcinoid (TC), atypical carcinoid
(AC), large-cell neuroendocrine carcinoma (LCNC), and SCLC. Purpose: to
evalue prognosis of pulmonary well differentiated NET and establish an
Italian registry.
Methods: From 1996 to 2007 our lung cancer working group followed 51
pulmonary NETs. 2/51 were metastatic at the diagnosis. 44/51 underwent
radical surgical resection with adenectomy. 2/51 TC had definitive endo-
bronchial laser, 3/51 had disostructive laser (2/3 followed by bilobectomy).
37/51 (72%) are TC. 11/51 (21%) are AC, 2/51 (4%) undetermined.
Results: follow-up at dec 07: 3/51 were lost. 1 AC dead 7 yrs after diagnosis
for progressive disease (liver metastasis, high CgA, and 3 yrs of octreotide).
1 undeterminated histology dead 1 yr after diagnosis (high CgA, octreotide
therapy). 7 had preoperating CgA: 2 high (1 developed hepatic metastasis, in
1 normalized and 48 mths DFS). 3 TC had progressive disease. 1 TC
(IA,high pre-lobectomy CgA), had persistent high CgA and hepatic lesion
octreoscan, 4 mths later: PR after 18 mths of octreotide. 1 TC (IB) with
normal pre-lobectomy CgA had carcinoid syndrome with high CgA and
octreoscan positivity, 4 mths later: negative restaging at 34 mths with 1 yr of
octreotide. A sixteen girl – TC IB – with high CgA (normal after pneumo-
nectomy) developed octreoscan thoracic lesions, 18 mths later. PR after 56
mths with radiometabolic therapy.
Conclusion: NETS are heterogeneous lung cancers. AC radically resected
had good prognosis (1/11 metastasis), sometimes TC gave metastasis (2/37).
Octreotide- and radiometabolic therapy can control metastatic disease. CgA
is not indicative of relapse but correlates with the extension of metastatic
disease. High CgA values are not predictive of carcinoid syndrome. It is
important to evalue CgA before and 2–3 mths after surgery. From this
experience, we want to propose – activation by January 07 - the creation of
an Italian registry of Net of the lung (all subtypes), with the collaboration of
other Italian centers (Niguarda Hospital in Milan, European Institute of
Oncology in Milan, and University of Insubria). The purpose is to have more
data about incidence, prognosis and treatment of this rare disease.
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SORAFENIB PLUS CARBOPLATIN/PACLITAXEL IN CHE-
MONAIVE PATIENTS WITH STAGE IIIB-IV NON–SMALL
CELL LUNG CANCER (NSCLC): INTERIM ANALYSIS (IA)
RESULTS FROM THE PHASE III, RANDOMIZED,
DOUBLE-BLIND, PLACEBO-CONTROLLED, ESCAPE
(EVALUATION OF SORAFENIB, CARBOPLATIN, AND
PACLITAXEL EFFICACY IN NSCLC) TRIAL
G. Scagliotti1, J. von Pawel2, M. Reck3, L. Cupit4, F. Cihon4, S. DiMatteo4,
J. O’Leary4, N. Hanna5 1University of Turin, Turin/ITALY; 2Asklepios-
Fachkliniken Munich-Gauting, Gauting/GERMANY; 3Hospital Grosshansdorf,
Grosshansdorf/GERMANY; 4Bayer Pharmaceuticals Corp, West Haven,
Connecticut/USA; 5Indiana University School of Medicine, Indianapolis,
Minnesota/USA
Background: Sorafenib is an oral multikinase inhibitor with anti-angiogenic
and antiproliferative activity via inhibition of VEGFRs, PDGFRs, c-Kit,
Flt-3, RET, and Raf kinase, and single-agent activity in phase I–II NSCLC
trials.
Methods: Eligible pts had unresectable stage IIIB/IV NSCLC, no prior
systemic treatment, ECOG PS 0–1, and a life expectancy of 12 weeks.
Patients were randomized to receive carboplatin AUC 6 d1  paclitaxel 200
mg/m2 d1 combined with either sorafenib 400 mg (PCS) or placebo (PCP)
orally, bid d2-19, q3w. Daily sorafenib 400 mg bid or placebo was continued
as maintenance therapy following up to 6 cycles of chemotherapy. Safety and
efficacy was monitored by the DMC throughout the study. The DMC
recommended termination of the study for futility based on findings from a
formal planned IA of efficacy at 384 death events.
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Results: 926 patients were randomized to treatment with PCS (n464) or
PCP (n462). Overall demographics were balanced between arms and
included: 63% male; 59% ECOG PS 1; 90% Stage IV disease; median age,
62 years and 24% squamous cell (SC) histology (219 pts). Baseline demo-
graphics were similar between SC and non-SC subsets. Preliminary efficacy
results revealed median overall survival (ITT analysis) 10.7 months in the
PCS group vs 10.6 months in the PCP group [HR (PCS/PCP), 95% CI1.16,
(0.95,1.43); P0.93, 1-sided]. From safety data currently available, the most
common causes of death in the ITT group were: PD, 292 (31.5%); other, 43
(4.6%); unknown, 11 (1.2%); study treatment toxicity, 9 (1.0%); and pneu-
monia, 4 (0.4%). Greater mortality was observed in the subset of patients
with SC treated with PCS, compared with those treated with PCP. Cause of
death in SC subset was PD 63 (28.8%), other 11 (5.0%), unknown 5 (2.3%),
study treatment toxicity 4 (1.8%) and respiratory failure 2 (0.9%). Fatal
pulmonary hemorrhage was reported in 13 pts (1.4%) overall, with 9 events
in the SCC subset (5 in PCS group, 4 in PCP group).
Conclusions: Based on this planned interim analysis, there was no clinical
benefit from the addition of sorafenib to standard PC chemotherapy in
NSCLC. PCS-treated patients with squamous-cell NSCLC (n107) had a
greater mortality rate than those receiving PCP (n112). As the final,
cleaned, database becomes available, additional analyses will be performed
to detect possible explanations for the efficacy and safety outcomes of the trial.
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